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 Rotenone is an organic pesticide and non-selective piscicide that is approved for 
use in the United States (US). In human epidemiological studies, rotenone exposure 
increases the risk of Parkinson’s disease (PD), the second most common 
neurodegenerative disorder in the US. Rotenone is a key toxicant used to study gene-
environment interactions in neuronal function and aging. In experimental studies, 
rotenone exposure recapitulates PD cellular pathology at environmentally relevant 
concentrations. It is a potent complex I inhibitor and promotes the production of reactive 
oxygen species. Oxidative damage and mitochondrial dysfunction activate critical 
transcription factors that regulate the cellular stress response. This retrograde signaling 
pathway alters chromatin structure via epigenetic mechanisms to regulate gene 
expression. Epigenetic modifications including DNA methylation and histone tail 
acetylation are persistent and can have a lasting effect on the functionality of a neuron. 
Investigating the mechanisms and patterning of these epigenetic modifications is critical 
for understanding the role of the epigenome in maintaining neuronal plasticity during 
aging. In this dissertation, we examined the molecular signatures of rotenone exposure 
on the epigenome. We investigated the role of the endogenous protein α-Synuclein (α-
Syn), a pathological hallmark of PD, in mediating the effects on chromatin. We 
discovered that oxidative stress-induced α-Syn interferes with the maintenance of DNA 
methylation patterns by interfering with the translocation of DNA methyltransferase I. 
The aggregation of α-Syn activates ATF4 signaling and represses the hypoxic response. 
We revealed that enhancer enriched PD-associated genetic variants, DNMT1-dependent 
regions, hypoxia-response elements, and CTCF transcription factor binding motifs were 
among the genomic elements most vulnerable to rotenone-induced oxidative damage 
and α-Syn toxicity. We hypothesize that mitochondrial dysfunction activates early 
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response transcription factors to regulate the balance and activity of DNA modifying 
enzymes in the nucleus and that α-Syn toxicity drives the direction of this response. 
There is currently no cure for PD and clinical strategies rely on treating symptoms that 
occur late after onset of pathology. Epigenetic modifications are persistent, but they are 
also reversible. This dissertation provides insights into molecular signatures of oxidative 
stress in the brain and introduces candidate regions for early biological markers and 
novel pharmaceutical targets.  
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1.1.1 Pesticide usage in the United States 
The United States is one of the largest consumers of pesticides in the world with 
total expenditures accounting for nearly 20% of the global market (Atwood et al. 2017). 
Unsurprisingly, herbicides constitute approximately half of the pesticides consumed and 
the agricultural sector accounted for most of the herbicides used between 2008-2012. 
However, private usage should not be disregarded with individual use in the home and 
garden consuming 30% of the 680 million pounds of herbicides and insecticides used in 
2012 (Atwood et al. 2017). This residential utilization of pesticides can expose susceptible 
populations including pregnant women and children (Michael and Alavanja 2009; Whyatt 
et al. 2002). The US regulation on the pesticide industry is more lenient than policies 
implemented by the European Union (EU) (Donley 2019). In 2016, 322 million pounds of 
pesticides used in the United States are banned in the EU. One such pesticide is the 
botanical insecticide rotenone.  
 Rotenone is an isoflavonoid that is found in many species of plants native to 
Southeast Asia, East Africa, and some parts of South America (US EPA 2007). It has 
historically been used in organic farming but registration of rotenone for use on food was 
cancelled by the EPA starting in 2007 (Islam 2006). Despite this cancellation, rotenone 
products could be sold until 2011 and currently rotenone is still exempt from a tolerance 
requirement allowing any amount of residue on food without violation of the law (77 FR 
59128, Sept. 26, 2012). The primary use of rotenone today is as a piscicide to terminate 
invasive or noxious species of fish. Permissible application concentrations can be up to 
250 ppb and can be applied to public and recreational waters (US EPA 2007). While it is 
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highly toxic in humans following acute inhalation or ingestion, the environmental 
persistence of rotenone is expected to be low and its half-life is estimated between days 
to weeks in water systems depending on various physiochemical factors including 
temperature and pH (Dawson et al. 1991; Turner et al. 2007).  
 The most prominent case study of rotenone toxicity is the accidental poisoning of 
a young girl with a lethal dose of 40 mg/kg (De Wilde et al. 1986). A separate case study 
involving an adult woman purposefully consuming 25 mg/kg of rotenone resulted in loss 
of consciousness and cardiac arrest (Wood et al. 2005). The US EPA has set a chronic 
reference dose of 4 µg/kg/day to protect vulnerable populations (US EPA 2007). While 
chronic toxicity studies have indicated developmental and reproductive toxicity, most 
human studies focus on the potential of rotenone in neurodegeneration (DeLamirande 
1992; Khera et al. 1982, US EPA 2007; USDA Forest Service; Uversky, V. 2004; Bertarbet 
et al. 2000).  
1.1.2 Epidemiological evidence of rotenone and neurodegeneration 
Rotenone freely crosses cell membranes and targets complex I of the oxidative 
phosphorylation chain in mitochondria (Greenamyre et al. 2001). Inhibition of complex I in 
the mitochondria creates deficits in cellular energy production and generates reactive 
oxygen species causing damage to intracellular lipids and nucleic acids. These features 
of rotenone toxicity focus on neuronal cells with high metabolic burden and vulnerability 
to oxidative stress.  
Mitochondrial dysfunction and inhibition of complex I have been associated with 
several neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, 
Friedreich's ataxia, Huntington’s disease, Amyotrophic lateral sclerosis, Leber’s optic 
neuropathy, and axonal peripheral neuropathies (Beal et al. 1998, Brown et al. 1992, 
Benienda et al. 2013). Inhibition of mitochondrial respiration in Parkinson’s disease (PD) 
became a focal point in the literature after a group of young adults developed symptoms 
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of Parkinsonism after injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a 
by-product and contaminant of synthetic heroin (Langston et al. 1984). These effects on 
mitochondrial function and oxidative phosphorylation were mirrored in idiopathic PD 
(Schapira et al. 2010, Parker et al. 2008). To examine these mechanisms of mitochondrial 
dysfunction and ATP depletion in PD, Betarbet (2000) used rotenone to inhibit complex I 
in-vivo and reproduced the neuropathological features of PD. This association of chronic 
pesticide exposure and nigrostriatal pathology initiated epidemiological studies to assess 
the risk of life-time exposure of rotenone with idiopathic PD. The Agricultural Health Study 
(AHS) is a prospective cohort of agricultural workers and their families organized with the 
intent to quantify disease risks from exposure to pesticides and agricultural chemicals 
(Alavanja et al. 1996). The Farming and Movement Evaluation Study is a nested case-
control study within the AHS which followed private applicators of pesticides and their 
spouses to determine the risk of lifetime pesticide use with PD diagnosis (Tanner et al. 
2011). Rotenone was the mitochondrial toxicant with the greatest association of PD with 
an odds ratio of 2.5 (95% CI, 1.3-4.7). While there are inconsistencies with the results 
from human data stemming from the limitations in assessing exposure and misdiagnosed 
Parkinson’s disease, most studies report a positive association in agricultural workers with 
ever use of pesticides and the onset of PD (Kamel et al. 2007; Dhillon et al. 2008; 
Firestone et al. 2005; Gorrell et al. 1998, Freire and Hoifman 2012). Users of rotenone 
were 2.5 times more likely to develop PD as nonusers and this association was consistent 
even when exposure was truncated as many as 15 years before diagnosis (Tanner et al. 
2011). Not only pesticide applicators are at risk but children living in rural environments 
and in residential areas that apply pesticides are also found to have increased risk of early-
onset PD even without prior genetic history (Semchuk et al. 1991, Simcox et al. 1995, Lu 
et al. 2000, Hancock et al. 2008).  
1.1.3 Parkinson’s disease in the United States 
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Parkinson’s disease (PD) is a chronic and highly progressive disorder with global 
incidence rates ranging from 10-18 per 100,000 person-years (Pringsheim et al. 2014). 
Industrialized nations see higher prevalence due to increased longevity with 1% of people 
affected over the age of 60. These numbers are only expected to increase with projections 
that worldwide prevalence will rise by 50% in 2030 (Dorsey et al. 2007). The estimated 
annual burden of Parkinson’s disease in the United States is over $20 billion and projected 
to exceed $50 billion after 2050 (Findley et al. 2007). Due to the heterogeneous nature 
and rapid progressivity of its symptoms, there is not a proficient strategy to treat 
Parkinson’s disease (Kalia and Lang 2015). Clinical strategies rely on the treatment of 
individual symptoms with the use of L-dopa, dopamine receptor stimulants, anti-
psychotics, or anti-inflammatory agents. This type of intervention strategy while 
moderately improving the quality of life for patients can significantly contribute to the 
economic burden of the disease and does little to impact disease trajectory. 
1.2 Background 
1.2.1 Clinical and molecular features of Parkinson’s disease 
The classical symptoms of PD involve loss of motor control resulting in tremors, 
muscle rigidity, and the reduced ability to initiate movement (bradykinesia). These 
symptoms stem from the loss of dopaminergic neurons in the substantia nigra of the 
midbrain (Kalia and Lang 2016). Neuronal death does not only occur in this region, 
however, but in other regions of the brain as well including the amygdala, the 
hypothalamus, and the hippocampus (Yang and Yu 2016). This creates disturbances in 
other dopamine pathways that result in non-motor symptoms including psychosis, sleep 
disorders, and olfactory impairment. These alternative symptoms typically occur 
prodromal and can predate the first signs of motor dysfunction by decades. Historically, 
however, the diagnosis of PD has been dependent upon the motor features of PD and the 
relative effectiveness of dopamine precursors in treatment (Marsili et al. 2018). This 
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causes serious limitations in the treatment of PD since the development of motor features 
such as bradykinesia is concurrent with approximately 60% of dopaminergic loss in the 
brain (Cheng et al. 2010). It also leads to misdiagnoses with up to 25% of PD patients 
diagnosed with idiopathic PD having a “Parkinson’s-like” syndrome that results from a 
separate cause such as Alzheimer’s, focal brain lesions, brain injury, or neuroleptic drug 
usage (Litvan et al. 1998). Recently, the Movement Disorder Society (MDS) released new 
criteria for diagnosing PD that considers prodromal and non-motor symptoms but the 
success of the MDS criteria strategy remains to be determined because of lack of adoption 
by physicians and the lack of pathological validation (Postuma et al. 2015, Marsili et al. 
2018).  
While the pervasive destruction of dopamine secreting neurons is central to 
pathology, the exact mechanism causing cell death has not been identified. Several 
cellular processes have been highlighted in PD pathogenesis including metabolism, 
protein trafficking, inflammation, synaptic transmission, and controlled degradation 
pathways (Dauer and Przedborski 2003, Michel et al. 2013). These processes can be 
linked to two prominent molecular features of PD pathogenesis: mitochondrial dysfunction 
and protein aggregation. Mitochondrial dysfunction has been well characterized in patients 
with both familial and sporadic forms of PD (Belsa et al. 2015, Bose and Beal 2016). 
Mutations or impairment of proteins involved in mitochondrial metabolism and 
mitochondrial stress response results in lowered ATP production, increased oxidative 
stress, promotion of inflammatory cytokines, and the initiation of apoptosis (Pickrell et al. 
2015). Alternatively, the oligomerization of mutated or mis-regulated proteins can lead to 
the formation of toxic insoluble fibrils known as inclusion bodies, or Lewy bodies (Kasten 
et al. 2013). Lewy bodies obstruct the secretion of dopamine and modify synaptic 
plasticity. They also inhibit intracellular degradation pathways that eliminate damaged or 
dysfunctional cell products and maintain cellular integrity. The failure of these pathways 
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to clear aggregated proteins promotes oxidative stress. Lewy bodies not only damage the 
host cell but may transfer toxic byproducts across synapses to neighboring cells causing 
local inflammation. Reactive oxygen species (ROS) are produced by mitochondrial 
dysfunction and Lewy body formation. ROS can also initiate or promote mitochondrial 
dysfunction and Lewy body formation (Anderson 2004, Hashimoto et al. 1998). Therefore, 
oxidative stress is a hallmark of PD creating a positive feedback loop between the 
weakening of homeostatic mechanisms and the propagation of pathological mechanisms. 
Oxidative stress can result from genetic mutations, inherited susceptibility genes, 
endogenous processes, and exogenous exposures. 
1.2.2 Etiology of Parkinson’s disease 
Epidemiological evidence supports a Mendelian component to PD with 
approximately 5-10% of total cases resulting from monogenetic inheritance (Ascherio and 
Schwarzschild 2016). These genes referred to as causative genes have low prevalence 
in the population but when inherited can lead to the aggressive onset of symptoms at 
younger ages (Farrer 2006, Shulte and Gasser 2011). Of these causative genes, the first 
identified was SNCA. SNCA is the gene that encodes alpha-Synuclein (α-Syn). The 
endogenous role for α-Syn is not well understood but there is evidence to suggest that it 
functions at the pre-synaptic terminal to regulate secretion and promote synaptic plasticity 
(Benskey et al. 2016). α-Syn has also been identified as the major component of Lewy 
bodies. Mutations in SNCA can promote Lewy body formation by altering the protein 
conformation to one with a greater propensity to aggregate. Other mutations in SNCA can 
increase the expression and accumulation of α-Syn by strengthening its promoter site for 
transcription and increasing its resistance to degradation pathways (Kasten et al. 2013).  
While genetics play a role in the onset of PD, 90% of diagnosed cases cannot be 
explained by genetics alone. In fact, less than 1% of early onset cases can be explained 
by any of the genes identified in GWAS studies (Ascherio and Schwarzschild 2016, 
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Schulte and Gasser 2011). However, no single causative factor has been identified in 
epidemiological studies. Therefore, the scientific community largely agrees that 
Parkinson’s disease is likely caused by the complex interaction of genetics and 
environmental exposures (Zanon et al. 2018).  
1.2.3 Rotenone-induced models of Parkinson’s disease 
 Multiple criteria are used to assess the value of environmentally induced animal 
models of PD including: (1) the presence of motor impairment stemming from loss of 
nigrostriatal neurons, (2) the responsiveness of the motor condition to dopamine agonists, 
(3) the formation of inclusion bodies, (4) and damage in other structures of the brain 
resulting in non-motor disturbances (Cicchetti et al. 2009). Rotenone exposure in rodent 
models of PD has been shown to replicate motor symptoms including bradykinesia and 
postural instability (Betarbet et al. 2000, Cannon et al. 2009). Furthermore, the severity of 
motor impairment correlated with striatal lesions and the loss of dopaminergic neurons 
caused by rotenone treatment (Betarbet et al. 2000, Cannon et al. 2009, Lapointe et al. 
2004). Motor behavior in rotenone-induced models is generally considered to be 
responsive to dopamine agonists (Betarbet et al. 2000, Cicchetti et al. 2009). However, 
inconsistencies remain with the specificity of rotenone toxicity to the central nervous 
system and the localization of lesions within nigrostriatal tissues (Ferrante et al. 1997, 
Lapointe et al. 2004, Benienda et al. 2013). While this non-specificity may be 
advantageous in reproducing non-motor symptoms such as sleeplessness, it could be 
more relevant to atypical PD than idiopathic PD (Garcia-Garcia et al. 2005). There are 
limitations of the model based on route of exposure. Most studies have relied on 
intravenous or subcutaneous injections of rotenone, but this exposure route can result in 
high rates of mortality in rodents (Sherer et a. 2003, Hooglinger et al. 2006). Though more 
recent studies have been able to overcome these challenges by intrastriatal infusion of 
rotenone (Carriere et al. 2014; Carriere et al. 2016), oral administration of rotenone 
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provides a more relevant approach. Low chronic exposures via ingestion have also been 
shown to increase locomotor deficits and reduce dopaminergic neurons in the striatum 
(Inden et al. 2011, Liu et al. 2017). However, interspecies variability in metabolism remains 
a limitation when extrapolating to humans in these studies.  
 Rotenone is a potent inhibitor of complex I of the mitochondrial respiratory chain 
and prevents the generation of ATP (Franco et la. 2010). The unavailability of an electron 
carrier from NADH to ubiquinone generates reactive oxygen species which can damage 
DNA, modify protein function, and degrade cellular lipids. This mechanism is mirrored in 
PD patients with reduced activity of complex I observed in the substantia nigra (Hoglinger 
et al. 2006). Mitochondrial damage can induce the release of cytochrome C and activate 
caspase mediated apoptosis. However, rotenone-induced cellular apoptosis is not 
dependent on complex I inhibition indicating other critical pathways of toxicity (Cabeza-
Arvelaiz and Schiestl 2012, Choi et al. 2008). 
 Rotenone alters the expression of genes in one-carbon metabolism which is 
essential for purine and pyrimidine biosynthesis in cell proliferation (Smirnova et al. 2016). 
Metabolic reprogramming occurs from deficits in cellular respiration but there exists a 
complex I independent pathway for rotenone-induced changes in metabolism (Cabeza-
Arvelaiz and Schiestl 2012). Rotenone destabilization of microtubules and the closure of 
mitochondrial voltage-dependent anion channels (VDACS) by disassembled tubulin are 
possible mechanisms to explain the effect of rotenone on mitochondrial membrane 
permeability independent of its effects on cellular respiration. Microtubules are key drivers 
of PD pathogenesis (Cartelli and Cappelletti 2017). Microtubule dynamics affect neurite 
outgrowth which is impaired in rotenone models of PD (Smirnova et al. 2016). The 
stabilization of microtubules also affects axonal transport and neurotransmission of 
dopamine in the striatum (Cartelli and Cappelletti 2017). 
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 Rotenone treatment in-vivo and in-vitro can promote the accumulation of α-Syn 
and the formation of Lewy bodies (Cannon et al. 2009, Franco et al. 2011, Sala et al. 2016; 
Yuan et al. 2015). Aggregation of α-Syn is associated with multiple adverse effects 
including endoplasmic reticulum stress, proteasome obstruction, autophagy dysfunction, 
and neurotransmission interference. The formation of α-Syn inclusion bodies is often 
attributed to oxidative damage from the mitochondria but can also result from the down 
regulation of endoplasmic reticulum chaperone proteins and the fluctuation of intracellular 
calcium ion concentrations (Sala et al. 2016; Yuan et al. 2015). Intracellular α-Syn is 
considered a critical factor in PD-associated neuronal cell death and may be the key to 
understanding gene-environment interactions in idiopathic PD.  
1.2.4 Epigenetic mechanisms mediate gene-environment interactions 
 Epigenetic mechanisms work at the interface of gene-environment interactions 
and are defined by heritable modifications of gene expression. Epigenetic modifications 
do not change the DNA sequence but rather regulate gene expression by modifying the 
accessibility of DNA to DNA binding proteins required for the initiation and/or elongation 
of transcription. Euchromatin, or open chromatin, is active and allows the binding of 
transcription factors at target genes. Heterochromatin, or closed chromatin, prevents the 
binding of the transcription machinery and silences genes. Epigenetic regulation is 
essential for proliferation, migration, and differentiation into individual cell types during 
development. Different timepoints of development are known as windows of susceptibility 
and exposures that occur during these windows of susceptibility cause disturbances in 
organ systems marked by epigenetic signatures. These signatures are then subjected to 
continuous editing in response to lifetime experiences modifying the risk of disease in 
adulthood (Martos et al. 2015). The most commonly studied of these epigenetic signatures 
are DNA methylation and histone tail modifications.  
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 DNA methylation refers to the addition of a methyl group to the 5' position of the 
cytosine ring (5mC). 5mC represents between 2-5% of all cytosines in the human genome 
and most commonly occurs when a cytosine is adjacent to a guanine (CG site) (Millar et 
al. 2003). DNA hypomethylation at gene promoters is generally associated with open 
chromatin and increased expression. DNA methylation at gene encoding regions can be 
complementary or skewed toward one allele which may determine the interaction of an 
environmental factor with a specific genotype (Kanthasamy et al. 2012). However, DNA 
methylation also occurs frequently at non-coding regions and at repetitive elements (Yang 
et al. 2004). DNA methylation changes at these regions can also cause genomic instability 
by changing the activation state of transposable elements that foster widespread changes 
in genetic expression (Hou et al. 2012, Li et al. 2015).   
Histone proteins package DNA and control the organization of DNA into structural 
units known as nucleosomes. Histone tails are enriched with positively charged amino 
acid residues lysine (K) and arginine (R). Histone tails can be covalently modified by 
acetylation to influence chromatin structure and the expression of genes (Wang et al. 
2008). Histone 3 (H3) is the most commonly modified histone protein and acetylation of 
histone 3 lysine 27 (H3K27ac) is pursued in the scientific community because it is known 
to distinguish active enhancers from “poised” enhancers which may become active after 
an external cue (Chen et al. 2017, Creyghton et al. 2010).  
1.2.5 Epigenetic insights in Parkinson’s disease 
Several studies have shown that blood, serum, and tissue samples from patients 
diagnosed with PD have differential methylation patterns than neurologically normal 
controls (reviewed in Lu et al. 2013, Labbe et al. 2016, Jakubowskia and Labriea 2017). 
One study looking at post-mortem brain tissue of PD patients showed lower global levels 
of methylation than controls (Matsumoto et al. 2010). These differential patterns varied 
between different regions of the brain and between different stages of disease. A later 
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study using DNA chip arrays to analyze the DNA methylome across three different regions 
in the spinal cord and brain confirmed differential methylation in PD cases that varied by 
region (Young et al. 2019). Two primary mechanistic explanations for global 
hypomethylation have been studied thus far in patients: (1) reductions in DNA 
methyltransferases and (2) increases in TET enzymes. DNA Methyltransferase 1 
(DNMT1), the enzyme predominately responsible for the maintenance of DNA methylation 
patterns, is reduced in the post mortem brain tissue samples from patients with PD 
(Desplats et al. 2011). There are also reports that levels of 5-hydroxymethylcytosine 
(5hmC), which is mediated by the TET1 enzyme and antagonizes 5mC, were higher in the 
cerebellum of PD patients (Stoger et al. 2017, Kaut et al. 2019). Further, a recent study 
revealed that reducing TET activity can protect human neurons from mitochondrial 
toxicant exposure in-vitro and rescue PD-associated motor phenotypes in mice (Wu et al. 
2020).  
Complementary to global methylation changes above, the methylation status of 
PD-relevant genes has been investigated in PD pathogenesis. The hypomethylation of 
several relevant genes including CYP2E1 (cytochrome p450 metabolic enzymes), TNF 
(Tumor Necrosis Factor inflammatory transcription factor), and PD-risk genes 
PARK2/PINK1 (mitochondrial damage sensors) (Cai et al. 2010, Kaut et al. 2012, Pieper 
et al 2008). In addition, clock genes (PER, CRY, BMAL1, and NPAS2) encode proteins 
that regulate circadian rhythms essential to main physiological homeostasis during aging. 
Blood samples from PD patients had decreased DNA methylation patterns and this altered 
expression of clock genes may contribute to the accelerated aging phenotype described 
by Horvath’s epigenetic clock (Horvath et al. 2013, Horvath and Ritz 2015, Lin et al. 2012, 
Mao et al. 2018).  Additionally, α-Syn encoding gene SNCA has been shown to have 
decreased methylation in the first intron which resulted in increased expression of the 
protein involved in the formation of Lewy bodies (Ai et al. 2014, Tan et al. 2014, De Boni 
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et al. 2011). The effect of reduced DNA methylation at SNCA intronic regions was reversed 
with administration of synthetic dopamine suggesting a role in dopaminergic neuronal 
activity with DNA methylation (Schmitt et al. 2015).  
 Histone acetylation codes are critical for maintaining neuronal function and 
regulating cell death (Saha and Pahan 2006). Hyperacetylation of histones has been 
observed in the post-mortem brain tissues of human patients and in toxicant-induced 
models of PD (Harrison et al. 2018). Studies have proposed that increased degradation 
of histone deacetylaces (HDACs) (Park et al. 2016) or lack of recruitment of HDACs to PD 
associated genes (Soldner et al. 2016, Hwang et al. 2017). The latter is evidenced by 
disrupted DNA binding of repressive complexes including REST and EMX2 and likely then 
also alter the methylation of histone proteins to silence chromatin (van Heesbeen and 
Smidt et al. 2019). HDAC inhibitor nicotinamide exacerbates motor symptoms and 
dopaminergic cells loss in rats (Harrison et al. 2019). Additionally, valproic acid, the HDAC 
inhibitor and psychiatric drug, has been associated with increased PD risk in elderly 
patients and withdrawal of the drug resulted in alleviated symptoms (Mahmoud and Tampi, 
2011). However, histone hyperacetylation varies depending on the brain region and cell 
type (Park et al. 2016). The acetylome in primary fibroblasts from PD patients can also 
vary by etiology of PD with genetic and idiopathic cases being characterized by 
hyperacetylation and hypoacetylation, respectively (Yakhine-Diop et al. 2018). This 
interdependence of disease subtype and histone pathological state may then explain 
conflicting reports that HDAC inhibitors have neuroprotective potential in clinical trials 
(Harrison et al. 2018).  
Regions affected by DNA hypomethylation and histone hyperacetylation result in 
the differential expression of genes involved in metabolism, inflammation, and autophagy 
(Labbe et al. 2016). Large disturbances in expression profiles of these genes drives 
cellular pathology by orchestrating several adverse events within neurons until cumulative 
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damage triggers cell death. These widespread changes in gene expression are persistent 
and neurons which survive the initial “hit” may retain a kind of “epigenetic memory” of the 
stressor which makes them more vulnerable to future stress (Smirnova et al. 2015). This 
explains the long latency period in disease onset and the delayed manifestation of motor 
symptoms.  
1.2.6 Epigenetic modifications in rotenone-induced models of PD 
Rotenone causes oxidative damage to DNA and is associated with modified DNA 
epigenetic patterns. Histone modifications are the most well-studied in rotenone models 
of PD. For example, pesticides paraquat and dieldrin are reported to cause 
hyperacetylation of lysine tails on histones (Song et al. 2010, Labbe et al. 2016). Similarly, 
complex I inhibitors, rotenone and MPTP, are associated with hyperacetylation and 
reduced histone deacetylase activity (Feng et al. 2015, Labbe et al. 2016, Sokhna et al. 
2019). The reduced activity in HDAC complex enzymes may be mediated by stress 
induced autophagy and the pharmacological HDAC activator Resveratrol is 
neuroprotective in rotenone treated neuronal cells in-vitro (Feng et al. 2015, Wang et al. 
2018, Park et al. 2016). Ketone bodies such as β-hydroxybutyrate produced from 
compensatory metabolic mechanisms due to deficient respiratory chain ATP generation 
have also been shown to affect HDAC activity levels (Sankha et a. 2014, Imamura et al. 
2006). However, these observations on global histone acetylation levels have not been 
consistent between models (Sokhna et al. 2019). For example, several studies have 
reported a protective effect of HDAC inhibitors from rotenone that rescues neurons from 
α-Syn related toxicity (Labbe et al. 2016, Sokhna et al. 2019, Zhang et al. 2016, Singh et 
al. 2017, Outeiro et al. 2007). Regardless the direction, it seems a delicate balance 




DNA methylation is correlated with chronic chemical exposure and 
neurodegeneration (Collota et al. 2013, Kwok et al. 2010). Mitochondrial dysfunction from 
chronic chemical exposure has long term effects on nuclear DNA methylation levels and 
complex I inhibition is associated with altered DNA methylation (5-mC) and DNA 
hydroxymethylation (5hmC) in-vitro (Bellizzi et al. 2012, Scola et al. 2014). Furthermore, 
DNA hypomethylation from pesticide exposure has been reported in human peripheral 
blood leukocytes which correlates with the DNA methylation patterns observed in PD 
patients (Kim et al. 2010, Hou et al. 2011).  While fewer studies have examined the 
methylome in result of rotenone exposure, there is evidence to suggest that DNA 
methylation inhibition exacerbates PD pathology and α-Syn toxicity in dopaminergic 
neurons exposed to rotenone (Wang et al. 2013).  
There are epigenetic processes that regulate gene expression on the transcript 
level. Small, non-coding RNAs known as microRNAS (miRNA) bind complementary 
sequences on messenger RNAs to prevent translation. miRNAs are critical for PD 
associated gene expression and are required to maintain neurons during aging (Labbe et 
al. 2016). Though the post-trascriptional regulation of gene expression is important to 
understand gene-environment interactions in neurotoxicity, it will not be the focus of this 
dissertation. Instead, this dissertation will focus on gene regulation that occurs at the 
chromatin level by studying DNA methylation and histone modifications.  
1.3 Overview of Specific Aims 
 The goal of this dissertation is to investigate chromatin-mediated gene regulation 
in rotenone induced neurotoxicity. Rotenone pathways of toxicity with respect to PD 
pathogenesis have been of significant interest in the scientific community for the past two 
decades and thus this dissertation will focus primarily on mechanisms of chromatin 
regulation in PD. However, it should be noted that these mechanisms are not considered 
16 
 
dopaminergic neuron specific and may have implications for other neuronal subtypes 
including peripheral neurons.  
 DNA 5-methylcytosine methylation and histone tail lysine acetylation are two 
examples of chromatin-mediated gene regulation. Because these epigenetic patterns are 
influenced by both genetic variability and environmental exposure, epigenetic 
mechanisms can bridge the gap to understanding gene-environment interactions in 
rotenone induced neurotoxicity. I hypothesizethat rotenone induced α-Syn accumulation 
and mitochondrial damage creates large disturbances in gene expression profiles that 
orchestrate cellular pathways of toxicity and cues cell-mediated apoptosis. To address this 
hypothesis, I propose the following three specific aims:  
1. To determine changes in chromatin-mediated gene regulation in human cells exposed 
to rotenone. 
 
2. To investigate the role of oxidative stress induced α-Synuclein accumulation in 
mediating epigenetic response to Rotenone. 
 
3. To investigate the role of mitochondrial damage on histone acetylation and chromatin 
accessibility in Rotenone-Induced cellular models of Parkinson’s disease. 
 
1.4 Innovation and Impact 
Multiple studies have been published using environmental exposures to observe 
pathological events within a cell. Furthermore, with advancements in the accessibility of 
high content technologies, the number of studies characterizing the transcriptome of 
exposed neurons via RNA-sequencing have increased. These “omics” studies have 
identified several molecular pathways, proteins, and genes as important players in 
neurodegeneration and PD. It is widely accepted that epigenetic mechanisms including 
DNA methylation and histone modifications are critical in mediating gene-environment 
interactions in PD, which is particularly critical in considering the interactions for 90-95% 
of PD cases. However, few studies have investigated the role of these mechanisms in 
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toxicant induced models of PD. Additionally, almost no studies to date aim to understand 
the mechanisms for how changes in these epigenetic patterns occur as a result of 
exposure. We take an innovative approach to studying gene-environment interactions by 
using a relevant exogenous exposure to investigate epigenetic mechanisms in neurons. 
In this dissertation, we use three separate human cell lines (HEK293, SH-5YSY, and 
LUHMES) which are commonly used to model neurobiology in-vitro. Each cell line adds a 
new layer of complexity with HEK293 being the simplest model. HEK293 is a human 
immortalized cell line derived originally from primary embryonic kidney cells but have been 
found to have a genetic signature similar to neurons (Stepanenko and Dmitrenko 2015). 
The SH-5YSY cell line is also an immortalized cell but neuronal in origin. The cells were 
derived from a metastatic neuroblastoma and display a catecholaminergic phenotype with 
the ability to synthesize dopamine (Xicoy et al. 2017). Lastly, the LUHMES cell line 
represents the most specific model for rotenone induced PD as it originates from non-
cancerous embryonic mesencephalic (midbrain) tissue and differentiates into fully mature 
differentiated dopaminergic neurons (Smirnova et al. 2016). While rotenone has toxic 
effects in multiple cell types, dopaminergic neurons are especially vulnerable to rotenone 
induced oxidative stress (Harris et al. 2018). Furthermore, degeneration of dopaminergic 
neurons is a primary feature of PD and it’s the loss of dopamine in the midbrain that causes 
motor deficits. We tested our proposed mechanisms for rotenone changes at multiple 
stages of neuronal maturation to determine which epigenetic modifications may be more 
important during exposures at early stages of development and which are more 
meaningful during adult exposures. This thesis will take an in depth look at gene 
expression, DNA methylation, histone acetylation, transcription factor binding, and 
chromatin accessibility to interpret rotenone mechanisms of toxicity and its implications in 
neurodegeneration. It will also highlight vulnerable regions of the genome and link these 
regions to their effects in cellular processes. These data can provide mechanistic insights 
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into the role of the epigenome on the aging brain and can inform clinical strategies for the 
diagnosis and treatment of neurodegenerative disorders such as PD.  
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ROTENONE INDUCED CHANGES OF EPIGENETIC 





PART A. Rotenone regulates chromatin by modifying global levels of DNA 5-
methylcytosine and Histone 3 Lysine 27 acetylation.  
2A.1 Abstract 
Epigenetic modifications can vary individual behavior by influencing neuronal gene 
expression and neural activity. Pesticide exposure is associated with epigenetic 
modifications that can impair neurite outgrowth, obstruct axonal transport, and diminish 
synaptic plasticity. These adverse effects hinder the cellular stress response in neurons 
making them more vulnerable to environmental factors and degeneration. Pesticides 
reduce global DNA methylation and rotenone is expected to have a similar response. 
Pathological histone hyperacetylation and increased enhancer activation is also caused 
by rotenone neurotoxicity. Therefore, rotenone toxicity may result from widespread 
changes in gene expression caused from the opening of chromatin and the unregulated 
binding of DNA transcription factors. In Part A of this chapter, we measured the cellular 
response to rotenone treatment after 24h and analyzed changes in chromatin mediated 
gene regulation. Rotenone reduced DNA methylation and increased histone H3 lysine 27 
acetylation (H3K27ac) globally across the human cell line HEK293. These epigenetic 
modifications were associated with the altered expression of over 2,000 genes (>1.5 fold 
change, FDR<0.05) which were largely involved in the oxidative stress response, 
transcription factor DNA binding activity, and chromatin organization. We hypothesize that 
rotenone-induced global chromatin changes cause instability that targets vulnerable 









Rotenone is a pesticide commonly used as a Parkinson’s disease model toxicant 
and has been shown to robustly replicate the physiological and molecular features of 
human PD in animal models (Cannon et al. 2009). It is estimated that chronic exposure to 
concentrations of approximately 20-30 nM of rotenone is enough to cause degeneration 
of dopaminergic neurons in the midbrain (Greenamyre et al. 2003). While rotenone is a 
potent inhibitor of complex I in the electron transport chain of mitochondria, higher doses 
of rotenone (>30nM) have off target effects by binding alternative proteins (Greenamyre 
et al. 1996, Harris et al. 2018). Therefore, rotenone is toxic to neurons outside of its role 
as a complex I inhibitor (Choi et al. 2008, Cabeza-Arvelaiz and Schiestl 2012). For 
instance, rotenone can cause mitochondrial dysfunction indirectly through the production 
of ROS via activation of microglia (Shaikh and Nicholson 2009) and may also reduce 
mitochondrial membrane potential by blockading voltage dependent anion channels on 
the outer mitochondrial membrane (Cabeza-Arvelaiz and Schiestl 2012). Rotenone also 
induces chromatin mediated gene regulation which can vary the expression of genes 
involved in neural activity and ultimately lead to changes in behavior (Kanthasamy et al. 
2012). 
Mitochondrial damage by rotenone provides feedback to the nucleus via two 
primary routes. The first involves the activation of transcription factors which initiate the 
transcription of genes involved in compensatory mechanisms (Wang et al. 2018). The 
transcriptomic response to rotenone has been well characterized and transcription factors 
including ATF4, NEF2L2, and p53 are activated to regulate cell proliferation, the oxidative 
stress response, and intrinsic apoptosis (Smirnova et al. 2016, Harris et al. 2018, Cabeza-
Arvelaiz and Shiestl 2012, Huang and Lou et al. 2019). The second route for mitochondrial 
feedback to the nucleus is through metabolic flux. One example is the metabolite Acetyl-
CoA which is used in the Krebs cycle to generate energy-rich ATP. Acetyl-CoA is also the 
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substrate for histone acetyltransferase enzymes which acetylate lysine-rich histone tails 
to regulate the transcription of genes (Mews et al. 2017). Acetyl CoA is variable and 
optimal acetyl-CoA concentrations are required to maintain the expression of functional 
genes in neurons. 
As discussed in Chapter 1.2, DNA methylation and histone acetylation are 
epigenetic modifications implicated in both genetic and sporadic Parkinson’s disease as 
well as in rotenone induced neurotoxicity. DNA hypomethylation has been reported in 
response to pesticide exposure (Hou et al. 2012) but no information exists on the effect of 
rotenone on global DNA methylation and chromosome stability. More information is known 
about histone acetylation patterns which are tightly coupled to gene expression and 
enhancer activation (Wang et al. 2008). Most studies agree that rotenone induced 
neurodegeneration is associated with pathological hyperacetylation as a result of impaired 
homeostatic activity of HATs and HDACs. (Song et al. 2010, Feng et al. 2015, Harrison et 
al. 2018, Huang and Lou et al. 2019, Park et al. 2016). This part of chapter 2 examines 
the effect of rotenone on cellular viability, metabolic capacity, and intracellular ROS after 
24h exposure in human cell line HEK293. It explores the enrichment of gene ontologies 
and pathways involved in rotenone exposure and it analyzes the effects of rotenone 
treatment on global levels of DNA 5-methylcytosine (5mC) and histone lysine 27 
acetylation (H3K27ac). While it has been shown that rotenone induced neurotoxicity is 
associated with changes in the epigenome, there is little information on what regions of 
the genome are susceptible to rotenone exposure and the effect of differential expression 
of these regions on pathogenesis. Part B of this chapter will cover the effects of rotenone 





2A.3 Materials and Methods  
2A.3.1 Cell culture and treatment of human cell line HEK293 
All media reagents and chemicals in cell culture were purchased from Sigma (St. 
Louis, MO). Human cell line HEK293 was grown in Dulbecco’s Modified Eagle Medium 
with high glucose, L-glutamine, and sodium pyruvate. Media was supplemented with 10% 
(v/v) heat inactivated fetal bovine serum and 1% (v/v) Penicillin-Streptomycin. HEK293 
cells were confirmed by ATCC. Cells were treated at approximately 70% confluency with 
rotenone or DMSO vehicle control (<0.001%) for 24 hours. Cell viability was measured 
with trypan blue (0.4%) staining and cells were counted manually with a hematocytometer. 
Mitochondrial viability was estimated with the Presto Blue viability reagent (ThermoFisher, 
Waltham, MA). The reagent was added at 10% (v/v) and incubated for 1h at 37°C before 
measuring fluorescence (excitation 530 nm/ emission 590 nm). Intracellular reactive 
oxygen species (ROS) were measured with the DCFDA intracellular ROS assay according 
to kit instructions (Abcam, Cambridge, UK). Statistical hypothesis testing was done with a 
one-way ANOVA and post-hoc pairwise t-test calculation with p-value correction using the 
false discovery rate (FDR) adjustment method. 
2A.3.2 RNA extraction and RNA sequencing library construction 
Total RNA was extracted from two replicates of DMSO or rotenone treated 
HEK293 using the trizol method (Invitrogen, Carlsbad, CA). A total of 2ug per sample was 
used for library construction using the TruSeq Sample Preparation kit from Ilumina (San 
Diego, CA). Poly-A containing mRNA molecules were isolated from total RNA using oligo-
dT attached magnetic beads. Isolated mRNA was then fragmented and synthesized into 
double stranded cDNA according to kit instructions. Ligation of unique Ilumina adapter 
indices was completed for each sample before bead purification. Libraries were loaded 
onto a 2% agarose gel and library products between 200-800 bp were purified using the 
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mini-Elute gel extraction kit from Qiagen (Hilden, Germany). Approximately 150 ng was 
sent for sequencing on a HiSeq 2000 platform with 100 bp paired-end reads.  
2A.3.3 RNA sequencing data analysis 
Adapter sequences were removed from the raw sequencing data and individual 
libraries were converted to the fastq format. Sequencing reads were aligned to the human 
genome (hg19) with TopHat2 (v2.0.9) (Kim et al. 2013). For mRNA analyses, the RefSeq 
database (Build 37.3) was chosen as the annotation references. Read counts of annotated 
genes were obtained by the Python software HTSeq-count (Anders et al. 2015). The read 
counts of each transcript were normalized to the length of the individual transcript and to 
the total mapped fragment counts in each sample and expressed as fragments per 
kilobase of exon per million fragments mapped (FPKM) of mRNAs in each sample. 
Differentially expressed genes were defined as those with a 1.5 fold change in expression 
using a FDR<0.05 from the edgeR package (Robinson et al. 2010). Gene Ontology 
annotation was done with Gorilla online platform and visualized with Revigo and 
Cytoscape (Eden et al. 2009; Supek et al. 2011; Otasek et al. 2019). Biological pathway 
enrichment was done with reactome (Fabregat et al. 2018). The top 5 pathways were 
reported though their enrichment was not significant after p-value correction with the false 
discovery rate method. Lastly, we used the Ingenuity Pathway Analysis tool (Qiagen, 
Hilden, Germany) for further pathway and functional annotation. 
(https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis)  
2A.3.4 Global DNA methylation analysis  
 Genomic DNA was extracted from two replicates of DMSO or rotenone treated 
HEK293 using Phenol: Chloroform: Isoamyl alcohol (1:1 ratio) (Sigma, St. Louis, MO). 
Global DNA methylation was first measured by dot blot analysis. Bisulfite treated DNA 
(30-60 ng/uL) was denatured at 95°C for 5 minutes and then cooled at 4°C for 5 minutes 
in a conventional thermocycler (Mycycler; Bio-Rad; Herclues, CA). DNA was spotted onto 
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0.45 micron nitrocellulose paper as 1 or 2 µL drops and dried for 30 minutes at room 
temperature. The membrane was UV crosslinked at 3000 Hz and incubated in anti-5mC 
primary antibody overnight at 4°C (Epigenetek 33D3; Farmingdale, NY). The membrane 
was washed with TBST and incubated with secondary antibody conjugated to HRP for 1 
hour at room temperature (Santa-Cruz Biotechnology anti-mouse IgG sc-2005; Dallas, 
TX). The membrane was washed again with TBST after secondary incubation and 
visualized with chemiluminescence (ProSignal Femto; Promethus; Raleigh, NC).   
2A.3.5 Western Blot for global H3K27ac 
HEK293 cells were collected after 24 hours treatment and histones were extracted 
using the Abcam Histone Extraction kit according to kit instructions (Cambridge, UK). 
Histone protein concentration was measured by Qubit Protein Assay from ThermoFisher 
(Waltham, MA). Protein (5 ug) was loaded onto 4-15% Bio-Rad Page Gels and transferred 
to 0.45 um nitrocellulose (Bio-Rad, Hercules, CA). The blots were incubated with H3K27ac 
primary antibody (1:1000; Abcam ab4729) overnight at 4°C and anti-rabbit IgG conjugated 
secondary antibody (1:5000, Santa Cruz Biotechnology Sc-2357) for 1h at room 
temperature. The histone protein was normalized to total histone 3 (H3; Abcam ab1791) 
and quantified with Image J software. We tested significance by comparing the ratio of 
H3K27ac/H3 with a two-tailed Student’s paired t-test.  
2A.4 Results  
2A.4.1 Rotenone exposure in human cells 
We tested three doses of rotenone (100-300 nM) for 24h and measured cell 
viability with two independent assays. The trypan blue exclusion assay measures plasma 
membrane integrity and there was no change in the penetrance of trypan blue between 
control and treatments (Figure 2.1). The Presto Blue viability assay measures cellular 
capacity to reduce resazurin to resorufin. This measurement was used as a proxy for 
mitochondrial status and we observed a decrease in reductive capacity in all treatment 
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groups compared to the control but only 200-300 nM was significant compared to the 
vehicle DMSO control (Figure 2.1). Finally, we measured the production of intracellular 
reactive oxygen species, a hallmark of complex I inhibition and a common cellular 
phenotype in neuronal cell death. Rotenone treatment significantly increased intracellular 
oxygen species only in the rotenone 200 nM group after 24h treatment (Figure 2.1). We 
used rotenone 200 nM for 24h for the rest of experiments based on these molecular 
responses.  
2A.4.2 Rotenone changes in gene expression 
 We used RNA-seq analyses to identify over 2000 differentially expressed genes 
(DEGs) in response to rotenone (Figure 2.2). To gain insights of impacted biological 
processes, we performed gene ontology enrichment analysis on 1853 of these DEGs with 
known HUGO (hgnc) symbol and cell description using a p-value threshold of p<10-3 
(Supplemental File 1). Among enriched biological processes, we observed a significant 
induction of the oxidative stress response, transcription factor activity, and chromatin 
organization (<10-3) (Figure 2.3). We observed a significant enrichment of genes involved 
in nucleic acid binding (<10-7) and DNA binding (<10-5) with the nuclear cell component 
being most represented (<10-5) (Figure 2.3). We analyzed pathway enrichment of the top 
200 genes with the largest change in expression using reactome pathways (Fabregat et 
al. 2018) (Table 2.1). Three of the top 5 pathways enriched in our data were major 
transcription factor pathways including SMAD, NOTCH, and TP53 which have implications 
in Parkinson’s disease reviewed in the discussion section. The Ingenuity Pathway analysis 
revealed the unfolded protein response and histone deacetylase Sirtuin signaling were 
additional canonical pathways affected by rotenone exposure (Table 2.2).   
2A.4.2 Rotenone changes in global epigenetic patterns 
We used dot blot method to qualitatively assess changes in DNA methylation 
levels in cells exposed to rotenone. The total 5mC level was detected with anti-5mC 
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antibody and visualized using chemiluminescence. After 24h, 5mC levels were strikingly 
reduced in genomic DNA (Figure 2.4). Next, we asked the extent to which rotenone 
exposure impacted histone acetylation. To investigate histone acetylation at active 
enhancers with PD-relevant SNPs, we selected H3K27ac mark (Wang et al. 2008) and 
examined H3K27ac levels from extracted histones using Western blot. We measured a 
significant 1.3-fold increase in H3K27ac in rotenone-treated cells compared to the DMSO 
vehicle control (p<0.05) (Figure 2.4).  
2A.5 Discussion 
We selected rotenone based on its ability to model gene-environment interactions 
in rodents and non-mammalian models of PD (Cannon and Greenamyre 2013; Johnson 
and Bobrovskaya 2015). We observed reduced mitochondrial viability and increased ROS 
after rotenone (200 nM) treatment for 24h. Our lowest dose of rotenone (100nM) for 24 
hours reduced mitochondrial viability but did not change levels of ROS (Figure 2.1). 
Interestingly, we observed the same trend for our highest dose of rotenone (Figure 2.1). 
We surmise that increased ROS was not observed in the highest dose because of the 
rapid reduction of oxidative metabolites from the induction and recruitment of antioxidant 
enzymes following a large dose.  
Intriguingly, rotenone has been shown to cause neurodegeneration by 
mechanisms unrelated to its effect on complex I (Sherer et al. 2007; Choi et al. 2008). The 
transcriptome and its regulation have become a focus for understanding these 
mechanisms outside of the electron transport chain (Cabeza-Arvelaiz and Shiestl 2012). 
We observed large scale changes in gene expression profiles and many of these genes 
were enriched in processes involved in gene regulation and chromatin organization 
(Figure 2.3). The pathway analysis of differentially expressed genes also revealed a large 
involvement in major intracellular transcription factor pathways (Table 2.1). For instance, 
SMAD proteins are critical for transducing signals from the transforming growth factor 
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(TGFβ) receptors at the plasma membrane which are essential for midbrain dopaminergic 
survival (Hegarty et al. 2014). Notch signaling is known have an important role in 
regulating genes involved in nervous system development and synaptic plasticity (Ables 
et al. 2011). Lastly, the TP53 pathway is perhaps the most well-known of the toxicant 
induced signaling mechanisms to control cell cycle progression and cellular survival. It is 
thus a critical regulator of programmed cell death in Parkinson’s disease and rotenone 
induced neurotoxicity (Venderova and Park 2012).  
Several studies have investigated transcriptomic changes in mammalian cells 
following rotenone treatment and reported changes in DNA damage repair and cell cycle 
progression (Cabeza-Arvelaiz and Shiestl 2012, Smirnova et al. 2016, Harris et al. 2018, 
Huang and Lou et al. 2019). One study focused on rotenone induced changes in the 
expression of genes involved in microtubule dynamics (Cabeza-Arvelaiz and Shiestl 
2012). Microtubules play a critical role in several neuronal processes including 
myelination, axonal transport, and neurite outgrowth. Rotenone has been shown to impair 
neurite outgrowth in dopaminergic neurons (Harris et al. 2018). Furthermore, rotenone 
inhibited axonal transport in an α-Synuclein (α-Syn) mutant induced pluripotent stem cell 
(iPSC) model of Parkinson’s disease by indirectly nitrating microtubules through increased 
nitrosative stress (Stykel et al. 2018). Our data show increases in the gene (TPPP) 
encoding tubulin-polymerizing promoting protein which under homeostatic conditions 
promotes myelination and the insulation of axons (Olah and Ovadi et al. 2019). However, 
unregulated TPPP can stimulate protein-protein interactions and has been associated with 
α-Synuclein formation of Lewy body inclusions.  
Protein aggregation resulting from the accumulation of disordered proteins initiates 
the endoplasmic reticulum mediated unfolded protein response. Our Ingenuity Pathway 
(IPA) analysis identified this response as our top canonical pathway (Table 2.2). We 
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observed a significant increase in its transcription factor ATF3 and its target genes. The 
cyclic AMP response element-binding (CREB) family transcription factors ATF3 and ATF4 
can be activated by both endoplasmic reticulum and mitochondrial stress. Their role in the 
stress response to rotenone and other mitochondrial complex I inhibitors has been well 
established (Krug et al. 2014, Smirnova et al. 2016, Harris et al. 2018). However, the role 
of CREB transcription factors and their recruitment of the p300/CBP histone 
acetyltransferase complex has yet to be fully explored in rotenone induced models of PD. 
Interestingly, our second top canonical pathway identified by IPA was the Sirtuin signaling 
pathway (Table 2.2). Sirtuins act as mitochondrial sensors and respond to mitochondrial 
stress by deacetylating lysine residues on DNA histone tails. This data supports an 
important role of the ATF stress response in maintaining the balance in histone 
acetyltransferase and deacetylase activity in neurons. 
Lastly, we compared our gene expression data to data generated in a 
complementary model of mitochondrial dysfunction. The rat dopaminergic neural cell line 
N27 was used to generate a knockout of the mitochondrial transcription factor A protein 
(TFAM) (Huang et al. 2019). TFAM regulates mitochondrial biogenesis and has been 
shown to closely mimic rotenone effects on chromatin in-vitro. In the N27 rotenone and 
the N27 TFAM knockout model, the NF-kβ inflammatory pathway was significantly down-
regulated (Huang et al. 2019). We also observed a significant decrease (-0.8 LFC, 
FDR<0.05) in the NF-kβ encoding gene (NFKB1) as well as a significant increase (0.7 
LFC, FDR<0.05) in its inhibitor protein (NFKBIB). NF-kβ has an interesting role in 
mediating the crosstalk between histone lysine acetylation and methylation which 
determines the expression of inflammatory genes (Karin et al. 2002). The effect of NF-kβ 
inhibition in rotenone treated cells on global histone patterns may also play a role in the 
accessibility of transcription factor binding sites in non-inflammatory pathways.  
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To determine if the gene expression changes discussed above were due to 
changes in global levels of epigenetic patterns, we performed a dot blot and Western blot 
to examine global levels of 5mC and H3K27ac (Figure 2.4). DNA methylation is the best 
studied epigenetic modification and small changes in methylation at regulatory regions of 
the genome can have substantial effects on genome integrity during aging. As seen with 
other pesticide models, we observed a global decrease in DNA methylation in response 
to rotenone. We also chose to look at global H3K27ac levels because it is tightly correlated 
with gene expression and vulnerable to environmentally driven enhancer activation (Wang 
et al. 2008). We observed a significant increase in H3K27ac across the genome. H3K27ac 
is not only an important mark to distinguish poised from active enhancers in bivalent 
chromatin, but it is also a critical epigenetic modulator in post-mitotic cells including 
dopaminergic neurons (Maze et al. 2015).  
 In summary, rotenone is a complex I inhibitor that impairs the mitochondrial 
electron transport chain resulting in increases in oxidative stress. However, the effect of 
rotenone on mitochondria, oxidative species, and cellular viability is not limited to its affinity 
to complex I. We hypothesize that rotenone induced mitochondrial dysfunction causes 
large-scale changes to gene expression profiles. These changes in expression are 
mediated by the opening of chromatin structure through reduced DNA methylation and 
increased activation of enhancers via H3K27ac. The perturbance of global chromatin 
structure causes a loss of genomic integrity and results in the orchestration of multiple 
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2A.7 Tables  
Table 2.1 Top pathway enrichment from Reactome pathways 
 
 














Figure 2.1 Cellular phenotype of HEK293 cells treated with rotenone (100, 200, 300 
nM) for 24h. 
A) Cell viability measured with the trypan blue exclusion assay expressed as percent 
viability relative to the control. DMSO is the vehicle control. B) Metabolic viability measured 
by the reductive capacity of mitochondria and expressed as percent viability relative to the 
control. DMSO is the vehicle control. C) Intracellular ROS was measured with DCFDA 
fluorescence assay and expressed as the fold change in fluorescence relative to the 
control. DMSO is the vehicle control and TBHP (250/500 uM) is the positive control. 
Significance testing was done with ANOVA. *p<0.05 compared to non-treated control. 





Figure 2.2 Volcano plot of differentially expressed genes in HEK293 exposed to 
rotenone. 
The volcano plot displays differentially expressed genes (>1.5 fold change; FDR<0.05) in 
HEK293 cells exposed to rotenone (200nM, 24h). The x-axis represents the change in 
expression (log2 fold change) and the y-axis represents the significance of that fold 
change by p-value adjusted by the false discovery rate method. 1853 genes were 
differentially expressed and used for downstream analysis with 1039 genes down-




Figure 2.3 Gene Ontology enrichment analysis of RNA-sequencing data. 
A) Gene Ontology molecular function enriched in our differentially expressed genes from 
rotenone treated HEK293 cells. B) Gene Ontology cellular component enriched. Color 
gradient indicate enrichment p-value: white <10-3; yellow 10-3-10-5; light orange 10-5-10-7). 
C) Network analysis of significantly enriched biological processes. Blue boxes enrichment 




Figure 2.4 Global epigenetic patterns in rotenone treated HEK293 cells. 
A) Global DNA methylation was visualized by dot blot method using anti-5mC antibody. 
Three biological replicates are shown in this image. B) Global histone H3K27ac levels 
were measured from total extracted histones using Western blot. Total histone H3 was 
used as the loading control. Three biological replicates are shown in this image. This 
Western blot was quantified using Image J software and is shown as the fold change in 
the amount of H3K27ac relative to the vehicle (DMSO) control. * p<0.05 using a paired 




PART B. Epigenetic vulnerability of insulator CTCF motifs at Parkinson’s disease-
associated genes in response to environmental rotenone. 
2B.1 Abstract 
CCCTC-binding factor (CTCF) is a regulatory protein that binds DNA to control spatial 
organization and transcription. The sequence-specific binding of CTCF is variable and is 
impacted by nearby epigenetic patterns. It has been demonstrated that non-coding genetic 
variants cluster with CTCF sites in topological associating domains and thus can affect 
CTCF activity on gene expression. Therefore, environmental factors that alter epigenetic 
patterns at CTCF binding sites may dictate the interaction of non-coding genetic variants 
with regulatory proteins. To test this mechanism, we treated human cell line HEK293 with 
rotenone for 24h and characterized its effect on global epigenetic patterns specifically at 
regulatory regions of Parkinson’s disease (PD) risk loci. We used RNA sequencing to 
examine changes in global transcription and identified over 2,000 differentially expressed 
genes (DEGs, >1.5-fold change, FDR<0.05). Among these DEGs, 14 were identified as 
PD-associated genes according to GWAS meta-data. We focused on eight genes that 
have non-coding risk variants and a prominent CTCF binding site. We analyzed 
methylation of a total of 165 CGs surrounding CTCF binding sites and detected differential 
methylation (|>1%|, q<0.05) in 45 CGs at 7 PD-associated genes. Of these 45 CGs, 47% 
were hypomethylated and 53% were hypermethylated. Interestingly, 5 out of the 7 genes 
had correlated gene upregulation with CG hypermethylation at CTCF and gene 
downregulation with CG hypomethylation at CTCF. We also investigated active H3K27ac 
surrounding the same CTCF binding sites within these 7 genes. We observed a significant 
increase in H3K27ac in 4 genes (FDR<0.05). Three genes (PARK2, GPRIN3, FER) 
showed increased CTCF binding in response to rotenone. Our data indicate that rotenone 
 
2 This chapter has been submitted for publication in Frontiers in Genetics. D.M. Freeman and Z. Wang (2020). 
45 
 
alters regulatory regions of PD-associated genes through changes in epigenetic patterns 
and these changes impact high order chromatin organization to increase the influence of 
noncoding variants on genome integrity and cellular survival. 
2B.2 Introduction 
 Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
in the United States (de Lau and Breteler 2006). More than 800 genetic association studies 
have been conducted to interpret genetic contribution to PD etiology (Coetzee et al. 2016; 
Lill et al 2012). Genome Wide Association Studies (GWAS) evaluate the association of 
common genetic variants to a phenotype or disease outcome. Since 2005, thousands of 
variants have been identified to have a significant association with a disease and more 
than 1,600 single nucleotide polymorphisms (SNPs) have been identified as genetic risk 
variants for PD (Lill et al. 2012). However, unlike rare monogenetic associations, the 
functional consequence of most of these variants have yet to be determined. Over 90% of 
all indexed SNPs including those associated with PD occur in non-coding regions of the 
genome (Maurano et al. 2012, Verstraeten et al. 2015). This discovery led to the 
hypothesis that SNPs in the human genome interact with regulatory elements to control 
gene expression (Wang et al. 2019). This is supported by expression of quantitative trait 
loci (eQTLs) defined as genetic regions that are enriched at positive GWAS sites and 
explain variability in the expressivity of a gene (Nica et al. 2010).  Despite these advances, 
it remains a challenge to determine which genetic variants in a broad region of variants is 
the driver of gene expression changes particularly when regulatory element interactions 
are long range (Do et al. 2016). SNPs cluster within enhancers and can modify PD risk. 
These observations of PD-associated SNPs have been described in multiple cell types 
(Coetzee et al. 2016). With this new evidence, studies are now focusing on interactions of 
regulatory elements to understand how genetic associations trigger disease biology within 
the brain.  
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CTCF can play a long-range cis-regulatory role that insulates genes from their 
surrounding signaling environment by directing chromatin looping (Phillips and Corces 
2009). Functional CTCF binding sites are required for the formation of distinct structural 
domains within three-dimensional chromosomal organization (Ong and Corces 2014; 
Tang et al. 2015). CTCF binding is dependent upon DNA sequence 
(CCGCGNGGNGGCAG) and allelic hypomethylation (Wang et al. 2012). Thus, genetic 
variants and epigenetic patterns within binding sites can contribute to dysfunctional CTCF 
allele-specific binding (Tang et al. 2015; Wang et al. 2019).  
Approximately 85% of PD cases cannot be explained by genetic predisposition alone 
(Verstraeten et al. 2015; Labbé et al. 2016; Franco et al. 2010). Therefore, it is likely that 
most cases are caused by the interplay of common SNPs with environmental factors. 
Environmental factors can modulate the association of a genetic variant with a disease 
(Lee et al. 2011). For instance, exposures that impact allele-specific methylated regions 
in the genome can influence CTCF binding and thus influences non-coding variants effect 
on genetic expression (Wang et al. 2019) (Figure 2.5). GWAS association signals are 
complex in that they can cover a broad region of DNA with several polymorphisms, so we 
focused on environmentally induced epigenetic changes in CTCF binding regions nearby 
risk associated genes to explore mechanisms of gene-environment interactions in PD. 
In our pesticide-induced cellular model, we used rotenone, a naturally occurring 
insecticide and potent inhibitor of complex I in the mitochondrial electron transport chain. 
Rotenone is a widely accepted PD toxicant and can robustly replicate pathology via 
depletion of ATP, generation of reactive oxygen species, damage of nigrostriatal tissues, 
and death of dopamine producing cells in the midbrain (Cicchetti et al. 2009; Dawson et 
al. 2002). It has also been shown to cause these types of cellular pathology in HEK293 
(Orth et al. 2003; Teixeira et al. 2018). DNA methylation and histone acetylation are 
epigenetic modifications implicated in rotenone induced neurotoxicity (Huang et al. 2019). 
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DNA hypomethylation has been reported in response to pesticide exposure (Hou et al. 
2012) and we discovered that rotenone reduces DNA methylation at DNMT1-dependent 
regions in the human genome (Freeman et al. 2020). Histone acetylation patterns have 
been more extensively studied in rotenone-induced PD due to its high correlation with 
gene expression and enhancer activation (Wang et al. 2008). Most studies agree that 
rotenone-induced neurodegeneration is associated with pathological hyperacetylation as 
a result of impaired homeostatic activity of HATs and HDACs (Feng et al. 2015, Harrison 
et al. 2018, Wang et al. 2018, Park et al. 2016, Huang and Lou 2019). 
In this study, we examined rotenone-induced changes in DNA methylation and histone 
acetylation patterns at CTCF binding sites adjacent to PD-associated genes. Eight 
selected genes all had identified disease risk SNPs in a non-coding region and were 
indexed by a meta-data analysis of over seven million human polymorphisms (Lill et al. 
2012). We hypothesize that rotenone exposure modifies epigenetic patterns at CTCF 
binding motifs and affects its allele-specific transcription factor binding. We postulate that 
this mechanism could mediate the interchange between genetic variants and regulatory 
elements controlling transcription and genomic stability.  
2B.3 Materials and Methods 
2B.3.1 Cell culture and treatment of human cell line HEK293 
 HEK293 cells were treated with rotenone (200 nM) for 24h according to the 
protocol in Chapter 2A.3.1. 
2B.3.2 RNA sequencing library construction and analysis 
The RNA sequencing data used for this subchapter was the same data reported 
in Chapter 2A.3.2-2A.3.3.  
2B.3.3 RNA sequencing validation with quantitative reverse transcription-PCR  
 RNA was converted to cDNA with the PrimeScript RT reagent kit according to kit 
instructions outline in Chapter 2B.3.6. We selected ten genes for quantitative PCR (qRT-
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PCR) analysis using primers listed in Table 2.3. The change in expression was normalized 
to the GAPDH housekeeping gene and expressed as fold change (2-ΔΔCT).  
2B.3.4 Identification and selection of Parkinson’s disease associated genes 
We identified Parkinson’s disease-associated genes using the National Health 
Genomic Research Institute GWAS Catalog (Buniello et al. 2019). We searched for all 
associations both reported and mapped using the trait “Parkinson’s disease” 
(EFO_0002508) which included 39 publications investigating genomic signatures of both 
familial and environmentally driven Parkinson’s disease as well as Lewy body pathology 
and Parkinsonism in frontotemporal lobe dementia. We calculated the frequency for 
various region types (non-coding, regulatory, coding) within the 246 known genetic 
variants provided by GWAS Catalog (Figure 2.5). We compared 399 reported and mapped 
genes to our list of differentially expressed genes. We then cross referenced these genes 
with the PD gene online resource which analyzed over 800 publications and seven million 
polymorphisms (Lill et al. 2012). We selected 5 genes that remained significant in the PD 
gene meta-analysis, were represented in at least 2 studies, and had their most significant 
variant in a non-coding region (Table 2.4). We also selected three additional genes from 
the PD gene database that were represented in our RNA sequencing data (Table 2.4). 
The first, UBOX5, was among the most significant polymorphisms identified by the meta-
analysis (Lill et al. 2012; Nalls et al. 2014). The other two, PARK2 and CHCHD2, have 
significant polymorphisms according to the PD gene database but are also reported to 
have autosomal mutations that contribute to familial disease cases (Lill, C. 2016).  
2B.3.5 Region selection for bisulfite and ChIP primer design 
CTCF transcription factor binding was observed using the Uniform Transcription 
Factor Binding data found in the ENCODE Regulation super track in UCSC Genome 
Browser. We selected all CTCF transcription factor binding sites detected with ChIP-Seq 
experiments from the ENCODE consortium from 2007-2012 (ENCODE 2012). We also 
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predicted which cytosine would overlap the binding motif using the CTCF binding 
prediction tool database v2.0 (Ziebarth and Bhattacharya 2013). Primer design was 
focused on CTCF binding sites for both Bisulfite sequencing and ChIP-PCR experiments 
(further described below).  
2B.3.6 Bisulfite-DNA conversion and Bisulfite-amplicon sequencing library construction 
 Genomic DNA was extracted from two replicates of DMSO or rotenone treated 
HEK293 using Phenol: Chloroform: Isoamyl alcohol (Sigma, St. Louis, MO). A total of 200 
ng DNA was Bisulfite-converted using the Sigma DNA Imprint Modification kit two-step 
protocol. Bisulfite-converted DNA (BS-DNA) was amplified with primers for selected 
regions designed with MethPrimer (Li and Dahiya 2002) (Table 2.5). Amplified BS-DNA 
products were run on a 2% EtBr agarose gel and purified using the mini-Elute gel 
extraction kit from Qiagen (Hilden, Germany). Purified products for each sample were 
pooled together and 1 ng was used for library preparation using the Ilumina Nextera DNA 
Library Preparation kit. Each sample was tagged with a unique Nextera XT adapter (San 
Diego, CA). Sequencing libraries were quality checked via Bioanalyzer and run on an 
Ilumina MiSeq platform to generate 150 bp paired end reads.  
2B.3.7 Bisulfite-amplicon sequencing analysis 
The raw fastq files were imported into the Galaxy web platform (Afgan 2016). 
Reads with quality score >30 were trimmed with Trim Galore (Krueger 2015). Reads were 
mapped to amplified sequences in the human genome (hg19) using bwa-meth (Pederson 
et al. 2014). MethylDackel was used for methylation calling and per-cytosine contexts 
were merged into per-CPG metrics (https://github.com/dpryan79/MethylDackel). 
Duplicates and singletons identified in alignment were ignored from the methylation call. 
Minimum and maximum per-base depths were 1000x and 100,000x, respectively. The 
output was selected for methylKit format. Coverage statistics and differentially methylated 
regions were calculated for CpG sites with methylKit installed in R (v3.5) (Akalin et al. 
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2012). Differentially methylated cytosines were defined as being present in both biological 
replicates, having a minimum absolute difference of 1% using the coverage weighted 
mean, and having a SLIM adjusted q-value<0.01 using the methylKit logistic regression 
model (Ning et al. 2011). The change in mean percent methylation (Δme) for all CpG sites 
within a defined region was calculated by taking the mean number of methylated versus 
non-methylated CpG sites from the pooled control and treated samples and using Fisher’s 
exact test FDR <0.05.  
2B.3.8 HEK293 Chromatin Immunoprecipitation 
All chemicals were purchased from Sigma unless otherwise noted (St. Louis, MO). 
HEK293 were harvested after 24 hours treatment and resuspended in fresh media at 
10x106 cells/ mL in a conical tube. Cells were fixed with 1% formaldehyde for 10 minutes 
at room temperature. Reaction was stopped with 0.2 M glycine and incubation at room 
temperature for 5 minutes. Fixed cells were centrifuged for 5 minutes at 300xg 4°C and 
washed with 1 mL cold PBS. Fixed cell pellet was stored at -80°C until chromatin 
immunoprecipitation (ChIP).  
Cell pellets were resuspended at approximately 1x106 cells/ 0.1 mL with PBS + 0.5 
% Triton-X + 1% protease inhibitor cocktail and incubated on ice for 10 minutes prior to 
centrifugation for 5 minutes at 400xg 4°C. The pellet was resuspended in TE buffer pH 
8.0 with protease inhibitor and PMSF. Cells were sonicated at high intensity for 30s on/ 
60s off until DNA fragments were within 200-800 bp as checked by 2% agarose gel. After 
sonication, samples were centrifuged for 15 minutes at 14,000xg 4°C to pellet insoluble 
material. Sheared chromatin was transferred to RIPA buffer and approximately 10% was 
saved for input DNA extraction.  
ChIP was done with Dynabeads Protein A (Invitrogen, Carlsbad, CA) and 4 ug of 
primary ChIP grade antibody (H3K27ac Abcam ab4729; CTCF Millipore 07-729; Rabbit 
IgG Santa Cruz Biotechnology sc-2025). Beads were washed with lithium chloride (LiCl 
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0.25M) buffer and immunoprecipitated DNA was extracted from beads using phenol: 
chloroform method. DNA was quantified using Qubit dsDNA high sensitivity assay 
(Thermo Fisher, Waltham, MA).  
2B.3.9 HEK293 ChIP PCR analysis 
We selected eight genes for quantitative real-time PCR (qRT-PCR) analysis using 
primers listed in Table 2.6. Primers were designed with NCBI Primer Blast at H3K27ac 
peaks surrounding the predicted CTCF binding site (Ye et al. 2012). All qRT-PCR 
reactions were performed on a 7500 Real-Time PCR system from Applied Biosystems 
(Foster City, CA) using the iTaq Universal SYBR Green Supermix from Bio-Rad (Hercules, 
CA). H3K27ac and CTCF enrichment was calculated from the Ct threshold value as a 
percent of the total input DNA. Rabbit IgG samples were used as a negative control. 
2B.4 Results 
2B.4.1 Alteration of PD-associated genes stands out upon rotenone exposure 
 The GWAS Catalog is a public database of approximately 72,000 variant-trait 
associations from over 3500 publications (Buniello et al. 2019). Out of 246 PD-associated 
variants with genetic sequence context information, 220 variants (89%) were in noncoding 
regions (intron, intergenic, regulatory, and exon) (Figure 2.5) Intronic variants constituted 
most of the known polymorphisms. We searched our DEGs for PD-associated genes and 
identified 14 genes from the GWAS Catalog (Appendix Table 1). Of these genes, 13 were 
also considered significant PD-associated genes according to meta-analysis data in 
PDgene (Lill et al. 2012). We validated the RNA sequencing results for 10 of these genes 
and were able to validate 8 of them with qPCR analysis (R2=0.96) (Figure 2.6). We 
selected five genes (ITGA8, GPRIN3, FER, CNKSR3, BMP4) and three additional genes 




2B.4.2 Selected genes contain prominent CTCF binding sites in their regulatory non-
coding regions 
 To examine any potential CTCF motifs within these selected genes, we visualized 
CTCF binding using experimental data from ENCODE and the CTCF binding prediction 
tool from the Cui Lab at the University of Tennessee (ENCODE 2012; Ziebarth and 
Bhattacharya 2013). Intriguingly, all selected genes had at least one prominent CTCF 
binding site in their regulatory non-coding region. We designed both bisulfite primers and 
ChIP primers at these sites using ENCODE regulation data from the Broad Institute 
(ENCODE 2012). The polymorphisms in these regions that were recognized by the SNP 
database (dbSNP; http://www.ncbi.nlm.nih.gov/SNP) were also analyzed with 
Regulomedb, a database that annotates SNPs with known or predicted interactions with 
regulatory elements in intergenic regions (Boyle et al. 2012). We determined SNPs within 
selected regions at 2 genes, GPRIN3 and FER, were present at CTCF binding sites and 
were active in the brain (Table 2.7). The rank of a single nucleotide polymorphism 
represents the number of available datasets for that polymorphism and the score is 
generated based on the integrated results from available datasets. In this analysis, the 
polymorphism listed at each gene were present in datasets from experimental 
transcription factor binding, matched transcription factor position-weight matrix (PWM), 
and DNase footprinting. We checked the HEK293 genome using the online database 
(http://hek293genome.org/v2/) and did not find either variant in our cells (Lin et al. 2014). 
This information provides additional evidence that CTCF binding sites among common 
non-coding variants may be critical in disease pathogenesis.  
2B.4.3 Rotenone alters DNA methylation patterns at CTCF binding sites in regulatory 
regions of PD-associated genes. 
Because CTCF binding is methylation sensitive and changes of CG methylation 
correlate to disease risks (Wang et al. 2018), we next examined a total of 284 CG 
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nucleotides from 8 regions surrounding our selected genes. Our amplicon-sequencing 
results demonstrated that 233 of these nucleotides met our minimum requirement of 
1000x coverage (Figure 2.7). From all CGs with >1000x coverage, 68 were differentially 
methylated across 7 of 8 genes (> l1%l, q<0.01). We focused our analysis on 165 CG 
sites that met minimum coverage requirements and overlapped predicted CTCF binding 
motifs at 7 of the selected genes. There were 45 differentially methylated CG sites and 
53% were hypermethylated (Table 2.8). Two of these CG sites, FER cg143 at 
chr5:102025097 and CHCHD2 cg217 at chr7:56174103, were significantly 
hypomethylated (FER cg143Δ=-4.4) and hypermethylated (CHCHD2 cg217Δ=1.7) at the 
predicted CTCF binding sequence (Figure 2.8). Two genes, PARK2 and UBOX5, were 
significantly hypomethylated (PARK2 Δ=-1.3) and hypermethylated (UBOX5Δ= 0.33) 
across the entire CTCF binding region with p<0.05 but did not remain significant after 
multiple hypothesis testing (FDR>0.05) (Figure 2.8). Collectively, we conclude that 




2B.4.4 Rotenone alters histone acetylation patterns at CTCF binding sites in regulatory 
regions of Parkinson’s disease associated genes. 
 Histone acetylation especially H3K27 acetylation is associated with regions of 
active chromatin and is critical in maintaining chromatin organization. We observed an 
increase in total H3K27ac levels in rotenone treated cells (1.3-fold change, p=0.02) 
(Chapter 2A Figure 2.4). We used ChIP-PCR to test whether local H3K27ac enrichment 
overlapped CTCF binding sites in PD associated genes. Four genes (GPRIN3, UBOX5, 
FER, BMP4) had significantly increased H3K27ac at CTCF binding motifs with FDR<0.05. 
One gene, CNKSR3, had reduced H3K27ac at its CTCF binding motif but was not 
statistically significant (p=0.07; FDR=1) (Figure 2.9). Interestingly, the H3K27 region 
amplified in qPCR overlapped at least one differentially methylated cytosine for all four 
significantly enhanced genes (Table 2.9). Only one of the genes without H3K27ac 
enrichment, CHCHD2, also had differentially methylated cytosines within the amplified 
region. These genes had both increased and decreased changes in percent methylation.  
2C.4.5 Rotenone increases CTCF binding at three PD-associated genes. 
 To determine whether altered DNA methylation and H3K27ac patterns would affect 
CTCF binding, we measured CTCF enrichment at its binding motif at 7 PD associated 
genetic loci. CTCF binding was increased at 3 genes (PARK2, GPRIN3, BMP4) (Figure 
2.10). BMP4 had one hypomethylated CG and increased H3K27ac within our selected 
region. There was an increase in CTCF binding and mRNA expression. PARK2 had two 
hypomethylated CGs but no increase in H3K27ac in its CTCF binding domain. In this 
region, CTCF binding increased and mRNA expression decreased. GPRIN3, unlike the 
other two genes, had more hypermethylated CGs within its CTCF binding motif but the 
closest CG to its consensus sequence was also hypomethylated. There was increased 
H3K27ac enrichment at GPRIN3 and increased CTCF binding. GPRIN3 mRNA was 





 Rotenone has been shown to cause neurodegeneration by mechanisms unrelated 
to its effect on complex I (Sherer et al. 2007; Choi et al. 2008). The transcriptome and its 
regulation have become a focus for understanding these mechanisms outside of the 
electron transport chain (Cabeza-Arvelaiz and Shiestl 2012). We observed large scale 
changes in gene expression profiles and many of these genes were enriched in processes 
involved in gene regulation and chromatin organization (Chapter 2A Figure 2.3). We 
searched the differentially expressed genes for non-coding risk variants associated with 
PD. We discovered 13 genes with significant association to PD using GWAS meta-data. 
We focused on eight genes (ITGA8, GPRIN3, FER, CNKSR3, BMP4, UBOX5, PARK2, 
and CHCHD2) that remained significantly associated in at least two studies with their most 
significant variant lying in a non-coding region (PDGene; Lill et al. 2014). UBOX5 was the 
most significantly associated variant according to GWAS meta-data. Furthermore, UBOX5 
was the only identified gene with its most significant non-coding variant having known 
interactions with regulatory elements such as CTCF (Regulomedb; Boyle et al. 2012). 
 UBOX5 is predicted to have a role in the ubiquitin proteasome system, a well-
known PD pathway involved in protein quality control and cellular detoxification (McNaught 
and Jenner 2001; McNaught et al. 2003). This pathway is involved in the function of 
multiple PD-associated genes most notably PARK2 which encodes a ubiquitin ligase. 
Mutations in PARK2 account for approximately 50% of familial early onset PD but the 
frequency of these mutations decrease with age (Bekris et al. 2010). These mutations 
generally occur at exon sequences but other less penetrant but significantly associated 
polymorphisms with higher frequency in the population occur more often at intronic or 
regulatory sequences of the gene. 
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 Each of the selected genes had a CTCF binding site determined by ENCODE and 
the CTCF prediction tool (ENCODE 2012; Ziebarth and Bhattacharya 2013). We used the 
online tool, Regulomedb, to investigate whether single nucleotide polymorphisms in these 
CTCF binding regions had evidence of an interaction with CTCF (Table 2.7). There was 
evidence of a CTCF interaction in the brain in 2 of the selected genes GPRIN3 and FER. 
This rank score generated by Regulomedb is indicative of the strength of the evidence for 
this interaction with 1 being the greatest. 
 CTCF binds regions with allele specific methylation and preferentially binds the 
unmethylated allele (Wang et al. 2018). The methylation status of these allele specific 
methylated regions is critical to functional CTCF binding and can explain as much as 41% 
of its variability (Wang et al. 2012). We have previously identified allele specific methylated 
regions in the human genome and verified their sensitivity to rotenone exposure (Martos 
et al. 2017; Freeman et al. 2020). Therefore, we hypothesized that CTCF binding sites at 
PD associated genes would also be vulnerable to rotenone. Out of 165 CG sites that met 
minimum coverage requirements and overlapped predicted CTCF binding motifs, we 
detected 45 differentially methylated cytosines (Table 2.9). In two of the genes, the 
cytosine within the CTCF consensus sequence were differentially methylated but not in 
any consistent direction (FER- hypomethylated; CHCHD2- hypermethylated) (Figure 2.7). 
We saw a similar trend in PARK2 and UBOX5 which had differential methylation across 
the whole binding region but did not change in a consistent direction (PARK2- 
hypomethylated) and (UBOX5-hypermethylated) (Figure 2.7). Overall there was a slight 
increase in hypermethylated cytosines (53%) indicating a potential decrease in CTCF 
binding capacity.  
 One of the primary functions of CTCF is to act as an insulator by blocking 
enhancer-promoter interactions (Phillips and Corces 2009). CTCF is thus tightly correlated 
with enhancer activity and its interaction with active enhancers topologically is much 
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greater than with silent regions of the genome (Ren et al. 2017). Histone acetylation 
patterns also determine chromatin structure and the histone mark H3K27ac is correlated 
with active enhancer regions (Creyghton et al. 2010; Wang et al. 2009). p300 is one of the 
primary histone acetyltransferase enzymes and loads the acetyl group onto the lysine tail 
of histone 3 at active regions. CTCF binding sites are often located next to at least one 
p300 binding site and interacts with p300 at chromatin with active acetylation (Ren et al. 
2017).  
 Histone acetylation patterns are vulnerable to environmental factors and like DNA 
methylation are heritable (Chinnusamy et al. 2009; Dai and Wang 2014; Zhu et al. 2018). 
It is likely that histone acetylation patterns also contribute to the role of genetic variants in 
disease pathogenesis. We tested H3K27ac levels at CTCF binding sites to determine if 
acetylation patterns were also sensitive to rotenone at PD-associated genes. We saw an 
increase in H3K27ac at four of the eight identified genes suggesting strong chromatin 
interactions with CTCF (FDR<0.05) (Figure 2.8). Notably, all four genes with H3K27ac 
also overlapped a differentially methylated cytosine within the CTCF binding region. This 
suggests a crosstalk mechanism with DNA methylation patterns and H3K27ac enrichment 
at CTCF binding sites to control chromosomal organization and SNP impacted gene 
expression.  
 We observed increased CTCF binding at 3 differentially expressed PD associated 
genes (Figure 2.18). PARK2 is a well-known genetic factor in PD as described earlier. 
Increased CTCF binding at its upstream enhancer decreased its expression thereby 
affecting its role in the ubiquitin proteasome system. BMP4 is a gene that encodes bone 
morphogenetic protein 4 and it regulates neurite outgrowth and axonal transport through 
the activation of the TGFβ/Smad pathway which is disrupted according to RNA 
sequencing reactome enrichment data (Chapter 2A Table 2.1). Increased CTCF binding 
was associated with increased BMP4 promoter expression which is essential for 
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dopaminergic neuron differentiation and survival (Hegarty et al. 2013, Hegarty et al. 2014).  
GPRIN3 encodes a protein involved in microtubule dynamics and neurite outgrowth which 
are both impaired in rotenone induced neurotoxicity (Cabeza-Arvelaiz and Schiestl 2012). 
Interestingly, increased CTCF binding occurred at GPRIN3 within an active transcription 
start site in the substantia nigra (Doyle et al. 2012). It is also associated with a fully 
penetrant Parkinson’s disease mutation causing a triplication of this loci and doubling of 
GPRIN3 mRNA transcripts (Devine et al. 2011). This observed increase in mRNA 
transcripts in a mature dopaminergic neuron differentiated from a patient was comparable 
to the observed 1.5-fold change increase in our rotenone treated cells. 
 The maintenance of CTCF binding is critical to genomic stability. These sites are 
not only vulnerable to environmental factors but are also enriched with disease associated 
genetic variants that accumulate proximal to CTCF in three dimensional domains (Wang 
et al. 2018; Sadowski et al. 2019). Our data explores gene-environment interactions in 
Parkinson’s disease by focusing on epigenetic patterns at vulnerable allele specific CTCF 
binding sites adjacent to PD associated genes. We conclude that both DNA methylation 
and histone acetylation patterns are vulnerable to environmental rotenone and rotenone 
induced chromatin opening results in increased CTCF binding. This may unlock the 
functional mechanisms explaining how non-coding genetic variants can dysregulate gene 
expression and promote disease pathology. It supports previous reports of rotenone being 
an effective toxicant to study gene-environment interactions in the brain (Cannon and 
Greenamyre 2010; Johnson and Bobrovskaya 2015). Lastly, it promotes the ongoing 
movement to include the environment and epigenetic regulation in population studies to 
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  AATAAACCACAAAAACTTCC 
CNKSR3 GTTTATATGTGGTTTGAAAATGTAG 
  AAAAATAAAAATAACCTTTCTATAAC 
UBOX5 TTGAAGTTTTTATTATAGTTAGGTTTG 
  TCCAAAAAAATATTTTCCCTCTACA 
ITGA8 GTATTTGGAATATTTAGGATTTG 
  CTAAATAACAACCACCCACC 
PARK2-CTCF TTTAGTTATAGTTTTGTTGGAAGGA 
  CAAAAACACAAAAAACAAAAAAACA 
GPRIN3 TAAAGGATTTTTGTGTAAAATGTGG 
  AAACTCTCACCTCCAAACTAACTCTAC 
FER TTAGTTTAGGGTTTAAGTTTTGTTTT 
  CCCAACCAAAAATACTCTACTAC 
BMP4 TTATTTTTTTTGGATTTTAGAGT 
  CTAAATATCTAACTTATCTCCCC 
BMP4 CAGGTAGCCTTGCTCACCAT 
  CCGGAAGCTAGGTGAGTGTG 
UBOX5 CTGAAGTTCTCACCACAGCCA 
  GAGGAGCCAGTATCTGTGTCG 
GPRIN3 TCGCATATCCCAAGCACCG 
  ATGAACAGTCGGGCAAGTGA 
FER TCAGGTTCTAGGTAGGTGCGT 
  GGGAGGATGAGCGGATGAC 
CNKSR3 CCTGGCGCAAATGCTATGG 
  CCGAGCCTGTCTGTTTTTGTT 
PARK2 CCTGCTGCTTTGAGCCTTTTT 
  TCAAAGGCTGTTGCTTGCTT 
CHCHD2 ACGTTCAATCTACCCCCGC 
  TCTACTGGGGCAATGACGC 
Gene chr:start SNP ID Rank Score 
GPRIN3 chr4:90228735 rs2116326 2a 0.96 
FER chr5:108084548 rs113728457 2a 0.92 
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Table 2.8 Differentially methylated CG sites at PD-associated genes 
 
CHR_GENE CG pvalue qvalue delta 
chr14_54422869_54423420_BMP4 54423352 5.48E-08 5.60E-08 -3.3 
chr20_3140226_3140678_UBOX5 3140420 2.59E-27 9.41E-27 2.3 
chr20_3140226_3140678_UBOX5 3140429 3.46E-34 1.62E-33 3.6 
chr4_90228647_90229070_GPRIN3 90228692 2.37E-07 2.24E-07 -1.1 
chr4_90228647_90229070_GPRIN3 90228700 1.87E-13 3.06E-13 1.3 
chr4_90228647_90229070_GPRIN3 90228702 3.42E-13 5.41E-13 1.2 
chr4_90228647_90229070_GPRIN3 90228709 1.23E-33 5.49E-33 -2.5 
chr4_90228647_90229070_GPRIN3 90228753 2.38E-09 2.82E-09 1.1 
chr4_90228647_90229070_GPRIN3 90228761 1.33E-13 2.29E-13 1.7 
chr4_90228647_90229070_GPRIN3 90228764 4.10E-07 3.73E-07 1.0 
chr4_90228647_90229070_GPRIN3 90228792 2.58E-11 3.61E-11 -1.2 
chr4_90228647_90229070_GPRIN3 90228822 4.03E-16 8.78E-16 1.7 
chr4_90228647_90229070_GPRIN3 90228849 1.47E-36 8.03E-36 2.7 
chr4_90228647_90229070_GPRIN3 90228860 3.23E-44 2.88E-43 1.8 
chr5_108084418_108084954_FER 102025087 1.53E-06 1.26E-06 -1.6 
chr5_108084418_108084954_FER 102025097 5.23E-76 8.56E-75 -4.4 
chr5_108084418_108084954_FER 102025117 1.62E-140 1.59E-138 -4.9 
chr5_108084418_108084954_FER 102025151 2.40E-14 4.62E-14 -1.3 
chr5_108084418_108084954_FER 102025176 2.79E-12 4.14E-12 1.6 
chr5_108084418_108084954_FER 102025225 1.05E-16 2.39E-16 1.9 
chr5_108084418_108084954_FER 102025228 1.12E-19 2.98E-19 3.4 
chr5_108084418_108084954_FER 102025231 1.23E-11 1.79E-11 -2.8 
chr5_108084418_108084954_FER 102025234 1.56E-15 3.26E-15 1.7 
chr5_108084418_108084954_FER 102025251 4.73E-03 2.52E-03 -1.8 
chr5_108084418_108084954_FER 102025320 5.38E-07 4.77E-07 1.9 
chr5_108084418_108084954_FER 102025330 3.76E-04 2.32E-04 1.3 
chr5_108084418_108084954_FER 102025334 2.60E-04 1.67E-04 -1.7 
chr5_108084418_108084954_FER 102025341 1.36E-15 2.90E-15 2.7 
chr5_108084418_108084954_FER 102025408 2.37E-07 2.24E-07 2.1 
chr5_108084418_108084954_FER 102025430 2.26E-03 1.28E-03 -1.4 
chr6_154830537_154830958_CNKSR3 154830543 8.22E-22 2.44E-21 -2.5 
chr6_154830537_154830958_CNKSR3 154830584 1.66E-24 5.63E-24 1.8 
chr6_154830537_154830958_CNKSR3 154830770 2.43E-59 2.65E-58 -1.5 
chr6_154830537_154830958_CNKSR3 154830810 1.02E-43 8.35E-43 1.7 
chr6_154830537_154830958_CNKSR3 154830817 3.60E-14 6.66E-14 -1.1 
chr6_154830537_154830958_CNKSR3 154830837 1.41E-93 6.93E-92 3.3 
chr6_154830537_154830958_CNKSR3 154830863 8.54E-20 2.33E-19 -1.0 
chr6_163277806_163278291_PARK2 163277841 3.89E-04 2.38E-04 -1.7 
chr6_163277806_163278291_PARK2 163277943 8.27E-07 7.12E-07 -2.0 
chr7_56173886_56174373_CHCHD2 56174016 1.67E-08 1.76E-08 -1.1 
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chr7_56173886_56174373_CHCHD2 56174033 4.52E-04 2.75E-04 -1.9 
chr7_56173886_56174373_CHCHD2 56174103 1.71E-05 1.29E-05 1.7 
chr7_56173886_56174373_CHCHD2 56174107 1.01E-08 1.11E-08 -1.1 
chr7_56173886_56174373_CHCHD2 56174149 2.07E-04 1.37E-04 1.6 
chr7_56173886_56174373_CHCHD2 56174179 3.24E-04 2.05E-04 1.2 
 
Table 2.9 Differentially methylated CG sites within H3K27ac enriched regions 
 
CHR_GENE CG pvalue qvalue delta 
chr14_54422869_54423420_BMP4 54423352 5.48E-08 5.60E-08 -3.3 
chr20_3140226_3140678_UBOX5 3140420 2.59E-27 9.41E-27 2.3 
chr20_3140226_3140678_UBOX5 3140429 3.46E-34 1.62E-33 3.6 
chr4_90228647_90229070_GPRIN3 90228822 4.03E-16 8.78E-16 1.7 
chr4_90228647_90229070_GPRIN3 90228849 1.47E-36 8.03E-36 2.7 
chr4_90228647_90229070_GPRIN3 90228860 3.23E-44 2.88E-43 1.8 
chr5_108084418_108084954_FER 1.02E+08 1.05E-16 2.39E-16 1.9 
chr5_108084418_108084954_FER 1.02E+08 1.12E-19 2.98E-19 3.4 
chr5_108084418_108084954_FER 1.02E+08 1.23E-11 1.79E-11 -2.8 
chr5_108084418_108084954_FER 1.02E+08 1.56E-15 3.26E-15 1.7 
chr5_108084418_108084954_FER 1.02E+08 4.73E-03 2.52E-03 -1.8 
chr5_108084418_108084954_FER 1.02E+08 5.38E-07 4.77E-07 1.9 
chr5_108084418_108084954_FER 1.02E+08 3.76E-04 2.32E-04 1.3 
chr5_108084418_108084954_FER 1.02E+08 2.60E-04 1.67E-04 -1.7 
chr5_108084418_108084954_FER 1.02E+08 1.36E-15 2.90E-15 2.7 
chr5_108084418_108084954_FER 1.02E+08 2.37E-07 2.24E-07 2.1 







Figure 2.5 Environmental factors alter CTCF interaction with non-coding variants. 
A) Genome wide association studies (GWAS) assess predisposition for disease by using 
unbiased genetic screens to associate single nucleotide polymorphisms (SNP) with 
complex traits. B) Parkinson’s disease-associated genetic variants were identified using 
the GWAS catalog and 90% (220 polymorphisms) were in non-coding regions of the 
genome. C) In cells exposed to environmental stress, cis-epigenetic mechanisms at CTCF 
binding motifs impact CTCF transcription factor binding and insulator activity. This can 







Figure 2.6 RNA sequencing validation with qRT-PCR. Linear calibration curve of RNA 




Figure 2.7 BS sequencing coverage of CpG sites within amplified regions at PD-
associated genes. The average total coverage for all CpG sites within the amplified 






Figure 2.8 Differential methylation within CTCF motifs at PD-associated genes 
A-B) Two genes, FER and CHCHD2, had differential methylation at CG sites within their 
predicted CTCF binding motif. The amplified region at both genes covered the first exon 
and intron. The highlighted blue CG sites are all with significant differential methylation (> 
|1%|; q-value<0.05). Red text emphasizes a common SNP. Orange text represents CTCF 
binding sites in the human genome identified by ENCODE. The bold orange text is the 
sequence motif predicted by the Cui Lab CTCF prediction tool (Ziebarth and Bhattacharya 
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2013). The output of the CTCF binding prediction tool is listed in the table with the name 
of the position weight matrix motif, motif sequence, motif length, strand orientation, and 
the integrated output score. C-D) Two genes, PARK2 and UBOX5, had significantly 
different methylation across the region. Each dot represents a CG within the region. Delta 
indicates the change in the mean CpG methylation percentage and the associated p-value 






Figure 2.9 CTCF site histone acetylation patterns in response to rotenone.  
The local abundance of H3K27ac within CTCF binding sites at Parkinson’s disease 
associated genes was measured with ChIP-PCR and expressed as the percent of total 
DNA input used for immunoprecipitation. The negative control for ChIP analysis was 
Rabbit IgG (shown in bottom panel). Significance was tested with paired student’s t-test 
using the percent input of vehicle (DMSO) vs rotenone and post-hoc analysis for multiple 





Figure 2.10 CTCF binding at PD-associated genes in response to rotenone.  
The local abundance of CTCF binding at Parkinson’s disease associated genes was 
measured with ChIP-PCR and expressed as the percent of total DNA input used for 
immunoprecipitation. The negative control for ChIP analysis was Rabbit IgG (shown in 
Supplemental Figure 6). Significance was tested with paired student’s t-test using the 
percent input of vehicle (DMSO) vs rotenone and post-hoc analysis for multiple 




THE CONSERVED DNMT1-DEPENDENT METHYLATION 
REGIONS IN HUMAN CELLS ARE VULNERABLE TO 
NEUROTOXICANT ROTENONE EXPOSURE. 
 
3.1 Abstract 
 Allele-specific DNA methylation (ASM) describes genomic loci that maintain CpG 
methylation at only one inherited allele rather than having coordinated methylation across 
both alleles. The most prominent of these regions are germline ASMs (gASMs) that control 
the expression of imprinted genes in a parent of origin- dependent manner and are 
associated with disease. However, our recent report reveals numerous ASMs at non-
imprinted genes. These non-germline ASMs are dependent on DNA methyltransferase 1 
(DNMT1) and strikingly show the feature of random, switchable monoallelic methylation 
patterns in the mouse genome. The significance of these ASMs to human health has not 
been explored. Due to their shared allelicity with gASMs, herein, we propose that non-
traditional ASMs are sensitive to exposures in association with human disease. We first 
explore their conservancy in the human genome. Our data show that our putative non-
germline ASMs were in conserved regions of the human genome and located adjacent to 
genes vital for neuronal development and maturation. We next tested the hypothesized 
vulnerability of these regions by exposing human embryonic kidney cell HEK293 with the 
neurotoxicant rotenone for 24h. Indeed,14 genes adjacent to our identified regions were 
differentially expressed from RNA-sequencing. We analyzed the base-resolution 
methylation patterns of the predicted non-germline ASMs at two neurological genes, 
HCN2 and NEFM, with potential to increase the risk of neurodegeneration. Both regions 
 
3 This chapter has been accepted for publication in Epigenetics and Chromatin. D.M. Freeman (2020). Co-
authors: Dan Lou, Yangqiang Li, Suzanne Martos. Corresponding author: Z. Wang.  
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were significantly hypomethylated in response to rotenone. Our data indicate that non-
germline ASMs seem conserved between mouse and human genomes, overlap important 
regulatory factor binding motifs, and regulate the expression of genes vital to neuronal 
function. These results support the notion that ASMs are sensitive to environmental factors 
such as rotenone and may alter the risk of neurological disease later in life by disrupting 
neuronal development.  
3.2 Introduction 
 
DNA methylation refers to the addition of a methyl group (CH3) to the cytosine 
base of DNA by DNA methyltransferases. This predominately occurs at cytosine-guanine 
adjacent sites known as CpG sites. For most genomic loci, DNA methylation is 
coordinated across both inherited alleles. However, some loci maintain CpG methylation 
at only one allele and these regions are described to have allele-specific methylation 
(ASM; previously known as differentially methylated region DMR) (Bartolomei and 
Tilghman 1997). The most well-known of these regions are germline ASMs which control 
the expression of imprinted genes in a parent of origin-dependent manner. Imprinted 
genes are crucial in development and are commonly associated with genetic disorders 
such as Beckwith-Wiedemann, Angelman, and Prader-Willi syndromes (Butler 2009). In 
addition to the control of imprinted gene expression, DNA methylation is key to maintain 
genome stability via silencing retrotransposons (Chen et al., 2007; Walsh et al., 1998).  
Investigations demonstrate that two types of genomic regions, imprinted germline 
ASMs and intracisternal A-particle (IAP)-like retrotransposons, seem vulnerable to 
environmental factors. Therefore, these two regions are proposed to be pivotal for 
understanding human disease in response to exposure and popularly pursued in animal 
and epidemiological studies (Jirtle and Skinner 2007; Murphy and Hoyo 2013). The former 
is attractive because exposure altered ASMs are anticipated to be faithfully transmitted to 
somatic cells during rounds of global demethylation and remethylation in early embryos 
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(Barlow and Bartolomei 2014; Kacem and Feil 2009). As a result, parental exposure can 
be epigenetically inherited to modify offspring phenotype (Freeman and Wang 2019). The 
latter is exemplified in mice by the bisphenol A-hypomethylated IAP at the agouti gene for 
variations of coat color and obesity, as well as by altered methylation of IAPs at AxinFu for 
tail kinkiness (Rakyan et al. 2003; Zhou et al. 2007).  
In our recent work, we developed two approaches, no-rescued DMRs (NORED) 
and methylation mosaicity analyses (MethylMosaic), to identify numerous genomic loci 
bearing potential ASMs (Martos et al. 2017). Both the known imprinted germline ASMs 
and newly identified ASMs are dependent on DNA methyltransferase 1 (DNMT1)(Li et al. 
2015). Many of these novel ASMs are presumably sequence (single nucleotide 
polymorphism; SNP)-influenced ASMs (Kerkel et al. 2008). For example, in a reciprocal 
cross between 129S1/SvlmJ and Cast/EiJ or between C57BL/6NJ and Cast/EiJ, the Cast 
allele with SNP C of Hcn2 ASM is always hypomethylated (i.e., independent of parental 
origin), whereas the 129 allele or the C57 allele with SNP A is always hypermethylated. 
Standing out of the previously appreciated sequence-dependent ASMs, a new paradigm 
of switchable ASMs that shows equal chances of either paternal or maternal allele to be 
methylated was revealed by our report (Martos et al. 2017). Importantly, the switchable 
feature seems also conserved in the human genome. At the DLGAP2 locus, independent 
evidence confirms a maternally imprinted ASM during pre-implantation switched to a 
random ASM in somatic tissues during gestation (Monteagudo-Sánchez et al. 2018). 
Collectively, the mouse genome or human genome contains more ASMs (including both 
sequence-dependent and switchable ASMs) than previously appreciated (Deng et al. 
2014, Martos et al. 2017, Monteagudo-Sanchez et al. 2018, Onuchic et al. 2018). The 
newly revealed random, switchable ASMs remind us of features in X chromosome 
inactivation, leading to a proposed hypothesis of regional autosomal chromosome 
inactivation (Wang et al. 2018). 
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Currently, germline ASMs are being increasingly considered in human disease; 
however, less studied are non-germline ASMs, which maintain CpG methylation at one 
allele independent of the parent of origin (Zhang et al. 2009, Deng et al. 2014, Martos et 
al. 2017). These regions regulate the expression of non-imprinted genes and these genes 
are hypothesized to have random monoallelic expression. Due to their predicted 
monoallelicity (DNA methylation and transcripts), we hypothesize that these regions are 
also targets for environmental factors and associated with disease like germline ASMs 
(Susiarjo et al. 2013).  
The goal of this study was to determine whether our identified candidate ASMs in 
the mouse genome were in conserved regions of the human genome and to explore the 
possible adverse effects of differential methylation in these regions by examining their 
tissue expressivity and functional enrichment. Lastly, we tested our hypothesis that genes 
adjacent to non-germline ASMs would be vulnerable to environmental factors by exposing 
human embryonic kidney HEK293 cells to the pesticide rotenone for 24h. We used whole 
transcriptome RNA-sequencing and targeted bisulfite-amplicon sequencing to evaluate 
changes in expression of adjacent genes and DNA methylation at candidate ASMs in 
response to rotenone. Indeed, our data demonstrate the vulnerability of these new, non-
traditional ASMs to environmental exposure (Freeman et al. 2020). 
3.3 Materials and Methods 
3.3.1 Identification of conserved DNMT1-dependent regions in the human genome 
Whole Genome Bisulfite Sequencing (WGBS) was used to analyze base resolution 
methylomes of a series of Dnmt1 (-/-), Dnmt3a (-/-), and Dnmt3b (-/-) murine embryonic 
stem cell lines (wild-type J1) as described previously (Li et al. 2015, Martos et al. 2017). 
DNMT1-dependent regions termed “NORED” were defined as regions with near complete 
loss of methylation in Dnmt1(-/-) compared to wild-type J1 that remained unable to recover 
methylation after the addition of exogenous Dnmt1 cDNA. To identify the conserved 
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DNMT1-dependent regions in the human genome, we used the UCSC Genome Browser 
LiftOver software to locate regions in the hg19 assembly from the mouse mm10 assembly. 
A text file of the chromosome positions (chr: start-end) for each putative ASM was 
uploaded into LiftOver and converted to the human hg19 assembly with a minimum ratio 
of 0.1 bases mapping for each region. The genomic location of each conserved region 
was analyzed in the UCSC Genome Browser window with NCBI RefSeq annotations. 
Transcription factor binding was observed using the Uniform Transcription Factor Binding 
data found in the ENCODE Regulation super track. We selected all transcription factor 
binding sites in H1-human embryonic stem cells (H1-hESCs) detected with ChIP-Seq 
experiments from the ENCODE consortium from 2007-2012 (ENCODE 2012). Imprinted 
genes from mouse and human genome were identified from the Jirtle Laboratory 
GeneImprint database (http://www.geneimprint.org/).  
3.3.2 Functional and tissue enrichment for candidate DNMT1-dependent genes in the 
human genome 
We restricted functional enrichment analysis of conserved human regions to those 
that had >70% base pair match for over 90% of the span of the identified region (Table 1). 
Pathway enrichment and network interactions for human genes nearest to these regions 
were calculated using the STRING database (Szklarczyk et al. 2014). Gene Ontology was 
used for functional annotations and significance was measured using Fisher’s exact test 
with a false discovery rate (FDR) <0.05. Network interactions were clustered using 
Cytoscape based on gene functional annotations in the reactome pathways (Fabregat et 
al. 2018). 
 The human DNMT1-dependent genes (Table 3.1) were used for tissue enrichment 
in EnrichR (Chen et al. 2013) using the ArchS4 database (Lachmann et al. 2018). The top 
six human tissues were reported with a p-value <0.01 adjusted using their correction for 
the Fisher’s exact test (Chen et al. 2013). Enrichment of tissue-specific genes was 
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performed using the TissueEnrich R package which uses gene expression data from the 
Human Protein Atlas (Jain and Tuteja 2018). Genes with an expression level of at least 
one transcript per million (TPM) were defined as tissue enriched when expression was at 
least five-fold higher in a distinct tissue compared to the expression of any other individual 
tissue and tissue enhanced when expression was at least five-fold higher in a distinct 
tissue compared to the total average expression of all other tissues. Group enriched genes 
were defined as genes with an expression level of at least one TPM and had at least five-
fold higher expression in a group of tissues compared to all tissues. These definitions were 
taken from TissueEnrich.  
3.3.3 Cell culture and treatment of human cell line HEK293 
HEK293 cells were treated with rotenone (200 nM) for 24h according to the 
protocol in Chapter 2A.3.1. 
3.3.4 RNA sequencing library construction and analysis 
The RNA sequencing data used for this subchapter was the same data reported 
in Chapter 2A.3.2-2A.3.3.  
3.3.5 Selection and tissue expression analysis of human DNMT1 dependent regions 
We examined differentially expressed genes in RNA-seq in common with the 
genes nearest to the conserved DNMT1-dependent regions in the human genome with 
>70% base pair match for over 90% of the span of the identified region in the mouse 
genome. Overlapping genes were entered into the Genotype-Tissue Expression (GTEx) 
database using the multi-gene query tool (GTEx Consortium 2013). Parkinson’s disease 
brain regions associated with motor function including the cerebellum, cortex, frontal 
cortex, spinal cord, substantia nigra, and basal ganglia were selected for further 
expression analysis. 
3.3.6 RNA sequencing validation with quantitative reverse transcription-PCR  
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Total RNA was extracted from an additional replicate of HEK293 treated with 
DMSO or rotenone using the same procedure as stated above. A total of 500ng RNA was 
converted to cDNA with the PrimeScript RT reagent kit with gDNA eraser from Takara 
(Kusatsu, Japan). We selected seven out of fourteen overlapping genes for quantitative 
PCR (qRT-PCR) analysis using primers listed in Table 3.2. All qRT-PCR reactions were 
performed on a 7500 Real-Time PCR system from Applied Biosystems (Foster City, CA) 
using the iTaq Universal SYBR Green Supermix from Bio-Rad (Hercules, CA). The 
change in expression was normalized to the GAPDH housekeeping gene and expressed 
as fold change (2-ΔΔCT).  
3.3.7 Bisulfite-DNA conversion and Bisulfite-amplicon sequencing library construction 
 Bisulfite DNA conversion and library preparation was done according to the exact 
same protocol in Chapter 2B 3.6-3.7 with primers designed to amplify DNMT1-dependent 
regions in Table 3.1. Primer sequences are listed in Table 3.3.  
3.4 Results 
3.4.1 DNMT1-dependent regions in the mouse and human genome. 
 Two approaches, NORED and MethylMosaic, independently identified over 2,000 
regions with DNMT1 dependency and allele-specific methylation. To simplify future 
interpretation, we focused on 207 overlapped regions (i.e., ‘NORED+MethylMosaic’ 
regions) to initiate our investigation. We compared these 207 regions from mouse and 
observed 145 of these regions were conserved in the human genome. Most regions 
identified in the human genome were highly conserved with >70% matched bases for more 
than 90% of the entire span of the region (Figure 3.1). Analyzing these regions in the 
genome browser, we noted that 70% of the conserved regions in the human genome were 
located in the gene body and approximately 50% of them had transcription factor binding 
sites in human embryonic stem cells (Figure 3.1). The two transcription factors that were 
the most significantly enriched were POL2RA and TAF1 with binding sites at 19% of 
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conserved DNMT1 regions. Both were concentrated around transcription start sites and 
regulate RNA polymerase II binding and processivity in gene transcription. The third most 
enriched transcription factor was CTCF with binding motifs in 17% of conserved regions 
and most often found within intragenic regions. The top transcription factors with binding 
motifs found in intergenic sites were CTCF, SIN3A, and RAD21. All three transcription 
factors are crucial in regulating chromatin structure to repress gene transcription and 
inhibition of these factors are closely associated with human disease (Davis et al. 2018; 
Witteveen et al. 2016; Zuin et al. 2014). We searched conserved human genes for known 
imprinted genes at germline ASMs using the GeneImprint database and found 20 known 
imprinted genes (Figure 3.1). Most of the human genes found at conserved DNMT1-
dependent regions had an unknown imprinted status and thus were considered candidate 
non-germline ASMs. Prior examination of DNA methylation in four independent mouse 
embryonic stem cell lines validated our hypothesis at one conserved gene (HCN2) that 
non-germline ASMs can exhibit a random, switchable pattern (Martos et al. 2017).  
3.4.2 Human DNMT1-dependent genes are enriched in cellular processes associated with 
cell-cell signaling. 
 Out of the 145 regions identified in the human genome, we selected 97 of the most 
highly conserved regions compared to the mouse genome. The genes nearest to these 
regions on the same allele (112 genes) were used for functional enrichment analyses 
(Table 3.1). We used Gene Ontology functional annotations to gain insights into the 
cellular processes associated with these genes and significance was determined from the 
Fisher’s exact test with p-value adjustment using false discovery rate method (FDR<0.05). 
We observed adjacent genes were highly associated with cell to cell interactions and 
signaling. The number of genes involved in this biological process as well as the 
significance of its enrichment (expressed as log base 2 false discovery rate) are shown in 
Figure 3.2. Genes regulating cell-cell adhesion belonged primarily to the cadherin protein 
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family. This agrees with previous reports showing monoallelic expression of 
protocadherins in Purkinje neurons (Esumi 2005). Gene Ontology of cellular components 
describe the subcellular compartments where enriched cellular processes and molecular 
functions occur. The plasma membrane and the pre-synapse were significantly enriched 
in our dataset in accordance with the enrichment of cell-cell interactions and calcium ion 
binding (FDR<0.05, Table 3.4).  
 The interaction of the proteins encoded by DNMT1-dependent genes was 
analyzed using the STRING database (Figure 3.2). The STRING database is a commonly 
used platform that summarizes the functional associations of a group of proteins. Out of 
the 112 selected protein encoding genes in humans, 98 nodes with 109 edges were 
detected with a medium confidence interaction score (>0.4). The interaction p-value (PPI) 
was less than 1x10-16, indicating that the number of associations was significant. We 
manually clustered genes with interactions using functional gene annotations. The largest 
cluster consisted of genes involved in cell-cell signaling including cadherins and cell 
surface adhesion molecules, cell trafficking chaperones, cytoskeleton proteins, and 
voltage-gated ion channels. Other significant pathways included developmental pathways 
of the nervous system and the vascular system.  
3.4.3 Human DNMT1-dependent genes are enriched in tissues of the brain.  
Given the evidence that DNMT1-dependent genes may play an important role in 
cell-cell adherence and communication as well as in nervous system development, we 
hypothesized that DNMT1-dependent genes may be highly expressed in the brain. We 
analyzed the enrichment of tissue expression using the ARCHS4 human tissue database 
in EnrichR. The ARCHS4 database reports publicly available RNA-sequencing across all 
tissues and cell types in approximately 85,000 human samples (Lachmann et al. 2018). 
Significant expression of the DNMT1-dependent genes in the adult and developing brain 
was observed (p <0.01, Figure 3.3). We also observed enrichment in the regions of the 
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brain associated with motor function control. These include structures such as the 
cerebellum, spinal cord, and the striatum which are directly involved with motor 
coordination as well as the superior frontal gyrus which contains the supplementary motor 
area activated in complex movements (Li et al. 2013, Sang et al. 2015).  
 To further determine if these genes were specific to neuronal tissues or if they have 
functionality across several tissues, we analyzed DNMT1-dependent genes for tissue 
specific enrichment using the TissueEnrich R package (Jain and Tuteja 2018). Genes with 
increased expression in one tissue compared to the expression in any other tissue were 
defined as tissue enriched while genes with increased expression in one tissue compared 
to the average of all tissues were defined as tissue enhanced. Group enriched genes were 
defined as genes that have increased expression in a group of tissues compared to all 
other tissues. Our analysis demonstrates that DNMT1-dependent genes conserved in the 
human genome have a significant abundance of tissue enhanced and group enriched 
genes within the brain, but not tissue enriched genes (Figure 3). From these data, we 
conclude that DNMT1-dependent genes are likely important in cellular processes in the 
fetal and adult brain.  
3.4.4 Five DNMT1-dependent genes are represented in genes for potential PD blood 
biomarkers in patients.  
To further explore the significance of identified human DNMT1-dependent genes, 
we evaluated the recent literature on potential blood biomarkers in Parkinson’s disease 
(PD) patients. Encouragingly, we observed five differentially methylated genes in these 
studies within our conserved human regions (Henderson-Smith et al 2018; Wang et al. 
2019). They are COL9A2, SCNN1A, AMICA1, SLC16A3, and DLK1. One of these genes, 
COL9A2, was also found to be differentially expressed in our rotenone treated cells 
(Henderson-Smith et al. 2018) (described below). Given that candidate PD biomarkers 
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and our DNMT1-dependent genes were selected by differing criteria, we consider five 
overlapping genomic regions to be promising toward our hypothesis.  
3.4.5 Human DNMT1-dependent genes are differentially expressed in response to 
rotenone in human cells. 
We have shown that DNMT1-dependent regions have conserved sequences in the 
human genome and are enriched at genes involved in cell to cell interactions. These 
genes have enhanced expression in the brain and may contribute to neurological 
dysfunction and disease in response to environmental stress. To test the hypothesized 
contribution, we focus on rotenone exposure. Rotenone is a mitochondrial complex I 
inhibitor that is known to disrupt neuronal cell function in Parkinson’s disease associated 
brain regions (Tanner 2011). These brain regions include the cerebellum, spinal cord, 
striatum, and basal ganglia. We treated human cell line HEK293 with rotenone (200 nM) 
for 24h. This dose was chosen based on previous reports in HEK293 and other neuronal 
cell models (Harris et al. 2018, Orth et al. 2003, Teixeria et al. 2018).  
Rotenone treatment had a substantial effect on the expression levels of over 2,000 
genes (≥1.5 fold, FDR≤0.05). We examined these differentially expressed genes with our 
identified human DNMT1-dependent genes and discovered 14 of them had been changed 
upon rotenone treatment (Table 3.5). We validated the expression of 7 these genes with 
qRT-PCR (R2= 0.69, Figure 3.4). We investigated whether these genes may contribute to 
rotenone-induced Parkinson’s disease by observing their expression in Parkinson’s 
disease tissues (Figure 3.5). All 14 genes were expressed in Parkinson’s disease regions 
(>1 TPM4) and 8 of the genes (PPFIA4, NEFM, HCN2, ADRA2C, COL9A2, LRRC8D, 
EML2, and KDM7A/JHDM1D) had pronounced expression in Parkinson’s disease regions 
(>35 TPM). Two genes, NEFM and HCN2, had significant expression (>100 TPM) in all 
 
4 TPM is abbreviated for transcript per one million reads. 
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selected regions and were identified by our tissue specific enrichment analysis as tissue 
enhanced and tissue enriched, respectively (Figure 3.5). We therefore selected NEFM 
and HCN2 for targeted methylation analysis based on their regional expression and 
significant up-regulation from both RNAseq and qRT-PCR analyses. The relevance and 
significance of HCN2 and NEFM in human development and diseases are detailed later 
in the discussion. 
3.4.6 DNMT1-dependent regions at HCN2 and NEFM are differentially methylated in 
response to rotenone in human cells. 
 Previously, germline ASMs are especially vulnerable to environmental exposure, 
thereby altering imprinted gene expression (Susiarjo et al. 2013). Herein, we determined 
the potential methylation changes of the defined DNMT1-dependent region at these two 
genes, NEFM and HCN2, with significant up-regulation in response to rotenone. We 
completed base-resolution bisulfite sequencing of these regions amplified with bisulfite 
PCR. After filtering of low-quality reads, approximately 42% of reads were mapped 
uniquely to the amplified regions. We observed high correlation between biological 
replicates and similar average coverage between control and treated samples (Figures 
3.6). The average CpG coverage for both genes in all samples was >15,000x. Of the 23 
predicted CpG sites within the amplified DNMT1-dependent region on exon 8 of HCN2, 
21 CpGs had adequate coverage (>1000x) in all samples and 14 CpGs were differentially 
methylated (Figure 3.7; Table 3.6). The mean percent methylation of all CpGs within the 
amplified DNMT1-dependent region was also significantly hypomethylated (Δme of -
1.84%, FDR<0.05) (Figure 3.7).  
 We saw a similar trend in the DNMT1-dependent region at exon 1 of NEFM. Of the 
39 predicted CpG sites within the amplified DNMT1-dependent region, 35 CpGs had 
adequate coverage in all samples and 13 of these CpGs were differentially methylated. A 
slight majority (54%) of these differentially methylated cytosines were hypomethylated 
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(Supplemental Figure 4). The overall change in methylation ratio for the entire region was 
significant but very low (<0.1% absolute difference, FDR<0.01). As a result, we decided 
to focus on the first 200 bp of the 500 bp amplified region, which overlap both the CpG 
island at exon 1 as well as a CTCF transcription factor binding site reported by ENCODE 
(ENCODE 2012). In this region, there was a slightly higher change in methylation (Δme of 
-0.12%, FDR<0.05). Additionally, we used the CTCF binding site prediction tool to 
determine the exact CpG sites within the CTCF binding motif (Ziebarth and Bhattacharya 
2013). One of the top hits predicted CpG binding on the negative strand at CpG sites 89-
96 within the defined NEFM region (Figure 3.8, Table 3.7). Three of these four CpG sites 
were differentially methylated with half of them having >2% reduced methylation.  
 These data enable us to conclude that the methylation status of DNMT1-
dependent regions in the human genome are vulnerable to the neurotoxicant rotenone. 
We found that the coding regions and transcription factor binding motifs may be among 
the DNA elements that are particularly susceptible to exposure. The changes in 
methylation we observed were similar in scale to observed differential methylation at gene-
encoding regions in the blood and brain of Parkinson’s disease patients (Masliah et al. 
2013; Navarro-Sanchez et al. 2018; Henderson-Smith et al. 2018; Wang et al. 2019). Both 
HCN2 and NEFM are regionally expressed in Parkinson’s disease tissues and their 





Our previous work identified DNMT1-dependent putative non-germline ASMs in 
the mouse genome. In this study, we analyzed these regions and found that 70% were in 
highly conserved regions with the human genome. In the human genome, our candidate 
loci were often located at gene-coding regions and half of them overlapped transcription 
factor binding sites (Figure 3.1). Our observations agreed with another recent study which 
identified genome-wide ASMs in human samples from a Norfolk Island genetic isolate 
(Benton et al. 2019). Methylated cytosines alter gene expression by influencing the binding 
of transcription factors to DNA. We listed the top transcription factor binding sites within 
our identified candidate regions in human embryonic stem cells using ENCODE 
experimental data (Figure 3.1). Unsurprisingly, three of these transcription factors were 
TAF1, TBP, and POL2RA which all have an essential role in initializing transcription. We 
were interested to see SIN3A and RBBP5 which both interact with histone modifying 
enzymes to regulate chromatin accessibility and are critical during neurodevelopment 
(Gabriele et al. 2018). Furthermore, SIN3A is recruited to the methyl-CpG binding protein 
MeCP2 to silence transcription. Mutations in MeCP2 cause an X-linked 
neurodevelopmental disorder known as Rett Syndrome and similarly impairment of SIN3A 
expression also causes developmental cognitive deficits (Witteveen et al. 2016). MeCP2 
and SIN3A have been linked to the establishment and maintenance of imprinting control 
regions but their effect on the expression of neighboring imprinted genes remains to be 
determined (Ma et al. 2015).  
CTCF is another transcription factor of interest with 17% of the DNMT1-dependent 
human regions overlapping the CCCTC-binding motif. CTCF is also critical in 
neurodevelopment and chromatin organization (Franco et al. 2014, Davis et al. 2018). 
CTCF mediates the formation of chromatin loops and thus can promote widespread 
changes in gene expression (Hou et al. 2008, Phillips and Corces 2009). When bound to 
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sequences known as insulator sequences, CTCF represses transcription by blockading 
promoter-enhancer interactions (Bell et al. 2000, Hark et al. 2000). CTCF and the 
stabilizing protein cohesion bind at numerous imprinted control regions (Rubio et al. 2008, 
Prickett et al. 2013). CTCF has been reported to preferentially bind unmethylated 
chromatin but binding affinity depends not only on the methylation status of the motif itself 
but the surrounding CpG sites as well (Li et al. 2017, Wang et al. 2012).  
Given the importance of imprinted gene clusters in development, we analyzed 
functional enrichment of our non-germline ASMs in the human genome. The most 
significant biological process associated with our gene set was cell to cell adhesion (Figure 
3.2). We observed a significant group of cadherins at DNMT1-dependent regions on 
chromosome 5. Cadherin proteins are expressed on the membrane of embryonic stem 
cells and are critical for their self-renewal by forming tight intracellular niches (Pieters and 
Frans van Roy 2014). The expression of cadherin subtypes on embryonic stem cells is 
variable and the patterning of cadherin expression also controls their differentiation. 
Protocadherins are involved in neuronal connectivity and this function extends from neural 
progenitors during development into postmitotic neurons in the adult brain (Sams et al. 
2016). Intriguingly, protocadherin is regulated by CTCF and deletion of CTCF in mice 
caused deficits in hippocampal learning and memory via dysregulation of protocadherin 
expression (Sams et al. 2016). The most significant molecular function was calcium ion 
binding and the pre-synaptic axon terminal was one of two most significant cellular 
components represented. This agreed with our network analyses where multiple genes 
were involved in cell trafficking and synaptic activity (Figure 3.2). We investigated whether 
developmental genes were specific to an individual tissue or group of tissues. These 
genes from DNMT1-dependent regions have significant enrichment of genes expressed 
in the cerebral cortex from two separate databases, EnrichR ArchS4 and Tissue Enrich 
Human Protein Atlas (Figure 3.3). Our data suggests that DNMT1-dependent non-
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germline ASMs have enhanced expression in the brain, which could be important for 
neurological development and cellular communication function.  
In our previous work, we characterized non-germline ASMs in the mouse genome 
at two genes, Hcn2 and Park7, with potential in Parkinson’s disease (Bonifati et al. 2003, 
Kim et al. 2005, Martos et al. 2017). The proper maintenance of the epigenome throughout 
aging is believed to have a major impact on the risk of neurodegeneration later in life 
(Gapp et al. 2014, Labbe et al. 2016). The influence of germline-ASMs on 
neurodegeneration has recently been of interest in the literature given their involvement 
in neurodevelopment but the effect of non-imprinted ASMs have not been well 
characterized (Gapp et al. 2014). To experimentally examine the association of identified 
ASMs in the human genome with Parkinson’s disease, we used human embryonic kidney 
cells with a neuronal lineage phenotype and treated them with rotenone for 24h 
(Stepanenko and Dmitrenko 2015). We observed several of our candidate genes were 
affected in response to rotenone treatment and half of these genes have regional 
expression in Parkinson’s disease associated regions (Figure 3.4). Among these genes, 
HCN2 and NEFM were determined from our tissue enrichment analysis to have a higher 
expression level in the brain than any other tissue. Additionally, experimental analysis of 
Hcn2 in the mouse genome suggests a random, switchable allele-specific methylation 
pattern that was independent of the parent-of-origin (Martos et al. 2017). We selected 
these two genes for methylation analysis to determine if conserved non-germline ASMs in 
the human genome were sensitive to environmental factors associated with Parkinson’s 
disease.  
The HCN2 gene encodes an isoform of the hyperpolarization-activated cyclic 
nucleotide-gated channel located on the membrane of neurons in the central and 
peripheral nervous system. HCN channels regulate neuronal plasticity and have the 
advantage of using both voltage dependent mechanisms as well as cAMP intracellular 
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signaling mechanisms (DiFrancesco et al. 1999). In the midbrain, these channels control 
the spontaneous activity of dopaminergic neurons and their dysfunction has been linked 
to the depletion of dopamine in Parkinson’s disease (Chen et al. 2011, DiFrancesco and 
DiFrancesco 2015, Good et al. 2011). In the human genome (hg19), the conserved 
DNMT1-dependent locus identified was 321 bp at a CpG island on exon 8 of the gene. 
We observed significant upregulation of mRNA expression levels (1.6-fold change, 
FDR<0.01) that correlated with DNA hypomethylation (-1.8%, FDR<0.05) of a 450 bp site 
surrounding the region of interest (Table 3.5; Figure 3.7; Table 3.6). Dysregulated HCN2 
expression could affect HCN2 channel activity leading to disrupted regulation of 
dopaminergic excitability.  
The NEFM gene encodes a subunit of neuron-specific intermediate filaments 
known as neurofilaments. Neurofilaments are primary components of myelinated axons 
and are essential for synaptic function (Yuan et al. 2017). Neurofilament subunit 
expression is tightly regulated to maintain proper stoichiometry. As such, aberrant 
expression of NEFM likely disrupts axonal growth and transport. Interestingly, 
neurofilament subunits including the NEFM protein are considered promising 
neurodegeneration biomarkers due to their cell specificity and sensitivity to neuronal 
damage (Khalil et al. 2018). In Parkinson’s disease patients, neurofilament proteins have 
been detected at higher levels in the cerebral spinal fluid, and more recently, in the blood 
(Abdo et al. 2007, Rosengren et al. 1996, Rojas et al. 2016). In our data, the conserved 
DNMT1-dependent locus covered a 150 bp region in exon 1 as well as a 1,650 bp region 
spanning exon 1 to intron 2. We observed significant upregulation of mRNA (1.7-fold 
change, FDR<0.01) and hypomethylation of a 200 bp section of the identified region at 
exon 1 (-0.12%, FDR<0.05). While the total change in percent methylation was relatively 
small, the selected region contained a CTCF binding site. Several CpG sites located within 
this CTCF binding motif had higher changes in methylation (>1%, adjusted q-value<0.01) 
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(Figure 3.8; Table 3.7). As mentioned previously, CTCF is hypersensitive to changes in 
DNA methylation and approximately 41% of CTCF binding variability has been attributed 
to DNA methylation (Wang et al. 2012). The lack of repressive signaling from CTCF could 
contribute to the observed increases in NEFM reported in Parkinson’s disease patients 
and the observed overexpression of NEFM associated with cytoplasmic inclusions in 
motor-impaired mice (Sosa et al. 2003, Liu et al. 2011, Wong et al. 1995).  
We evaluated the recent literature on candidate blood biomarkers in Parkinson’s 
disease patients and observed five differentially methylated genes (COL9A2, SCNN1A, 
AMICA1, SLC16A3, and DLK1) in these studies within our conserved human regions 
(Henderson-Smith et al 2018; Wang et al. 2019). Of these genes, COL9A2 was 
differentially expressed in our rotenone treated cells and was determined to have high 
regional expression in the substantia nigra (Table 2, Figure 4) (Henderson-Smith et al. 
2018). This observation is strengthened with another study that has found that 
differentially methylated genes in the blood have high concordance with differentially 
methylated genes in the brain (Masliah et al. 2013). These data partially support our 
hypothesis that environmentally induced changes in DNMT1-dependent ASMs in the 
human brain can alter the risk of neurodegeneration. 
DNMT1 expression in neural stem cells is essential for adult neurogenesis and the 
survival of adult neurons in the brain (Noguchi et al. 2015). We’ve shown that non-germline 
ASMs are dependent on DNMT1 in mice. The goal of this study was to identify conserved 
DNMT1-dependent regions and putative non-germline ASMs in the human genome and 
test the vulnerability of these regions to a neurotoxicant associated with Parkinson’s 
disease. Our work identified candidate, non-germline ASMs with DNMT1 dependence as 
enriched in the human brain. We discovered 14 genes have altered expression (>1.5-fold 
change) at predicted ASMs in response to rotenone.  We quantified methylation of 2 
identified regions at adjacent genes (HCN2 and NEFM) known to increase the risk for 
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Parkinson’s disease and observed significant hypomethylation. In the future, a larger 
panel of these identified regions in the human genome will be tested in other cells lines at 
varying points in neuronal differentiation to determine the role of non-germline ASMs on 
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Table 3.4 Gene Ontology cell component enrichment analysis 
 

















Table 3.5 Human DNMT1-dependent Genes Altered by rotenone* 
 
Gene Log2FC FDR Region 
Type 
Function/Process 
MYH3 -1.62 3.31E-09 intragenic myosin protein; cell 
movement and transport 
PPFIA4 -1.37 2.59E-13 intragenic neurotransmitter release 
synaptic function 
COL9A2 -0.79 1.53E-04 intragenic collagen; extracellular matrix 
organization 
DNAAF3 -0.78 3.59E-02 intragenic dynein protein assembly; cell 
movement 
LRRC8D -0.78 8.42E-05 intragenic ion channel protein; 
neurotransmission 
PLEKHG4 -0.65 2.74E-03 intragenic guanine exchange factor; cell 
signaling 
ADRA2C 0.59 2.93E-02 intergenic neurotransmitter release 
synaptic function 
EML2 0.62 5.99E-05 promoter microtubule protein; synaptic 
function 




KDM7A 0.67 1.16E-04 intergenic histone demethylase; 
neurodevelopment 
PHLDB3 0.76 3.75E-04 intragenic enzyme binding; cell growth 
and proliferation 
GIPR 0.76 2.37E-02 promoter gastric inhibitory peptide; 
insulin release 
BCL3 0.78 2.00E-02 intragenic proto-oncogene; cell growth 
and proliferation 
NEFM 0.80 4.33E-07 intragenic neurofilament; synaptic 
function 
 
* Log2FC is the log base 2 fold change of the FPKM read counts of the rotenone treated 
HEK293 relative to the vehicle control. FDR is the adjusted p-value using the false 





Table 3.6 CpG Methylation HCN2 
 
CpG site q-value Δme 
42 6.8E-18 -7.0 
54 5.4E-06 -2.6 
58 3.3E-04 -1.8 
78 1.7E-04 -1.7 
140 8.3E-19 -3.9 
142 3.6E-13 -3.3 
160 2.5E-25 -6.0 
164 7.6E-17 -5.0 
180 3.0E-13 -4.9 
364 5.0E-05 -1.2 
406 2.3E-04 1.0 
420 1.2E-12 1.7 
444 5.4E-06 1.5 
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Figure 3.1 Characterization of DNMT1-dependent regions from mouse conserved in 
human genome.  
A) The percent span of the DNMT1-dependent regions in mouse covered by the identified 
human conserved regions. Pie chart represents the percentage of all identified conserved 
regions in the human genome that fall into each category. B) The percent base pair match 
of the DNMT1-dependent regions in mouse with the identified human conserved regions. 
Pie chart represents the percentage of all conserved regions in the human genome that 
fall into each category. C) The percentage of all conserved regions in the human genome 
that are located within the promoter, the gene body, or in non-coding intergenic regions. 
D) The top transcription factor binding sites found within all human conserved regions. E) 
The percentage of known germline ASMs in our conserved DNMT1-dependent regions 







Figure 3.2 Functional enrichment analysis of DNMT1-dependent genes conserved 
in the human genome.  
A) Gene Ontology enrichment for cellular processes and molecular functions from the 112 
selected human DNMT1-dependent genes (adjusted p-value; false discovery rate 
FDR<0.05). B) Network interactions from STRING database with an interaction 






Figure 3.3 Tissue enrichment analysis of DNMT1-dependent genes conserved in the 
human genome.  
A) The top 6 tissues represented from the 112 selected human DNMT1-dependent genes 
(adjusted p-value<0.01) scored from Enrich R using the ArchS4 human tissue database 





that are tissue-enriched, tissue-enhanced, or group-enriched genes within the cerebral 
cortex from Tissue Enrich (adjusted p-value shown). 
 
Figure 3.4 RNA sequencing validation with qRT-PCR.  
Fold change comparison of RNA sequencing results versus qRT-PCR results and the 
linear calibration curve of RNA sequencing results with qRT-PCR results expressed as 





Figure 3.5 Regional expression of DNMT1-dependent genes altered by rotenone. 
Human DNMT1-dependent genes that were differentially expressed (≥1.5 fold change, 
false discovery rate FDR≤0.05) in response to rotenone were used for regional expression 
analysis in the Genotype-Tissue Expression (GTex) database. Brain regions selected are 
associated with Parkinson’s disease pathogenesis and important for motor function 
control. The heat map was generated using GTex and organization is clustered by gene 
function and tissue function. The color of each square indicates the level of expression of 






Figure 3.6 Bisulfite amplicon sequencing analysis 
A) Correlation coefficients of Bisulfite sequencing data between biological replicates of 
control and rotenone treated samples. B) Sequencing coverage of CpG sites within 
amplified regions at HCN2 and NEFM. The average total coverage for all CpG sites within 






Figure 3.7 Altered CpG methylation at HCN2 human DNMT1-dependent locus. A) 
Genomic location of identified HCN2 DNMT1-dependent region. The DNA element and 
distance from the transcription start site is annotated in black. The primer region box 
indicates the amplified region for Bisulfite-sequencing. B) The percent methylation of all 
CpG sites within the amplified region. Delta indicates the change in the mean CpG 
methylation percentage and the associated false discovery rate. C) The percent 
methylation of individual CpG sites within the amplified region. Significant differentially 






Figure 3.8 Altered CpG methylation at NEFM human DNMT1-dependent locus.  
A) Genomic location of identified NEFM DNMT1-dependent region. The DNA element and 
distance from the transcription start site is annotated in black. The transcription factor 
binding site for CTCF was annotated from ENCODE v2 and ENCODE Uniform TFBS 
tracks in Genome Browser. The primer region box indicates the amplified region for 
Bisulfite-sequencing. B) The percent methylation of all CpG sites within the first 200 base 
pairs of the amplified region. Delta indicates the change in the mean CpG methylation 
percentage and the associated false discovery rate. C) The percent methylation of 
individual CpG sites within the amplified region. Significant differentially methylated 




ALPHA-SYNUCLEIN MEDIATES CHANGES IN DNA 
METHYLATION PATTERNS IN HUMAN NEURONS BY 
INTERFERING WITH DNMT1 TRANSLOCATION AND 




 The aggregation of the neural protein α-Synuclein (α-Syn) is a hallmark of 
Parkinson’s disease (PD) pathology and has become an attractive target for 
pharmaceutical intervention. Our data indicate that rotenone promotes α-Syn 
accumulation, and our previous study demonstrated vulnerability of DNA methylation 
patterns at allele-specific methylated regions and CTCF binding sites to the PD toxicant 
rotenone. Herein we hypothesized that rotenone-induced α-Syn mediates changes in DNA 
methylation patterns, causing global epigenetic reprogramming and genomic instability. 
To test our hypothesis, we treated human neuronal cell line SH-5YSY with rotenone for 
24h and reported that rotenone induced α-Syn interacts with DNA methyltransferase1 
(DNMT1). This interaction was associated with reduced DNMT1 translocation to the 
nucleus and global reductions in DNA 5-methylcytosine. Reduction of α-Syn expression 
significantly increased nuclear levels of DNMT1 (1.3-fold, p<0.05) and fortified 
mitochondria to rotenone exposure. Analysis of transcriptomic changes caused by 
rotenone exposure in control α-Syn and knockdown α-Syn neurons revealed a significant 
increase in the cellular defense response (p<10-3) and the differential expression of genes 
that regulate p53 activation, dopamine synthesis, neurogenesis, and one-carbon 
metabolism. Intriguingly, α-Syn accumulation suppressed the hypoxic response to 
rotenone in SH-5YSY and altered the expression of prominent DNMT1-dependent 
imprinted genes. We discovered that targeting α-Syn partially rescued the hypoxic 
response and up-regulated the expression of hypoxia inducible factor (HIF1α) target 
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genes. The rescue of the hypoxic response can activate DNA methyltransferases and has 
the potential to increase DNA methylation patterns at imprinted control regions of DNMT1-
dependent genes. We concluded that α-Syn knockdown did in fact rescue methylation 
patterns at both hypoxic response elements and in allele-specific methylated regions 
indicating a critical role for α-Syn mediating the epigenome.  
4.2 Introduction 
 
 Alpha-synuclein (α-Syn) is an endogenous protein that localizes to the pre-
synaptic membrane and associates with synaptic vesicles to facilitate neurotransmission 
(Ghiglieri et al. 2018). The structure of α-Syn consists of a lysine-rich, lipid-binding amino 
terminus and a disordered, acidic carboxyl terminus which interacts with synaptic proteins 
including the SNARE complex and the dopamine active transporter (Lashuel et al. 2013). 
The expression of α-Syn requires tight regulation. A lack of α-Syn can induce behavioral 
motor deficits (Abeliovich et al. 2000) and leads to a reduction of dopaminergic neurons 
in the substantia nigra during development (Garcia-Reitboeck et al. 2013). However, 
overexpression of α-Syn can drive oligomerization and disrupt neuronal function 
preventing proper neurotransmission (Scott et al. 2010). α-Syn aggregation into inclusion 
bodies (i.e. Lewy bodies) is associated with a disease phenotype known as a 
synucleinopathy and is a prominent feature in PD. 
 The gene encoding α-Syn is SNCA, and it was among the first genetic risk factors 
for PD (Singleton et al. 2004). Point mutations in the gene can promote misfolding and 
accumulation (Scott et al. 2010, Ghiglieri et al. 2018). Copy number variations are also 
associated with pathological Lewy bodies (Singleton et al. 2003) and reported to have a 
dose-response relationship with the risk of PD (Singleton et al. 2004). Oxidative stress 
and mitochondrial dysfunction can induce Lewy body formation in experimental models 
making α-Syn a powerful driver of both familial and sporadic PD (Uversky et al. 2001).  
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 α-Syn also regulates gene expression and affects the expression of genes involved 
in the cellular stress response, epigenome editing, and dopamine synthesis (Baptista et 
al. 2003, Desplats et al. 2011, Motyl et al. 2018). DNA methylation regulates SNCA 
expression (Jowaed et al. 2010) and regulatory methylation has been reported at intron 1 
of the SNCA gene (de Boni et al. 2015). Levodopa, the current primary treatment for PD, 
replaces dopamine in the brain and is associated with increased DNA methylation (Lu et 
al. 2013). DNA methylation and α-Syn aggregation are inversely correlated but the nature 
of their interaction remains a challenge to characterize (Jowaed et al. 2010, Kantor et al. 
2018). However, it has been demonstrated in a genetic model of PD, that α-Syn 
aggregation can inhibit the functional role of DNA methyltransferases (DNMTs) in-vitro 
(Desplats et al. 2011).  
 Rotenone-induced oxidative stress causes a conformational change in α-Syn and 
accelerates its fibrillization in-vitro (Uversky et al. 2001). Our previous data demonstrate 
that rotenone causes global decreases in DNA methylation and affects methylation 
patterns at allele-specific methylated regions with dependence on DNA methylation 
enzyme, DNA methyltransferase I (DNMT1) (Freeman et al. 2020). We have also 
examined altered DNA methylation within CTCF binding motifs at PD associated genes 
that modified CTCF binding and insulator activity (Chapter 2B). These changes can have 
widespread effects on chromatin organization and genomic stability.   
 The first goal of this study was to examine the association of rotenone-induced α-
Syn with DNMT1 activity in a human neuronal cell line. Our data revealed that 
accumulated α-Syn reduced global DNA methylation patterns in SH-5YSY cells (Figure 
4.2). Our data agreed with another study in SH-5YSY that used viral induced 
overexpression of α-Syn to show decreases in global DNA methylation (Desplats et al. 
2011). Studies have shown that inhibition of DNMT1 with the pharmacological inhibitor 5-
Aza-2′-deoxycytidine increases the sensitivity of neurons to rotenone (Wang et al. 2013) 
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and that knockdown of SNCA expression makes neurons less susceptible to oxidative 
damage (Zharikov et al. 2015). Our next goal was to investigate the consequences of 
these findings by analyzing changes in the transcriptome and methylome of neuronal cells 
to rotenone both with and without α-Syn (using RNAi knockdown in SH-5YSY) influence. 
Our hypothesis is that rotenone-induced α-Syn mediates dysregulated maintenance of the 
methylome in neurons by impacting DNMT1 translocation to the nucleus (Figure 4.1).  
4.3 Materials and Methods 
 
4.3.1 Cell culture and treatment of human cell line SH-5YSY 
All media reagents and chemicals in cell culture were purchased from Sigma (St. 
Louis, MO). SH-5YSY were grown in Dulbecco’s Modified Eagle Medium with high 
glucose, L-glutamine, and sodium pyruvate. Media was supplemented with 10% (v/v) heat 
inactivated fetal bovine serum and 1% (v/v) Penicillin-Streptomycin. SH-5YSY cells were 
confirmed by ATCC. Cells were treated at approximately 60% confluency with rotenone 
(200 nM) or DMSO vehicle control (<0.001%) for 24h.  
4.3.2 Rotenone induced α-Syn accumulation 
 SH-5YSY cells were collected after 24 hours treatment and cells were lysed with 
Pierce IP lysis buffer (ThermoFisher, Waltham, MA) with 1% protease inhibitor cocktail 
(P8340, Sigma, St. Louis, MO). Protein concentration from lysate was measured by Qubit 
Protein Assay from ThermoFisher (Waltham, MA). Protein (30 µug) was loaded onto 4-
15% Bio-Rad Page Gels and transferred to 0.45 um nitrocellulose (Bio-Rad, Hercules, 
CA). The blots were incubated with α-Syn primary antibody (1:2500; Abcam ab138501) or 
GAPDH (1:5000; Sigma G9545) overnight at 4°C and anti-rabbit IgG conjugated 
secondary antibody (1:5000, Santa Cruz Biotechnology Sc-2357) for 1h at room 
temperature. Blots were visualized with chemiluminescence using ECL from GE 
Healthcare (Sigma, St. Louis, MO). We normalized α-Syn protein to GAPDH and 
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quantified with Image J software. We tested significance by comparing the ratio of α-
Syn/GAPDH with a two-tailed Student’s paired t-test.  
4.3.3 Global DNA methylation analysis 
 Genomic DNA was extracted from three replicates of DMSO- or rotenone-treated 
SH-5YSY using 1:1:1 Phenol: Chloroform: Isoamyl alcohol (Sigma, St. Louis, MO). Global 
DNA methylation was first measured by dot blot analysis. Bisulfite treated DNA (30-60 
ng/µL) was denatured at 95°C for 5 minutes and then cooled at 4°C for 5 minutes in a 
conventional thermocycler (Mycycler; Bio-Rad; Herclues, CA). DNA was spotted onto 0.45 
micron nitrocellulose paper as 1 or 2 uL drops and dried for 30 minutes at room 
temperature. The membrane was UV crosslinked at 3000 Hz and incubated in anti-5mC 
primary antibody overnight at 4°C (Epigenetek 33D3; Farmingdale, NY). The membrane 
was washed with TBST and incubated with secondary antibody conjugated to HRP at 
room temperature (Santa-Cruz Biotechnology anti-mouse IgG sc-2005; Dallas, TX). The 
membrane was washed again with TBST after secondary incubation and visualized with 
chemiluminescence using Promethus ProSignal Femto-ECL Reagent (20-302, Genesee 
Scientific, San Diego, CA).  
4.3.4 Co-immunoprecipitation of DNMT1 with α-Syn 
 SH-5YSY cells were collected after 24 h treatment and cells were lysed in Gibco 
phosphate buffer saline (PBS) pH 7.4 (ThermoFisher, Waltham, MA). PBS was 
supplemented with 1.25 M sucrose, 0.5 M EDTA (E9884), 0.5 M EGTA (E3889), 1% 
protease inhibitor cocktail (P8340), and 0.5% Triton-X (T8787) (Sigma, St. Louis, MO). 
Protein concentration from lysate was measured by Qubit Protein Assay from 
ThermoFisher (Waltham, MA). Protein input (10%) was saved before co-
immunoprecipitation. We bound 4 µg α-Syn (Abcam 13850) and rabbit IgG (negative 
control, Cell Signaling Technologies 2729) at room temperature before being incubated 
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with protein lysate (0.5-1 mg) at 4°C overnight. After incubation, beads were washed and 
resuspended in the lysis buffer with 4x Laemmli. 
 Samples were denatured with bead at 95°C for 5 minutes and then loaded onto 4-
15% Bio-Rad Page Gels (Bio-Rad, Hercules, CA). We transferred the proteins to 0.45 µm 
nitrocellulose membrane and incubated with α-Syn (1:2500; Abcam ab138501) and 
DNMT1 (1:1000, Imgenex IMG-261A) overnight at 4°C. We incubated with secondary anti-
rabbit and anti-mouse IgG (1:5000, Santa Cruz Biotechnology sc-2357 & sc-2005) for 1h 
at room temperature. The blots were visualized by chemiluminescence with Promethus 
ProSignal Femto-ECL Reagent (20-302, Genesee Scientific, San Diego, CA).  
4.3.5 siRNA transfection and treatment of human cell line SH-5YSY 
SH-5YSY cells were plated in regular cell culture (4.3.1) until they reached 40% 
confluency. The media was then replaced with Opti-MEM with no additional supplements 
and transfected with lipofectamine RNAiMAX (ThermoFisher, Waltham, MA). The siRNA 
for SNCA knockdown was purchased with the TriFECTa DsiRNA Kit (ID hs.Ri.SNCA.13) 
from IDT Technologies (Coralville, IA). We first tested transfection conditions after 24h 
with the TYE 563 transfection control provided by the TriFECTa kit at 10nM concentration. 
We tested three separate double-stranded siRNA for SNCA knockdown after 24h post-
transfection using qRT-PCR (details 4.3.10) using primers for SNCA (F: 
GCAGCCACTGGCTTTGTCAA; R: AGGATCCACAGGCATATCTTCCA). We ran 
Western blot after 48h post-transfection to ensure α-Syn protein level was also reduced 
after knockdown (details 4.3.2). We chose siRNA-2 (hs.Ri.SNCA.13.2) at 10 nM and used 
a scramble siRNA at the same concentration for the negative control (Neg Ctrl). Cells were 
treated based on Table 4.1. After transfection (36h), the media was replaced with fresh 
Opti-MEM containing treatment (DMSO or 200 nM rotenone), lipofectamine RNAiMAX, 
and 5 nM siRNA (scramble or SNCA) for 24h.   
4.3.6 Toxicity assays on control and α-Syn knockdown SH-5YSY cells 
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 Mitochondrial viability was estimated with the Presto Blue viability reagent 
(ThermoFisher, Waltham, MA). The reagent was added at 10% (v/v) and incubated for 1h 
at 37°C before measuring fluorescence (excitation 530 nm/ emission 590 nm). Intracellular 
reactive oxygen species (ROS) were measured with the DCFDA intracellular ROS assay 
according to kit instructions (Abcam, Cambridge, UK). Mitochondrial number was 
estimated with Mitotracker Red FM (Invitrogen, M22425). Following treatment, cells were 
incubated with Mitotracker (500 nM) for 1h at 37 °C. Cells were fixed with 1.5% 
formaldehyde for 10 mins at room temperature before fluorescence was measured at 
580/640 nm. Mitochondrial DNA (mtDNA) copy number was estimated from 5 ng total 
DNA using a qPCR method published by Grady et al. 2014. We compared the 
mitochondrial gene ND1 (F: ATGGCCAACCTCCTACTCCT; R: 
GCGGTGATGTAGAGGGTGAT) to genomic genes BECN1 (F: 
CGAGGCTCAAGTGTTTAGGC; R: ATGTACTGGAAACGCCTTGG) and B2M (F: 
CCAGCAGAGAATGGAAAGTCAA, R: TCTCTCTCCATTCTTCAGTAAGTCAACT). 
Statistical hypothesis testing with results from toxicity assays was done with a one-way 
ANOVA and the post-hoc Tukey honest significant differences test to correct for multiple 
hypotheses. The expression data from mtDNA quantification was analyzed with a one-
way ANOVA and post-hoc pairwise t-test calculation with p-value correction using the false 
discovery rate (FDR) adjustment method. 
4.3.7 Nuclear localization of DNMT1 in response to rotenone 
 Cells were lysed with PBS lysis buffer (from 4.3.4) with only 0.05% Triton-X. Whole 
cell lysate (20%) was saved to test nuclear isolation. Cells were centrifuged at 600 x g for 
6 minutes at 4°C and the supernatant was removed from the nuclei. Nuclei were washed 
in lysis buffer without supplementation and resuspended in fresh PBS lysis buffer with 
0.5% Triton-X. Whole cell lysate and nuclear lysate was sonicated in an Ultrasonic Bath 
Sonicator three times for ten seconds each. We ran 15 µg of the whole cell lysate versus 
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the nuclear lysate on Western blot with nuclear marker H3 (1:1000, ab1791), cytoplasmic 
marker GAPDH (1:1000, G9549), and DNMT1 (1:1000, IMG-261A). We quantified DNMT1 
in both whole cell lysate and nuclear lysate relative to H3 using Image J software. We 
tested significance by comparing the ratio of DNMT1/H3 with a two-tailed Student’s paired 
t-test and a post-hoc false-discovery p-value correction. 
4.3.8 RNA extraction and RNA sequencing library construction 
Total RNA was extracted from two replicates of SH-5YSY using the Trizol method 
(Invitrogen, Carlsbad, CA). A total of 2 μg per sample was used for library construction 
using the TruSeq Sample Preparation kit from Ilumina (San Diego, CA). Poly-A containing 
mRNA 3molecules were isolated from total RNA using oligo-dT attached magnetic beads. 
Isolated mRNA was then fragmented and synthesized into double stranded cDNA 
according to kit instructions. Ligation of unique Ilumina adapter indices was completed for 
each sample before bead purification. Libraries were loaded onto a 2% agarose gel and 
library products between 200-800 bp were purified using the mini-Elute gel extraction kit 
from Qiagen (Hilden, Germany). Approximately 150 ng was sent for sequencing on a 
HiSeq-X platform with 100 bp paired-end reads. 
4.3.9 RNA sequencing analysis  
 The raw BCL files were converted into FastQ files using CASAVA 1.8.2 (CASAVA).   
Raw sequencing reads were processed using TaRGETII RNA-seq pipeline which was 
prepared for large size RNA-seq sample processing 
(https://github.com/ShaopengLiu1/RNA-seq_QC_analysis). Cutadapt (V2.8) (Martin 
2011) was used to remove any remaining adapter sequences from the high throughput 
sequencing reads. Sequencing reads were aligned to the human genome (hg38) with 
STAR aligner (v2.5.4b) (Dobin et al. 2013). For mRNA analyses, the Gencode database 
(Gencode version 27) was chosen as the annotation reference. Read counts of annotated 
genes were counted using featureCount from the SubRead package (Liao et al. 2013). 
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The raw read counts of each transcript were normalized by library size, then further 
normalized based on empirical controls using RUVg from the RUVseq package (REF-
PMID: 25150836). Differentially expressed genes were defined as those with a 1.5-fold 
change in expression using an FDR<0.05 from the edgeR package (Robinson et al. 2010). 
Gene Ontology annotation was done with the GOrila and the EnrichR online platforms and 
visualized with Revigo (Eden et al. 2009; Chen et al. 2013; Supek et al. 2011). Biological 
pathway analysis was done with KEGG Human Pathways 2019 and reactome pathway 
analysis (Kaneisha et al. 2019; Fabregat et al. 2018).  
4.3.10 qRT-PCR validation 
 Total RNA was extracted from an additional replicate of control and α-Syn 
knockdown. Both control and knockdown SH-5YSY cells treated with DMSO or rotenone 
were used using the same procedures as stated above. A total of 500 ng RNA was 
converted to cDNA with the PrimeScript RT reagent kit with gDNA eraser from Takara 
(Kusatsu, Japan). We selected twelve genes for quantitative PCR (qRT-PCR) analysis 
using primers listed in Table 4.2. All qRT-PCR reactions were performed on a 7500 Real-
Time PCR system from Applied Biosystems (Foster City, CA) using the iTaq Universal 
SYBR Green Supermix from Bio-Rad (Hercules, CA). The change in expression was 
normalized to the GAPDH housekeeping gene and expressed as fold change (2-ΔΔCT).  
4.3.11 Bisulfite-DNA conversion and Bisulfite-amplicon sequencing library construction 
Genomic DNA was extracted from two replicates of DMSO or rotenone-treated 
SH-5YSY using Phenol: Chloroform: Isoamyl alcohol (Sigma, St. Louis, MO). A total of 
200 ng DNA was Bisulfite-converted using the Sigma DNA Imprint Modification kit two-
step protocol. Bisulfite-converted DNA (BS-DNA) was amplified with primers for selected 
DNMT1-dependent regions and hypoxic pathway regions designed in MethPrimer (Li and 
Dahiya 2002) (Table 4.3). Amplified BS-DNA products were run on a 2% EtBr agarose gel 
and purified using the mini-Elute gel extraction kit from Qiagen (Hilden, Germany). Purified 
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products for each sample were pooled together and 1 ng was used for library preparation 
using the Ilumina Nextera DNA Library Preparation kit. Each sample was tagged with a 
unique Nextera XT adapter (San Diego, CA). Sequencing libraries were quality checked 
via Bioanalyzer and run on an Ilumina NovaSeq platform to generate 150 bp paired end 
reads.  
4.4.12 Bisulfite-amplicon sequencing analysis 
The raw fastq files were imported into the Galaxy web platform (Afgan 2016). 
Reads with quality score >30 were trimmed with Trim Galore (Krueger 2015). Reads were 
mapped to amplified sequences in the human genome (hg38) using bwa-meth (Pederson 
et al. 2014). MethylDackel was used for methylation calling and per-cytosine contexts 
were merged into per-CPG metrics (https://github.com/dpryan79/MethylDackel). 
Duplicates and singletons identified in alignment were ignored from the methylation call. 
Minimum and maximum per-base depths 3were 1000x and 100,000x, respectively. The 
output was selected for methylKit format. Coverage statistics and differentially methylated 
regions were calculated for CpG sites with methylKit installed in R (v3.5) (Akalin et al. 
2012). Differentially methylated cytosines were defined as being present in both biological 
replicates, having a minimum absolute difference of 0.1% using the coverage weighted 
mean, and having a SLIM adjusted q-value<0.05 using the methylKit logistic regression 
model (Ning et al. 2011). The change in mean percent methylation (Δme) for all CpG sites 
within a defined region was calculated by taking the mean number of methylated versus 
non-methylated CpG sites from the pooled control and treated samples and using Fisher’s 
exact test p<0.05.  
4.5 Results 
4.5.1 Rotenone-induced a-Syn accumulation is associated with DNA hypomethylation. 
 We selected a rotenone dose of 200 nM for 24h based on our results in HEK293 
(Chapter 2A.4.1). This dose was also shown by other labs to induce endogenous protein 
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levels of α-Syn in SH-5YSY cells (Sala et al. 2013, Chorfa et al. 2013). We checked with 
Western blot and observed significant accumulation of α-Syn (1.3-fold change, p<0.05) 
(Figure 4.2). We examined global DNA methylation with dot blot and observed genome-
wide reductions like those found in HEK293 cells (Chapter 2 Figure 2.4) (Figure 4.2). 
Together, we conclude that rotenone exposure-induced α-Syn leads to DNA 
demethylation. 
4.5.2 Co-immunoprecipitation of DNMT1 occurs only in rotenone treated cells.  
 To explore the mechanism behind changes in global DNA methylation after 
exposure, we tested our hypothesis that accumulated α-Syn impacts DNMT1 from 
maintaining methylation patterns. Co-immunoprecipitation of α-Syn pulled down DNMT1 
only in rotenone-treated cells but not in control cells, thus providing evidence that 
endogenous α-Syn can interact with DNMT1 inside the cell after exposure (Figure 4.3). 
Because rotenone exposure induced more α-Syn within treated cells, it may suggest that 
either increased protein level of α-Syn or exposure-altered conformation changes of α-
Syn (or both) initiated protein-protein interaction. 
4.5.3 siRNA transfection and knockdown of SNCA in SH-5YSY neuronal cell line. 
 Given the fact that copy number variations of the SNCA gene linearly increases 
risks for familial PD (Singleton et al. 2004), it suggests that dysregulated α-Syn 
(presumably over a threshold) plays a causal role in PD pathogenesis. To explore the 
hypothesized role of accumulated α-Syn in PD, we aim to use RNAi to reduce rotenone-
induced α-Syn, and then check cellular responses. We optimized transfection conditions 
by using visual transfection of the TYE-563 fluorescent dye with fluorescence microscopy 
(Figure 4.4). We tested SNCA knockdown with three independent siRNAs provided by the 
IDT TriFECTa kit using qRT-PCR and chose hs.Ri.SNCA.13.2 based on its ability to 
significantly reduce both SNCA transcripts and α-Syn protein in non-treated and rotenone 
treated SH-5YSY cells (Figure 4.4). The knockdown efficiency of siRNA in qRT-PCR was 
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0.07-fold in non-treated cells and 0.16-fold in rotenone treated cells (p<0.01). The protein 
level of α-Syn was reduced -1.0-fold in non-treated cells and -0.8-fold in rotenone treated 
cells (p<0.05).  
4.5.4 α-Syn knockdown cells were resistant to rotenone toxicity in-vitro.  
 To determine the extent to which α-Syn knockdown cells were resistant to rotenone 
toxicity, we used four independent tests of mitochondrial viability and function (Figure 4.5). 
We used the Presto Blue viability assay to measure mitochondrial reduction capacity as a 
proxy for mitochondrial viability. α-Syn knockdown resulted in significantly higher viability 
of mitochondria treated with rotenone when compared to the negative control cells. 
Oxidative stress is a common result of mitochondrial damage and we observed increases 
in intracellular ROS in rotenone-treated HEK293 cells (Chapter 2A.4.1). In our SH-5YSY 
model, rotenone increased intracellular ROS only in control cells. There was an increase 
in ROS in negative control cells (1.2-fold change) but it was not significant. There was no 
observed increase in oxidative species in knockdown cells. The number of mitochondria 
was estimated with the Mitotracker FM Red fluorescent dye. Both control and negative 
control cells had reduced mitochondrial fluorescence signal in response to rotenone (0.5-
fold and 0.6-fold, respectively) (p<0.05). There was no change in fluorescence in rotenone 
treated knockdown cells. Lastly, we used mtDNA copy number as a surrogate for 
mitochondrial function using the relative abundance of genes encoded by nuclear DNA 
(BECN1 and B2M) with a gene encoded only in mitochondria (ND1). Mitochondrial gene, 
ND1, encodes the mitochondrial electron transport chain complex I which is targeted by 
rotenone. This region is highly conserved in mitochondria and reported to be closely 
associated with mitochondrial respiratory function (Grady et al. 2014). We observed a 
significant decrease in mtDNA copy number in control and negative control cells but not 
in α-Syn knockdown cells. This was consistent regardless of which genomic gene was 
used to estimate relative copy number. Therefore, our data demonstrate that targeting α-
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Syn protects neuronal cell line SH-5YSY viability by fortifying mitochondria from 
propagated oxidative damage induced by rotenone (Figure 4.5). Altogether, we conclude 
that α-Syn plays a critical role in mediating the effects of the mitochondrial stress response 
on chromatin structure in neurons.  
4.5.5 DNMT1 nuclear protein in response to rotenone is increased in α-Syn knockdown 
neurons. 
 We showed that rotenone-induced α-Syn can interact with DNMT1 in control SH-
5YSY cells. To investigate whether this interaction can obstruct DNMT1 from translocating 
to the nucleus, we measured nuclear levels of DNMT1 protein in control and knockdown 
cells exposed to rotenone (Figure 4.6). In control cells, rotenone did not affect whole cell 
concentrations of DNMT1 protein but decreased nuclear protein (control: 0.56-fold; 
negative control: 0.68-fold). In α-Syn knockdown cells, rotenone did not affect whole cell 
or nuclear concentrations of DNMT1. Nuclear DNMT1 level was increased in rotenone-
treated α-Syn knockdown compared to the negative control (p<0.05).  
4.5.6 Rotenone alters the expression of genes involved in mitochondrial and neuronal 
health.  
 To gain insights of rotenone alteration at the transcriptomic level, we examined 
changes in the transcriptome of rotenone treated control cells using RNA sequencing. 
RNA-seq analyses identified 526 genes differentially expressed in response to exposure 
(FDR<0.05). Most of the genes identified are involved in functions within the nucleosome 
or at the neuronal synapse (Figure 4.7). Another cellular structure involved in the cellular 
response was the axolemma which is the membrane of the neuronal axon responsible for 
maintaining the action potential to support neurotransmission. The biological processes 
significantly altered were involved in glucose metabolism, ATP generation, and the cellular 
response to hypoxia (Figure 4.7). We focused on which of these processes were up-
regulated versus down-regulated in our dataset using a ranked list of our genes separated 
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by log2FC and ordered by significance (FDR) (Figure 4.7). Processes involved in cell 
death and the mitochondrial mediated intrinsic apoptotic pathway were among those up-
regulated. We also observed TP53 activation, DNA damage response, and cell cycle 
arrest in our pathway enrichment analysis using reactome (p<0.01). In contrast, 
neurogenesis and neuronal development and maturation were down-regulated. We 
highlighted four genes with a key role in these pathways in Figure 4.7. The significance of 
these genes is in the discussion section.  
4.5.7 Rotenone treatment in α-Syn knockdown cells alters the oxidative stress response. 
 We identified 128 genes that were differentially expressed in response to rotenone 
in knockdown cells. The axon remained a primary cellular component for these genes. 
Only three biological processes were significantly enriched (FDR<0.05) (Figure 4.7). 
These biological processes are relevant to the hypoxic response and are hypothesized to 
have a role in neurodegeneration as discussed in the discussion section. Among up-
regulated genes, central nervous system neuronal differentiation and the bone 
morphogenesis pathway were represented using Gene Ontology annotations (p<0.05). 
The down-regulated genes were enriched in biological processes associated with cell 
migration and mesenchymal cell proliferation (Figure 4.7).  
 We also analyzed the enriched molecular functions in knockdown cells exposed to 
rotenone (p<0.05) (Figure 4.7). The top molecular functions represented (p<0.001) 
included carbonic anhydrase activity in the antioxidant response and transmembrane 
transporter activity. Carbonic anhydrases are regulators of the oxidative metabolism of 
glucose and thus play a part in the propagation of damage induced by intracellular ROS 
(Shah et al. 2013). Transmembrane water and ammonia transporters are also critical to 
maintain cellular homeostasis under cellular stress. For instance, dysregulated 
intracellular concentrations of ammonia initiate mitochondrial permeability in apoptosis 
(Rama et al. 2005). While α-Syn knockdown does not prevent oxidative stress caused by 
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rotenone inhibition of mitochondrial respiration, we did not discover the same associated 
effects on ATP generation, neurogenesis, or neuronal differentiation. This agrees with our 
earlier conclusion that targeting α-Syn confers resistance by strengthening mitochondria 
from propagated oxidative damage caused by rotenone complex I inhibition (Figure 4.5).  
 4.5.8 α-Syn knockdown increases the expression of genes in the cellular defense 
response. 
 Out of the 526 genes differentially expressed in rotenone-treated negative control 
cells and 129 genes in rotenone-treated α-Syn knockdown cells, 73 genes overlapped 
both datasets. These concordant genes were involved in endothelial cell migration, 
mesenchymal transition, and transporter activity as noted in the knockdown cells (Figure 
4.7). To compare the differences in the cellular response to rotenone, we analyzed 
differential gene expression between rotenone-treated negative control cells and 
rotenone-treated α-Syn knockdown cells. There were 190 altered genes that altered the 
cellular response to rotenone. We analyzed the functional annotation of all differentially 
expressed genes as a single rank list in the order of expression (high Log2FC to low 
Log2FC) and revealed the enrichment the cellular defense response mediated by α-Syn 
knockdown (p<0.001) (Figure 4.8).  We analyzed the pathways involved in these 190 
genes with the 2019 KEGG Human pathway database (Figure 4.8). The top pathways with 
p<0.001 were one-carbon metabolism and HIF-1α signaling. We looked at which 
pathways were associated with up-regulated versus down-regulated genes. We 
discovered that HIF-1α signaling was correlated with up-regulated genes (p<0.001) and 
TGF-β signaling was correlated with down-regulated genes (p<0.05). HIF-1α signaling in 
the hypoxic response to rotenone was significantly increased in α-Syn knockdown cells 
even after p-value adjustment for multiple hypotheses (p<0.001, q<0.05). We selected 12 
genes from Tables 4.4 and 4.5 for validation by qRT-PCR. We observed similar trends in 
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expression between datasets and the linear curve had a correlation coefficient (R2) of 0.66 
(Figure 4.9). 
 In general, the ischemic response mediated by HIF1α results in DNA 
hypermethylation due to the activation of DNA methyltransferases (Tothova et al. 2018). 
HIF1α depletion is also associated with increased homocysteine levels which lowers 
methylation capacity. Protein unfolding is associated with HIF1α repression therefore we 
hypothesize the effect of rotenone on hypoxia response via α-Syn aggregation. We 
examined DNA methylation patterns at hypoxia-response elements (HRE) in the promoter 
regions of differentially expressed hypoxia response genes to determine if α-Syn down-
regulation was mediated by its interaction with DNMT1 (Table 4.4).  
4.5.9 DNMT1-dependent genes with allele-specific methylated regions are differentially 
expressed in α-Syn knockdown cells.  
 We previously investigated DNMT1-dependent regions in the human genome and 
showed that DNA methylation patterns in two of these PD associated regions, at HCN2 
and NEFM, were vulnerable to rotenone exposure (Freeman et al. 2020). Similarly, we 
tested the extent to which DNMT1-dependent genes would also be affected in our 
rotenone-treated SH-5YSY cells and α-Syn knockdown would reverse altered DNA 
methylation patterns due to uninhibited DNMT1 nuclear translocation. We discovered 5 
genes in our rotenone treated negative control cells but none of these overlapped DNMT1-
dependent genes altered in rotenone treated HEK293 (Chapter 3; Table 3.5). Three genes 
(IGF2, KCNQ101T1, NNAT) were significantly up-regulated in α-Syn knockdown cells 
compared to the negative control. All three genes are imprinted and have neurological 
significance which is detailed in the discussion section.   
4.5.10 Differential methylation patterns in α-Syn knockdown cells exposed to rotenone. 
DNA methylation at regions within HIF1-α transcription factor binding sites and 
within DNMT1-dependent regions was used to investigate genomic resilience to rotenone 
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treatment as a result of α-Syn knockdown (Table 4.3). We examined a total of 175 CG 
nucleotides from 10 regions surrounding 8 genes between rotenone treated negative 
control cells and rotenone treated α-Syn knockdown cells. From these nucleotides, 96 
CGs from 4 genes met our minimum coverage requirement >1000x in all four samples 
(Figure 4.10). We determined 91 CGs were differentially methylated (> | 0.1% |, q<0.01). 
We first focused on 3 genes involved in the hypoxic response (NDRG1, ID2, CDKN1A). 
All three genes had 36 differentially methylated CGs from a total of 43 CGs covering each 
hypoxic response element bound by HIF1α (Table 4.6). All three genes were significantly 
hypomethylated across each region (p=2x10-16) from Fisher’s Exact test (Figure 4.11). The 
decrease in DNA methylation at hypoxic response elements was correlated with the 
increase in the expression of genes NDRG1 and ID2 but not CDKN1A. We conclude that 
the increase in cellular defense via hypoxia response was partially mediated by DNA 
methylation at HIF1α binding elements in α-Synuclein knockdown cells exposed to 
rotenone. In the future, ChIP analysis of HIF1α binding will be useful in further examining 
this proposed effect of α-Syn on the hypoxic response. 
We next examined DNMT1-dependent regions which were previously shown to be 
vulnerable to rotenone (Chapter 3). We measured DNA methylation at five DNMT1-
dependent genes identified by RNAseq (Table 4.5). Of these five genes, DLK1 and GNAS 
had differentially methylated CGs that met our criteria (Table 4.7). One gene, NNAT, was 
measured when we loosened the criteria to calculate differential methylation of all CG sites 
with adequate coverage in at least one replicate. The other two genes, IGF2 and 
KCNQ101T1, did not have adequate CG coverage after normalization. 
For DLK1, all 13 CGs within the DNMT1-dependent region in the gene body were 
differentially methylated and 70% were hypomethylated compared to the rotenone treated 
control cells (Table 4.7). Interestingly, methylation across the entire DNMT1-dependent 
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region was hypermethylated albeit the changes were small (delta= 0.33%, p=8x10-10) 
(Figure 4.12). DNA hypermethylation of the gene body at DLK1 has been reported in the 
blood of PD patients in a cross-sectional analysis (delta= 0.2%, p=1x10-6). This suggests 
that the methylation state of the DNMT1 dependent region at DLK1 may be important in 
PD pathogenesis and could serve as a biomarker.  
For, GNAS the DNMT1-dependent region covered the promoter/intron 1 as well as 
the exon 1 sequences. We measured significant differential methylation at 42 of the 50 
CGs within this region and 71% of them were hypermethylated (Table 4.7). To determine 
if the entire region was differentially methylated, we divided it into two separate 500 bp 
amplicons and compared percent methylation with Fisher’s Exact test (p<0.05). The 
region covering the promoter and intron 1 was significantly hypermethylated (delta = 2.3%, 
p=3X10-7) while the region at exon 1 was not changed (delta= 0.55%, p=0.3) (Figure 4.12). 
Despite NNAT not being adequately covered in all replicates, we tested whether 
differential methylation correlated with the increased mRNA expression observed in α-Syn 
knockdown cells (Table 4.7). Like GNAS, we divided the entire DNMT1-dependent region 
at NNAT into two amplicons covering the promoter and intron 1. Out of the 28 CGs 
analyzed in the first region (chr20:37520661-37521558), 21 CGs met our criteria in at least 
one replicate and 86% of those CGs were hypomethylated (Table 4.7). The change in 
DNA methylation across the region was a striking -11.6% (p=2x1016). These results 
support our hypothesis that rotenone-induced α-Syn accumulation mediates changes in 
DNA methylation at vulnerable loci such as DNMT1-dependent regions. DNA methylation 
changes create genomic instability and can alter the expression of genes critical to 




 SH-5YSY neuroblastoma cells were treated with rotenone 200 nM for 24 h to 
induce features of Parkinson’s cellular pathology including reduced viability, decreased 
mitochondria and mtDNA copy number, increased oxidative stress, and dysfunction in 
metabolic state. While the SH-5YSY cell line is not specific to dopaminergic neurons, it is 
commonly used to model dopaminergic neurotoxicity in-vitro and genomics approaches 
have verified that genes associated with neuronal function and PD pathology are in-tact 
(Krishna et al. 2014). Importantly, we use PD as a model system to study rotenone’s 
effects on the neuronal epigenome because it’s association with pathology is well-studied 
in both human and animal models (as discussed in Chapter 1.1 and 1.2). However, 
rotenone toxicity is not specific to dopaminergic neurons (Betarbet et al. 2000, Zagoura et 
al. 2017, Pamies et al. 2018) and neither is α-synucleinopathy (Braak et al. 1995). The 
most commonly recognized α-synucleinopathy outside of the substantia nigra is Lewy 
body dementia in which toxic aggregation of α-Syn occurs within hippocampal neurons 
and causes cognitive deficits (Vekrellis and Stefanis 2012, Hall et al. 2014). Other central 
nervous system cells that can be affected by α-Syn accumulation are glial cells which 
regulate neuroinflammation and oligodendrocytes that maintain axonal integrity (Leushel 
et al. 2013). Peripheral spinal cord neurons are also vulnerable to α-Syn overexpression. 
Synucleinopathy has been described in elderly patients and it was postulated that α-Syn 
toxicity may have originated in peripheral neurons before moving into the nigrostriatal 
tissues (Braak et al. 2007, Sumikura et al. 2015, Feng et al. 2016). This postulation is 
supported by the Braak theory of PD progression in which the disease initiates in the 
periphery in the brain stem and moves in temporal pattern through susceptible regions of 
the midbrain and the cortex (Braak et al. 2003). With this evidence, SH-5YSY was 
considered a suitable model to understand the role of α-Syn in mediating changes to DNA 
methylation patterns at early stages of disease pathogenesis (Figure 4.1).  
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 Consistent with previous studies in SH-5YSY, we observed a significant increase 
in α-Syn protein accumulation after rotenone treatment (Figure 4.2) and this result was 
comparable to the accumulation caused by common SNCA point mutations (A30P and 
G51D) in in-vitro dopaminergic neurons (Ysselstein et al. 2015). This increase was also 
comparable to the increase seen in PD patients with a triplication of the SNCA locus and 
2-fold increases in SNCA transcripts (Miller et al. 2004). This increase in α-Syn protein 
correlated with observed decreases in global DNA methylation patterns in the same cells 
(Figure 4.2). Genome-wide DNA hypomethylation was also observed in our HEK293 cell 
model (Chapter 2A Figure 2.4). This evidence agrees with DNA hypomethylation observed 
as a result of exposure with alternative pesticides (Collota et al. 2013) and with human 
epidemiological studies reporting DNA hypomethylation in the post-mortem brain tissues 
of PD patients (Matsumoto et al. 2010, Desplats et al. 2011, Lu et al. 2013, Labbe et al. 
2016).  
 DNMT1 depletion and mis-localization in post-mortem human cortex samples from 
patients with PD and Lewy body dementia was reported to be associated with DNA 
hypomethylation at CpG islands regulating the expression of PD associated genes 
including the gene encoding α-Syn, SNCA (Desplats et al. 2011). This same study used 
lentiviral overexpression of α-Syn in rat dopaminergic neurons in culture and discovered 
that DNMT1 mis-localization may be mediated by the association of α-Syn with DNMT1 in 
the cytoplasm of neurons thereby sequestering from its role in the nucleus. We used our 
rotenone induced α-Syn model in human SH-5YSY cells and assessed the proposed 
interaction with co-immunoprecipitation (Figure 4.3). Our data supported the hypothesis 
that accumulation of α-Syn can interact with DNMT1. We also observed a trend of 
decreased nuclear DNMT1 protein that was significantly increased with the knockdown of 
SNCA expression by RNAi but not in overall protein levels measured in the whole cell 
(Figure 4.6).  
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 Inhibition of DNA methylation activates the expression of SNCA ((Jowaed et al. 
2010) and thus we hypothesize that exposure creates a positive feedback loop of α-Syn 
accumulation and sequestration of DNMT1. Therefore, α-Syn is an attractive target to 
interfere with rotenone’s toxic effects on the methylome. Studies have reported the 
increased resilience of PD toxicant models in response to targeting α-Syn. For instance, 
α-Syn knockout mice had more dopamine in nigrostriatal tissues than wild-type mice 
exposed to the mitochondrial complex I inhibitor MPTP (Thomas et al. 2011). This was 
also replicated in SH-5YSY cells in which knockdown of the SNCA gene increased cellular 
viability and attenuated mitochondrial dysfunction in response to the same chemical (Wu 
et al. 2009). This resilience of α-Syn silencing is mirrored in rotenone inhibition of complex 
I (Zharikov et al. 2015). Targeting α-Syn with short hairpin RNA (shRNA) improved 
nigrostriatal integrity and motor function in rats exposed to rotenone via intraperitoneal 
(i.p.) injection. We investigated mitochondrial resistance to rotenone exposure in our SH-
5YSY cell model and found significant improvement of mitochondrial function and viability 
in rotenone treated α-Syn knockdown cells compared to negative control cells (Figure 4.5).  
 Since α-Syn expression is correlated with the oxidative stress response and 
apoptosis in SH-5YSY cells (Habig et al. 2009), we compared the transcriptome of α-Syn 
knockdown cells to the negative control cells after treatment. We observed similar results 
to Habig et al. that decreased α-Syn was associated with less p53-mediated apoptosis 
activation in response to oxidative stress. We showed the significant up-regulation of two 
of these genes, CDKN1A and BBC3, in relation to this pathway in Figure 4.7. The cyclin-
dependent kinase inhibitor, p21, is encoded by the CDKN1A gene and promotes cell cycle 
arrest in response to oxidative damage.  The Bcl-2 binding component, or better known 
as PUMA, is encoded by BBC3 and is a transcriptional target of p53. PUMA induces 
cytochrome c release in apoptosis by activating apoptotic factors to increase the outer 
mitochondrial membrane permeability. Neither of these genes were altered in rotenone 
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treated α-Syn knockdown cells but they were also not up-regulated in the rotenone treated 
knockdown versus the negative control cells indicating that the decrease in p53 activation 
may be small.  
 It is also established that α-Syn regulates dopaminergic neurogenesis and the 
expression of genes involved in dopamine synthesis (Baptista et al. 2003, Garcia-
Reitboeck et al. 2013). In our rotenone-treated negative control cells, neurogenesis and 
neuronal differentiation were among the processes associated with down-regulated genes 
(Figure 4.7). We showed the significant suppression of two genes involved in these 
processes, TH and IGF2 (Figure 4.7). Tyrosine hydroxylase is an enzyme encoded by the 
TH gene and is the rate limiting step in dopamine synthesis. It serves as a dopaminergic 
marker in the central nervous system and Parkinson’s disease patients have reductions 
in TH-positive cells in the substantia nigra. A study in murine dopaminergic neurons 
revealed that overexpressed α-Syn reduces the immunoreactivity of tyrosine hydroxylase 
and nigrostriatal cell loss over time (Alerte et al. 2009). Rotenone treatment only 
suppressed tyrosine hydroxylase expression in negative control cells and suggests that 
rotenone-induced α-Syn accumulation reduces the amount of dopamine in the central 
nervous system. We hypothesize that α-Syn is inversely correlated with the expression of 
tyrosine hydroxylase as a result of oxidative stress restructuring of chromatin architecture. 
We predict this relationship is also affected by metabolic conditions as amino acid 
deprivation can induce the repression of HIF1α via the unfolded protein response (Tothova 
et al. 2018).   
 IGF2 encodes the insulin-like growth factor 2 protein hormone that stimulates 
nervous system development and enhances neurite outgrowth (Jeong et al. 2013). It is a 
gene of interest in the epigenetics community because of its monoallelic expression 
pattern and the established presence of an intergenic control region (ICR) that regulates 
its expression through DNA methylation. IGF2 is also interesting because of its role in the 
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hippocampus to control proliferation of neural stem cells and thus is critical in adult 
neurogenesis (Bracko et al. 2012). For decades, evidence of adult neurogenesis was 
lacking especially within the striatum. However, recent advances in lineage tracing 
techniques have allowed us to observe dopaminergic neuronal regeneration from 
precursor cells and uncover new insights into neuronal loss in aging (Morrison 2016). 
Intriguingly, we discovered significant up-regulation of IGF2 gene expression in rotenone 
treated α-Syn knockdown cells compared to rotenone treated control cells. Therefore, it is 
possible that α-Syn knockdown confers cellular resilience to PD toxicants through 
manipulation of DNA methylation at regulatory regions of the IGF-2 locus.  
 In both negative control and knockdown cells, we detected biological processes 
related to the oxidative stress response (Figure 4.7). For example, mesenchymal cell 
proliferation and transition can promote tissue regeneration and thus be protective against 
oxidative damage in the brain (Bui et al. 2009). This process was diminished regardless 
of α-Syn status in rotenone-treated neurons. Therefore, we predict that the oxidative stress 
response to mitochondrial complex I inhibition initiates changes in chromatin regulation to 
induce the expression of genes against oxidative damage.  
 We detected a significant change in the defense response of cells exposed to 
rotenone in α-Syn knockdown cells (Figure 4.8).  For example, the hypoxia response 
pathway was influenced by α-Syn accumulation (Figure 4.8). We discovered significant 
enrichment of target genes involved in HIF-1α transcription factor signaling in all datasets 
(Table 4.4). We also discovered a significant up-regulation of almost all these target genes 
with α-Syn knockdown. We concluded that rotenone toxicity interferes with the cellular 
response to hypoxia and that α-Syn had a role in that effect. It is currently unclear if α-Syn 
accumulation directly impedes HIF-1α transcription factor activity or indirectly modulates 
its activity through the induction of p53 (Sermeus and Michiels 2011). This is further 
supported by a recent study reporting that stimulation of the hypoxic response is 
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neuroprotective in a rotenone-induced model of PD in rats (Kandil et al. 2019). Given our 
previous data that rotenone affects DNA methylation patterns at allele specific 
transcription factor binding sites, we chose to investigate the role of α-Syn mediated DNA 
methylation changes at the hypoxia response element regulatory binding motifs at 
differentially expressed target genes NDRG1, ID2, and CDKN1A.  
 We examined DNA methylation at 43 CG nucleotides overlapping the HIF1α 
response element at three hypoxia target genes and discovered differential methylation at 
36 CGs (Table 4.6). All three genes were significantly hypomethylated in response to 
rotenone in α-Syn knockdown cells (Figure 4.11). Two of these genes, NDRG1 and ID2, 
had correlated up-regulation of gene expression with DNA hypomethylation. Both genes 
encode proteins involved in DNA damage repair and transcription regulation in response 
to oxidative stress. Alternatively, CDKN1A was up-regulated in rotenone treated negative 
control cells but not in knockdown cells. We observed a decrease in DNA methylation at 
the hypoxic response element in this gene but it’s conflicting role in both hypoxia and p53 
mediated apoptosis is likely the reason for the observed transient gene expression. 
 We also saw significant changes in the one-carbon metabolism pathway when 
comparing rotenone treatment in α-Syn knockdown. The effect of rotenone and 
mitochondrial stress on one-carbon metabolism has been widely documented (Bao et al. 
2016, Smirnova et al. 2016, Ron-Haril et a. 2018). It is well understood that the primary 
methyl donor to DNMT1 is S-adenosylmethionine (SAM), a co-substrate of the one-carbon 
metabolic process and a critical part of our understanding for how nutritional status and 
dietary exposures can determine phenotypes through the epigenome (Anderson et al. 
2012). PD patients with α-Syn Lewy body inclusions have varying concentrations of SAM 
in their blood and patients with SAM concentrations indicative of higher DNA methylation 
levels had better cognitive prognosis than those with less methylation potential (Obeid et 
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al. 2009). Homocysteine is an amino acid produced after the methyl transfer from SAM to 
DNMT1. Homocysteine levels increase with age and elevated plasma homocysteine has 
been observed in PD patients (O’Suilleabhain et al. 2004). Increased homocysteine 
concentrations without further stimulation of the folate pathway to regenerate SAM 
reduces the methylation potential of neurons and has been shown to increase the 
susceptibility of dopaminergic neurons in a mouse model of MPTP induced mitochondrial 
dysfunction (Duan et al. 2002). Our data indicates that α-Syn may also mediate the DNA 
methylation response to rotenone and other mitochondrial toxicants through the 
availability of methyl donating groups and that combined with significant decreases in 
nuclear DNMT1 there will be widespread changes in DNA methylation and gene 
regulation.   
 Finally, we hypothesized that α-Syn effects on DNMT1 substrate availability and 
translocation would enhance the vulnerability of allele-specific methylated regions in the 
human genome. We analyzed transcriptomic data for DNMT1-dependent genes 
characterized in Chapter 3 and identified five of the genes in rotenone-treated negative 
control cells. Three genes were significantly increased in knockdown compared to the 
negative control (Table 4.5). The three genes (IGF2, KCNQ101T, NNAT) are all known 
imprinted genes with monoallelic expression patterns regulated by an ICR with a specific 
DNA methylation pattern. They are also all highly expressed in the brain and have 
biological relevance to PD pathology. We discussed the role of IGF2 in neurogenesis 
above. Neuronatin, encoded by NNAT, is also associated with neuronal development and 
its regulation of calcium signaling in dendrites is critical in maintaining synaptic plasticity 
during aging (Oyang et al. 2011). Lastly the long, noncoding RNA encoded by KCNQ101T 
is the regulatory, antisense transcript of a potassium voltage gated channel required to 
propagate an action potential in neurotransmission. We investigated changes in DNA 
methylation patterns at DNMT1-dependent genes to determine if increased vulnerability 
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of allele-specific methylated regions and ICRs are correlated with α-Syn expression and 
aggregation.  
 We examined 132 CGs at DNMT1-dependent regions across 5 genes and 
identified three genes with differential methylation. We previously showed α-Syn 
decreases DNA methylation at two DNMT1-dependent genes (HCN2 and NEFM) which 
are critical for synaptic plasticity. In this study, we identified two genes, DLK1 and GNAS, 
were significantly hypermethylated in response to rotenone in α-Syn knockdown cells 
compared to the rotenone treated negative controls (Figure 4.12). This supports our 
hypothesis that rotenone-induced α-Syn mediates DNA methylation changes by 
interfering with DNMT1 translocation to the nucleus. While global DNA hypomethylation 
and regional hypomethylation at several DNMT1-dependent genes was observed in 
control cells exposed to rotenone; it is expected that other sites may experience 
hypermethylation due to the cooperative roles of DNA methyltransferases (DNMT3a/b) 
and the active demethylase TET enzymes. It should also be considered that our current 
methods measuring nuclear DNMT1 considers the soluble fraction of protein and not 
DNMT1 that may have remained attached to the chromatin. We investigated whether 
these patterns from existing DNMT enzymes may also be changed by α-Syn knockdown 
by examining the CGs within the NNAT gene which was significantly up-regulated in 
rotenone treated α-Syn knockdown cells. While we were not able to achieve adequate 
coverage of NNAT in all samples, we were able to compare methylation of CGs within the 
NNAT intron 1 in at least one biological replicate per treatment group. We observed a 
striking decrease in DNA methylation at 18 of the 21 CGs analyzed and an overall 11.6 
decrease in methylation across the selected intron region. This change in methylation was 
associated with a 0.9 log2 fold change in mRNA expression. We conclude based on this 
evidence that α-Syn mediates regional increases and decreases in DNA methylation 
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levels and disrupts the expression of proteins such as NNAT which are critical in 
maintaining synaptic activity during aging.   
 It is widely accepted that DNA methylation regulation of gene expression is an 
important risk factor in PD particularly within idiopathic cases where environmental 
exposures and lifestyle factors drive disease etiology. The aggregation of α-syn protein 
has been recognized as a hallmark of PD and a root cause of neuronal dysfunction and 
death. It has also been established that α-Syn accumulation and DNA methylation are 
inversely correlated (Jowaed et al. 2010) either by activation of demethylation enzymes 
(Wu et al. 2020) or via inactivation of core DNA methyltransferases (Desplats et al. 2011).  
Few studies have investigated these mechanisms and even fewer studies have attempted 
to investigate these mechanisms in an environmental toxicant induced model of PD. 
 There is currently no cure for PD and treatment relies on dopamine replacement 
therapy. Targeting α-Syn has already been a focus of some clinical trials but directly 
targeting its expression with RNAi can be deleterious to neurons due to the endogenous 
role of α-Syn at the synapse (Savitt and Jankovic 2019). There has been success in early 
phase trials by targeting α-Syn oligomers rather than monomeric α-Syn at the synapse 
(Deeg et al. 2015). However, these drugs also face challenges in specifically targeting 
oligomers given the flexibility of α-Syn’s conformational state (Lashuel et al. 2013). Other 
pharmaceutical targets include inducing degradation systems to break down aggregated 
α-Syn via inhibition of mammalian target of rapamycin (mTOR) but have also been largely 
unsuccessful due to off-target effects (Sardi et al. 2018). Interestingly, targeting the DNA 
methylation machinery may be a safer, more viable method to regulate α-Syn expression 
and aggregation in neurons. A recent study used a CRISPR deactivated Cas9 fused with 
the catalytic domain of the de novo methyltransferase (DNMT3b) to remethylate intron 1 
of the SNCA gene which is tightly coupled to its expression (Kantor et al. 2018). They 
discovered that targeted re-methylation of the SNCA gene regulated α-Syn aggregation 
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and rescued disease-related cellular phenotypes in a human induced pluripotent stem cell 
model (iPSC) with triplication of the SNCA locus. Given our findings that targeting α-Syn 
in undifferentiated neurons stimulated neurogenesis, we believe that targeted DNA 
methylation should also be used on undifferentiated, dopaminergic precursor cells rather 
than solely mature, post-mitotic neurons to determine the efficacy of this intervention on 
adult neurogenesis in nigrostriatal tissues.  
 In summary, we conclude that α-Syn knockdown conferred both mitochondrial and 
genomic resilience to rotenone treatment. This resilience may be due to changes in DNA 
methylation at susceptible loci which is mediated by aggregated α-Syn through (1) DNMT1 
sequestration in the cytoplasm, (2) inhibition of the hypoxic response, or (3) altered ratio 
of methyl-substrate in one-carbon metabolism. In the future, understanding the temporal 
association of α-Syn accumulation with the loss of TH+ neuronal cells will be critical in 
understanding the role of protein aggregation in mediated the oxidative stress signaling to 
the nucleus. It will also be critical to understand how neural activity both regulates and is 
changed by this process of α-Syn-induced loss of heterochromatin. These novel 
mechanisms for α-Syn’s role on the epigenome have the potential to increase success in 
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Table 4.1 Treatment scheme for siRNA knockdown cells 
 
DMSO Rotenone 
  (<0.002% v/v) 
(200 nM) in 
DMSO 
DMSO Ctrl Rot Ctrl 
Control- 




Rot Neg Ctrl 
Negative Control- 
Transfection control with scramble, non-target 
siRNA 
DMSO siRNA Rot siRNA 
siRNA- 
Knockdown with siRNA targeting SNCA.  
 
Table 4.2 qRT-PCR primers for RNA sequencing validation 
   
Gene Forward Reverse 
CDKN1A TGTCCGTCAGAACCCATGC AAAGTCGAAGTTCCATCGCTC 
DLK1 CTTTCGGCCACAGCACCTAT TGTCATCCTCGCAGAATCCAT 
FBXO8 CCTACCTGAATGCAACTGACC CATCCAGGATACCCTTGGACA 
GNAS TGCCTCGGGAACAGTAAGAC GCCGCCCTCTCCATTAAAC 
HERC3 TGTTGGGGATATTGGTCTCTGG CCCTTGGTGTTCAAACCACAT 
ID2 AGTCCCGTGAGGTCCGTTAG AGTCGTTCATGTTGTATAGCAGG 
IGF2 GTGGCATCGTTGAGGAGTG CACGTCCCTCTCGGACTTG 
KCNQ101T TTGGTAGGATTTTGTTGAGG CAACCTTCCCCTACTACC 
TH GGAAGGCCGTGCTAAACCT GGATTTTGGCTTCAAACGTCTC 
NDRG1 GTCCTTATCAACGTGAACCCTT GCATTGGTCGCTCAATCTCCA 
NNAT ACTGGGTAGGATTCGCTTTTCG ACACCTCACTTCTCGCAATGG 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 




















































Table 4.4 HIF-1α target genes with hypoxia-response elements in RNA sequencing  
 
HIF-1α hypoxia target genes 
DMSO x Rot Neg Ctrl DMSO x Rot siRNA Rot x Rot siRNA 
↓IGF2 ↓IGF2 ↑IGF2 
↓NDRG1 ↓NDRG1 ↑NDRG1 
↓ID2 ↓ VEGFA ↑ID2 




↓ ADM   ↑LDHA 
↓ BNIP3     
↓LDHA     
 
Neg Ctrl indicates SH-5YSY transfected with scramble siRNA and siRNA indicates  
SH-5YSY transfected with SNCA targeted DsiRNA. 
red arrows indicate up-regulation or down-regulation of expression.  
Underline indicates genes used for Bisulfite-amplicon sequencing.  
 
 
Table 4.5 DNMT1-dependent regions in RNA sequencing  
 
DNMT1-dependent genes 
DMSO x Rot Neg Ctrl DMSO x Rot siRNA Rot x Rot siRNA 
↓KCNQ1OT1 ↓KCNQ1OT1 ↑KCNQ1OT1 
↓IGF2 ↓IGF2 ↑IGF2 
↓DLK1   ↑NNAT 
↓GNAS     
↑HERC3   
 
↓FBXO8     
 
Neg Ctrl indicates SH-5YSY transfected with scramble siRNA and siRNA indicates  
SH-5YSY transfected with SNCA targeted DsiRNA.  
red arrows indicate up-regulation or down-regulation of expression.  




Table 4.6 Differentially Methylated CG sites at hypoxia response genes 
 
Gene CpG delta 
CDKN1A 36683981 -0.2 
CDKN1A 36684008 14.9 
CDKN1A 36684038 -10.2 
CDKN1A 36684073 1.1 
CDKN1A 36684087 -10.7 
CDKN1A 36684101 -2.1 
CDKN1A 36684115 -7.6 
CDKN1A 36684131 -1.3 
CDKN1A 36684134 3.4 
CDKN1A 36684142 -6.1 
CDKN1A 36684157 -2.5 
CDKN1A 36684172 1.1 
CDKN1A 36684183 0.3 
CDKN1A 36684192 -10.8 
CDKN1A 36684212 13.9 
CDKN1A 36684218 -3.1 
CDKN1A 36684229 -0.5 
ID2 8680132 0.7 
ID2 8680176 -2.1 
ID2 8680193 -3.3 
ID2 8680234 -4 
ID2 8680246 -5.1 
ID2 8680264 1.7 
ID2 8680299 -0.7 
ID2 8680414 1.6 
ID2 8680437 0.9 
ID2 8680442 -5 
NDRG1 133350589 0.8 
NDRG1 133350593 0.6 
NDRG1 133350619 0.7 
NDRG1 133350635 1.1 
NDRG1 133350651 -0.5 
NDRG1 133350689 -17.3 
NDRG1 133350720 2.5 
NDRG1 133350734 0.2 





Table 4.7 Differentially Methylated CG sites at DNMT1-dependent regions 
 
Gene CpG delta 
DLK1 100808288 2.3 
DLK1 100808295 -0.4 
DLK1 100808346 -1.2 
DLK1 100808475 -3.9 
DLK1 100808480 -1.6 
DLK1 100808489 -2.8 
DLK1 100808491 1.0 
DLK1 100808498 0.2 
DLK1 100808509 -0.5 
DLK1 100808516 -0.3 
DLK1 100808534 -0.4 
DLK1 100808545 -1.8 
DLK1 100808660 13.7 
GNAS_1 5882612 0.5 
GNAS_1 5882617 4.7 
GNAS_1 5882626 2.4 
GNAS_1 5882633 3.4 
GNAS_1 5882638 4.5 
GNAS_1 5882645 3.0 
GNAS_1 5882650 6.7 
GNAS_1 5882658 3.8 
GNAS_1 5882674 4.4 
GNAS_1 5882682 6.6 
GNAS_1 5882733 -3.0 
GNAS_1 5882741 3.2 
GNAS_1 5882750 8.4 
GNAS_1 5882778 6.1 
GNAS_1 5882812 5.8 
GNAS_1 5882823 -2.6 
GNAS_1 5882835 5.5 
GNAS_1 5882838 -6.4 
GNAS_1 5882862 7.9 
GNAS_1 5882871 -3.0 
GNAS_1 5882878 -5.6 
GNAS_1 5882883 -1.6 
GNAS_1 5882888 1.0 
GNAS_1 5882893 2.3 
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Gene CpG delta 
GNAS_1 5882897 1.5 
GNAS_2 588555134 -4.5 
GNAS_2 588555136 -2.3 
GNAS_2 588555167 4.6 
GNAS_2 588555187 1.6 
GNAS_2 588555208 -0.6 
GNAS_2 588555220 0.3 
GNAS_2 588555222 -4.8 
GNAS_2 588555235 -7.8 
GNAS_2 588555249 0.6 
GNAS_2 588555267 -11.1 
GNAS_2 588555290 1.7 
GNAS_2 588555295 2.2 
GNAS_2 588555317 0.5 
GNAS_2 588555320 1.3 
GNAS_2 588555333 0.2 
GNAS_2 588555346 2.3 
GNAS_2 588555349 5.7 
NNAT_1 37520886 2.4 
NNAT_1 37520931 -0.5 
NNAT_1 37520962 -0.4 
NNAT_1 37520984 -4.5 
NNAT_1 37521026 -36.1 
NNAT_1 37521029 3.1 
NNAT_1 37521069 -20.8 
NNAT_1 37521076 16.3 
NNAT_1 37521118 -32.6 
NNAT_1 37521129 -17.0 
NNAT_1 37521167 -19.0 
NNAT_1 37521169 -17.2 
NNAT_1 37521175 -17.7 
NNAT_1 37521188 -14.4 
NNAT_1 37521192 -14.2 
NNAT_1 37521205 -12.2 
NNAT_1 37521207 -12.3 
NNAT_1 37521214 -12.5 
NNAT_1 37521216 -8.6 
NNAT_1 37521222 -12.8 







Figure 4.1 Illustration of rotenone-induced α-Syn sequestration of DNMT1.  
Oxidative damage caused by rotenone exposure promotes α-Syn misfolding and 
aggregation. We hypothesize that accumulated α-Syn interacts with DNMT1 outside of 









Figure 4.2 Rotenone-induced α-Syn accumulation is associated with DNA 
hypomethylation. 
 A) Global DNA hypomethylation from three biological replicates of SH-5YSY exposed to 
rotenone (200 nM, 24h) was observed using dot blot with anti-5methylCytosine (5mC) 
antibody. B) Protein was extracted from the same cells and α-Syn accumulation was 
measured with Western blot. Western was quantified with Image J and the relative ratio 
of α-Syn/ GAPDH (loading control) was used for significance testing with a paired 






Figure 4.3 Rotenone-induced α-Syn interacts with DNMT1 within the whole cell.  
A) α-Syn was immunoprecipitated by magnetic bead from rotenone treated SH-5YSY. B) 
DNMT1 was immunoprecipitated with α-Syn only in cells exposed to rotenone. IgG was 
used as the negative control. IP = immunoprecipitated and indicates the antibody used in 






Figure 4.4 SH-5YSY siRNA transfection.  
A) The efficiency of transfection conditions was tested with TYE-563 fluorescence control 
at 10 nM for 24h. B) TriFECTa kit DsiRNA hs.Ri.SNCA.13.2 at 10 nM was selected to 
knockdown SNCA transcript levels. The transcript expression of SNCA was measured 
after siRNA transfection and/or rotenone treatment (day 3) using qRT-PCR. * p<0.05 
compared to non-treated control; # p<0.05 compared to non-treated negative control 
(scramble siRNA). C) Western blot of α-Syn was used to correlate changes in transcript 
expression with protein levels on day 3 post-transfection. SH-5YSY siRNA knockdown of 






Figure 4.5 Mitochondrial resistance to rotenone treatment in α-Syn knockdown.  
A) The viability of mitochondria was estimated from cellular metabolic capacity using a 
resazurin based viability assay. The results are shown as the %viability compared to non-
treated cells. B) Intracellular ROS was quantified using the DCFDA fluorescence assay 
and results are shown as the fold change in fluorescence compared to the non-treated 
cells. C) The number of mitochondria was measured with the Mitotracker FM Red 
fluorescence dye. The results are shown as the fold change in fluorescence compared to 
the non-treated cells. D) Mitochondrial DNA copy number is used to approximate 
mitochondrial function with higher copy numbers representing more robust mitochondria. 
The relative expression of two nuclear genes, BECN1 and B2M, were compared to 
mitochondrial gene ND1 using qPCR. Significance testing was done with a one-way 






Figure 4.6 DNMT1 nuclear localization in response to rotenone treatment.  
Nuclear proteins were isolated from rotenone treated SH-5YSY control and α-Syn 
knockdown cells. Input was collected prior to nuclear isolation for whole cell control. H3 
was used as the nuclear marker and GAPDH as the non-nuclear/cytoplasmic marker to 
test nuclear fragment purity. DNMT1 was measured from both whole cell lysate and 
nuclear lysate using H3 as the loading control. Protein was quantified with Image J and 





Figure 4.7 RNA sequencing of rotenone treated SH-5YSY control and α-Syn 
knockdown.  
A) Gene Ontology cellular component annotation for DMSO versus rotenone treated 
negative control (scramble siRNA) SH-5YSY. Color indicates adjusted p-value and size of 
circle indicates the number of genes within that annotation represented in the dataset. B) 
Gene Ontology biological processes enriched in DMSO versus rotenone treated negative 
control cells. The x-axis represents the adjusted p-value using false discovery rate (FDR). 
C) The up-regulated and down-regulated biological processes in DMSO versus rotenone 
treated negative control cells are shown in the top graph with the x-value representing the 
Log2(p-value). The bottom graph shows the expression of key genes within these 
pathways. Blue is up- regulated and orange is down-regulated. D) Gene Ontology 
biological processes enriched in DMSO versus rotenone treated α-Syn knockdown cells. 
The x-axis represents the adjusted p-value using false discovery rate (FDR). E) Gene 
Ontology molecular functions represented in our dataset (not significant after p-value 
adjustment). Node color represents significance with dark orange being the most 







Figure 4.8 Comparison of transcriptomic changes in rotenone treated control 
versus α-Syn knockdown cells.  
A) Heat map showing gene expression changes in rotenone treated negative control (Rot 
NC) and rotenone treated knockdown (Rot KD). B) Venn diagram of commonly shared 
differentially expressed genes (>1.5 fold change; FDR<0.05). There were 73 overlapping 
genes between datasets. C) Gene Ontology biological process enriched in genes 
differentially expressed between rotenone treated control and rotenone-treated 
knockdown. Yellow box indicates significance (p<0.001). D) The top pathways 
represented from the 2019 Kegg pathway database. The x-axis represents significance 





Figure 4.9 RNA sequencing validation with qRT-PCR.  
Fold change comparison of RNA sequencing results versus qRT-PCR results in 12 
selected genes and the linear calibration curve of RNA sequencing results with qRT-PCR 






Figure 4.10 Bisulfite amplicon sequencing CpG coverage. 
A)  Coverage of CG nucleotides within hypoxia response elements at hypoxia target 
genes: NDRG1, ID2, CDKN1A.  B)  Coverage of CG nucleotides within DNMT1-dependent 
genes:  DLK1, GNAS, NNAT.  The average total coverage for all CpG sites within the 
amplified region is indicated by the straight line for negative control and the dash line for 





Figure 4.11 Altered CpG methylation at hypoxia response genes. 
A) Genomic location of hypoxia response element at three HIF1α hypoxia target genes. 
The DNA element and distance from the transcription start site is annotated in black. The 
primer region box indicates the amplified region for Bisulfite-sequencing. The green CG 
box indicates CpG islands, if applicable. The orange box indicates a CTCF insulator 
binding motif. The dark blue box indicates the HIF1α (HNF1a) binding motif and the 
hypoxia response element. B) Significant differentially methylated cytosines are defined 
by Δ>0.1%; q-value<0.05. The percent methylation of all CpG sites within the amplified 
region shown. Delta indicates the change in the mean CpG methylation percentage and 





Figure 4.12 Altered CpG methylation at DNMT1-dependent genes. 
A) Genomic location of DNMT1-dependent regions. The DNA element and distance from 
the transcription start site is annotated in black. The primer region box indicates the 
amplified region for Bisulfite-sequencing. The green CG box indicates CpG islands, if 
applicable. The orange box indicates a CTCF insulator binding motif. B) Significant 
differentially methylated cytosines are defined by Δ>0.1%; q-value<0.05. The percent 
methylation of all CpG sites within the amplified region shown. Delta indicates the change 





THE INTEGRATED STRESS RESPONSE TO ROTENONE 
EXPOSURE INCREASES H3K27 ENHANCER ACTIVATION AND 
ALTERS METABOLIC REPROGRAMMING IN HUMAN 
NEURONAL CELLS. 
5.1 Abstract 
 Mitochondrial dysfunction and oxidative stress are common pathological features 
of Parkinson’s disease (PD). Our previous work demonstrates mitochondrial dysfunction 
altering enhancer activity. Intriguingly, PD-associated genetic variants also reside in 
enhancer regions. This evidence prompted us to link histone H3 acetylation, particularly 
H3 lysine 27 acetylation (H3K27ac), a maker of active enhancers, to the mitochondrial 
damage response. Herein, we investigated the role of the integrated stress response to 
rotenone in mediating H3K27ac enhancer activation by perturbing the balance of 
intracellular histone acetyltransferase PCAF with the nuclear histone deacetylase HDAC2. 
We used transcriptomics in combination with chromatin immunoprecipitation PCR (ChIP-
PCR) to correlate the expression of genes involved in the integrated stress response with 
H3K27ac levels. We discovered that rotenone-induced mitochondrial damage significantly 
up-regulated the Activating Transcription Factor 4 (ATF4) signaling pathway and 
increased intracellular PCAF protein levels. We concluded that ATF4 recruitment of PCAF 
increased enhancer activation of pro-apoptotic genes, CHOP and PUMA, which are 
known targets of the integrated stress response. We determined that ATF4 activation was 
associated with increased enhancer activation of metabolic genes PDP2 and ACSL6, 
which initiate metabolic reprogramming under oxidative stress and increase acetyl-CoA 
substrate availability. We also measured rotenone-induced intracellular reactive oxygen 
species and its inverse association with HDAC2 to facilitate pathological hyperacetylation. 
Our data demonstrate that the ATF4 mediated integrated stress response is an early 
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internal cue to regulate gene expression and propagate DNA damage induced by 
mitochondrial dysfunction.  
5.2 Introduction 
 Rotenone inhibition of oxidative phosphorylation mimics cellular pathologies 
associated with Parkinson’s disease (PD) including mitochondrial dysfunction, ATP 
depletion, cell cycle inhibition, oxidative stress, and the unfolded protein response 
(Kanthasamy et al. 2012, Xiong et al. 2011). Intracellular stress on the mitochondria and 
endoplasmic reticulum activates signaling cascades for secondary messengers and 
transcription factors to regulate the expression of genes involved in metabolic 
reprogramming, cell proliferation, and cell death. As a result, retrograde signaling from 
damaged organelles to the nucleus can shift the balance of chromatin modifying enzymes 
like histone acetyltransferases (HATs) and histone deacetylases (HDACs).  
 Histone acetylation refers to the post-translational modification of histone proteins 
that regulate the transcription of genes. Histone 3 (H3) is the most extensively modified of 
the histone proteins and histone mark H3K27ac is pursued in the scientific community 
because it is known to distinguish active enhancers from “poised” enhancers, which may 
become active after an external cue (Creyghton et al. 2010). The directional changes of 
H3 acetylation in PD pathology has been controversial and is dependent upon brain region 
and cell type (Gebremedhin and Rademacher 2016, Harrison et al. 2018). It has been 
suggested that H3 acetylation patterns in PD may also be dependent upon its etiology, 
with one study showing differences in basal acetylation levels between a patient with 
genetic (LRRK2- linked) disease and idiopathic (wild-type) disease (Sokhna et al. 2019, 
Yakhine-Diop et al. 2018). In addition, this study found varying levels of HDACs between 
genetic and idiopathic PD patients. There have even been discrepancies within PD models 
using complex I inhibitors. Rotenone and metformin have both been associated with 
hyperacetylation (Song et al. 2011, Feng et al. 2015, Fang et al. 2020) while MPTP has 
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been associated with both hyperacetylation and hypoacetylation (Gardian et al. 2004, Park 
et al. 2016).  
 Despite conflicting evidence, it is widely agreed upon that the homeostatic balance 
between HATs and HDACs in the nucleus is critical to maintain neuronal function and the 
tipping point of that balance is based on both genetic and environmental factors. Based 
on our previous report that mitochondrial dysfunction induced hyperacetylation in neurons 
(Huang et al. 2019), we hypothesized that rotenone-induced mitochondrial damage would 
initiate mitochondrial quality control signaling cascades that impairs genome-wide H3K27 
enhancer activation. Herein, we focused on the role of the integrated stress response 
mediated by ATF4 in mediating histone acetylation of enhancers in our human neuronal 
cell line SH-5YSY. We investigated the mechanistic role of ATF4 in pathological 
hyperacetylation by examining its induction of histone acetyltransferase P300/CBP 
Associated Factor (PCAF), its regulation of pro-apoptotic gene expression, and its 
influence on acetyltransferase substrate availability. We also look at indirect effects of the 
integrated stress response and the inverse correlation mitochondrial reactive oxygen 
species (ROS) on nuclear HDAC2 depletion. 
5.3 Materials and Methods 
5.3.1 Cell culture and treatment of human cell line SH-5YSY 
All media reagents and chemicals in cell culture were purchased from Sigma (St. 
Louis, MO). SH-5YSY were grown in Dulbecco’s Modified Eagle Medium with high 
glucose, L-glutamine, and sodium pyruvate. Media was supplemented with 10% (v/v) heat 
inactivated fetal bovine serum and 1% (v/v) Penicillin-Streptomycin. SH-5YSY cells were 
confirmed by ATCC. Cells were treated at approximately 80% confluency with rotenone 
(200 nM) or DMSO vehicle control (<0.001%) for 24h. 
5.3.2 Mitochondrial complex I inhibition  
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 We estimated mitochondrial complex I inhibition based on a protocol by Diwakar 
et al. 2008. All reagents were purchased from Sigma (St. Louis, MO). We collected cells 
in homogenization buffer provided by the protocol at a cell density of approximately 1x106 
per 100 µL. We used a 22’ syringe to homogenize cell lysate and incubated on ice for 20 
minutes. Cells were centrifuged at 1000xg for 10 minutes at 4°C. The supernatant was 
collected and mitochondria were collected with centrifugation at 14,000xg for 30 minutes 
at 4°C. The supernatant was then removed from the mitochondria and the pellet was 
resuspended in 50-100 µL of fresh homogenization buffer. The mitochondria were 
sonicated in an Ultrasonic Bath Sonicator for 10 minutes at 4°C with 30 seconds on/ 60 
seconds off. The lysate was then freeze/thawed at -80°C 3 times for 15 minutes each. The 
protein concentration after freeze/thaw cycles was measured using Qubit Protein Assay.  
 Fresh assay buffer was prepared using recipe by Diwakar et al. 2008 with 3 mM 
potassium cyanide (instead of sodium cyanide) and 2 µg/mL of antimycin was added 
immediately before use. In a 24-well plate, 25-50 µg of mitochondrial lysate was added to 
each well with 10 µL of 2.5 mM ubiquinone and assay buffer to a total volume of 500 µL. 
For negative control wells, 25-50 µg of mitochondrial lysate was added to assay buffer 
with no ubiquinone to a total of 500 µL. Wells were pre-incubated for 2 minutes at room 
temperature and then 20 µL of 5 mM β-NADH was added to each well. The absorbance 
at 340 nm was measured every 30 seconds for 2 minutes. The ΔA340/min is equal to the 
slope of the line for β-NADH oxidation with ubiquinone subtracted by the slope of the line 












5.3.3 Mitotracker FM Red and mtDNA copy number quantification 
 Mitochondrial number was estimated with Mitotracker Red FM (Invitrogen, 
M22425). Following rotenone treatment, cells were incubated with Mitotracker (500 nM) 
for 1h at 37 °C. Cells were fixed with 1.5% formaldehyde for 10 mins at room temperature 
before fluorescence was measured at 580/640 nm. Mitochondrial DNA (mtDNA) copy 
number was estimated from 5 ng total DNA using a qPCR method published by Grady et 
al. 2014. We compared the mitochondrial gene ND1 (F: ATGGCCAACCTCCTACTCCT; 
R:GCGGTGATGTAGAGGGTGAT) to genomic genes BECN1  
(F:CGAGGCTCAAGTGTTTAGGC; R: ATGTACTGGAAACGCCTTGG) and B2M 
(F:CCAGCAGAGAATGGAAAGTCAA, R: TCTCTCTCCATTCTTCAGTAAGTCAACT). 
5.3.4 Western blot for global H3K27ac 
SH-5YSY cells were collected after 24 hours treatment and histones were 
extracted using the Abcam Histone Extraction kit according to kit instructions (Cambridge, 
UK). Histone protein concentration was measured by Qubit Protein Assay from 
ThermoFisher (Waltham, MA). Protein (5 µg) was loaded onto 4-15% Bio-Rad Page Gels 
and transferred to 0.45 um nitrocellulose (Bio-Rad, Hercules, CA). The blots were 
incubated with H3K27ac primary antibody (1:1000; Abcam ab4729) overnight at 4°C and 
anti-rabbit IgG conjugated secondary antibody (1:5000, Santa Cruz Biotechnology Sc-
2357) for 1h at room temperature. The histone protein was normalized to total histone 3 
(H3; Abcam ab1791) and quantified with Image J software. We tested significance by 
comparing the ratio of H3K27ac/H3 with a two-tailed Student’s paired t-test.   
5.3.5 RNA extraction and RNA sequencing library construction 
Total RNA was extracted from two replicates of SH-5YSY using the Trizol method 
(Invitrogen, Carlsbad, CA). A total of 2ug per sample was used for library construction 
using the TruSeq Sample Preparation kit from Illumina (San Diego, CA). Poly-A containing 
mRNA molecules were isolated from total RNA using oligo-dT attached magnetic beads. 
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Isolated mRNA was then fragmented and synthesized into double stranded cDNA 
according to kit instructions. Ligation of unique Illumina adapter indices was completed for 
each sample before bead purification. Libraries were loaded onto a 2% agarose gel and 
library products between 200-800 bp were purified using the mini-Elute gel extraction kit 
from Qiagen (Hilden, Germany). Approximately 150 ng was sent for sequencing on a 
HiSeq-X platform with 100 bp paired-end reads. 
5.3.6 RNA sequencing analysis  
 The raw BCL files were converted into FastQ files using CASAVA 1.8.2 (CASAVA).   
Raw sequencing reads were processed using TaRGETII RNA-seq pipeline which was 
prepared for large size RNA-seq sample processing 
(https://github.com/ShaopengLiu1/RNA-seq_QC_analysis). Cutadapt (V2.8) (Martin 
2011) was used to remove any remaining adapter sequences from the high throughput 
sequencing reads. Sequencing reads were aligned to the human genome (hg38) with 
STAR aligner (v2.5.4b) (Dobin et al. 2013). For mRNA analyses, the Gencode database 
(Gencode version 27) was chosen as the annotation reference. Read counts of annotated 
genes were counted using featureCount from the SubRead package (Liao et al. 2013). 
The raw read counts of each transcript were normalized by library size, then further 
normalized based on empirical controls using RUVg from the RUVseq package (REF-
PMID: 25150836). Differentially expressed genes were defined as those with a 1.5-fold 
change in expression using an adjust p-value (false discovery rate) <0.05 from the edgeR 
package (Robinson et al. 2010). Gene Ontology annotation was done with GOrila and 
visualized with Revigo (Eden et al. 2009; Supek et al. 2011). Biological pathway analysis 
was done with reactome pathway analysis (Fabregat et al. 2018).  
5.3.7 qRT-PCR validation   
 Total RNA was extracted from an additional replicate of control and α-Syn 
knockdown SH-5YSY treated with DMSO or rotenone using the same procedures as 
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stated above. A total of 500ng RNA was converted to cDNA with the PrimeScript RT 
reagent kit with gDNA eraser from Takara (Kusatsu, Japan). We selected six genes for 
quantitative PCR (qRT-PCR) analysis using primers listed in Table 5.1. All qRT-PCR 
reactions were performed on a 7500 Real-Time PCR system from Applied Biosystems 
(Foster City, CA) using the iTaq Universal SYBR Green Supermix from Bio-Rad (Hercules, 
CA). The change in expression was normalized to the GAPDH housekeeping gene and 
expressed as fold change (2-ΔΔCT).  
5.3.8 SH-5YSY chromatin immunoprecipitation 
All chemicals were purchased from Sigma unless otherwise noted (St. Louis, MO). 
SH-5YSY were harvested after 24 hours treatment and resuspended in fresh media at 
10x106 cells/ mL in a conical tube. Cells were fixed with 1% formaldehyde for 10 minutes 
at room temperature. The reaction was stopped with 0.2 M glycine and incubation at room 
temperature for 5 minutes. Fixed cells were centrifuged for 5 minutes at 300xg 4°C and 
washed with 1 mL cold PBS. The cell pellet was stored at -80°C until chromatin 
immunoprecipitation (CHIP).  
Cell pellets were resuspended at approximately 1x106 -cells/ 0.1 mL with PBS + 
0.5 % Triton-X + 1% protease inhibitor cocktail and incubated on ice for 10 minutes prior 
to centrifugation for 5 minutes at 400xg 4°C. The pellet was resuspended in TE buffer pH 
8.0 with protease inhibitor and PMSF. Cells were sonicated at high intensity for 30s on/ 
60s off until DNA fragments were within 200-800 bp as checked by 2% agarose gel. After 
sonication, samples were centrifuged for 15 minutes at 14,000xg 4°C to pellet insoluble 
material. Sheared chromatin was transferred to RIPA buffer and approximately 10% was 
saved for input DNA extraction.  
ChIP was done with Dynabeads Protein A (Invitrogen, Carlsbad, CA) and 4 µg of 
primary ChIP grade antibody (H3K27ac Abcam ab4729 or Rabbit IgG Santa Cruz 
Biotechnology sc-2025). Beads were washed with lithium chloride (LiCl 0.25M) buffer and 
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immunoprecipitated DNA was extracted from beads using phenol: chloroform method. 
DNA was quantified using Qubit dsDNA high sensitivity assay (Thermo Fisher, Waltham, 
MA).  
5.3.9 SH-5YSY ChIP PCR analysis 
We selected eight genes for quantitative PCR (qPCR) analysis using primers listed 
in Table 5.2. All qPCR reactions were performed on a 7500 Real-Time PCR system from 
Applied Biosystems (Foster City, CA) using the iTaq Universal SYBR Green Supermix 
from Bio-Rad (Hercules, CA). H3K27ac enrichment was calculated from the Ct threshold 
value as a percent of the total input DNA. Rabbit IgG samples were used as a negative 
control.  
5.3.10 Western Bblot for PCAF and HDAC2 
 Cells were lysed with PBS lysis buffer (from 4.3.4) with 0.05% Triton-X. Cells were 
syringe homogenized and incubated on ice for 20 minutes. Approximately 50% cell volume 
was saved for whole cell lysate. Cells were centrifuged at 600 x g for 6 minutes at 4°C and 
the supernatant was removed from the nuclei. Nuclei were washed in lysis buffer without 
supplementation and then resuspended in fresh PBS lysis buffer with 0.5% Triton-X. 
Whole cell lysate and nuclear lysate was sonicated in an Ultrasonic Bath Sonicator 3 times 
for 10 seconds each. We ran 15 µg of the whole cell lysate versus the nuclear lysate on 
Western blot with nuclear marker H3 (1:1000, Abcam ab1791), cytoplasmic marker 
GAPDH (1:1000, Sigma G9549), HDAC2 (1:500, Millipore 05-814), and PCAF (1:500, 
Bethyl A301-666). We quantified PCAF in whole cell lysate normalized to GAPDH. We 
quantified HDAC2 in the nucleus normalized to H3. We tested significance by comparing 
the ratio of antibody/loading control with a two-tailed Student’s paired t-test. 
5.3.11 Acetyl-CoA Assay 
 SH-5YSY cells were scraped from plates after treatment (no trypsin) using the 
assay buffer from the Abcam acetyl-CoA assay kit (ab87546). Cells were homogenized 
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by syringe and centrifuged at 10,000xg for 10 mins 4°C. The supernatant was 
deproteinated with ice cold perchloric acid (1M) from Sigma (St. Louis, MO). The 
deproteinated sample was centrifuged for 2 min at 13,000xg 4°C and transferred to a new 
tube. The sample was neutralized with 2M KOH (Sigma) and centrifuged again at 
13,000xg for 15 minutes at 4°C. The supernatant was used for acetyl-CoA according to 
kit instructions using 50 uL of sample per well. Samples were compared to a standard 
curve ranging from 0-60 pmol and calculated as pmol/ul. Significance testing was done 
with a two-tailed paired Student’s t-test.   
5.4 Results 
5.3.1 Rotenone complex I inhibition hinders mitochondrial function. 
 To characterize mitochondrial complex I inhibition, we examined the changes in 
absorbance from βNADH oxidation outlined in the protocol by Diwakar et al. 2008. Control 
mitochondrial complex I activity was 1157±396 nM/min per mg protein. Rotenone reduced 
activity by 0.55-fold (643±295 nM/min per mg protein) (Figure 5.1) To measure 
mitochondrial potential, we used the DCFDA fluorescence assay and the intensity 
decreased by 0.74-fold ±0.07 (p<0.05) with rotenone exposure (Figure 5.1). Next, we used 
mtDNA copy number as another determinant of mitochondrial function by analyzing the 
number of copies of the mitochondrial gene ND1, which encodes complex I, against two 
separate genomic genes BECN and B2M. The number of ND1 copies remained consistent 
in both tests with 385 ± 17 (vs BECN) and 467± 14 (vs B2M). There was significant 
depletion of mitochondrial DNA copy number using both genes (Figure 5.1). The number 
of ND1 copies decreased to 243±14 and 337±19, respectively.  
5.3.2 Rotenone H3K27 enhancer activation is associated with global transcriptome 
changes.  
 Histones were extracted from DMSO and rotenone treated SH-5YSY and the 
global level of enhancer mark H3K27ac was estimated with Western blot. We observed a 
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significant 1.2-fold increase in H3K27ac levels with rotenone treatment (p<0.01) (Figure 
5.2). This increase was similar in scale to the observed increase in HEK293 cells from 
Chapter 2 Figure 2.3 and in rat dopaminergic neurons in Huang et al. 2019. Because 
H3K27ac is tightly correlated with gene expression, we analyzed global changes in gene 
expression with RNA-seq from two biological replicates. We discovered 1897 genes were 
differentially expressed in response to rotenone treatment (>1.5-fold change, FDR<0.05). 
The majority (73%) were down-regulated and 121 genes were changed more than 9-fold. 
The top genes (by Log2FC) were RSPO (-12 LOG2FC, FDR<10-60); HNF1A (-8.4 
LOG2FC, FDR<10-10); ASNS (3.3 LOG2FC, FDR<10-20); and GD15 (3.6 Log2FC, 
FDR<10-20). These genes are involved in TGFβ, HIF-1α, ATF4, and WNT transcription 
factor signaling (Figure 5.2). To validate our RNA-seq results, we completed qRT-PCR 
validation on six selected genes involved in the ATF4 signaling response (Figure 5.2). 
 To determine what transcriptional target genes were enriched in our dataset, we 
used the TRUUST transcription factor database which uses a sentence-based text mining 
approach from over 20 million PubMed articles to determine regulatory networks (Han et 
al. 2018). This network analysis gave us four transcription factors with target genes 
enriched in our dataset that were significant after p-value adjustment (FDR<0.05) (Table 
5.3). We also looked at pathway enrichment with reactome pathways (Figure 5.2) 
(Fabregat et al. 2018). Only two pathways were significantly enriched from down-regulated 
genes and both involved chromatin-opening. The up-regulated genes were enriched with 
pathways involving the unfolded protein response (ATF4), amino acid deprivation (ASNS) 
and oxidative stress induced senescence (p21). These pathways and transcription factors 
are further described in the Discussion section.  
5.3.3 Rotenone-induced ATF4 signaling increases intracellular acetyltransferase. 
 The transcription factors ATF4 (Figure 5.2) and ATF3 were significantly up-
regulated in our RNA-seq dataset (0.8 LOG2FC, FDR<0.01) as was the EIF2α kinase 
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responsible for its activation (1 LOG2FC, FDR<0.01). Additionally, their target genes were 
enriched in our differentially expressed genes including those targets involved in neuronal 
apoptosis (PUMA, TRIB3, p21, and CHOP). ATF4 is a prominent stress factor and 
mediates the integrated stress response. It is a basic region/leucine zipper (bZIP) 
transcription factor and regularly forms heterodimers with CAAT/enhancer-binding protein 
(C/EBP) for DNA binding (Gachon et al. 2001). ATF4 and C/EBP then recruit histone 
acetyltransferases to enhancer sites to promote opening of chromatin for transcription. 
ATF4 is responsible for the recruitment of P300-CBP Associated Factor (PCAF) which 
acts as a cofactor for the transcriptional regulation of the pro-apoptotic CHOP (DDIT3) 
gene (Cherasse et al. 2007). We examined PCAF in rotenone-treated cells with up-
regulated ATF4 gene expression. Indeed, a significant increase in intracellular PCAF 
protein (7.5-fold change, p<0.05) was detected from four biological replicates. Next, we 
characterized the H3K27ac enrichment at enhancers of ATF4 pro-apoptotic target genes 
(CHOP, PUMA, TRIB3, and p21) that were all significantly up-regulated in our RNA-seq 
data. Two of these genes, PUMA and CHOP, had significantly increased acetylation at 
enhancers (Figure 5.3). Both genes increased by approximately 6% compared to the 
vehicle control (FDR<0.05).  
5.3.4 Rotenone increases acetylation of metabolic genes involved in acetyl-CoA 
synthesis.  
 Intracellular PCAF is associated with increased acetylation at enhancers of ATF4 
target genes PUMA and CHOP.  PCAF has acetyltransferase activity independent of 
P300/CBP and is known to regulate cell cycle arrest in cancer cells (Love et al. 2012). 
PCAF preferentially acetylates H3 lysine 9 and lysine 14 residues. However, the activity 
and specificity of acetyltransferases can be modulated by the availability of their substrate 
(Ronowske et al. 2018). In our RNA-seq dataset, we noticed a down-regulation of 
glycolytic genes and up-regulation of genes involved in the tricarboxylic acid (TCA) cycle 
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(Figure 5.4). Acetyl-CoA is the primary substrate for histone acetyltransferase enzymes 
and its concentration in neuronal tissues is important for neuronal function (Mews et al. 
2017). Therefore, the metabolic shift caused by the integrated stress response may be 
responsible for increasing acetyl-CoA substrate levels and global acetylation patterns. We 
revealed increased H3K27ac at enhancers of 2 acetyl-CoA genes (ACSL6 and PDP2) 
(Figure 5.4). The level of H3K27 enhancer activation was increased by 8% and 3%, 
respectively (FDR<0.05). To explore potential responsibility, we measured the acetyl-CoA 
metabolite concentration using the acetyl-CoA Pico-Probe Fluorometric assay from three 
separate experiments. Unexpectedly, we discovered a decrease in total acetyl-coA from 
2 pmol/μl to 1.6 pmol/μl (p<0.05).  
5.3.4 Rotenone-induced oxidative stress reduces nuclear histone deacetylase.  
 We investigated the role of histone deacetylase enzymes rather than histone 
acetyltransferase activity on the acetylation patterns of enhancers exposed to rotenone. 
We measured intracellular oxidative stress in response to rotenone treatment and 
observed a significant 1.4-fold change increase in ROS (p<0.05) (Figure 5.5). HDAC2 is 
a ubiquitously expressed nuclear enzyme with global histone deacetylase activity 
(Grozinger et al. 1999). We observed a significant decrease in HDAC2 in the nucleus of 
rotenone treated neurons (0.55-fold, p<0.05) that was inversely correlated with the 
increase in intracellular ROS (Figure 5.5).   
5.5 Discussion 
 The role of histone acetylation in PD remains to be elucidated. However, multiple 
reports show that pesticide-induced models of PD have pathological hyperacetylation 
(Song et al. 2010, Song et al. 2011, Feng et al. 2015, Huang et al. 2019).  We measured 
global levels of H3K27ac because of its role in marking active enhancers and its tight 
coupling to the transcriptome (Creyghton et al. 2010). We saw a significant increase in 
global H3K27ac after treatment with rotenone agreeing with our previous report in rat 
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dopaminergic neurons treated with rotenone (Huang et al. 2019). We used RNA-
sequencing to correlate changes in gene expression with observed enhancer activation. 
We analyzed differentially expressed genes (DEGs) for target genes of known 
transcription factors using the TRUUST text mining database (Han et al. 2018). We 
discovered four transcription factors with targets significantly enriched in our dataset 
(Table 5.3).  
 The most significant transcription factor, HIF1α, and its cofactor, VHL, are both 
associated with the hypoxia response. Most of the target genes were down-regulated 
which agrees with our previous finding that the hypoxic response was reduced in response 
to rotenone (Chapter 4 Figure 4.8). This is supported by other studies that show increasing 
HIF1α activity is neuroprotective and can improve the redox environment of dopaminergic 
neurons (Zhang et al. 2011). The activity of HIF1α can be modified by post-translational 
modifications including ubiquitination by VHL. The induction of p53 can also have a 
negative effect on HIF1α activity through competitive inhibition of P300 histone 
acetyltransferase (Schmid et al. 2004). We observed an increase in H3K27ac at genes 
associated with p53-mediated intrinsic apoptosis (Figure 5.3) and this may indicate that 
the reduced activity of HIF1α may be mediated by p53 recruitment of histone 
acetyltransferases.  
 The transcription factor ASCL1, or MASH1, was also enriched among our DEGs. 
This protein regulates the transcription of genes involved in neurogenesis and neuronal 
differentiation. ASCL1 is of importance in PD literature for its capacity to convert human 
fibroblasts into induced neurons without transitioning first into pluripotent stem cells (Xu et 
al. 2017). This is critical because adult cells may maintain age-related changes in their 
epigenome and prevent errors stemming for a force state of high proliferation potential 
before re-differentiation. ASCL1 is also responsible for the transcription of genes involved 
in metabolic shift during dopaminergic maturation (Zheng et al. 2016). Post-mitotic 
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neurons rely more heavily on ATP production from oxidative phosphorylation and regulate 
the expression of glycolytic genes. The appropriate shut down of aerobic glycolysis is 
critical for neuronal differentiation and survival. 
 The final enriched transcription factor and the focus of our study was ATF4.  We 
also checked the pathway enrichment of up-regulated genes and discovered that ATF4-
mediated integrated stress response was the primary signaling pathway triggered in 
response to rotenone. The integrated stress response is stimulated by protein 
aggregation, glucose deprivation, and hypoxia (Pitale et al. 2017). ATF4 is the primary 
regulator of the mitochondrial stress response and is activated upon mtDNA depletion and 
complex I inhibition as seen in Figure 5.1 (Quiros et al. 2017, Kasai et al. 2019, Kim et al. 
2013).  
  ATF4 is ubiquitously expressed in low levels but chronic cellular stress causes 
sustained overexpression and induces intrinsic apoptotic pathways. In the rat substantia 
nigra, lentiviral overexpression of ATF4 transcripts by 3.2-fold significantly decreased the 
number of dopaminergic neurons (Gully et al. 2016). In our rotenone-treated neurons, we 
observed a significant up-regulation of ATF4 and activator EIF2 kinase by 1.7-fold and 2-
fold, respectively (Figure 5.2). We also measured increased H3K27ac at enhancers of 
pro-apoptotic genes in Figure 5.3. There was increased enhancer activation at genes 
CHOP and PUMA in response to ATF4 up-regulation. This agrees with reports that ATF4 
pro-apoptotic pathways up-regulate CHOP to activate PUMA to increase mitochondrial 
membrane permeability and facilitate the release of cytochrome C (Huang et al. 2015). 
The N-terminus of ATF4 binds to histone acetyltransferases and this interaction stabilizes 
the transcription factor (Cherasse et al. 2007).  The recruitment of histone 
acetyltransferase PCAF is responsible for the transcriptional regulation of CHOP. We saw 
an increase in intracellular PCAF protein with rotenone treatment (Figure 5.3). While ATF4 
mediated integrated stress is responsible for the enhancer acetylation in pro-apoptotic 
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genes after rotenone treatment, the ability for recruited PCAF to explain global 
hyperacetylation remains dependent upon the availability of substrate.  
 Histone acetyltransferase activity requires optimal acetyl-CoA concentrations from 
oxidative metabolism and their specificity also varies with acetyl-CoA availability 
(Pietrocola et al. 2015). Therefore, rates of acetyl-CoA conversion and its 
compartmentalization have a role in diverse neurological pathologies (Ronowska et al. 
2018). This has been demonstrated in hippocampal neurons in which reductions in acetyl-
CoA synthetase (ACSS2) resulted in decreased histone acetylation and impaired 
expression of memory-related genes (Mews et al. 2017). Rotenone exposure and ATF4 
signaling impairs glucose metabolism and metabolically reprograms cells to utilize fatty 
acids (Han and Kaufman et al. 2016, Seo et al. 2009, Worth et al. 2014). In one study by 
Worth et al. 2014 in SH-5YSY neurons, rotenone treatment decreased glycolytic acetyl-
CoA production but maintained intracellular acetyl-CoA levels through increased fatty acid 
mitochondrial import and β-oxidation. ATF4 signaling has a similar response and results 
in the accumulation of short chain fatty acids via enhanced import (Han and Kaufman et 
al. 2016). We observed a down-regulation of genes encoding glycolytic metabolites 
including PGK1 (-0.9 log2FC, FDR<0.001) which has been shown to protect against 
complex I inhibition in mice by supporting glycolytic ATP production (Cai et al. 2019). We 
discovered an increase in ACSL6, a long-chain acyl-CoA synthetase which supports β-
oxidation in the mitochondria (Figure 5.4) (Soupene and Kupyers et al. 2008). This gene 
was also actively enhanced by H3K27ac suggesting a possible mechanism for ATF4 
transcription factor activity to cause global hyperacetylation.  
 Pyruvate dehydrogenase is the enzyme responsible for the conversion of acetyl-
CoA from pyruvate, the primary metabolite of glycolysis. The pyruvate dehydrogenase 
complex has a critical role in neuronal oxidative metabolism and its activity is sensitive to 
changes in metabolic programming (Park et al. 2018). Pyruvate dehydrogenase activity is 
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regulated by post-translational phosphorylation in which the pyruvate dehydrogenase 
kinase (PDK1) inactivates the enzyme and the pyruvate dehydrogenase phosphatase 
(PDP2) re-activates it. Mitochondrial dysfunction and complex I inhibition results in 
sustained activation of the pyruvate dehydrogenase complex and increases global acetyl-
CoA levels and reduces lactic acid needed for anaerobic ATP production (Park et al. 
2018). These changes in cellular metabolite concentrations are associated with 
neurological disease. We discovered both a decrease in the gene encoding PDK1 (-1.5 
log2FC, FDR<5x10-9) and an increase in the gene encoding PDP2 (1.0 log2FC,  
FDR<5x10-5) (Figure 5.4). We also saw increases in the genes encoding enzymes ME1 
and PCK2 which take metabolites of the TCA cycle and convert them back to pyruvate 
(Figure 5.4). We discovered increased H3K27ac at the enhancer of the PDP2 gene further 
supporting our hypothesis that mitochondrial dysfunction can promote histone 
hyperacetylation through increased substrate availability of acetyl-CoA. However, we 
were not able to see increases in intracellular acetyl-CoA in rotenone treated cells (Figure 
5.4). Acetyl-CoA levels fluctuate rapidly and can be difficult to measure within whole cell 
extracts (Pietrocola et al. 2015). Thus, our inability to see increases in acetyl-CoA in the 
nucleus may have been due to varying concentrations of acetyl-CoA within subcellular 
compartments that was not detectable with our assay. This is supported by another study 
that shows rotenone-induced mitochondrial damage can promote the translocation of the 
pyruvate dehydrogenase complex from the mitochondria to the nucleus (Sutendra et al. 
2014). Nuclear pyruvate dehydrogenase remains active by blocking PDK1 inhibition and 
its sustained activity in the nucleus facilitates pathological hyperacetylation despite 
decreases in cytosolic acetyl-CoA.  
 Finally, rotenone-induced complex I inhibition, oxidative stress, ATF4 activation, 
and metabolic shift does not only affect the activity of histone acetyltransferase enzymes 
but can also directly influence histone deacetylases. HDAC2 is a class I histone 
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deacetylase that is ubiquitously expressed in the nucleus (Seto et al. 2014). It is well 
established that intracellular ROS and nitrosative stress can be potent inhibitors of HDAC2 
activity (Kreuz and Fischle 2016). It has also been reported that metabolic reprogramming 
as a result of mitochondria dysfunction can increase the synthesis of HDAC2 inhibitor β-
hydroxybutyrate (βHOB) from fatty acid catabolism. Rotenone increases in βHOB in 
multiple human cell lines including SH-5YSY has already been reported by Basu and Blair 
(2011). We observed an increase in both intracellular ROS induced by rotenone exposure 
and the reduction of nuclear HDAC2 protein levels (Figure 5.5). We examined metabolic 
shift in response to rotenone exposure and discovered the up-regulation of genes involved 
in lipid metabolism. Of these genes, HMGCS1, which encodes the HMG CoA synthase 
was significantly increased by 2-fold (FDR<10-3). This enzyme is involved in the production 
of ketones from fatty acids and is a rate-limiting enzyme in the production of βHOB. 
Furthermore, it has been shown in murine hippocampal neurons that HDAC2 regulates 
the apoptotic factor FOXO3a from binding p21 cell cycle kinase inhibitor (Peng et al. 2015). 
However, increased intracellular ROS can inhibit HDAC2 regulation of FOXO3a and 
increases histone 4 lysine 16 (H4K16) acetylation at the transcription start site of p21. We 
observed an increase in p21 expression but not an increase in H3K27ac (Figure 5.4). This 
supports the role of the integrated stress response induced HDAC inhibition in causing 
non-specific global hyperacetylation across all histone proteins. We recommend further 
studies using metabolomic approaches investigate the nuclear concentrations of acetyl-
CoA and βHOB in response to mitochondrial dysfunction. 
 In summary, rotenone-induced mitochondrial dysfunction and mtDNA depletion in 
human neuronal cell line SH-5YSY activated the integrated stress response mediated by 
ATF4 and was associated with global increases in H3K27ac. Enhancer activation was 
observed at pro-apoptotic genes, CHOP and PUMA, which are regulated by ATF4 
transcription factor activity through the induction and recruitment of PCAF. The role of the 
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integrated stress response in metabolic reprogramming also increased acetylation at 
enhancers of genes involved in mitochondrial lipolysis (ACSL6) and pyruvate 
dehydrogenase activation (PDP2) which provides a pathway for increased acetyl-CoA 
substrate availability and non-specific histone acetyltransferase activity. Furthermore, 
intracellular ROS and the production of ketones strengthens rotenone-induced 
pathological hyperacetylation by degrading nuclear HDAC2. This pathway gives additional 
insights into the intersection of multiple pathways that provide feedback to the nucleus 
from mitochondria. It supports the critical role of the integrated stress response and ATF4 
signaling in maintaining the delicate balance between histone acetyltransferase and 
histone deacetylase enzymes. It also provides evidence that ATF4 mediated changes in 
histone acetylation patterns at metabolic genes could provide early cues for metabolic 
shift and the dysregulated production of primary metabolites in chromatin regulation. 
Epigenetic cues that occur prior to motor pathology can aid in earlier diagnosis and 
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5.7 Tables  
Table 5.1 qRT-PCR primers for RNA-seq validation 
 
ATF4 CTCCGGGACAGATTGGATGTT GGCTGCTTATTAGTCTCCTGGA 
EIF2 AAGGGGATACCCAAACAGAGG TTCATCAGCTTCCAAATCCTTGT 
CEBPB CTTCAGCCCGTACCTGGAG GGAGAGGAAGTCGTGGTGC 
JUN TCCAAGTGCCGAAAAAGGAAG CGAGTTCTGAGCTTTCAAGGT 
DDIT3 GGAAACAGAGTGGTCATTCCC CTGCTTGAGCCGTTCATTCTC 
CDKN1A TGTCCGTCAGAACCCATGC AAAGTCGAAGTTCCATCGCTC 
 
Table 5.2 ChIP-PCR primers for H3K27ac 
 
ATF4 cttccgggacagattggatgtt ggctgcttattagtctcctggac 
EIF2 aaggggatacccaaacagagg ttcatcagcttccaaatccttgt 
CEBPB cttcagcccgtacctggag ggagaggaagtcgtggtgc 
JUN tccaagtgccgaaaaaggaag cgagttctgagctttcaaggt 
DDIT3 ggaaacagagtggtcattccc ctgcttgagccgttcattctc 
CDKN1A tgtccgtcagaacccatgc aagtcgaagttccatcgctc 
 
Table 5.3 TRUUST 2019 analysis 
TF p-value FDR 
ATF4 2.50E-05 0.014 
ACSL1 2.94E-05 0.017 
VHL 3.06E-05 0.009 






Figure 5.1 Rotenone exposure causes mitochondrial dysfunction.  
A) Rotenone-induced complex I inhibition was measured by in-vitro assay using the 
absorbance reduction of oxidized βNADH with or without the presence of the electron 
donator, ubiquinone. The complex I activity is expressed as nM βNADH oxidized/ assay 
duration(min) * protein concentration (mg). B) Mitotracker FM Red was used to quantify 
intracellular mitochondria using the intensity of their fluorescence at 580/640 nm. The 
results are shown in fold change in fluorescence intensity. C) Mitochondrial DNA depletion 
was estimated using qPCR to measure copy number of mitochondrial gene (ND1) relative 
to two genomic genes, BECN (solid color) and B2M (striped). Mitochondrial DNA depletion 





Figure 5.2 Rotenone enhancer activation causes global changes in gene 
expression. 
 A) The volcano plot of differentially expressed genes (DEGs) with the x-axis representing 
their change in expression (log2FC) and the y-axis representing the significance of that 
change (-log(P-value)). Down-regulated genes (log2FC<-1) were highlighted in blue and 
up-regulated genes (log2FC>1) were highlighted in orange. B) qRT-PCR validation for six 
genes selected from RNA sequencing data shows similar changes in gene expression in 
an additional replicate. C) Reactome pathway enrichment analysis with adjusted p-value 
(FDR<0.05) was used to determine pathways enriched in down-regulated versus up-
regulated genes. Down-regulated pathways are in blue and up-regulated pathways are in 
orange. The x-axis represents the significance expressed as the -log2(FDR). D) Histone 
enhancer mark H3K27ac was observed by Western from extracted histones after rotenone 
treatment. H3K27ac was significantly increased in rotenone treated neurons after 
normalizing to histone 3 (H3) nuclear loading control protein. The quantification is shown 
below the Western and is expressed as fold change in chemiluminescence of DMSO. All 






Figure 5.3 Rotenone-induced ATF4 signaling increases histone acetyltransferase 
PCAF and acetylates genes involved in apoptosis. 
 A) We measured the intracellular protein level of P300-CBP Associated Factor (PCAF) 
from four biological replicates. PCAF acts a cofactor to ATF4 in rotenone treated cells. We 
saw a significant up-regulation after quantification (right of Western) by normalizing PCAF 
to the intracellular loading control GAPDH. The results are expressed as fold change in 
antibody chemiluminescence relative to vehicle control (DMSO) after normalization. 
Significance testing was done with a two-tailed Student’s t-test (* p<0.05). B) Pro-apoptotic 
genes under transcriptional control of ATF4 were observed in our differentially expressed 
genes from RNA sequencing. Their changes in expression (log2FC) and the significance 
of that change in expression (adjusted p-value FDR) are shown in the table. C) The 
H3K27ac enrichment of enhancers at ATF4 pro-apoptotic target genes are shown by 
ChIP-PCR. Rabbit IgG was used as the negative control for immunoprecipitation. 
Significance was tested with a two-tailed Student’s t-test and multiple hypotheses were 





Figure 5.4 Rotenone exposure increases acetylation of enhancers at metabolic 
genes.  
 A) Metabolic genes used for H3K27ac enrichment with CHIP-PCR are shown in the table. 
These genes were all significantly up-regulated in our RNA sequencing data. Their 
expression (log2FC) and the significance of their change in expression (adjusted p-value 
FDR) are also shown. B) The image shows more metabolic genes differentially expressed 
in our RNA sequencing data and their role in synthesizing acetyl-CoA, the substrate for 
histone acetyltransferase enzymes. Genes in red are differentially expressed and their 
arrow represents the direction of their change in expression. C) The H3K27ac enrichment 
of enhancers at up-regulated metabolic genes involved in acetyl-CoA synthesis are shown 
by CHIP-PCR. Rabbit IgG was used as the negative control for immunoprecipitation. 
Significance was tested with a two-tailed Student’s t-test and multiple hypotheses were 
corrected using the false discovery rate method (* FDR<0.05). D) The amount of 
intracellular acetyl-CoA substrate was measured after rotenone treatment using the 
Abcam PicoProbe Fluorometric assay. The results are shown in pmol/ul of deproteinized 





Figure 5.5 Rotenone-induced oxidative stress is associated with decreased nuclear 
histone deacetylase enzyme HDAC2.  
A) We measured intracellular reactive oxygen species within rotenone treated neurons 
using the DCFDA fluorometric assay. The results are shown as the fold change in 
fluorescence intensity in rotenone treated cells relative to the vehicle control (DMSO). B) 
We extracted nuclear proteins from three biological replicates of rotenone treated neurons 
and measured concentrations of global histone deacetylase HDAC2. The quantification 
for the Western is shown below and expressed as the fold change in chemiluminescence 
relative to the nuclear loading control H3. Significance testing for all results was done with 




SUMMARY OF MECHANISTIC INSIGHTS AND 
TRANSLATABILITY TO DOPAMINERGIC NEURONS 
 
6.1 Summary of rotenone effects on the neuronal epigenome 
 Rotenone is an organic pesticide with epidemiological evidence connecting its use 
to increased risks of neurodegeneration and Parkinsonism in agricultural workers and their 
families. It is a potent mitochondrial complex I inhibitor and has been shown to impair 
motor function in rodents at concentrations as low as 20 nM in the brain (Greenamyre et 
al. 2001). Though the deleterious effect of rotenone on cellular respiration is well-
established, it is not required for rotenone to deplete the number of dopaminergic cells in-
vitro (Choi et al. 2008). In cell models, rotenone exposure recapitulates pathological 
hallmarks of neuronal dysfunction and aging including oxidative stress, protein 
aggregation, metabolic reprogramming, and p53 mediated apoptosis. We used two 
human cell lines (HEK293 and SH-5YSY) to model rotenone toxicity and to study the 
mechanisms involved in gene-environment interacts relevant to Parkinson’s disease (PD). 
The goal of this dissertation was to characterize global changes in epigenetic patterns in 
response to rotenone and to discern the molecular mechanisms involved in early stages 
of pathogenesis. We also aimed to identify vulnerable regions of the genome and to 
interpret the role of their dysregulated expression on neuronal function.  
 We began our exploration into rotenone mediated changes in chromatin regulation 
by focusing on DNA methylation. Global decreases in DNA methylation have been 
reported in patients with PD and Lewy body dementia, a neurodegenerative disorder with 
distinct aggregation of α-Synuclein (α-Syn) protein (Matsumoto et al. 2010). We 
discovered that 200 nM rotenone exposure for 24h caused striking reductions in total 5-
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methylcytosine (5mC) in genomic DNA from both cell lines. Allele-specific CTCF 
transcription factor binding was altered in response to rotenone and modified the 
expression of PD genetic risk factors. We also identified regions with allele-specific 
methylation (ASM) and predicted genes with monoallelic expression were among those 
vulnerable to rotenone exposure. These regions which we previously determined were 
dependent on the DNA methyltransferase I (DNMT1) enzyme, included both germline 
imprinted regions and non-germline regions with a novel, switchable ASM phenotype. 
Both regions are of interest for understanding the patterning and persistence of DNA 
methylation as a result of exposure because they are hypothesized to be largely resistant 
to global demethylation events during development (Martos et al. 2017, Freeman and 
Wang 2019). The vulnerability of these regions to rotenone supports the hypothesis that 
early life exposures can cause a rewiring of neuronal activity that promotes pathology over 
time (Braak et al. 2003).  
 Rotenone induced hypomethylation was associated with the accumulation of α-
Syn. We revealed that accumulated α-Syn interacts with DNMT1 after rotenone treatment 
and sequesters it from the nucleus (Figure 6.1). This was supported by the resilience of 
DNMT1-depedent regions to rotenone in α-Syn knockdown neurons. Furthermore, 
targeting α-Syn increased cellular resistance to rotenone and improved mitochondrial 
function. We analyzed HIF1α signaling and reported the novel finding that α-Syn 
accumulation diminishes the hypoxic response and sensitizes cells to mitochondrial 
damage.  
 Histone acetylation is the other most studied epigenetic mark in PD pathogenesis. 
While there are conflicting results based on brain region, disease etiology, and neuronal 
cell type, it is broadly agreed upon that rotenone exposure causes hyperacetylation of 
Histone 3 (H3) proteins (Song et al. 2011, Park et al. 2016, Huang et al. 2019). 
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Additionally, acetylation of H3 lysine 27 (H3K27) is tightly coupled to open chromatin and 
active enhancers (Creyghton et al. 2010). We explored the role of the cellular integrated 
stress response to mitochondrial damage on the recruitment of histone acetyltransferase 
(HAT) and deacetylase enzymes (HDAC). We found that ATF4 signaling not only 
increased enhancer activation mark H3K27ac at pro-apoptotic genes but also increased 
metabolic expression toward the generation of acetyl-CoA (Figure 6.1). The distribution of 
acetyl-CoA is critical for neuronal function and its availability determines the activity of 
HATs (Ronowska et al. 2018). Rotenone-induced oxidative stress was also associated 
with reduced histone deacetylase 2 (HDAC2) protein in the nucleus thereby supporting 
pathological hyperacetylation (Feng et al. 2015).  
  In conclusion, rotenone inhibition of mitochondrial complex I generates a redox 
environment that facilitates α-Syn misfolding and aggregation. The accumulation of α-Syn 
inhibits DNMT1 maintenance of the methylome and prevents the HIF1α mediated 
response to hypoxia. The propagation of oxidative stress and mitochondrial damage 
activates the integrated stress response and disrupts the balance of histone modifying 
enzymes in the nucleus. These two independent but complementary mechanisms cause 
global changes in gene expression profiles that destabilize neuronal activity and weaken 
the aging brain.  
6.2 The LUHMES Dopaminergic Model 
 While Braak’s hypothesis describes a spatial and temporal progression of neuronal 
death from the periphery to the cortex, the clinical definition of Parkinson’s disease is 
defined by death of dopaminergic neurons in the midbrain (Braak et al. 2003, Braak et al. 
2007). A limitation of our current data is that neither HEK293 or SH-5YSY are specific for 
a mature dopaminergic neuron. In contrast, the LUHMES (lund human mesencephalic) 
cell line is derived from a healthy, mesencephalic tissue and is conditionally immortalized 
197 
 
with a tetracycline-controlled v-myc transgene. These cells can be differentiated into 
mature dopaminergic neurons in 2D and 3D models of disease (Krug et al. 2013, Harris 
et al. 2017). Unlike induced pluripotent stem cell (iPSC) models, these genes are 
predetermined for the dopaminergic lineage and therefore do not present challenges with 
multi-cellular phenotype effects (Harris et al. 2017). They also lack epigenetic memory 
remaining from the tissue of origin (Kim et al. 2010).  
 Complex I inhibition with MPP+ and rotenone have been tested in LUHMES 
models (Krug et al. 2013, Krug et al. 2014, Smirnova et al. 2016, Harris et al. 2018). 
Differentiated neurons were able to form tissue-like interactions in-vitro and complex I 
inhibition significantly reduced neurite outgrowth (Smirnova et al. 2016). While 100 nM 
was the lowest observed adverse effect level for mitochondria function and morphology, 
doses as low as 50 nM had large effects on the transcriptome (Harris et al. 2018). From 
these experiments, rotenone (100 nM) for 48h resulted in similar decreases in 
mitochondrial viability and membrane potential as our cellular models. Furthermore, 
complex I inhibition by rotenone exposure (Smirnova et al. 2016) and MPP+ (Krug et al. 
2014, Smirnova et al. 2016) shifted cellular metabolism. One-carbon metabolism was 
altered to increase the production of glutathione in the oxidative stress response. This led 
to an overall increase in homocysteine levels which is associated with reduced DNA 
methylation patterns in the blood of PD patients (Obeid et al. 2009). We discovered that 
rotenone changes in one-carbon metabolism were associated with α-Syn accumulation 
and that aggregation may contribute to the sensitivity of cells to complex I inhibition (Duan 
et al. 2002). These studies also identified ATF4 as a superordinate regulator of early 
changes in gene expression in LUHMES (Krug et al. 2014, Smirnova et al. 2016). ATF4 
signaling reduced glucose flux and increased non-glycolytic pyruvate production similar to 
our findings in Chapter 5.  
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 Based on the concurring evidence found in our analysis of early transcriptomic 
changes to complex I inhibition, we hypothesized that rotenone treatment at 200 nM for 
24 or 48h would produce similar trends in the epigenome of LUHMES cells as in the SH-
5YSY non-dopaminergic neuronal cell line. We also hypothesized that dopaminergic 
neurons would be more vulnerable to rotenone exposure because of their selective 
vulnerability to stress (Hirsch et al. 1988). This increased susceptibility is predicted to be 
a result of their high energy demand and the innate reactive oxygen species (ROS) 
generated in dopamine synthesis (Chan et al. 2010). Additionally, experiments in SH-
5YSY were done in a proliferating immortalized cell with enhanced PI3K/Akt signaling 
activity to promote survival in response to mitochondrial complex I inhibition (Santo et al. 
2012, Zhu et al. 2012).  
6.3 Cell culture and treatment of LUHMES cells 
 Cell culture of LUHMES was done based on methods by Krug et al. 2014 and 
Harris et al. 2017. We chose to culture cells in 2D versus 3D to reduce variability between 
cell lines. The timeline used in cell culture and treatment is presented in Figure 6.2. Flasks 
and 6-well plates were coated with poly-L-ornithine and fibronectin at least 24h prior to 
attachment with LUHMES (recipe Table 6.1). We cultured proliferating, undifferentiated 
LUHMES cells attached to a 75cm2 flask to a confluency of approximately 80% in 
proliferating media (recipe Table 6.2). We pre-differentiated LUHMES in a large 175cm2 
flaks with approximately 6x106 cells for 24h in proliferation medium and then changed the 
media to differentiation medium supplemented with tetracycline to turn off expression of 
v-myc. The cells were then grown in differentiation medium for an additional 48h. Cells 
were seeded into 6-well plates at 1x106 cells per 2 mL wells for treatment with rotenone. 
Cells were fully differentiated after 72 h on day 5 (d5) and treated with rotenone on d6 or 
d7. Rotenone (200 nM) was diluted into differentiation medium with DMSO as a vehicle 
control (<0.002% v/v). After treatment, Presto Blue reagent was added at 10% (v/v) and 
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incubated for 1h at 37°C before measuring fluorescence (excitation 530 nm/ emission 590 
nm). Cells were then washed and collected for additional experiments.  
6.4 LUHMES cells were not more susceptible to rotenone exposure. 
 We quantified mitochondrial viability as a measure of its metabolic capacity to 
reduce resazurin to resorufin. We did not see a decrease in viability at either timepoint in 
response to rotenone (Figure 6.2). Although, LUHMES cells treated with rotenone (100 
nM) for 48h in 3D decreased mitochondrial viability by 20%, the same dose in 2D did not 
decrease viability in a study by Krug et al. 2013. While no effects on the mitochondria were 
observed, both Smirnova et al. 2016 and Krug et al. 2013 observed diminished neurite 
outgrowth and transcriptomic changes in response to rotenone before other molecular 
endpoints.  
6.5 LUHMES cells had increased α-Syn expression but not DNA methylation. 
 All methods for LUHMES used the same protocols as SH-5YSY in Chapter 4.3. 
We used qRT-PCR for SNCA gene expression analysis and observed significant up-
regulation of transcripts after 24h exposure (Figure 6.3). We did not observe the increased 
expression of SNCA after 48h exposure. This may be due to the up-regulation of post-
transcriptional controls for protein aggregation. We observed a significant increase in mir-
34 after rotenone treatment in SH-5YSY but not in SNCA knockdown neurons. This 
miRNA is up-regulated in response to rotenone in rat striatal dopaminergic neurons (Horst 
et al. 2018) and has been shown to target SNCA specifically in-vitro (Kabaria et al. 2014).  
 We decided to focus on DNA methylation from LUHMES after 24h rotenone 
treatment using the dot blot analysis of 5mC. We did not observe any change in DNA 
methylation after rotenone treatment (Figure 6.3). We concluded that α-Syn accumulation 
wasn’t associated with DNA hypomethylation in this model because of the lack of cell cycle 
progression and neuronal activity in LUHMES cell culture.  
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 Active DNA demethylation in post-mitotic cells is still controversial (Ooi et al. 2008, 
Gavin et al. 2013) but evidence does suggest a role of active demethylation in reactivating 
silenced genes in mature neuronal cells (Chen et al. 2003, Martinowich et al. 2003). DNMT 
inhibitors can decrease DNA methylation in post-mitotic neurons in-vitro and up-regulate 
the expression of neurotropic genes to stress (Feng et al. 2010, Levenson et al. 2006, 
Ravindran et al. 2005). However, this change in DNA methylation may be activity 
dependent and thus their demethylation relies on neural electrical signals from adjacent 
neurons (Nelson et al. 2008). While LUHMES cells are electrically active in culture, 
heterogeneity in activity may cause a loss of effect seen with a low sensitivity method 
(Harris et al. 2018). Furthermore, other studies have shown that while DNMT1 is a critical 
factor in adult neurogenesis and the survival of proliferating cells in the cortex, the 
requirement for DNMT1 expression is extinguished after maturation (Noguchi et al. 2015).  
6.6 Global H3K27ac enhancer enrichment was maintained in LUHMES cells.  
 Global H3K27ac enrichment in LUHMES was detected using the same protocols 
as SH-5YSY in Chapter 5.3. We extracted histones from LUHMES cells treated with 
rotenone for 24h and quantified changes in enhancer activation mark H3K27ac (Figure 
6.4). We discovered a significant 1.8-fold increase in H3K27ac (p<0.05) which was 
stronger than the increase observed in rotenone treated HEK293 (1.3-fold) and SH-5YSY 
(1.2-fold). We concluded that the integrated stress response was activated early upon 
rotenone exposure and led to the significant up-regulation in pro-apoptotic genes and 
those involved in metabolic reprogramming (Chapter 5). This was replicated by 
experiments in LUHMES where significant increases in the integrated stress response to 
complex I inhibition was observed by Smirnova et al. 2016 and Krug et al. 2014. Krug et 
al. 2014 also reported similar changes in glycolytic flux and pyruvate production indicating 
possible increases in acetyl-CoA concentrations.  
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 Histone modifications are critical during neurogenesis for the stage and site 
dependent regulation of gene expression in different populations of neuronal cells (Gray 
et al. 2015, Mo et al. 2015). It has long been established that neuronal activity and synaptic 
plasticity requires remodeling of the chromatin landscape to control the expression of 
genes involved in cognition and behavior (Guan et al. 2002). Critical periods that begin 
immediately after learning require strict temporal regulation of gene expression for long-
term potentiation and memory formation (Peixoto and Abel 2013).  These mechanisms 
are directed by transcription factors and the recruitment of histone modifying enzymes to 
the chromatin. For example, in sensory neurons, the immediate activation of CREB 
proteins including ATF4 control the ratio of HATs/HDACs at plasticity genes to strengthen 
or prune the affected synapse (Feng et al. 2007). Chromatin modifying enzymes at 
enhancers can even oscillate rhythmically with external stimuli which is seen with 
HAT/HDACs at the regulatory regions of circadian genes (Etchegaray et al. 2003). With 
modern advancements in next generation sequencing, we are gaining insights into the 
shaping of nuclear architecture at single-cell resolution to understand how chromatin 
accessibility is manipulated by neural activity (Gallegos et al. 2018, Su et al. 2017).  
 Chromatin accessibility changes driven by neural electrical impulses were 
enriched at enhancers (Su et al. 2017). This can have a significant impact on the function 
of dopaminergic neurons which have a specific patterning of open chromatin regions that 
are intrinsic to their cellular subtype (Gendron et al. 2019). A recent study in LUHMES 
cells also reports the significance of enriched H3K27ac and chromatin accessibility to the 
molecular signature of differentiated dopaminergic neurons versus undifferentiated 
precursors (Pierce et al. 2018). These open chromatin regions control the expression of 
transcription factors involved in neurogenesis and importantly were enriched for regions 
with PD-risk associated single nucleotide polymorphisms (SNPs). The enrichment of PD 
associated SNPs at active enhancers has been reported in multiple cell lines across 
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various tissues (Coetzee et al. 2016). Genetic variants at active enhancers can alter 
transcription factor binding as we reported in Chapter 2B where PD associated SNPs at 
active H3K27ac marked enhancers altered the binding of the CTCF insulator. Altered 
transcription factor binding has also been shown in mouse ex-vivo dopaminergic neurons 
that had disease associated SNPs at activated enhancers surrounding the SNCA gene 
(McClymont et al. 2018).  
6.7 Histone 3 variant H3.3 dynamics in rotenone treated LUHMES 
 H3K27ac is linked to a non-canonical H3 variant (H3.3). Non-canonical variant 
H3.3 only differs from canonical variants of H3 (H3.1/H3.2) by 4-5 amino acid residues but 
has many functional differences. For example, H3.3 is the only H3 variant that is 
expressed independent of cellular replication (Chen and Jin, 2017). H3.3 is localized to 
active regions of the genome and controls activity-dependent gene expression (Maze et 
al. 2015). Thus, it is essential for regulating chromatin in post-mitotic neurons (Jin and 
Felsenfeld, 2007). H3.3 accumulates with age in the human brain and is associated with 
maintaining neuronal plasticity. Historically, it was accepted that histone variants were 
stable leaving post-translational modifications of nucleosomes as the primary 
mechanisms for regulating gene expression. However, recent studies have shown that 
histones are dynamic, and incorporation of newly synthesized histone variants throughout 
life is important for marking active genes in neuronal plasticity (Maze et al. 2015). Histone 
turnover affects the intrinsic stability of H3 variants and makes them vulnerable to 
environmental exposure (Chen and Jin, 2017). The overexpression of H3.3 and its 
incorporation into the chromatin can impair neuronal function in the aging brain thereby 
contributing to disease. To explore the connection of increased H3K27ac with H3.3, we 
measured H3.3 in rotenone treated LUHMES cells (Figure 6.4). As expected, we saw 
correlated increases in H3.3 variant (1.8-fold change) with H3K27 enhancer activation. It 
is important to mention that we discovered rotenone treatment significantly down-
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regulated multiple genes including H3 genes at the H1 cluster in our SH-5YSY cells. The 
H1 cluster encodes repetitive histones proteins that form the nucleosome and the 
expression of these genes can affect the deposition of newly synthesized histone variants 
(Dunleavy et al. 2011).  
6.8 Future directions in LUHMES dopaminergic models 
6.8.1 Rotenone effects on dopaminergic neurogenesis 
 We observed DNA hypomethylation in rotenone treated proliferating neurons (SH-
5YSY) (Chapter 4). We did not see a change in DNA methylation in response to rotenone 
treatment in fully, differentiated dopaminergic neurons in culture (Figure 6.3). The role of 
DNA methyltransferases in the survival of post-mitotic neurons is not well understood. For 
instance, Feng et al. 2010 found that DNMTs regulate synaptic activity and survival of 
mature forebrain cortical neurons while Noguchi et al. 2015 found that DNMT1 expression 
was no longer required for the activity of mature hippocampal neurons. It is widely 
accepted, however, that DNMT expression is critical for the survival and maturation of 
neural progenitor cells (Fan et al. 2001, Hutnick et al. 2009). Hypomethylation of 
proliferating cells altered the expression of genes involved in apoptosis and differentiation. 
The expression of DNMT1 was also critical for the survival and migration of cortical 
interneurons which play an essential role in the circuitry between brain regions (Pensold 
et al. 2016).  
 We hypothesize that rotenone-induced hypomethylation alters the proliferation and 
differentiation of neural progenitor cells in the developing and adult brain. We propose 
treating LUHMES cells with rotenone at different timepoints during pre-differentiation and 
during the 72h maturation period between d3-d5 (Figure 6.2). The expression and 
methylation of genes involved in neurogenesis, axonal transport, and neuronal 
morphology would be correlated to the detected number of mature TH+ dopaminergic 
neurons with immunofluorescence. Disruption of dopaminergic maturation and the 
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connectivity of the striatum to the motor cortex could explain the long latency between 
exposure and extensive dopaminergic cell death. For instance, it was shown that 
agricultural workers exposed to rotenone had a similar increase in PD risk regardless of 
the time of exposure cessation (Tanner et al. 2011). Thought it has been previously 
thought that neurogenesis in the adult brain is extremely limited, it has more recently been 
proven that the differentiation of proliferating cells into functional dopaminergic neurons in 
the adult substantia nigra Is feasible (Zhao et al. 2002, Arzate et al. 2019).  
6.8.2 Rotenone changes in DNA methylation in stimulated dopaminergic neurons 
 DNA methylation in somatic cells has traditionally been viewed as stable and that 
active demethylation was rare (Ooi et al. 2008). This implied that DNA was only passively 
demethylated with replication and that changes in DNA methylation would be propagated 
in dividing cells well after the removal of the stressor (Suzuki and Bird, 2008). More 
recently, it is understood that DNA methylation enzymatic activity persists outside of 
replication including during transcription (Metivier et al. 2008) and during DNA repair 
(Yamagata et al. 2012). The role of oxidative damage and DNA repair mechanisms in 
regulating DNA methylation is supported in hippocampal neurons in which DNA damage 
inducible gene GADD45b acts as a negative regulator of memory formation (Sultan et al. 
2012). This indicates that DNA methylation patterns in post-mitotic neurons rely on the 
balance of DNA methyltransferases and DNA demethylase enzymes (TET) much like with 
histone modifying enzymes (Gavin et al. 2013).  
 The activities of these enzymes are activity dependent (Nelson et al. 2008). DNA 
methylation stabilizes neuronal interactions in the hippocampus and that hippocampal 
electrical activity sustained the expression of de novo DNA methyltransferase 3a 
(Levenson et al. 2006, Oliveira et al. 2012). Similarly, neural activity stimulates TET1 
enzymes in cortical neurons and reactivated the expression of the neural growth factor 
encoded by BDNF (Martinowich et al. 2003). Intriguingly, we discovered that our human 
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DNMT1-dependent regions with sensitivity to rotenone exposure encoded proto-
cadherins, voltage-gated ion channels, synaptic proteoglycans, and microtubules involved 
in facilitating neurotransmission (Chapter 3). We hypothesize that while LUHMES cells in-
vitro are capable of electrical activity, the effect of rotenone on neural activity in culture 
overwhelms the ability of the cell to facilitate active demethylation. We propose that mature 
dopaminergic neurons are first depolarized with treatment of potassium chloride (KCl) 
before rotenone treatment (Martinowich et al. 2003). Alternatively, a novel tool may be 
used to deliver direct current electrical stimulation to cultured neurons before treatment 
(Mobini et al. 2018). 
6.8.3 Rotenone effects on dopaminergic neural activity related enhancer activation. 
 We observed global increases in the acetylation of enhancers in LUHMES cells 
treated with rotenone for 24h (Figure 6.4). Chromatin accessibility and enhancer activation 
is critical to maintain synaptic plasticity during aging (Su et al. 2019, Pierce et al. 2018). 
Similar to DNA methylation enzymes, the activity of histone modifying enzymes are also 
related to neural activity (Feng et al. 2007). Rotenone injection into the peritoneal cavity 
reduces electric neuronal activity in adult rats (Darbinyan et al. 2017). It can also interfere 
with neuronal polarity, inhibit axogenesis, and destabilize microtubules (reviewed in Bisbal 
and Sanchez, 2019).  
 We propose that rotenone restricted neural activity in dopaminergic neurons is 
mediated by changes in histone acetylation of enhancers. The location of active 
enhancers may be correlated with genes involved in synaptic plasticity using chromatin 
immunoprecipitation (ChIP)- sequencing. Lastly, the role of chromatin accessibility in 
controlling electrical impulses should be investigated with ATAC-seq and patch-clamp 
electrophysiology in LUHMES. In a previous experiment, rotenone-induced changes in 
LUHMES neural activity were ameliorated after rotenone wash-out (Harris et al. 2018). It 
206 
 
would be interesting to see if H3K27ac and chromatin organization was amended after 
recovery from rotenone treatment.  
6.8.4 Rotenone effects on histone variant turnover dynamics 
 Histone 3 non-canonical variant H3.3 is tightly coupled to gene expression and 
active enhancers. We revealed rotenone increased H3.3 levels with elevated H3K27ac. 
H3.3 accumulates in neurons with aging and we hypothesize that this accumulation is 
associated with pathological hyperacetylation in response to rotenone. Furthermore, H3.3 
turnover in chromatin is dependent on proteasome degradation which is known to be 
obstructed in PD (Kanthasamy et al. 2012). We have found no prior studies that examine 
the involvement of histone variant H3.3 in PD pathogenesis. However, it seems likely that 
the deposition of histone H3.3 and its incorporation into the nucleosome is critical for 
maintaining longevity in post-mitotic dopaminergic neurons in the midbrain. The 
acetylation of H3.3 histone versus the canonical H3 histones should be investigated with 
mass spectrometry. For example, the relationship of age accumulated H3.3 was 
determined to be a causal factor in the histone methylation landscape in mouse 
hepatocytes (Tvardovskiy et al. 2017). Targeting H3.3 may also provide a novel target to 
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Table 6.2 Proliferation medium recipe for LUHMES culture 
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Table 6.3 Differentiation medium recipe for LUHMES culture 






















 6.11 Figures  
 
Figure 6.1 Mechanistic insights into rotenone mediated epigenetic alterations. 
We used rotenone to induce mitochondrial complex I inhibition and oxidative stress in 
HEK293 and SH-5YSY immortalized cell lines. Oxidative stress promotes accumulation 
of α-Syn which interferes with DNMT1 translocation into the nucleus to maintain global 
DNA methylation patterns. Mitochondrial stress and the unfolding protein response also 
activate the integrated stress response via ATF4 transcription factor signaling. ATF4 
induced histone acetyltransferase recruitment to the chromatin and the up-regulated 
expression of metabolic genes increases the pyruvate dehydrogenase complex 
production of acetyl-CoA. The generation of reactive oxygen species and activation of 
post-translational modifying proteins degrades HDAC2 nuclear protein and prevents 






Figure 6.2 Cell culture timeline and LUHMES mitochondrial viability  
A) LUHMES cells were grown in-vitro in proliferation medium before pre-differentiation. 
Differentiation was started in a 175cm2 flask in media supplemented with tetracycline to 
turn off the v-myc proto-oncogene. The cells were seeded into 6 well plates for treatment 
and differentiation was complete after d3. The cells were treated with rotenone (200 nM) 







Figure 6.3 LUHMES SNCA accumulation and DNA methylation 
A)  Rotenone treatment in LUHMES cells increased the expression of α-Syn encoding 
gene SNCA transcripts after 24h (solid bar) but not 48h (striped bar). The y-axis is 
expressed in fold change relative to the housekeeping gene, GAPDH. * p<0.05.  
B) Global DNA methylation was qualitatively assessed with dot blot using an antibody for 






Figure 6.4 Global enhancer activation mark H3K27ac and H3 variant H3.3 
A)  Rotenone treatment in LUHMES cells increased the acetylation of enhancer regions 
assessed with Western of H3K27ac levels in extracted histones. Rotenone treatment 
significantly increased H3K27ac relative to total H3 by 1.8-fold (p-value =0.03). 
B) We measured non-canonical histone variant (H3.3) in rotenone treated LUHMES. H3.3 




POTENTIAL FOR CROSSTALK BETWEEN METHYLATION AND 
ACETYLATION 
7.1 Introduction 
 In this dissertation, we focused on two primary epigenetic mechanisms, DNA 
methylation and histone acetylation, that have been studied in experimental models of 
rotenone neurotoxicity. Additionally, these mechanisms have been examined in the blood 
and post-mortem tissues of Parkinson’s disease (PD) patients.  
 DNA methylation is widely agreed to be reduced in PD patients but the extent of 
this hypomethylation is variable by region and cell type (Matsumoto et al. 2010). We 
examined two cellular models of rotenone neurotoxicity and discovered rotenone 
treatment reduces global DNA methylation patterns. Areas of vulnerability include 
imprinted control regions, non-germline ASMs, allele-specific transcription factor binding 
sites, and stress response elements. This response was not observed in the post-mitotic 
dopaminergic neurons and we hypothesized that it was the lack of replication or neural 
activity that explained the variability in methylation (Chapter 6).  
 Histone acetylation is controversial, and studies have suggested that 
hyperacetylation versus hypoacetylation depends on the region and other etiological 
factors (Yakhine-Drop et al. 2018). Our rotenone treated cells agreed with most reports 
that mitochondrial complex I inhibition is associated with pathological hyperacetylation 
(Song et al. 2010, Feng et al. 2015, Huang et al. 2019). This phenotype was replicated in 
post-mitotic dopaminergic neurons. We focused on the acetylation of histone 3 lysine 27 
(H3K27ac) because of its role in marking active enhancers from poised enhancers 
(Creyghton et al. 2010). Enhancer activation and chromatin opening are molecular 
signatures of maturation and neural activity (Pierce et al. 2018, Su et al. 2019). However, 
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histone acetylation at other lysine residues is also likely. For example, H3 lysine 56 
(H3K56) acetylation may be a site of interest due to its role in regulating nucleosome 
assembly and histone variant turnover (Matsumoto et al. 2005, Li et al. 2008). There is 
also interest in the role of histone methylation. While, this paper focuses on histone 
acetylation, H3 lysine 4 (H3K4) methylation plays a significant role in marking active 
enhancers. This histone modification is also associated with neural activity and is required 
for most cognitive functions within the hippocampus (Collins et al. 2019). In fact, 
dysregulated expression and function of histone lysine methyltransferases are often found 
in neurodevelopmental disorders. Like H3 acetylation patterns, H3 methylation is often 
correlated with histone variant H3.3 and one study showed that H3.3 accumulation may 
explain open-chromatin modification, H3 lysine 36 di-methylation (H3K36me2), increases 
with age (Maze et al. 2018). 
 Synaptic plasticity is maintained during aging by the active homeostatic balance 
between epigenetic enzymes. Intriguingly, our investigation into the mechanisms behind 
DNA methylation and histone acetylation changes in response to rotenone intersected at 
multiple points in the mitochondrial signaling pathway to the chromatin. For instance, the 
hypoxic response was significantly reduced in response to rotenone treatment in SH-
5YSY that was recovered after α-Synuclein knockdown (Chapter 4). The integrated stress 
response mediated by ATF4 regulates cellular apoptosis and activation of p53 (Pitale et 
al. 2017). The interaction of ATF4, hypoxic transcription factor HIF1α, and TP53 within the 
cytoplasm plays a crucial role in the balance of epigenetic modifying enzymes recruited to 
the chromatin. We hypothesize that mitochondrial dysfunction activates early response 
transcription factors to regulate the balance and activity of DNA modifying enzymes in the 
nucleus and that α.-Synuclein toxicity drives the direction of this response. 
7.2 Mitochondrial stress response and α-Syn in mediating the epigenome. 
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 Neurons are metabolically active cells with high energy demands required to 
propagate action potentials long distances via myelinated axons to facilitate 
neurotransmitter release from the post-synaptic membrane. This energy requirement is 
estimated to account for as much as 20% of the body’s total energy consumption (Alle et 
al. 2009). The cellular capacity to adapt its metabolic response in response to external 
stimuli to meet its energy demands requires widespread modifications to chromatin 
structure that causes long-term changes to organismal function (Jimenez-Chillaron et al. 
2012). This has been proven in the famed Dutch Famine cohort where nutrient deprived 
babies born to mothers with low caloric intake during the third trimester suffered from 
higher morbidity risk in adulthood that extended into future generations (Stein et al. 2000). 
Metabolic disruption and mitochondrial dysfunction are common features among almost 
all neurological disorders with distinct importance in neurodegeneration (Sebastian et al. 
2017).  In PD, the generation of reactive oxygen species from mitochondrial dysfunction 
is a hallmark of disease pathogenesis and results in the crosstalk of multiple pathways 
that promote oxidative damage induced loss of heterochromatin (Kreuz and Fischle et al. 
2016). In our cellular models of rotenone neurotoxicity, we confirmed two immediate 
transcription factor responses to mitochondrial complex I inhibition was the hypoxia 
response by HIF1α and the unfolded protein response by ATF4.  
 Mitochondrial damage sensing proteins upregulate the activity of the mitochondrial 
unfolded protein response in C. elegans (Tian et al. 2016). The communication between 
mitochondrial sensors and the endoplasmic reticulum unfolded protein response has also 
been reported in mammals and is regulated by both the activating kinase (PERK) and the 
ubiquitin ligase (PARK2) (Bouman et al. 2011, Ivanova et al. 2018). PARK2 is responsive 
to changes in mitochondrial membrane potential and is the most common genetic mutation 
in familial PD (Bekris et al. 2010). We previously determined that the CTCF binding motif 
at the PARK2 enhancer was vulnerable to rotenone induced changes in DNA methylation 
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and resulted in altered CTCF insulator binding activity (Chapter 2B). Ubiquitin ligases, 
PARK2 and pVHL, regulate the hypoxic response by marking HIF1α for degradation and 
can strengthen the interaction of ATF4 and TP53 with histone acetyltransferase p300 
(Sermeus and Michels et al. 2011, Tothova et al. 2018).  
 The lack of HIF-1α is associated with reductions in dopaminergic neurons in culture 
and in the substantia nigra of knockout mice (Milosevic et al. 2007). Interestingly, HIF1α 
is expressed in hypoxia (low oxygen) and normoxia (normal oxygen) and its expression 
increases DNA methylation via reduced activity of demethylases (Cimmino et al. 2019). 
The hypoxic response also depletes intracellular acetyl-CoA concentrations and thus 
alters the activity of histone acetyltransferases (Golovko et al. 2006, Tothova et al. 2018). 
Inhibition of the hypoxic response by the unfolded protein response can therefore promote 
histone acetylation. The integrated stress response to mitochondrial complex I inhibition 
and oxidative stress stimulates the opening of chromatin via histone acetyltransferases 
and promotes DNA demethylation via the enhanced expression of transcription and DNA 
repair genes (PPAR and GADD45b) (Golovko et al. 2006). Furthermore, ATF4 is a key 
regulator of the mitochondrial one-carbon metabolism pathway as evidenced by our RNA-
sequencing data in rotenone induced hyperacetylated neurons (Chapter 5) (Kasai et al. 
2018). One-carbon metabolism is significantly altered in complex I inhibited SH-5YSY as 
well as in LUHMES (Krug et al. 2014). This pathway regulates the antioxidant stress 
response via the transsulfuration pathway which directly alters the metabolite 
concentrations of homocysteine. Increases in neuronal homocysteine has been observed 
in PD patients and is associated with reduced DNA methylation and reduced recruitment 
of histone deacetylases (HDAC) (O’Suilleabhain et al. 2004, Tothova et al. 2018). The 
lack of nuclear HDACs caused by oxidative stress can diffuse disruptions in DNA 
methylation patterns. For instance, the nuclear interaction of HDAC2 with DNMT3a2 is 
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reported to be important for maintaining DNA methylation of imprinted control regions 
during development (Ma et al. 2015).  
 Mitochondrial damage sensing proteins and molecular chaperones mediating the 
endoplasmic reticulum stress response are all sensitive to the accumulation of α-
Synuclein. We discovered recovery in the expression of hypoxia response genes with the 
knockdown of α-Synuclein expression (Chapter 4). In addition, α-Synuclein knockout mice 
had reductions in acyl-CoA synthetase expression that was rescued by the 
overexpression of wild-type but not mutant SNCA gene (Golovko et al. 2006). We 
concluded that fatty acid metabolism was critical for maintaining histone acetylation in 
response to rotenone and reported increased H3K27ac at enhancers of fatty acid beta-
oxidation gene ACSL6 (Chapter 5). We do not know whether α-Synuclein accumulation 
directly interferes with HIF1α signaling directly through protein-protein interactions or 
indirectly through the activation of the integrated stress response. However, it seems that 
α-Synuclein toxicity plays a critical role in the regulation of the epigenome.  
7.3 Lysine methylation of histones in rotenone treated cells 
 Histone lysine methylation is less studied in terms of rotenone-induced 
neurotoxicity or PD. Injection of complex I inhibitor is associated with changes in lysine 
methylation at enhancers and is responsive to treatment with Levodopa (Nicholas et a. 
2008). Lysine methylation can indicate both repressed and open chromatin. Active 
enhancers are flagged by lysine methylation specifically H3 lysine 4 di-or-tri-methylation 
(H3K4me2 or H3K4me3). Alternatively, H3K4 mono-methylation or H3K4me1 are 
considered primed enhancers when not associated with increased H3K27ac and have 
lower levels of transcription that can be activated in response to an external stimulus. 
H3K4me1 still has an important role in chromatin organization as it facilitates the 
recruitment of the cohesion complex responsible for promoting chromatin looping during 
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transcription (Creyghton et al. 2010). Di-methylation of H3 lysine 36 (H3K36me2) is also 
associated with open chromatin to facilitate DNA damage repair and is tightly coupled to 
age-related levels of H3.3 similar to H3K27ac (Maze et al. 2018). Finally, repressed 
chromatin is associated with the methylation status of H3 lysine 9 (H3K9) and H3K9me2 
has been reported to have an important role in regulating synaptic activity through the 
expression of post-synaptic SNARE complexes (Sugeno et al. 2016). The overexpression 
of α-Synuclein has been shown to negatively regulate the expression of these synaptic 
proteins via increased histone methylation of H3K9.  
 Like with other histone modifying enzymes, the balance of histone 
methyltransferases and histone demethylases regulate gene expression and genomic 
stability. Increased oxidative stress and high levels of homocysteine restrict histone 
methylation via alterations in one-carbon metabolism. Interestingly, we revealed that 
rotenone-induced DNA hypomethylation may also increase the expression of the lysine 
demethylase, KDM7A, which is encoded at a vulnerable DNMT1-dependent region 
(Chapter 3 Table 3.5). The demethylation activity of KDM7A is known to reduce 
methylation at H3K9 and upregulate expression of synaptic proteins.  
 The lysine demethylases (KDMs) encoded by the JmjC gene family are also 
regulated by mitochondrial metabolism. Rotenone-induced production of the TCA cycle 
metabolite fumarate inhibits KDMs and increases H3K4 enhancer activation via 
methylation (Kreuz and Fischle et al. 2016). ATF4 is activated by disruptions in 
mitochondrial metabolic activity and can also stimulate the expression of JMJD3 (or 
KDM6B) which demethylates H3K27me3, an enhancer repressor mark, to promote global 





 Post-mitotic neurons were once considered to have stable chromatin. However, 
recent advancements have provided evidence that neuron depolarization reshapes 
nuclear organization and thus chromatin regulation is essential for the plasticity of aging 
neurons. Early mitochondrial dysfunction causes epigenetic reprogramming that can lead 
to persistent alterations of neural activity and behavior throughout life. Metabolic changes 
can vary in the brain in accordance with the energy demands of the cell. For example, 
dopaminergic neurons require more energy and therefore may be more sensitive to 
mitochondrial dysfunction than other neuronal subtypes (Chan et al. 2010). Chromatin 
regulation is also variable and depends on the activation of immediate transcription factors 
involved in the cellular stress response. For instance, we observed an increase in ATF4 
activation and a decrease in HIF1α response in rotenone treated neurons. This selective 
activation of the early stress response was associated with the accumulation of α-
Synuclein and therefore may explain some differences in the pathology between Lewy 
body-associated PD and atypical PD (Kasten et al. 2013). The observed effects at 
chromatin can also be variable because of the distinct sensitivities of chromatin modifying 
enzymes to oxidative stress, metabolic disturbances, and protein unfolding. While 
pathological hyperacetylation was observed in all cell models treated with rotenone, DNA 
methylation patterns were not consistent between proliferating cells and post-mitotic 
neurons. This may be due to increased passive demethylation during replication in 
proliferative cells or lack of electrically activated demethylation.  
 In summary, our data investigate a novel mechanism demonstrating how 
mitochondrial dysfunction and protein aggregation can change global chromatin 
architecture. We explore the importance of early response transcription factors and the 
presence of accumulated α-Synuclein in mediating the crosstalk between chromatin 
modifying enzymes. Targeting mitochondrial quality control proteins and α-Synuclein 
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aggregates have had little success in clinical trials. We propose that targeting down-
stream transcription factor complexes with chromatin modifying enzymes may improve 
pharmaceutical strategies in PD. We hypothesize that metabolites generated from the 
early stress response pathways and their epigenetic signature could be useful for creating 
early diagnostic biomarkers. This is supported by the presence of α-Synuclein protein in 
the blood (Matsumoto et al. 2017), enriched PD-associated genetic variants in active 
enhancers of non-neuronal cell types (Coetzee et al. 2016), and the concordance of DNA 
methylation patterns between blood and brain tissues (Masilah et al. 2013). Though 
mapping epigenetic responses to mitochondrial dysfunction in neurons is complex, we 
predict a unique molecular signature exists that is specific to a class of toxicant (i.e. 
complex I inhibitor) and/or underlying etiological factor (i.e. Lewy body formation). 
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Supplemental File 1: Chapter 2 differentially expressed genes from rotenone treated 
HEK293 
 
Genename logFC FDR 
STC1 -3.87 2.3E-50 
PPP1R10 -1.88 4.1E-40 
RN7SL1 -2.15 9.5E-37 
ADAMTS1 1.76 1.7E-35 
SH3BP5-AS1 -2.06 3.7E-34 
NCOA5 -2.01 1.2E-31 
ZNF37A -1.71 2.1E-30 
MT-TQ 2.97 1.8E-29 
CYR61 1.88 7.4E-26 
PCF11 -1.54 1.6E-25 
ZNF605 -1.60 4.4E-25 
KRCC1 -2.00 7.2E-25 
MT-TP 2.82 7.6E-25 
SAT1 1.79 5.3E-24 
RN7SL2 -1.88 5.8E-24 
HIST2H2BE 2.91 5.8E-24 
ZSWIM5 -1.67 3.6E-23 
TSC22D3 1.47 2.4E-22 
FOSB 1.86 1.3E-21 
ALMS1-IT1 2.54 3.2E-21 
RIPK1 -1.93 7.0E-21 
MEX3B 1.65 7.8E-21 
THAP9-AS1 1.53 5.7E-20 
ILF3-AS1 1.65 2.4E-19 
PFKFB4 -1.85 3.6E-19 
BRD2 1.35 4.7E-19 
SOX4 1.19 7.9E-19 
C1QTNF6 -1.68 1.0E-18 
JUN 1.42 1.6E-18 
PIM1 1.35 1.7E-18 
ZNF280C 1.25 2.4E-18 
RN7SK -4.17 4.1E-18 
ZNF587B -1.78 9.9E-18 
ARC 1.87 1.8E-17 
HSPA5 1.17 2.4E-17 
MSMO1 1.58 3.5E-17 
TGIF1 1.41 6.2E-17 
DOK3 -2.57 1.1E-16 
PAQR6 -1.56 1.6E-16 
MT-TA 2.80 2.1E-16 
WDR52 -1.87 7.4E-16 
B3GALT6 -1.47 9.3E-16 
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PPP1R18 1.20 1.0E-15 
GAB2 1.67 1.7E-15 
LRRC37A9P -1.84 3.0E-15 
CAPN12 1.78 1.7E-14 
IQCE -1.12 2.2E-14 
SAMD9 -1.83 2.3E-14 
CYP2U1 -1.61 2.4E-14 
FZD6 -1.29 3.0E-14 
ZBED3 -1.12 4.3E-14 
PER1 1.37 6.7E-14 
LGR5 -1.14 1.0E-13 
C15orf38 -1.17 1.1E-13 
ZC3H4 -1.48 1.3E-13 
MYB 1.53 1.8E-13 
INSIG1 1.24 2.0E-13 
TUFM 1.05 2.0E-13 
TSC22D2 1.10 2.0E-13 
PPFIA4 -1.37 2.6E-13 
PPP1R32 1.95 3.1E-13 
TAF1D 1.14 3.9E-13 
PRKACB -1.19 4.3E-13 
MID1IP1 1.29 4.6E-13 
SDHAP3 -1.33 6.0E-13 
LINC00680 -1.59 1.4E-12 
NUTM2D -1.90 1.6E-12 
AK4 -1.04 2.8E-12 
LOX -1.87 3.8E-12 
SLC39A3 1.57 4.1E-12 
KCNAB3 -2.35 4.2E-12 
BBC3 1.50 4.4E-12 
FAM46B 2.42 4.4E-12 
CNN2 1.15 5.1E-12 
WNK4 -1.62 5.1E-12 
PGK1 -1.08 5.1E-12 
LRRC37A4P -1.19 6.3E-12 
RBM15 1.00 7.6E-12 
FKRP -1.19 1.1E-11 
MT-ND2 -0.97 1.1E-11 
HYAL3 -2.19 1.2E-11 
C12orf4 -1.12 1.3E-11 
LCMT2 -1.39 1.5E-11 
SULF1 -1.18 1.5E-11 
DNAJA1 -1.01 1.7E-11 
HMGCS1 1.01 2.2E-11 
GPR75 -1.54 2.2E-11 
SQLE 0.94 2.6E-11 
ATF3 1.24 3.9E-11 
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RPL18A 0.95 4.6E-11 
FOXD2-AS1 1.28 4.6E-11 
RHOB 1.14 4.8E-11 
MAX -0.98 4.9E-11 
H1F0 1.07 5.4E-11 
C11orf95 -1.03 5.6E-11 
P2RY11 -1.70 5.7E-11 
CSRNP1 1.44 6.2E-11 
MYC 1.03 6.3E-11 
P4HA1 -1.32 7.5E-11 
EXO5 -1.22 1.0E-10 
ADAM1A -1.86 1.1E-10 
SCRN3 -1.05 1.2E-10 
LDLR 0.97 1.2E-10 
FAM212B -1.27 1.5E-10 
ZNF302 -0.95 1.5E-10 
PRNP -0.91 1.7E-10 
SLC16A13 -1.32 1.8E-10 
GRB7 1.29 1.8E-10 
CHAMP1 -0.96 1.9E-10 
MT-CYB -0.85 2.0E-10 
ANKRD29 -1.25 2.1E-10 
ZNF37BP -0.91 2.1E-10 
LRIF1 -1.14 2.2E-10 
FAM178A -1.02 2.2E-10 
JUNB 1.63 2.3E-10 
GNRHR2 2.62 2.4E-10 
LINC00863 -1.47 2.5E-10 
SFPQ -0.88 2.5E-10 
SERTAD3 1.19 2.6E-10 
RNF168 1.01 2.8E-10 
IKBIP -1.25 2.8E-10 
SLC16A9 -1.43 2.8E-10 
ZNF449 0.97 3.0E-10 
ID3 1.32 3.2E-10 
TUFT1 1.00 3.7E-10 
PSKH1 -1.27 4.8E-10 
GBE1 -1.21 4.8E-10 
ZNF526 1.01 4.8E-10 
PARP9 -1.39 5.5E-10 
PRIMPOL -1.22 5.8E-10 
BNIP3 -1.22 5.8E-10 
RBM12 -0.94 6.3E-10 
DUSP1 1.08 6.3E-10 
ZNF252P -1.45 6.7E-10 
TMEM45A -1.20 6.7E-10 
ZNF333 1.03 6.9E-10 
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RPL13AP5 2.61 7.4E-10 
ACTG1 0.88 7.5E-10 
EMILIN3 -1.18 8.3E-10 
ZNF467 1.71 8.8E-10 
SRD5A3 -1.08 9.6E-10 
PDE3B -1.21 9.7E-10 
SACS -0.93 1.1E-09 
KLF9 0.92 1.1E-09 
CTGF 1.35 1.1E-09 
OVGP1 1.26 1.2E-09 
PLOD2 -1.19 1.2E-09 
C22orf46 -1.07 1.3E-09 
IER2 0.97 1.4E-09 
TINCR 1.82 1.5E-09 
PDP2 0.97 1.5E-09 
HFM1 -1.46 1.7E-09 
SRR -1.20 1.7E-09 
NREP -0.94 1.8E-09 
LPAR1 -1.12 1.8E-09 
ZFX -0.90 1.9E-09 
MIR210HG -3.61 2.1E-09 
EPC2 -0.99 2.1E-09 
MTND2P28 -0.93 2.3E-09 
BRPF3 -0.91 2.4E-09 
METTL7B -1.55 2.7E-09 
HELB 1.35 2.9E-09 
C1orf63 0.91 3.1E-09 
NR4A2 1.68 3.1E-09 
ASMTL 1.18 3.3E-09 
MYH3 -1.62 3.3E-09 
JAG1 0.90 3.4E-09 
SLC25A29 0.93 3.5E-09 
HNRNPL 0.80 3.8E-09 
NIPAL2 -1.61 4.5E-09 
NEK9 -0.83 4.7E-09 
QRICH2 -2.31 4.8E-09 
FANCE 1.02 4.8E-09 
GFOD2 1.02 5.0E-09 
FAM131A 1.18 5.2E-09 
METTL22 0.91 5.2E-09 
MNX1 1.05 5.7E-09 
DPY19L2P2 -1.48 5.7E-09 
FLNA 0.85 7.0E-09 
ARHGAP8 1.54 7.2E-09 
CHTF8 -0.93 7.2E-09 
FAM134B -1.58 7.7E-09 
MAST3 0.99 8.2E-09 
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HGSNAT -0.92 9.1E-09 
ZC3H12C -1.41 9.2E-09 
GLUL 0.78 9.7E-09 
SRSF6 -0.80 9.9E-09 
MMP15 1.10 1.1E-08 
ZNF555 1.19 1.1E-08 
MUC19 -1.32 1.2E-08 
ZNF74 0.97 1.3E-08 
ZNF75A -0.95 1.3E-08 
TRPM4 1.11 1.3E-08 
ZNF883 -1.22 1.3E-08 
KIAA1683 -2.92 1.4E-08 
STAT4 -1.45 1.5E-08 
SH3D21 -1.25 1.5E-08 
CDKN2B 1.27 1.5E-08 
SLC29A2 0.88 1.6E-08 
WNT3 -1.06 1.6E-08 
ZNF551 -1.27 1.7E-08 
AMPD3 -1.92 1.8E-08 
CDT1 1.01 1.9E-08 
ZBTB43 0.95 2.0E-08 
KCTD15 -0.84 2.3E-08 
CDK13 -0.86 2.5E-08 
CSPG4P12 -1.06 2.6E-08 
SLC1A4 -1.36 2.7E-08 
TBX19 1.53 2.8E-08 
HOTAIRM1 0.97 2.8E-08 
ZNF497 -2.32 3.0E-08 
MFAP3 -0.96 3.0E-08 
NAA10 1.00 3.0E-08 
IGSF10 -1.21 3.7E-08 
DGCR5 -1.12 4.3E-08 
EXOC8 0.86 4.3E-08 
SH2D3A 1.04 4.3E-08 
TEX15 -0.98 4.3E-08 
RPL17 1.03 4.3E-08 
AGPAT3 -0.83 4.7E-08 
SPOCK2 -1.72 4.7E-08 
EIF3I 0.78 4.7E-08 
MIER2 0.87 4.9E-08 
MVP 1.29 5.0E-08 
DDIT3 1.05 5.0E-08 
RPPH1 -3.28 5.1E-08 
YJEFN3 -1.12 5.3E-08 
MCM3AP-AS1 -1.08 5.4E-08 
DCP1B -1.05 5.4E-08 
ZBTB1 -1.02 5.7E-08 
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PSPC1 -0.80 6.1E-08 
AURKC 1.45 6.1E-08 
RNF122 1.09 6.2E-08 
SALL4 1.82 6.2E-08 
EIF5A 0.98 6.3E-08 
ZNF235 -1.24 6.4E-08 
JAK3 1.68 6.4E-08 
RBBP6 -0.91 6.4E-08 
KIAA1161 0.94 6.6E-08 
RP1L1 1.83 7.0E-08 
DDB2 -0.81 7.1E-08 
GCAT 1.09 7.1E-08 
FAM84B 0.76 7.4E-08 
BNIP3L -1.08 7.4E-08 
PIEZO2 -1.13 7.5E-08 
IL12A 1.27 7.5E-08 
DRAP1 0.93 8.1E-08 
SRSF3 -0.76 8.4E-08 
ICAM5 1.00 8.4E-08 
LDHA -0.74 8.5E-08 
NR1D1 1.24 8.5E-08 
TRAK2 -0.86 8.6E-08 
ZDHHC22 1.05 8.6E-08 
ZNF585B -0.89 8.6E-08 
CCDC124 0.82 8.9E-08 
ZNF594 -1.34 8.9E-08 
ALX4 -1.01 9.2E-08 
ZNF239 -1.02 9.6E-08 
ANKRD9 1.04 9.7E-08 
FASTKD5 -1.00 1.0E-07 
RAB3A 1.28 1.0E-07 
MR1 -1.09 1.1E-07 
PPP1R15A 0.96 1.1E-07 
ZNF41 -1.09 1.2E-07 
CARD6 -1.43 1.2E-07 
TRIP11 -0.82 1.4E-07 
MT-ND6 0.78 1.4E-07 
HES1 0.99 1.4E-07 
GFOD1 0.95 1.4E-07 
UCP3 -2.38 1.4E-07 
EGLN1 -0.86 1.4E-07 
ZNF559 -1.22 1.5E-07 
ZNF559 -1.22 1.5E-07 
PSMG3-AS1 -1.64 1.5E-07 
MEIS1 0.83 1.5E-07 
NAB2 1.01 1.6E-07 
FLVCR2 -2.16 1.6E-07 
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POLR1E 0.84 1.7E-07 
PPAPDC1B 1.07 1.8E-07 
SNHG1 0.80 1.8E-07 
GNB3 -1.08 1.8E-07 
HMCN1 -0.89 1.8E-07 
CENPC 0.91 1.8E-07 
SEMA3B -1.52 1.8E-07 
ZNF736 -0.89 1.8E-07 
GAD1 1.21 1.9E-07 
IGHMBP2 0.82 1.9E-07 
ZSCAN5A -1.40 2.0E-07 
LYSMD1 0.81 2.0E-07 
ZMYND8 -0.78 2.3E-07 
MESDC2 -0.76 2.3E-07 
SIRT5 -0.93 2.4E-07 
TET1 0.80 2.4E-07 
PLXNA4 -1.11 2.4E-07 
SNX27 0.76 2.5E-07 
ACTB 1.02 2.6E-07 
ATF5 -1.06 2.6E-07 
PLEKHH3 1.06 2.6E-07 
MANSC1 -1.21 2.7E-07 
FLRT2 -0.87 2.8E-07 
LMBR1L 0.80 2.8E-07 
AHNAK2 -0.85 2.8E-07 
NSL1 -0.81 2.8E-07 
CLK3 0.91 2.8E-07 
TTC9C 0.88 2.9E-07 
ZBTB12 -0.91 3.0E-07 
FAM46C 0.99 3.3E-07 
ZNF330 0.80 3.4E-07 
HES7 1.77 3.6E-07 
KLHL11 0.96 3.7E-07 
TRNP1 -1.00 4.2E-07 
AMMECR1 -0.77 4.2E-07 
SAMD8 0.86 4.2E-07 
NEFM 0.80 4.3E-07 
DLX5 1.07 4.6E-07 
CCDC162P -1.23 4.7E-07 
CCNB1IP1 0.79 4.8E-07 
GADD45A 0.90 4.8E-07 
IQCH-AS1 -1.21 5.0E-07 
NUPL2 -0.82 5.3E-07 
SF1 -0.75 5.4E-07 
ZNF117 -1.15 5.5E-07 
BRMS1L -0.91 5.5E-07 
MAN2B1 0.88 5.6E-07 
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SEC13 0.73 5.7E-07 
SLC22A23 -0.87 5.9E-07 
COL17A1 -0.99 6.1E-07 
HECA 0.84 6.1E-07 
FER -0.86 6.2E-07 
SPRY3 1.14 6.3E-07 
TMEM209 -0.74 6.4E-07 
HSD17B10 0.76 6.6E-07 
SLC2A11 -1.18 6.6E-07 
HOXD13 0.73 6.9E-07 
KLHL42 -0.81 7.0E-07 
LRP11 -0.75 7.1E-07 
PDIA5 0.89 7.1E-07 
C17orf97 -2.15 7.6E-07 
BRCC3 -0.81 7.6E-07 
ARRDC3 0.94 7.7E-07 
POLR3D 0.73 8.0E-07 
C2orf43 -1.00 8.2E-07 
ADAM8 -1.90 8.2E-07 
MPST 0.80 8.4E-07 
MFSD5 -1.05 8.4E-07 
ECSIT 0.85 8.5E-07 
TMEM64 -0.93 8.6E-07 
DDT 0.90 9.3E-07 
FAM162A -0.72 9.4E-07 
LENG8-AS1 1.27 9.6E-07 
LINC00115 1.50 9.9E-07 
NSD1 -0.72 1.0E-06 
HBP1 0.87 1.0E-06 
RIPK4 0.96 1.0E-06 
ANXA2R 1.83 1.0E-06 
ANKRD34B -1.11 1.0E-06 
ZNF780B -0.90 1.0E-06 
DUSP6 1.34 1.0E-06 
PPP1R15B 0.70 1.1E-06 
PHKG1 1.86 1.1E-06 
MEF2A -0.73 1.1E-06 
HSP90B1 0.72 1.2E-06 
TADA2A -0.76 1.2E-06 
FBXL21 -0.98 1.2E-06 
APPBP2 -0.74 1.2E-06 
MPZ 1.38 1.3E-06 
METTL21B 1.15 1.4E-06 
RFX7 -0.84 1.4E-06 
ZBTB3 1.35 1.4E-06 
CCNO 1.02 1.4E-06 
RAB7L1 0.79 1.4E-06 
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ICK -0.79 1.4E-06 
GATAD1 0.79 1.5E-06 
IRGQ 0.76 1.5E-06 
SOGA1 -0.84 1.5E-06 
MT-ND1 -0.80 1.6E-06 
ZMYND11 -0.73 1.6E-06 
PPIL6 -1.41 1.7E-06 
HMMR -0.78 1.7E-06 
LINC00174 -0.93 1.7E-06 
FDFT1 0.68 1.7E-06 
YAE1D1 -0.83 1.8E-06 
ZNFX1 0.75 1.9E-06 
HOXA11 0.88 1.9E-06 
PTCHD4 -1.64 1.9E-06 
ASH1L-AS1 1.65 2.0E-06 
C1GALT1C1 -1.06 2.0E-06 
C10orf12 0.77 2.0E-06 
SUN2 0.77 2.0E-06 
CHP1 0.70 2.1E-06 
BCAS2 -0.72 2.1E-06 
ZNF777 -0.76 2.1E-06 
PSD4 -1.43 2.1E-06 
VCPIP1 0.80 2.1E-06 
ERN1 0.81 2.1E-06 
UMPS -0.79 2.3E-06 
MTMR3 0.69 2.3E-06 
NDUFA4L2 -2.13 2.3E-06 
TBC1D3F -1.01 2.3E-06 
JRKL 0.82 2.3E-06 
PPP1R26 0.76 2.3E-06 
ANKEF1 -0.92 2.4E-06 
ZDHHC11 -1.04 2.5E-06 
CREBRF 0.87 2.5E-06 
FEM1C 0.84 2.5E-06 
RPAP2 -0.85 2.5E-06 
OLIG2 1.48 2.5E-06 
ZNF697 0.78 2.6E-06 
RN7SL3 -2.08 2.7E-06 
GTF3A 0.74 2.7E-06 
LINC00858 -1.48 2.8E-06 
RER1 -0.77 2.8E-06 
SLC26A10 -0.90 2.8E-06 
GATAD2B 0.69 2.8E-06 
C9orf156 -1.14 2.9E-06 
ZNF655 -0.79 2.9E-06 
C17orf59 1.31 3.1E-06 
PAPOLA -0.66 3.1E-06 
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HECTD2 -0.88 3.2E-06 
LINC01125 -1.27 3.2E-06 
CD83 -0.91 3.2E-06 
TEX261 -0.71 3.2E-06 
ZNF644 -0.83 3.3E-06 
F8 -1.20 3.3E-06 
CPSF6 -0.66 3.4E-06 
PROX1 0.99 3.4E-06 
GAL 0.88 3.6E-06 
NDUFA13 -1.41 3.6E-06 
STK38 -0.73 3.7E-06 
ZNF829 -0.73 3.7E-06 
ZNF470 -0.99 3.7E-06 
ANKRD27 0.69 3.7E-06 
CHSY3 -1.12 3.8E-06 
ST6GALNAC4 1.00 3.8E-06 
USP40 -0.79 3.8E-06 
ZNF292 -0.85 3.9E-06 
ZEB1 0.90 4.0E-06 
POU3F2 0.78 4.2E-06 
TMEM159 1.19 4.2E-06 
SCARA3 -0.84 4.3E-06 
TOE1 -0.75 4.3E-06 
TMEM80 -0.96 4.3E-06 
GAS5 0.74 4.3E-06 
ELOVL2 -0.70 4.5E-06 
SNRPA 0.70 4.5E-06 
MRPL55 0.72 4.6E-06 
SLC25A25 0.86 4.7E-06 
NDUFS8 0.83 4.8E-06 
RBM26-AS1 -1.89 4.8E-06 
NRN1 -0.87 4.8E-06 
B4GALT6 -0.87 4.8E-06 
RNF207 -0.98 4.9E-06 
LINC00965 -1.61 4.9E-06 
KBTBD6 0.75 4.9E-06 
ZEB1-AS1 0.97 4.9E-06 
DNAH6 -1.15 4.9E-06 
GABARAPL1 0.75 4.9E-06 
GRIN2C -3.06 4.9E-06 
GADD45B 0.90 4.9E-06 
DNAH1 -0.95 5.2E-06 
CABLES1 -0.79 5.3E-06 
RBM4B -0.97 5.5E-06 
CAMLG 0.75 5.7E-06 
C1R -1.14 5.7E-06 
MFAP3L -0.81 5.9E-06 
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SAP30L -0.87 6.2E-06 
SYNE3 1.21 6.3E-06 
ZNF418 -2.63 6.4E-06 
POLR2J4 -1.62 6.4E-06 
DNAJC19P5 2.46 6.5E-06 
EPHA6 0.79 6.7E-06 
C6orf211 -0.75 6.7E-06 
FAM214B 0.94 6.7E-06 
LINC00649 -0.85 6.8E-06 
PLXDC1 -1.19 6.9E-06 
ZFP36 0.87 6.9E-06 
RABAC1 0.71 7.0E-06 
TMEM127 -0.76 7.1E-06 
ZNF66 -1.82 7.1E-06 
KLF4 0.95 7.1E-06 
MVB12A 0.82 7.1E-06 
ITGA8 -0.78 7.2E-06 
EPDR1 -0.87 7.3E-06 
TEF 0.83 7.3E-06 
EIF3C 0.79 7.8E-06 
VAX1 -1.85 7.9E-06 
ZNF542 -1.31 7.9E-06 
PNP 0.84 8.0E-06 
HMBOX1 0.74 8.0E-06 
ZFAND2B 0.97 8.2E-06 
PHF20L1 -0.72 8.2E-06 
ZUFSP 0.78 8.2E-06 
FAM66C -1.37 8.3E-06 
CCP110 0.72 8.3E-06 
TICRR 0.68 8.4E-06 
PAIP2B 0.69 8.4E-06 
PRRT4 -0.81 8.4E-06 
PPM1J 1.21 8.5E-06 
APCDD1 -0.93 8.5E-06 
TUBE1 0.78 8.7E-06 
CLDND2 1.57 8.8E-06 
HTRA1 -0.72 9.0E-06 
WHAMM 0.75 9.0E-06 
BRICD5 -1.47 9.0E-06 
SMYD5 0.73 9.1E-06 
STON2 0.76 9.1E-06 
FLT1 -0.79 9.2E-06 
MLH3 -0.72 9.2E-06 
RAB33B 0.86 9.3E-06 
DACT3 1.11 9.4E-06 
C6orf136 0.81 1.0E-05 
TIGD1 0.84 1.0E-05 
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ZBTB38 -0.87 1.0E-05 
ALG6 -0.83 1.0E-05 
NDUFS6 0.68 1.0E-05 
OGT -0.66 1.0E-05 
LCA5L -2.68 1.0E-05 
DCBLD2 -0.69 1.0E-05 
CHRNA10 -3.00 1.0E-05 
ZFHX2 -1.09 1.1E-05 
GAN 0.70 1.1E-05 
DNAH10OS 0.98 1.2E-05 
CLN5 -1.02 1.2E-05 
JOSD1 -0.72 1.2E-05 
C22orf39 0.83 1.2E-05 
LXN -0.84 1.2E-05 
FKBP14 0.79 1.2E-05 
HSD17B7P2 1.50 1.2E-05 
FBXO4 -1.45 1.3E-05 
ANTXR1 -0.66 1.3E-05 
YPEL3 1.01 1.3E-05 
NTMT1 0.77 1.3E-05 
WASH7P 0.96 1.3E-05 
SLC25A5 0.66 1.3E-05 
ZDHHC24 0.93 1.3E-05 
RGS16 0.96 1.3E-05 
RPLP2 0.69 1.3E-05 
RAB23 -0.74 1.3E-05 
KLHL24 0.85 1.3E-05 
ABI3BP -1.43 1.3E-05 
LINC00641 -0.68 1.4E-05 
IQCC 0.86 1.4E-05 
TMEM198B -0.70 1.4E-05 
PYGO1 -0.89 1.4E-05 
MTERF -0.96 1.4E-05 
SLC38A10 -0.72 1.4E-05 
MSTO2P 0.98 1.4E-05 
SLC29A3 -1.11 1.4E-05 
PMEPA1 -0.99 1.5E-05 
FASN 0.69 1.5E-05 
BEND3 -0.80 1.6E-05 
H2AFY2 -0.65 1.6E-05 
LYPD6 -0.94 1.6E-05 
TTC12 -0.79 1.6E-05 
SNHG3 0.90 1.6E-05 
CCDC138 -0.73 1.6E-05 
NETO2 -0.65 1.6E-05 
HCG18 -0.71 1.7E-05 
PTK2B -0.93 1.7E-05 
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MYO15B -0.95 1.7E-05 
SDF2L1 1.35 1.7E-05 
MUM1L1 -0.95 1.7E-05 
CD99 0.71 1.7E-05 
RAG1 -2.33 1.7E-05 
MYOM2 -1.17 1.7E-05 
KPNA6 0.64 1.7E-05 
TIPARP 0.74 1.8E-05 
MRPL52 0.75 1.8E-05 
NDUFB8 1.41 1.8E-05 
HIST1H4E -2.47 1.8E-05 
HDX -1.28 1.8E-05 
SSH1 -0.64 1.8E-05 
BOLA3-AS1 0.72 1.9E-05 
SOX9 0.88 1.9E-05 
IER3 0.85 1.9E-05 
CCER2 -2.00 1.9E-05 
ALDH1L2 -0.63 1.9E-05 
ADAM21 -2.37 2.0E-05 
KATNAL2 -1.10 2.0E-05 
ENO3 -0.88 2.0E-05 
C7orf49 -0.72 2.0E-05 
TSPYL1 0.68 2.0E-05 
RDM1 0.88 2.0E-05 
PDK1 -0.74 2.0E-05 
THNSL1 -0.84 2.1E-05 
TMSB4X 0.69 2.1E-05 
CYP26A1 1.14 2.1E-05 
ACLY 0.65 2.1E-05 
EDARADD -0.95 2.1E-05 
EEF1A2 0.90 2.2E-05 
PDP1 0.74 2.2E-05 
RPS15 0.70 2.2E-05 
RPUSD3 0.69 2.3E-05 
ZIK1 -1.20 2.3E-05 
ARHGAP31 -0.82 2.3E-05 
RPLP1 1.01 2.3E-05 
LHX9 -0.99 2.3E-05 
SAMD11 -0.70 2.3E-05 
MANF 0.70 2.3E-05 
HOXC13 0.78 2.3E-05 
COX18 0.83 2.4E-05 
MOCOS -1.24 2.4E-05 
SPDL1 -0.67 2.4E-05 
YOD1 0.75 2.4E-05 
CSRP2BP -0.78 2.4E-05 
CNKSR3 0.65 2.4E-05 
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LRP8 0.67 2.4E-05 
ASF1A -0.74 2.5E-05 
FZD8 0.81 2.5E-05 
CYB5D2 -0.92 2.5E-05 
ORAOV1 -0.70 2.5E-05 
HOXA-AS2 0.86 2.5E-05 
DUSP8P5 1.11 2.5E-05 
ZNF75D -0.70 2.5E-05 
PLAGL2 -0.63 2.5E-05 
CXorf38 0.84 2.6E-05 
AGGF1 -0.65 2.6E-05 
PPP6R3 -0.61 2.6E-05 
DOCK8 -0.91 2.6E-05 
YPEL2 0.71 2.6E-05 
OGFR 0.72 2.6E-05 
SRBD1 -0.78 2.7E-05 
TAF1A 0.91 2.7E-05 
RBM47 -0.97 2.8E-05 
HLCS -0.78 2.8E-05 
APH1B -0.80 2.8E-05 
ASF1B -0.67 2.8E-05 
CSF1 -0.78 3.0E-05 
GPC4 0.63 3.0E-05 
NFKB1 -0.82 3.0E-05 
HYLS1 -0.93 3.0E-05 
ZNF554 -0.81 3.0E-05 
TPPP 0.80 3.1E-05 
SHISA4 -1.96 3.1E-05 
SLTM -0.61 3.1E-05 
GTF2H2 0.85 3.1E-05 
FNTB -1.12 3.2E-05 
PTMA 0.62 3.2E-05 
PTRH2 -0.65 3.2E-05 
NMRK1 -0.99 3.2E-05 
IL18R1 -1.00 3.3E-05 
AIFM2 -2.10 3.3E-05 
GOLGA8A -0.62 3.3E-05 
BABAM1 1.07 3.3E-05 
CROCCP2 0.72 3.4E-05 
TRIM52-AS1 0.75 3.5E-05 
SNHG10 0.82 3.5E-05 
WDR33 -0.60 3.7E-05 
HUNK -0.78 3.7E-05 
ARL16 0.74 3.8E-05 
ULBP2 0.87 3.8E-05 
ZSCAN25 -0.73 3.8E-05 
LONRF2 -0.66 3.9E-05 
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ZNF112 -1.05 3.9E-05 
SYNM -0.66 3.9E-05 
SLC31A1 0.64 3.9E-05 
ARHGDIA 0.79 4.1E-05 
NDE1 0.63 4.1E-05 
USP31 0.71 4.1E-05 
RRM2 0.60 4.1E-05 
SNRPB 0.94 4.1E-05 
ZNF852 -1.30 4.1E-05 
SSH3 -1.89 4.2E-05 
ZNF780A -0.82 4.3E-05 
HOXA9 0.75 4.3E-05 
ZNF549 -0.83 4.3E-05 
HLA-E 0.61 4.4E-05 
ZNF140 -0.85 4.6E-05 
PAFAH2 -0.88 4.6E-05 
ZDBF2 -0.77 4.7E-05 
SLC30A6 -0.72 4.7E-05 
SMAD7 0.72 4.8E-05 
SLC9A2 -1.64 4.8E-05 
ZNF274 -0.62 4.9E-05 
PPIC 0.78 5.0E-05 
GOLGA2 0.66 5.0E-05 
GPRASP1 -1.60 5.1E-05 
RSRC2 0.78 5.1E-05 
AKAP17A 0.67 5.1E-05 
C8orf31 -1.31 5.1E-05 
RPGRIP1L -0.71 5.1E-05 
GBAP1 -0.95 5.2E-05 
GTPBP1 0.70 5.3E-05 
SMIM19 -0.81 5.4E-05 
PIK3CA 4.25 5.4E-05 
TTC30A -0.90 5.4E-05 
FAXC -0.68 5.5E-05 
SMARCAD1 -0.61 5.6E-05 
WBSCR22 0.64 5.6E-05 
ERVK3-1 -0.65 5.7E-05 
ELK4 0.84 5.8E-05 
RNF6 -0.61 5.8E-05 
KMT2E-AS1 1.35 5.9E-05 
LHFPL4 -0.86 6.0E-05 
EML2 0.62 6.0E-05 
ZNF804A -1.66 6.0E-05 
ASNSD1 -0.65 6.1E-05 
PANK1 -0.76 6.1E-05 
DZIP3 -0.66 6.1E-05 
ALKBH6 0.76 6.1E-05 
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SP8 1.19 6.4E-05 
DDIT4 0.67 6.4E-05 
F3 1.07 6.4E-05 
LHX4 0.82 6.5E-05 
BRCA1 -0.66 6.5E-05 
DPH7 0.68 6.5E-05 
ADAT2 0.67 6.5E-05 
ZNF577 -0.87 6.6E-05 
NUDT22 0.92 6.6E-05 
E2F2 0.70 6.7E-05 
ZNF480 -0.76 6.8E-05 
AP3B2 -0.92 6.9E-05 
C17orf80 -0.74 7.0E-05 
LINC00202-1 -0.80 7.2E-05 
ERLIN1 0.60 7.2E-05 
HN1 0.63 7.3E-05 
ANKRD11 -0.59 7.4E-05 
FAM114A2 -0.66 7.5E-05 
JAGN1 -0.80 7.5E-05 
SHISA2 0.78 7.5E-05 
NPM3 0.61 7.5E-05 
HABP4 0.78 7.5E-05 
SERTAD2 0.73 7.5E-05 
RRP15 -0.64 7.6E-05 
DTX3L -1.21 7.6E-05 
CLDN15 -0.73 7.7E-05 
ZNF649 -0.76 7.8E-05 
FAM124A -1.52 7.9E-05 
IL11RA -0.80 7.9E-05 
HNRNPU-AS1 0.64 7.9E-05 
LINC00632 0.93 7.9E-05 
ALPK2 -1.78 7.9E-05 
EID2B 0.97 8.0E-05 
HCG11 -0.80 8.1E-05 
ZWINT -0.59 8.1E-05 
ZBTB16 1.03 8.1E-05 
SLC1A1 -0.75 8.2E-05 
AAR2 -0.66 8.2E-05 
LRRC8D -0.78 8.4E-05 
VARS 0.61 8.6E-05 
RBM11 0.75 8.6E-05 
TMEM62 -1.01 8.8E-05 
LAMP1 0.63 8.8E-05 
USP49 0.64 8.8E-05 
NHP2 0.62 8.8E-05 
TRMT11 0.65 8.8E-05 
DDX6 -0.62 8.8E-05 
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TTC18 -1.08 8.8E-05 
NRIP1 -0.63 8.9E-05 
CCDC61 0.98 8.9E-05 
CCDC81 2.28 9.0E-05 
CD101 -1.14 9.0E-05 
KDELR1 0.58 9.0E-05 
UBAP1L -1.02 9.0E-05 
MBLAC2 -0.72 9.0E-05 
ANKMY1 -0.80 9.1E-05 
ZNF85 -0.75 9.1E-05 
ANGPT1 -0.97 9.2E-05 
TBC1D22A -0.68 9.2E-05 
LINC00638 -1.76 9.3E-05 
SIGMAR1 0.59 9.4E-05 
PSMG4 0.77 9.5E-05 
ANTXR2 -0.67 9.5E-05 
CIRBP-AS1 -1.14 9.7E-05 
GTF2H1 -0.65 9.7E-05 
ISCA1 -0.69 9.8E-05 
XYLB -0.71 9.9E-05 
DPP7 -1.07 1.0E-04 
C10orf118 0.73 1.0E-04 
SLC35A5 -0.76 1.0E-04 
ITGA2 -0.69 1.0E-04 
DHFRL1 -1.04 1.0E-04 
CCRN4L 0.86 1.0E-04 
DENND6B -1.13 1.0E-04 
SCGB2B2 -1.39 1.0E-04 
NEU3 0.64 1.0E-04 
EPC1 -0.63 1.1E-04 
RAPGEF5 0.64 1.1E-04 
GUCY1A3 -0.76 1.1E-04 
BASP1 0.79 1.1E-04 
KIAA1211L -1.63 1.1E-04 
SNHG15 0.59 1.1E-04 
TRPC1 -0.74 1.1E-04 
AEN -0.61 1.1E-04 
CXorf40A -0.73 1.1E-04 
ATAD5 0.59 1.1E-04 
AP5B1 -0.82 1.1E-04 
PALMD -0.95 1.1E-04 
HCFC2 0.69 1.1E-04 
SYNC -1.76 1.1E-04 
NUAK2 1.17 1.1E-04 
PHC3 0.64 1.1E-04 
IER5 0.74 1.1E-04 
RNF128 -0.71 1.1E-04 
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KDM7A 0.67 1.2E-04 
TMPO-AS1 -0.81 1.2E-04 
BARHL2 1.38 1.2E-04 
TRMT10A -0.81 1.2E-04 
OLFML2A -1.08 1.2E-04 
KLF6 0.65 1.2E-04 
PHACTR1 0.70 1.2E-04 
PUSL1 0.84 1.2E-04 
ST6GALNAC3 -0.79 1.2E-04 
KIAA1875 -1.58 1.3E-04 
NYNRIN -0.70 1.3E-04 
HMGB3 0.58 1.3E-04 
SMOC2 -2.11 1.3E-04 
CCDC9 0.73 1.3E-04 
BTRC -0.63 1.3E-04 
LIAS 0.91 1.3E-04 
BEND5 -1.62 1.3E-04 
HIVEP3 -0.72 1.4E-04 
RPL18 0.64 1.4E-04 
CTU2 0.83 1.4E-04 
ZNF229 -0.83 1.4E-04 
AARSD1 1.20 1.4E-04 
CDK17 0.65 1.4E-04 
COL7A1 -0.82 1.4E-04 
PPP1R26-AS1 -1.24 1.4E-04 
RIMKLA -0.98 1.4E-04 
ZNF583 -0.87 1.4E-04 
LINC00839 -0.94 1.5E-04 
COTL1 0.72 1.5E-04 
AK9 -1.05 1.5E-04 
ZNRD1 0.78 1.5E-04 
ZNF484 0.99 1.5E-04 
NUP214 -0.58 1.5E-04 
NAT6 0.85 1.5E-04 
HEY2 1.06 1.5E-04 
ZNF217 0.74 1.5E-04 
ZNF793 -0.69 1.5E-04 
AMER1 -0.67 1.5E-04 
LPCAT4 0.74 1.5E-04 
TFRC -0.61 1.5E-04 
SNCAIP -0.85 1.5E-04 
LYPLAL1 -0.71 1.5E-04 
CDKN1B 0.58 1.5E-04 
RAD52 0.63 1.5E-04 
COL9A2 -0.79 1.5E-04 
FOXC2 1.18 1.5E-04 
SLC25A24 -0.65 1.6E-04 
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BCL9L 0.74 1.6E-04 
HS3ST3A1 0.78 1.6E-04 
PPHLN1 -0.59 1.6E-04 
IBA57 -0.69 1.6E-04 
KCNB1 -1.32 1.7E-04 
SUSD2 -2.18 1.7E-04 
DPY19L2 -1.05 1.7E-04 
MIR34A -1.60 1.7E-04 
EP400NL -0.66 1.7E-04 
RIC8B -0.68 1.7E-04 
MTMR1 -0.59 1.7E-04 
N6AMT2 -1.07 1.7E-04 
ZNF688 -1.13 1.7E-04 
C5 -1.89 1.8E-04 
GJA5 -1.40 1.8E-04 
C5orf28 -0.95 1.8E-04 
KIAA1407 -0.97 1.8E-04 
SLC38A9 -0.66 1.8E-04 
PRPSAP1 0.59 1.8E-04 
IFIT5 -0.61 1.9E-04 
HSPA2 -0.72 1.9E-04 
LIG4 -0.69 1.9E-04 
GPR27 -0.70 1.9E-04 
ASIC3 -0.97 1.9E-04 
VAPB -0.65 1.9E-04 
PAWR 0.63 1.9E-04 
PARD6B 0.97 2.0E-04 
UFSP1 -1.76 2.0E-04 
ZNF708 -0.81 2.0E-04 
CEACAM19 -0.73 2.0E-04 
DUSP7 0.69 2.0E-04 
CHCHD2 0.90 2.0E-04 
LYRM7 -0.69 2.0E-04 
PIGC -0.68 2.0E-04 
SENP5 0.63 2.1E-04 
PRX 0.79 2.1E-04 
AGER -1.04 2.1E-04 
FHL3 0.93 2.1E-04 
FBXO46 0.75 2.1E-04 
ANK3 -0.59 2.1E-04 
SEMA7A 0.84 2.1E-04 
DTYMK 0.71 2.1E-04 
MXD1 0.68 2.2E-04 
KIAA0232 -0.64 2.2E-04 
TMEM254-AS1 -1.34 2.2E-04 
KIAA1549L -0.63 2.2E-04 
RICTOR 0.69 2.2E-04 
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ZC3H12A 0.74 2.2E-04 
ZNF790 -0.74 2.2E-04 
TLR3 -1.37 2.3E-04 
SIK2 -0.63 2.3E-04 
N4BP2 -0.66 2.3E-04 
CDC27 -0.59 2.3E-04 
ADAMTS10 -0.70 2.3E-04 
ATP1A3 0.68 2.3E-04 
BCHE -0.74 2.3E-04 
CHURC1 -0.96 2.3E-04 
ZNF121 0.59 2.3E-04 
ZCWPW1 -1.00 2.3E-04 
ID4 0.66 2.4E-04 
KBTBD11 -0.83 2.4E-04 
UBXN8 -0.70 2.4E-04 
TUBB2B 0.61 2.4E-04 
C9orf37 0.79 2.4E-04 
DDAH2 0.74 2.5E-04 
SIRPA -0.65 2.5E-04 
SGK3 0.98 2.5E-04 
GCDH 0.66 2.6E-04 
INPP5D -0.73 2.6E-04 
IGSF8 0.73 2.6E-04 
DNM1P35 -1.82 2.6E-04 
NRP2 0.63 2.6E-04 
SLC26A7 -0.94 2.6E-04 
GTPBP3 0.64 2.6E-04 
CENPF -0.58 2.6E-04 
TMEM194B -0.99 2.6E-04 
IGDCC4 -0.69 2.6E-04 
HIST3H2A 1.22 2.6E-04 
SNED1 -0.86 2.7E-04 
TDRD6 -1.38 2.7E-04 
BNIP1 0.70 2.7E-04 
MROH6 -1.08 2.7E-04 
ITPKC 0.66 2.7E-04 
CCDC85B 1.55 2.7E-04 
LIPT2 -1.01 2.7E-04 
ALDH1A3 -0.70 2.7E-04 
AKAP8L 0.59 2.7E-04 
NDUFS7 0.66 2.7E-04 
MAF 0.64 2.7E-04 
ZNF765 -0.78 2.8E-04 
ZNF827 -0.78 2.8E-04 
HSPA1B 0.65 2.8E-04 
SLC19A2 0.69 2.8E-04 
TTN-AS1 -0.73 2.8E-04 
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PGBD2 -1.33 2.9E-04 
STARD5 0.84 2.9E-04 
RHOQP1 1.40 2.9E-04 
VSTM4 -0.78 2.9E-04 
CSPG5 -0.76 2.9E-04 
FAM69A -0.64 3.0E-04 
DACT1 0.68 3.0E-04 
UBE2S 0.75 3.0E-04 
CISH 0.95 3.0E-04 
RPRD2 -0.60 3.0E-04 
CRELD1 0.64 3.0E-04 
ZNF354C -0.93 3.0E-04 
TMEM165 -0.62 3.0E-04 
C12orf65 0.66 3.0E-04 
PIM3 0.66 3.1E-04 
TRPT1 0.84 3.1E-04 
DPYSL4 -1.01 3.1E-04 
BUD13 0.60 3.1E-04 
C2CD2 -0.63 3.1E-04 
NAALADL1 1.78 3.2E-04 
TIRAP -0.77 3.2E-04 
STRADA 0.79 3.2E-04 
STAG1 -0.63 3.2E-04 
CFI -0.99 3.2E-04 
KIF24 -0.70 3.2E-04 
ARHGAP28 -0.73 3.3E-04 
GPRIN3 0.60 3.3E-04 
PHF3 0.61 3.3E-04 
THRB -0.61 3.3E-04 
TMEM18 -0.61 3.3E-04 
MSRB3 -0.61 3.3E-04 
DRAM1 -0.99 3.3E-04 
SCAMP5 -0.65 3.3E-04 
ZNF124 -1.33 3.4E-04 
SLC37A2 1.06 3.4E-04 
MED17 -0.66 3.4E-04 
RASA4CP -1.98 3.5E-04 
USB1 0.62 3.6E-04 
MBNL1-AS1 0.91 3.6E-04 
TRPA1 -1.22 3.6E-04 
PRICKLE4 -0.81 3.6E-04 
SNAPC2 1.01 3.6E-04 
PIH1D2 -1.83 3.7E-04 
PCGF1 0.62 3.7E-04 
SNX18P7 -1.72 3.7E-04 
PHLDB3 0.76 3.7E-04 
WDR63 -0.81 3.8E-04 
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STOX1 -0.97 3.8E-04 
POLR3B -0.62 3.9E-04 
TMEM79 0.80 3.9E-04 
GPER1 -1.43 3.9E-04 
TROVE2 0.59 3.9E-04 
ADSSL1 1.00 3.9E-04 
GLRX5 0.59 4.0E-04 
FZD5 0.62 4.0E-04 
MEF2C -0.61 4.0E-04 
NKX2-8 1.49 4.0E-04 
TBC1D8 0.60 4.1E-04 
DYNLL1-AS1 -1.03 4.1E-04 
SNORA75 1.69 4.1E-04 
CD55 0.61 4.2E-04 
EMP1 0.86 4.2E-04 
CMBL 0.58 4.2E-04 
RGMB 0.64 4.3E-04 
ZNF615 0.66 4.4E-04 
CCNJL -1.19 4.4E-04 
DISP1 -0.68 4.4E-04 
SLC25A1 0.62 4.5E-04 
MYH15 -1.36 4.5E-04 
ETNK1 -0.62 4.5E-04 
GDNF-AS1 -0.85 4.5E-04 
ZNF581 0.90 4.5E-04 
PEX3 -0.60 4.6E-04 
SRGAP2C 0.83 4.6E-04 
CCDC89 -1.64 4.6E-04 
PPDPF 0.87 4.6E-04 
C2orf72 -0.74 4.6E-04 
CREG2 1.42 4.7E-04 
ANKRD31 -1.62 4.7E-04 
ITPRIP 0.65 4.7E-04 
NECAP2 -0.61 4.7E-04 
C2CD2L 0.78 4.8E-04 
ZNF202 -0.65 4.9E-04 
RGPD5 1.65 4.9E-04 
DLX2 0.63 5.0E-04 
ATL1 -0.93 5.0E-04 
COLGALT1 0.61 5.0E-04 
NKX2-4 -0.77 5.0E-04 
RND1 1.00 5.0E-04 
TXLNB -0.95 5.1E-04 
MAFK 0.90 5.1E-04 
FBLN2 1.77 5.2E-04 
NPC1L1 -1.20 5.2E-04 
FAM86HP -1.73 5.2E-04 
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RUVBL2 0.62 5.3E-04 
RLTPR 0.95 5.3E-04 
ZNF519 -0.70 5.3E-04 
C22orf26 -1.63 5.4E-04 
AKIP1 0.67 5.5E-04 
ZFP36L1 0.76 5.5E-04 
ZNF782 -1.01 5.6E-04 
LYPD3 1.13 5.7E-04 
ADM 0.65 5.7E-04 
FGFR3 0.59 5.8E-04 
ZNF32 -0.70 5.8E-04 
SIX4 0.61 5.8E-04 
DLX6 0.60 5.9E-04 
AMH -1.02 5.9E-04 
TEX264 -0.61 5.9E-04 
EIF4A1 0.62 5.9E-04 
FOS 0.92 5.9E-04 
HIST1H1E -2.09 5.9E-04 
CDK5R1 0.69 5.9E-04 
DDTL -0.97 5.9E-04 
CBX7 -0.77 5.9E-04 
PIGP -0.62 6.0E-04 
ARNT2 -0.60 6.0E-04 
C19orf82 -1.39 6.1E-04 
TOR1A -0.63 6.2E-04 
CCDC110 -1.32 6.2E-04 
DHRS7B -0.71 6.2E-04 
CCDC102A -1.10 6.3E-04 
URGCP -0.60 6.3E-04 
USP4 0.58 6.4E-04 
UBOX5 0.65 6.5E-04 
GUCY1B2 -1.16 6.6E-04 
PKD1P6 0.69 6.6E-04 
C21orf67 -1.31 6.6E-04 
RAD51C -0.68 6.7E-04 
C3orf62 -1.15 6.7E-04 
KLHL3 -0.62 6.7E-04 
IRAK1BP1 -0.62 6.7E-04 
GCNT1 0.70 6.8E-04 
OR2A1-AS1 -0.98 6.8E-04 
ZNF574 0.70 6.8E-04 
WASH6P 0.80 6.8E-04 
CASP8 -0.59 6.9E-04 
CCDC19 1.41 7.0E-04 
TMEM254 -0.67 7.0E-04 
HOTTIP -1.05 7.0E-04 
HOXA7 -0.71 7.2E-04 
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ZNF394 0.74 7.3E-04 
ZNF404 -0.94 7.3E-04 
DGKZ 0.65 7.3E-04 
AKIRIN2 0.65 7.3E-04 
ARID3A 0.64 7.4E-04 
C16orf52 -0.74 7.4E-04 
TMEM5 -0.69 7.5E-04 
CNEP1R1 0.77 7.5E-04 
CTBP1-AS2 -0.59 7.5E-04 
TP53RK -0.73 7.6E-04 
MRPL43 0.59 7.6E-04 
STAC3 -1.02 7.7E-04 
HOMEZ -0.60 7.8E-04 
BCDIN3D -0.86 7.9E-04 
RLIM 0.59 7.9E-04 
CTSO -0.91 8.0E-04 
GPX1 0.67 8.0E-04 
TMEM132B -0.84 8.1E-04 
CCDC47 -0.63 8.1E-04 
TNS3 -0.60 8.1E-04 
PDRG1 0.72 8.1E-04 
ENPP5 0.73 8.1E-04 
LRRC66 -1.85 8.1E-04 
IRS2 0.63 8.2E-04 
C15orf57 0.67 8.2E-04 
ZNF699 0.86 8.2E-04 
CARF -0.84 8.3E-04 
DHRSX -0.82 8.3E-04 
MALAT1 0.71 8.4E-04 
TRAM2-AS1 -0.88 8.5E-04 
SLC16A14 -0.64 8.5E-04 
MESP2 1.72 8.6E-04 
TK2 -0.86 8.7E-04 
CCDC14 -0.59 8.9E-04 
RBM3 0.64 8.9E-04 
EEF1A1P19 1.74 9.0E-04 
TMEM39B -0.71 9.2E-04 
ARG2 0.62 9.2E-04 
ZNF107 -0.64 9.2E-04 
PTER -0.63 9.2E-04 
LINC01002 0.90 9.2E-04 
PRIMA1 -0.78 9.3E-04 
RMND1 0.61 9.3E-04 
TENC1 -0.65 9.4E-04 
KDM4D -0.87 9.5E-04 
BCL7B -0.73 9.5E-04 
POLN -0.76 9.8E-04 
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ZWILCH -0.62 9.8E-04 
PAX1 -0.88 9.8E-04 
NKX6-1 0.79 9.9E-04 
XRCC4 -0.79 9.9E-04 
CACNG8 -0.93 1.0E-03 
PTPRZ1 -0.77 1.0E-03 
SLC6A8 0.61 1.0E-03 
TMEM98 -0.60 1.0E-03 
TLE3 0.58 1.0E-03 
PGM2L1 0.64 1.0E-03 
ZNF681 -1.23 1.0E-03 
RIPK2 0.60 1.0E-03 
THSD7A -1.06 1.0E-03 
EIF4A2 0.60 1.0E-03 
RMRP -3.25 1.0E-03 
ZNF724P 0.75 1.0E-03 
IFIT1 -0.71 1.0E-03 
NUPR1 -1.05 1.1E-03 
FBXO27 0.76 1.1E-03 
SSPO -0.88 1.1E-03 
NACC2 -0.62 1.1E-03 
LRRIQ1 -1.10 1.1E-03 
FAM193B 0.71 1.1E-03 
ERV3-1 -0.74 1.1E-03 
FTX -1.69 1.1E-03 
HCN2 0.66 1.1E-03 
NXPH3 0.92 1.1E-03 
C14orf28 1.01 1.1E-03 
THAP3 0.70 1.1E-03 
WDR31 -1.07 1.1E-03 
FANCM 0.61 1.1E-03 
FBXL2 0.71 1.1E-03 
SNORD117 1.07 1.1E-03 
SLC16A6 -1.12 1.1E-03 
PHF1 0.62 1.1E-03 
DEPTOR 0.63 1.1E-03 
ZNF570 0.60 1.1E-03 
BAMBI 0.63 1.2E-03 
TNFRSF12A 1.16 1.2E-03 
HERC6 -0.68 1.2E-03 
OXTR 0.87 1.2E-03 
DLL1 0.62 1.2E-03 
CDC37L1 0.67 1.2E-03 
ZNF296 0.87 1.2E-03 
SCN5A -0.94 1.2E-03 
ZNF783 -0.65 1.2E-03 
TTPAL -0.72 1.2E-03 
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FAM118B -0.75 1.2E-03 
ANKDD1A 1.30 1.2E-03 
VPS18 -0.72 1.2E-03 
ING3 -0.65 1.3E-03 
ELOF1 0.62 1.3E-03 
ZNF853 -0.61 1.3E-03 
TTLL11 -0.79 1.3E-03 
VCPKMT 0.77 1.3E-03 
DUSP10 0.68 1.3E-03 
C15orf61 0.83 1.3E-03 
SDCBP2 1.13 1.3E-03 
MORN1 -0.76 1.3E-03 
PYROXD1 -0.73 1.3E-03 
SLC9A8 -0.63 1.3E-03 
KIAA1045 -1.27 1.3E-03 
ATG4D 0.66 1.3E-03 
RBAK -0.62 1.3E-03 
PHF21B 0.76 1.3E-03 
SRP14-AS1 -0.91 1.3E-03 
ZNF471 -0.74 1.3E-03 
MAP2K7 0.62 1.4E-03 
TLR5 -1.59 1.4E-03 
TMEM67 -0.60 1.4E-03 
NAT9 0.61 1.4E-03 
MAD2L2 0.61 1.4E-03 
ZNF627 0.76 1.4E-03 
LINC00176 -1.32 1.4E-03 
ITPRIPL2 -0.61 1.4E-03 
PEX11A -0.66 1.4E-03 
TRAM1 -0.64 1.4E-03 
ISL2 0.64 1.4E-03 
DGCR11 1.25 1.4E-03 
CALHM2 0.61 1.4E-03 
PDE4B -0.87 1.5E-03 
SBNO2 0.70 1.5E-03 
C12orf5 -0.66 1.5E-03 
NAT1 -0.89 1.5E-03 
CALCB 0.72 1.5E-03 
AP4S1 -1.44 1.5E-03 
RASSF4 -0.75 1.5E-03 
TXNDC5 0.97 1.5E-03 
MIEF2 0.64 1.5E-03 
SPPL2A -0.65 1.5E-03 
ZNF268 -0.62 1.5E-03 
TBX2 0.66 1.5E-03 
MAMDC4 -0.90 1.5E-03 
PPARGC1A 0.76 1.5E-03 
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TBC1D17 0.68 1.6E-03 
NEK11 -1.31 1.6E-03 
LINC-PINT 1.10 1.6E-03 
HOXC8 -0.59 1.6E-03 
NEXN -0.59 1.6E-03 
CLGN -0.83 1.6E-03 
TNFAIP8L3 1.55 1.6E-03 
ARMCX4 -1.37 1.6E-03 
RAB36 -0.76 1.6E-03 
CEP97 0.59 1.6E-03 
RGS7BP -0.92 1.6E-03 
DHDH 1.13 1.6E-03 
LINC01023 1.66 1.6E-03 
ACSS3 0.73 1.7E-03 
DOLK -0.71 1.7E-03 
XKR5 -1.14 1.7E-03 
PDCD7 0.59 1.7E-03 
MAFF 1.45 1.7E-03 
f 0.62 1.7E-03 
EDA2R -0.70 1.7E-03 
GEM 0.71 1.7E-03 
CUZD1 -1.12 1.7E-03 
SCN2A -1.59 1.7E-03 
WNK3 0.62 1.7E-03 
SDAD1P1 -1.15 1.7E-03 
MAPKAPK5-AS1 0.78 1.7E-03 
SHROOM1 -0.69 1.7E-03 
ACTRT3 -1.53 1.8E-03 
METTL25 -1.01 1.8E-03 
KLF16 0.69 1.8E-03 
HIST1H2BJ 1.06 1.8E-03 
PTHLH 1.15 1.8E-03 
TAGLN -1.09 1.8E-03 
SPSB2 0.86 1.8E-03 
LIMK1 0.71 1.8E-03 
COX5A 0.72 1.8E-03 
RPS6KB2 0.60 1.8E-03 
PAXIP1-AS2 -0.95 1.8E-03 
MURC -1.03 1.9E-03 
GDNF -0.85 1.9E-03 
AOC2 0.64 1.9E-03 
CYP4X1 -0.62 1.9E-03 
TPH1 -1.71 1.9E-03 
IQCH -1.00 1.9E-03 
SHC2 -0.79 1.9E-03 
DHRS1 0.68 1.9E-03 
PTPMT1 -0.80 2.0E-03 
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FIGN 0.63 2.0E-03 
S1PR2 0.84 2.0E-03 
KRAS 1.02 2.0E-03 
ANKHD1-
EIF4EBP3 -1.63 2.1E-03 
TDRD12 -1.17 2.1E-03 
SKIL 0.67 2.1E-03 
TMEM134 0.74 2.1E-03 
MGMT 0.65 2.1E-03 
FAM86B3P 0.58 2.1E-03 
TRIM36 0.62 2.1E-03 
ZNF695 1.16 2.1E-03 
ALG11 -0.86 2.1E-03 
UBALD2 0.83 2.1E-03 
P2RY1 0.67 2.1E-03 
HSF4 -0.93 2.1E-03 
STK17B 0.69 2.1E-03 
MYLIP 0.67 2.2E-03 
ZNF528 -0.80 2.2E-03 
TEAD4 0.61 2.2E-03 
PEX6 -0.58 2.2E-03 
CHCHD5 0.76 2.2E-03 
MAEA -0.66 2.2E-03 
KCNMB3 -1.35 2.2E-03 
ZNF425 -1.28 2.2E-03 
SLC7A11 -0.70 2.2E-03 
TMEM117 -0.62 2.2E-03 
PKIA -0.60 2.2E-03 
GNG5 0.63 2.2E-03 
MSTN -1.33 2.2E-03 
TRAF1 -0.99 2.2E-03 
GRB14 0.72 2.2E-03 
HELQ -0.72 2.2E-03 
SCAND2P 0.62 2.2E-03 
PRSS27 -1.12 2.3E-03 
MDH1B -1.75 2.3E-03 
RHBDF1 0.60 2.3E-03 
TNFAIP8L1 0.71 2.3E-03 
C9orf89 0.85 2.3E-03 
DCHS1 -0.94 2.3E-03 
CDKN2D 0.83 2.3E-03 
TMEM168 -0.65 2.3E-03 
OPHN1 0.58 2.3E-03 
ARFRP1 0.66 2.3E-03 
PPP4R1L 0.67 2.3E-03 
WDR4 0.58 2.3E-03 
SLC25A19 0.63 2.3E-03 
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TUSC1 -0.71 2.3E-03 
VWDE 0.61 2.3E-03 
BEAN1 -1.21 2.3E-03 
NFIL3 0.64 2.4E-03 
AMY2B -1.12 2.4E-03 
LPAR3 0.61 2.4E-03 
CASC2 -0.99 2.5E-03 
NFKBIB 0.74 2.5E-03 
SHPK 1.21 2.5E-03 
FBXL19-AS1 -0.74 2.5E-03 
SAMD1 0.61 2.6E-03 
ZNF836 -1.44 2.6E-03 
ZNF502 -0.96 2.6E-03 
TPST1 -0.59 2.6E-03 
IL6R 0.60 2.6E-03 
MRPL1 -0.77 2.6E-03 
SCN1B 0.92 2.6E-03 
SDCBP2-AS1 -1.31 2.6E-03 
NFATC4 -0.61 2.6E-03 
PAM16 1.05 2.6E-03 
ZNF862 -0.61 2.6E-03 
FZD10-AS1 -1.46 2.6E-03 
NHLH2 -1.82 2.7E-03 
RHBDL3 -0.59 2.7E-03 
C1RL -0.83 2.7E-03 
PLEKHG4B -0.65 2.7E-03 
XRCC6BP1 0.69 2.8E-03 
THEM4 -0.60 2.8E-03 
DTX4 -0.61 2.8E-03 
SH2B3 0.58 2.8E-03 
LDOC1 0.62 2.8E-03 
ITGB1BP2 -1.17 2.8E-03 
LRRC17 -1.19 2.9E-03 
AP4E1 -0.66 2.9E-03 
TEAD3 0.61 2.9E-03 
SREBF1 -0.61 2.9E-03 
DLL4 1.03 2.9E-03 
NHSL2 -0.84 2.9E-03 
GRK4 -0.73 3.0E-03 
RNF19B 0.58 3.0E-03 
FN3K -1.24 3.0E-03 
SOCS3 1.25 3.0E-03 
ANPEP 1.58 3.0E-03 
PRR22 -1.14 3.0E-03 
RASL11B 0.73 3.1E-03 
WDR45 -0.61 3.1E-03 
TMEM41B 0.58 3.1E-03 
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CCDC53 -0.62 3.1E-03 
TTC3P1 -1.09 3.1E-03 
QPCTL 0.62 3.2E-03 
KCTD21 -0.89 3.2E-03 
CHST2 0.90 3.2E-03 
HAPLN3 0.58 3.2E-03 
NR0B1 1.18 3.3E-03 
APOLD1 -0.67 3.3E-03 
ROMO1 0.60 3.3E-03 
LINC00648 -1.21 3.3E-03 
C1orf145 -1.17 3.4E-03 
BSCL2 -0.90 3.4E-03 
RGMA 0.60 3.4E-03 
CABLES2 -0.59 3.4E-03 
ZNF385C -1.01 3.4E-03 
MCF2L -0.61 3.4E-03 
PDXP 1.63 3.4E-03 
ZNF337-AS1 -0.87 3.4E-03 
PDK4 0.76 3.4E-03 
CCDC28B 0.65 3.4E-03 
RUSC1-AS1 -1.08 3.4E-03 
ALPK1 -0.59 3.5E-03 
FAM86EP -0.99 3.5E-03 
PARK2 -0.82 3.5E-03 
MC1R -1.06 3.6E-03 
ALG5 -0.67 3.6E-03 
CDH10 -0.72 3.6E-03 
DENND2C 0.59 3.6E-03 
PRKAR1B -0.63 3.6E-03 
CLHC1 -0.76 3.6E-03 
FHOD1 0.60 3.7E-03 
DNAJB9 0.68 3.7E-03 
NXT2 -0.61 3.7E-03 
SLC35B3 -0.58 3.7E-03 
LRRC57 0.62 3.8E-03 
ZNF34 0.74 3.8E-03 
KIAA1456 -1.08 3.8E-03 
MARVELD3 0.70 3.9E-03 
PKD2 -0.64 3.9E-03 
CACNA2D3 0.80 3.9E-03 
SLC6A16 -0.73 3.9E-03 
ZSCAN30 -0.58 3.9E-03 
EPN1 0.58 3.9E-03 
TCIRG1 -1.18 4.0E-03 
KIAA1024 -0.58 4.0E-03 
SPATA18 -0.64 4.0E-03 
NPPC 1.04 4.0E-03 
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CCDC176 -1.10 4.0E-03 
IRX3 0.68 4.0E-03 
SOS1-IT1 0.81 4.0E-03 
LINC00467 -0.73 4.1E-03 
ZNF485 -0.77 4.1E-03 
FRY 0.59 4.2E-03 
SNHG17 0.60 4.2E-03 
EXTL3-AS1 0.93 4.3E-03 
NPTX1 -0.61 4.3E-03 
H1FX 0.59 4.3E-03 
FAM83H-AS1 -0.80 4.3E-03 
NPL -0.64 4.3E-03 
CRY2 0.62 4.4E-03 
RNASET2 0.64 4.4E-03 
GKAP1 0.63 4.5E-03 
B3GAT2 -0.78 4.5E-03 
C8orf48 -1.45 4.5E-03 
TFEB 0.82 4.5E-03 
GNB2 0.70 4.6E-03 
MTG1 -0.70 4.6E-03 
METAP1D -0.63 4.6E-03 
ZNF284 0.70 4.6E-03 
MBD3 -0.59 4.6E-03 
CLEC11A 1.07 4.6E-03 
FOXD3 0.97 4.8E-03 
ADRB1 1.10 4.8E-03 
RNF170 -0.61 4.8E-03 
FAM226A 1.15 4.9E-03 
FAM226B 1.15 4.9E-03 
RHBDL1 -1.00 4.9E-03 
SSR4P1 -1.64 4.9E-03 
RAB27B -0.82 5.0E-03 
NELFB 0.59 5.1E-03 
PTMS 0.61 5.1E-03 
HSCB 0.77 5.1E-03 
PRR4 -1.03 5.1E-03 
C6orf183 -0.59 5.2E-03 
ZNF10 -0.65 5.2E-03 
KRTCAP2 0.66 5.2E-03 
KCTD18 -0.59 5.2E-03 
WDR96 -1.46 5.2E-03 
KCNJ4 0.96 5.2E-03 
FILIP1L -1.46 5.2E-03 
ZNF382 -0.70 5.2E-03 
PLAG1 0.68 5.3E-03 
PILRA -1.09 5.4E-03 
RHPN1 -0.98 5.4E-03 
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OMA1 -0.61 5.4E-03 
FOXN4 -0.74 5.4E-03 
PITX1 0.61 5.4E-03 
ABCC8 -0.72 5.5E-03 
ZBED3-AS1 -0.90 5.5E-03 
SNORD94 1.01 5.5E-03 
PTGES2 0.74 5.6E-03 
SLC23A3 -1.63 5.7E-03 
EPM2A -0.65 5.7E-03 
PHLDA1 0.66 5.7E-03 
IFT88 -0.59 5.8E-03 
GOLGA2P5 -0.74 5.8E-03 
SNORD101 1.46 5.9E-03 
CCDC180 -1.71 5.9E-03 
C19orf52 0.61 6.0E-03 
SLC25A34 -1.55 6.0E-03 
PAXIP1-AS1 0.76 6.0E-03 
ABCG1 0.99 6.1E-03 
LSMEM1 1.25 6.1E-03 
SNORD83A 0.90 6.1E-03 
TGM2 -0.85 6.1E-03 
HOXA10-AS -0.66 6.2E-03 
ZSCAN12P1 -1.27 6.2E-03 
WEE2-AS1 -1.25 6.2E-03 
C1orf50 0.62 6.2E-03 
FAM50B -0.71 6.2E-03 
CDO1 -0.64 6.3E-03 
GLIPR1 -0.73 6.4E-03 
ZNF611 -0.65 6.4E-03 
OSGEPL1 -0.59 6.4E-03 
MAP2K6 -0.61 6.4E-03 
MID1IP1-AS1 -1.15 6.4E-03 
DMTN -0.93 6.5E-03 
SEMA3G -0.79 6.6E-03 
TEX35 -1.41 6.6E-03 
RERG -1.18 6.7E-03 
PRR13 0.59 6.7E-03 
NKX2-5 0.81 6.7E-03 
PCBD2 -0.76 6.8E-03 
HSD17B7 0.76 6.8E-03 
WDR81 -0.67 6.8E-03 
EMC9 0.64 6.9E-03 
EFCAB6 -1.10 6.9E-03 
C6orf165 0.92 6.9E-03 
C6orf163 -1.21 6.9E-03 
SPINK5 -1.04 6.9E-03 
LINC00526 1.27 7.0E-03 
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SCARNA10 -1.32 7.2E-03 
GTPBP10 -0.66 7.2E-03 
REPS2 -0.69 7.4E-03 
ST3GAL2 0.58 7.4E-03 
IQCG -0.69 7.4E-03 
FAM195A 0.84 7.4E-03 
EIF3J-AS1 0.70 7.4E-03 
ARL6IP6 -0.61 7.5E-03 
MGLL 0.81 7.5E-03 
SCUBE1 -0.59 7.5E-03 
LINC01123 1.11 7.5E-03 
ORAI2 0.58 7.5E-03 
C11orf70 -0.79 7.5E-03 
SRSF8 -0.71 7.6E-03 
STEAP1 -0.62 7.7E-03 
TPI1P2 -1.60 7.7E-03 
TTC32 -0.59 7.7E-03 
HIST1H1C 0.74 7.7E-03 
FAM86C2P -0.65 7.8E-03 
PNPLA3 0.64 7.8E-03 
BEST1 -1.00 7.8E-03 
TRIM59 0.82 7.8E-03 
ZDHHC1 -0.74 7.9E-03 
C19orf10 0.68 7.9E-03 
IFT80 -0.60 7.9E-03 
QDPR 0.64 7.9E-03 
TSPAN2 -0.69 7.9E-03 
BHLHB9 -0.73 8.0E-03 
PALM2 0.73 8.2E-03 
BCL7C 0.61 8.3E-03 
SNORD69 0.85 8.3E-03 
PTGER2 -1.17 8.6E-03 
JAKMIP1 -1.09 8.7E-03 
CLDN4 0.92 8.7E-03 
CARD9 -1.39 8.8E-03 
BCL10 0.58 8.8E-03 
EMILIN2 0.60 8.8E-03 
FAM149A -0.68 8.9E-03 
MAP6 -1.04 8.9E-03 
NME5 -0.93 9.0E-03 
REG1A 1.01 9.0E-03 
MBOAT1 0.63 9.1E-03 
BIN3 -0.58 9.1E-03 
HSD3B7 -1.25 9.2E-03 
NRG4 -0.60 9.2E-03 
PRR7 1.09 9.3E-03 
SNORD20 1.45 9.3E-03 
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IFI27 -0.82 9.3E-03 
ELMO3 -1.11 9.3E-03 
C16orf46 1.34 9.4E-03 
FAM96B 0.58 9.4E-03 
CYP2D6 -1.24 9.4E-03 
BRAF 0.67 9.5E-03 
RGS9 -0.87 9.6E-03 
CACTIN-AS1 -1.17 9.6E-03 
ZBED5-AS1 -1.16 9.6E-03 
GABRA5 -0.59 9.6E-03 
FAM174B -0.78 9.6E-03 
NDUFC2 -0.78 9.7E-03 
SYNPO2 -1.49 9.8E-03 
LOH12CR1 0.58 9.9E-03 
ICA1L -0.65 9.9E-03 
SMIM4 0.87 9.9E-03 
FOLR1 -0.91 9.9E-03 
DLK2 1.22 9.9E-03 
TMEM99 -0.59 1.0E-02 
TCHH -0.83 1.0E-02 
CCT6P3 0.67 1.0E-02 
CCDC147-AS1 1.11 1.0E-02 
MED31 -0.59 1.0E-02 
ZBTB11-AS1 -1.02 1.0E-02 
CNR1 -1.24 1.0E-02 
RELL2 0.62 1.0E-02 
C10orf10 0.72 1.0E-02 
KCTD17 0.58 1.1E-02 
DNAJC5G -1.36 1.1E-02 
HILPDA -0.69 1.1E-02 
C1orf116 1.01 1.1E-02 
RPL18AP3 1.44 1.1E-02 
MT2A 0.70 1.1E-02 
FERMT1 -1.36 1.1E-02 
STK31 -1.19 1.1E-02 
EHBP1L1 -0.60 1.1E-02 
UBE2V1 0.83 1.1E-02 
INE1 0.81 1.1E-02 
TMEM17 -0.89 1.1E-02 
SYTL4 0.63 1.1E-02 
KIAA0391 0.97 1.1E-02 
C7orf63 0.72 1.1E-02 
SNORA33 1.30 1.1E-02 
KCNC1 -0.65 1.1E-02 
BMP8B -0.63 1.1E-02 
FAM132B -0.58 1.1E-02 
ZBTB7C -0.63 1.1E-02 
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BMP4 0.59 1.2E-02 
EXOSC4 0.76 1.2E-02 
ZNF32-AS2 0.98 1.2E-02 
NAT14 0.60 1.2E-02 
CHL1 -0.95 1.2E-02 
CXXC4 -0.60 1.2E-02 
TMEM51-AS1 -1.20 1.2E-02 
IER5L 1.19 1.2E-02 
SPSB1 -0.68 1.2E-02 
STYK1 0.75 1.2E-02 
PPAN -0.89 1.2E-02 
CDH7 -0.58 1.2E-02 
INCA1 -1.31 1.3E-02 
MRPS31P5 0.98 1.3E-02 
LRRTM4 -0.74 1.3E-02 
PLEKHF1 0.76 1.3E-02 
DMPK -0.62 1.3E-02 
SPAG17 -1.43 1.3E-02 
CCDC7 -0.99 1.3E-02 
HRSP12 -0.61 1.3E-02 
CCDC178 -1.32 1.3E-02 
ANKRD24 -0.79 1.3E-02 
WAS -1.21 1.3E-02 
PLEKHN1 1.03 1.3E-02 
ZNF707 0.61 1.3E-02 
TMEM27 -1.14 1.3E-02 
PDE7B -1.22 1.3E-02 
HCG15 -0.85 1.3E-02 
SMN2 -0.67 1.4E-02 
CDK15 -0.84 1.4E-02 
SNORD17 0.72 1.4E-02 
PLIN1 -0.88 1.4E-02 
LY6G5B -0.75 1.4E-02 
PABPC1P3 1.12 1.4E-02 
DUOX2 -1.33 1.4E-02 
SNRNP25 0.65 1.4E-02 
FGF5 -0.80 1.4E-02 
FLVCR1-AS1 0.90 1.4E-02 
ANKLE1 -1.07 1.4E-02 
IL12RB2 -0.63 1.4E-02 
ZBTB8B 0.66 1.4E-02 
CYP27B1 -0.65 1.5E-02 
NDST4 -1.23 1.5E-02 
TMEM54 0.92 1.5E-02 
CAMK2B -1.17 1.5E-02 
PTPRB -0.82 1.5E-02 
LURAP1 0.74 1.5E-02 
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POF1B -1.26 1.5E-02 
DRP2 0.73 1.5E-02 
PPP1R3F -0.82 1.5E-02 
PINK1-AS -0.67 1.5E-02 
SNX18P3 -0.83 1.5E-02 
HSPB1 0.59 1.5E-02 
CCDC183-AS1 -0.69 1.5E-02 
HBQ1 1.25 1.5E-02 
SPSB3 0.60 1.5E-02 
APLF -0.83 1.5E-02 
MIR4519 0.97 1.5E-02 
BTBD19 -0.71 1.5E-02 
HYPK 0.63 1.5E-02 
FAM131B 0.77 1.6E-02 
NACAD -0.91 1.6E-02 
PSMD6-AS2 -0.99 1.6E-02 
TMEM169 -1.37 1.6E-02 
HNRNPA3P6 1.06 1.6E-02 
ARMC12 -1.28 1.6E-02 
KLF15 0.66 1.6E-02 
LINC00909 -0.77 1.6E-02 
ANKRD20A4 0.93 1.7E-02 
SAMD15 -1.02 1.7E-02 
CAPN10-AS1 0.85 1.7E-02 
ID1 0.88 1.7E-02 
GOLGA8R -0.79 1.7E-02 
LINC01021 -0.75 1.7E-02 
PPAPDC1A -0.87 1.7E-02 
AMIGO1 -0.73 1.7E-02 
XK -0.69 1.7E-02 
CYBRD1 -0.64 1.7E-02 
HES4 0.68 1.7E-02 
WDR72 -0.71 1.7E-02 
C15orf59 -0.66 1.7E-02 
COL24A1 -0.67 1.7E-02 
EPPK1 -0.81 1.7E-02 
CHRNB1 0.79 1.7E-02 
RPS15A 0.63 1.8E-02 
CTNNA3 -0.84 1.8E-02 
ZNF628 0.80 1.8E-02 
ZNF28 -0.61 1.8E-02 
CYP3A5 -0.75 1.8E-02 
OTUD1 0.64 1.8E-02 
CCDC122 -0.61 1.8E-02 
RRAS 0.78 1.9E-02 
CLYBL -0.62 1.9E-02 
CYP2J2 -0.69 1.9E-02 
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LINC01003 1.27 1.9E-02 
NEUROG2 1.16 1.9E-02 
TMEM155 -1.05 1.9E-02 
GLIS1 0.69 1.9E-02 
MTUS2 1.21 1.9E-02 
TECTA -0.85 1.9E-02 
SLC8A3 -0.82 1.9E-02 
CEP44 0.67 1.9E-02 
IFITM3 0.84 2.0E-02 
TMEM44-AS1 -0.98 2.0E-02 
RNF180 -0.86 2.0E-02 
T -1.26 2.0E-02 
CYP4F26P -0.73 2.0E-02 
TGFB1 0.72 2.0E-02 
CCDC181 0.69 2.0E-02 
BCL3 0.78 2.0E-02 
C9orf16 0.63 2.0E-02 
SLC26A4 -1.24 2.0E-02 
NOTCH2NL -0.59 2.1E-02 
USP2-AS1 1.02 2.1E-02 
TBC1D10A 0.68 2.1E-02 
TNS1 -0.63 2.1E-02 
DDX47 0.77 2.1E-02 
NRAS 1.16 2.1E-02 
ABCA8 -0.68 2.1E-02 
SLC46A3 -0.70 2.1E-02 
OCEL1 0.68 2.1E-02 
MKX -0.62 2.1E-02 
GJB7 -0.63 2.1E-02 
SLC52A2 0.59 2.2E-02 
MAPK13 0.77 2.2E-02 
ARHGEF37 -0.66 2.2E-02 
ZNF805 0.62 2.2E-02 
RDH14 -0.65 2.2E-02 
PDE3A -0.80 2.2E-02 
BFSP1 -0.98 2.2E-02 
IFIT2 -1.13 2.2E-02 
RAB4B 0.84 2.2E-02 
BHLHE41 -0.62 2.3E-02 
KLRAP1 -0.67 2.3E-02 
PLA2G7 -0.61 2.3E-02 
C2CD4C -1.09 2.3E-02 
LINC01116 -1.03 2.3E-02 
KCNE4 -0.98 2.3E-02 
BBS5 0.66 2.3E-02 
CEL -1.02 2.4E-02 
KRT8P12 0.65 2.4E-02 
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SLC17A7 1.09 2.4E-02 
GIPR 0.76 2.4E-02 
ZNF17 -0.58 2.4E-02 
GPR137C -0.58 2.4E-02 
RGS5 -0.61 2.4E-02 
LIN7B 0.59 2.4E-02 
TTC25 -0.93 2.4E-02 
B3GALT5 -0.68 2.4E-02 
HSPB6 -1.19 2.4E-02 
UNC5A -0.91 2.4E-02 
STEAP1B -0.65 2.4E-02 
CCDC107 0.66 2.4E-02 
RIBC2 -0.67 2.4E-02 
MAFB 0.65 2.5E-02 
MSRA 0.92 2.5E-02 
SPRY2 0.59 2.5E-02 
TMEM126A 0.66 2.5E-02 
NDNF -0.66 2.5E-02 
CRIP3 0.91 2.5E-02 
TSACC -0.75 2.6E-02 
LRRIQ3 -1.21 2.6E-02 
CCDC144CP -0.70 2.6E-02 
RFTN2 -1.13 2.6E-02 
U2AF1L4 0.68 2.6E-02 
FAM66D -1.25 2.7E-02 
SBF2-AS1 -0.76 2.7E-02 
SYNGR4 -0.99 2.7E-02 
SUV420H2 0.64 2.7E-02 
KNDC1 -0.77 2.7E-02 
CXorf24 1.06 2.8E-02 
CUBN -0.85 2.8E-02 
MIR1254-1 0.83 2.8E-02 
ZNF582 -0.64 2.8E-02 
CELSR3 -0.59 2.8E-02 
FAM157A 0.62 2.8E-02 
DIO2 -0.97 2.9E-02 
LRRN2 -1.09 2.9E-02 
LINC00893 -0.75 2.9E-02 
ADRA2C 0.59 2.9E-02 
ZCCHC18 0.95 2.9E-02 
RDH16 0.89 2.9E-02 
LRRTM2 -0.78 2.9E-02 
GLDN -0.61 2.9E-02 
NEB -1.06 3.0E-02 
LAMTOR5-AS1 -0.84 3.0E-02 
GLUD1P3 0.70 3.0E-02 
TMCC1-AS1 -0.92 3.0E-02 
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TRPM3 -0.93 3.0E-02 
PIK3IP1 0.71 3.0E-02 
KCNJ11 1.01 3.0E-02 
HLX 0.61 3.1E-02 
CCDC144A -1.03 3.1E-02 
OVOL2 0.95 3.1E-02 
EOMES -0.61 3.1E-02 
WDR78 -0.92 3.1E-02 
MUC20 -1.11 3.2E-02 
ARIH2OS 1.13 3.2E-02 
CDHR3 -0.67 3.2E-02 
GATA6-AS1 0.73 3.2E-02 
PTH1R -1.19 3.2E-02 
SH2D4A -1.19 3.2E-02 
SCARNA17 -1.28 3.2E-02 
PCSK1N 0.90 3.2E-02 
DDX60 -0.59 3.2E-02 
RPL28 0.59 3.2E-02 
FOXP3 -1.18 3.2E-02 
FAM203A -0.66 3.2E-02 
DNAJC22 -0.58 3.3E-02 
ZNF846 -0.77 3.3E-02 
DNAJC30 -0.62 3.4E-02 
FER1L4 -0.75 3.4E-02 
MRPS17 -0.72 3.5E-02 
ATP5D 0.60 3.5E-02 
LRRC69 -1.07 3.5E-02 
URAHP 0.81 3.6E-02 
SMCO4 0.69 3.6E-02 
MIF 0.59 3.6E-02 
DNAAF3 -0.78 3.6E-02 
LINC00461 -0.84 3.6E-02 
INA -0.68 3.6E-02 
TMEM184A -1.20 3.6E-02 
ZC3H6 0.58 3.7E-02 
zfhx2-as1 -0.87 3.7E-02 
CYP4F32P -0.73 3.7E-02 
SNORA66 1.02 3.8E-02 
FRMD3 -1.03 3.8E-02 
TMEM145 -0.59 3.8E-02 
SPIN3 -0.63 3.9E-02 
MLKL -0.88 4.0E-02 
ZNF429 -0.60 4.0E-02 
SENP8 -0.59 4.1E-02 
EFCAB4B -0.66 4.1E-02 
SRRM5 -0.81 4.1E-02 
ZNF571-AS1 -0.80 4.1E-02 
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COL9A1 -0.61 4.2E-02 
C1orf213 0.72 4.2E-02 
SRRM2-AS1 -0.62 4.3E-02 
RMDN2 -1.00 4.3E-02 
AKAP3 -0.92 4.3E-02 
SLC2A4 0.69 4.3E-02 
SNX18P16 -1.08 4.4E-02 
GPR3 0.85 4.4E-02 
CCNT2-AS1 -0.86 4.4E-02 
PCDH1 0.61 4.4E-02 
ADPRHL1 -0.62 4.5E-02 
CPLX1 0.66 4.5E-02 
RXRG -0.94 4.5E-02 
ZMYND10 -0.86 4.5E-02 
NAIP -0.82 4.5E-02 
EMR2 -0.66 4.6E-02 
GPC2 0.61 4.7E-02 
CDK5R2 1.07 4.7E-02 
C12orf60 -0.79 4.7E-02 
SNORA50 0.92 4.7E-02 
NIPSNAP3B 0.73 4.7E-02 
COL4A4 -0.69 4.8E-02 
ZNF23 0.75 4.9E-02 
ACRC -0.64 5.0E-02 





Supplemental File 2: Chapter 4 differentially expressed genes from rotenone treated 
SH-5YSY negative control. 
 
Genename logFC FDR 
RSPO1 -5.81 5.13E-60 
TFAMP1 -4.17 1.05E-54 
AC104129.1 -5.55 4.82E-42 
AL136529.1 -4.31 2.23E-39 
TMEM51-AS1 -3.05 8.19E-39 
BHLHE40 -3.21 1.22E-38 
NEDD9 -4.31 1.63E-37 
C20orf166-AS1 -3.43 2.85E-36 
CA12 -4.55 1.98E-33 
AC138028.2 -3.60 1.06E-30 
CXCR4 -3.95 2.74E-30 
AC134312.1 -3.18 3.68E-28 
CARTPT -3.96 3.68E-28 
AC135782.1 -3.33 5.43E-27 
AC138028.1 -3.93 9.53E-27 
GPER1 -4.27 2.20E-26 
TRIM29 -3.36 3.96E-25 
TSPEAR-AS1 -2.44 1.54E-24 
SOBP -2.40 3.11E-24 
KCNQ1OT1 -2.68 1.57E-23 
CFAP43 -2.85 1.59E-23 
TSPEAR-AS2 -2.57 4.77E-23 
AL109615.3 -3.45 1.02E-21 
ELFN1 -2.78 2.94E-21 
GDF10 -2.66 7.91E-21 
CABP7 -2.26 1.12E-20 
VEGFA -2.31 1.31E-20 
TLX1 -2.91 1.13E-19 
CARMN -2.91 6.25E-19 
AQP1 -2.39 1.75E-18 
HSPB7 -2.66 2.01E-18 
AC134312.4 -3.14 3.09E-18 
HTR1E -2.21 4.73E-18 
NXPH4 -3.16 1.69E-16 
AQP10 -3.33 1.89E-16 
ADM -2.29 2.76E-16 
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AC074389.2 -3.80 3.22E-16 
NRP1 -2.12 3.39E-16 
DARS-AS1 -3.17 2.03E-15 
NTNG2 -2.44 2.29E-15 
MCHR1 -3.14 2.65E-15 
AP001065.1 -2.15 2.73E-15 
LINC00304 -3.06 3.67E-15 
OLFM1 -2.14 3.80E-15 
DUSP7 -2.38 4.37E-15 
RTL1 -1.70 4.65E-15 
ID2 -2.14 1.17E-14 
LINC02348 -2.71 3.39E-14 
SLC2A1 -1.76 3.98E-14 
NDUFA4L2 -2.83 7.89E-14 
PTK6 -2.89 3.06E-13 
CERK -1.73 3.22E-13 
HEY1 -2.02 3.35E-13 
N4BP3 -1.86 3.61E-13 
SOX9 -1.82 5.42E-13 
CU639417.2 -2.35 6.28E-13 
EPB41L4B -1.91 7.67E-13 
ZMAT4 -2.07 1.17E-12 
NDRG1 -1.82 3.89E-12 
LRRC4 -2.20 5.22E-12 
DIO3 -2.14 5.93E-12 
ANGPTL4 -2.17 9.19E-12 
HK2 -1.59 1.22E-11 
SSUH2 -1.73 1.58E-11 
PPP1R3C -2.12 3.39E-11 
LINC01679 -2.23 3.65E-11 
AC027228.2 -1.60 5.01E-11 
FAM43A -2.21 8.76E-11 
CYB561 -1.49 1.32E-10 
ZNF469 -1.53 2.38E-10 
SLC18A1 -2.11 3.02E-10 
STARD13 -1.60 3.47E-10 
PFKFB4 -1.53 3.71E-10 
TMEM51 -1.65 4.94E-10 
APLN -1.96 6.64E-10 
OLFML2A -1.78 8.10E-10 
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GDF15 1.87 1.19E-09 
PDK1 -1.41 1.78E-09 
SLC35D3 -1.72 1.78E-09 
RGS4 -1.64 2.43E-09 
QRICH2 -1.72 2.68E-09 
FOSL2 -1.65 3.19E-09 
CDKN1C -3.21 4.67E-09 
PRCD -1.69 5.23E-09 
SYT8 -2.21 5.26E-09 
TNNI2 -2.57 6.49E-09 
KCNMA1 -1.52 9.21E-09 
DOK3 -1.75 9.43E-09 
KIAA1614 -1.36 1.24E-08 
C2CD4B -2.77 1.32E-08 
EGLN3 -1.85 1.66E-08 
ASNS 1.81 1.88E-08 
GABRP -1.73 2.06E-08 
AC015802.5 -2.02 2.17E-08 
FOS -1.58 2.55E-08 
PDZD7 -1.37 2.63E-08 
CABP1 -1.87 2.80E-08 
IGF2-AS -2.01 2.90E-08 
SH2D5 1.70 4.16E-08 
PPP1R3B -1.30 5.03E-08 
PIEZO1 -1.84 5.33E-08 
DIO3OS -1.66 8.51E-08 
GPRC5B -1.49 8.62E-08 
LINC01963 -1.44 8.79E-08 
HIST1H2AC -1.67 9.51E-08 
LDHA -1.50 1.02E-07 
ADORA2A -1.49 1.30E-07 
TBX2-AS1 1.39 1.45E-07 
FAM167A -1.39 1.63E-07 
PFKFB3 -1.33 1.77E-07 
DDC -1.66 2.46E-07 
CYGB -1.52 2.79E-07 
EPAS1 -1.26 3.36E-07 
HSPA5 -1.16 3.81E-07 
CDKN1A 1.19 4.34E-07 
LSP1 -1.64 4.96E-07 
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IGF2 -2.31 5.88E-07 
AL513477.1 -1.61 6.81E-07 
SSR4P1 -1.65 8.11E-07 
EML1 -1.21 8.48E-07 
CDH23 -1.34 8.79E-07 
AK4 -1.15 1.51E-06 
AASS 1.29 1.73E-06 
CHRND -1.43 1.74E-06 
AL021368.2 1.56 1.94E-06 
NCOA5 -1.15 2.51E-06 
MIR210HG -2.38 2.64E-06 
SLC16A12 -1.47 2.88E-06 
DGCR9 -1.40 3.13E-06 
HIST1H2BD -1.45 5.05E-06 
C8orf58 -1.38 5.59E-06 
SCML4 -1.39 5.59E-06 
AP001062.1 -1.54 8.01E-06 
COX4I2 -1.92 9.61E-06 
PRODH -1.61 1.06E-05 
DRGX -1.15 1.34E-05 
KCNC1 -1.09 1.79E-05 
AC026688.2 -1.14 2.04E-05 
ST3GAL6 -1.09 2.16E-05 
CCND1 -1.09 2.28E-05 
LINC02151 -1.32 2.52E-05 
LOXL2 -1.20 2.64E-05 
CACNG8 -1.15 2.72E-05 
HMCN2 -1.15 3.47E-05 
P4HA1 -1.05 3.50E-05 
SFXN3 -1.07 4.64E-05 
BDKRB2 -1.29 5.08E-05 
GPR146 -1.64 5.15E-05 
SGMS1-AS1 -1.16 5.36E-05 
AC015802.3 -1.49 6.73E-05 
STS -1.21 7.78E-05 
SLC37A2 1.52 7.84E-05 
TBC1D30 -1.17 8.02E-05 
PDE4C -1.04 8.11E-05 
KCNC4 1.14 8.12E-05 
DNAH10 -1.18 9.21E-05 
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ADPRHL1 -1.49 9.68E-05 
AC010680.2 -1.40 9.94E-05 
AC011700.1 -1.32 1.06E-04 
CFAP44 -0.99 1.09E-04 
PIPOX -1.30 1.11E-04 
DDB2 0.97 1.13E-04 
TSNAXIP1 -1.23 1.20E-04 
ARHGEF4 0.99 1.68E-04 
KLF10 -0.98 1.77E-04 
INHBE 1.57 1.80E-04 
ZMAT3 0.99 1.80E-04 
HNRNPM -0.96 1.81E-04 
HIST1H2BK -1.33 2.03E-04 
C17orf97 -1.43 2.03E-04 
GGT5 -1.18 2.15E-04 
ZNF425 -1.11 2.17E-04 
ADARB1 -0.95 2.18E-04 
XYLT1 -0.94 2.83E-04 
ETS2 -0.93 3.05E-04 
MZF1-AS1 -1.22 3.14E-04 
DIRAS2 1.14 3.23E-04 
EGR1 -1.04 3.23E-04 
KDM3A -0.90 3.41E-04 
PLXNA2 -0.90 3.80E-04 
CEBPB 1.43 3.95E-04 
ARHGAP45 -1.22 4.53E-04 
BNIP3 -1.15 4.67E-04 
ZNF804A -0.91 4.68E-04 
HSPA8 -0.88 4.68E-04 
FOXR2 -1.09 5.03E-04 
PEAR1 -0.94 5.05E-04 
MYO15B 0.97 5.24E-04 
ARHGEF37 -0.94 5.28E-04 
CYR61 1.17 5.50E-04 
KLF15 0.98 5.50E-04 
CLCNKA -0.98 5.53E-04 
DLK1 -1.20 5.64E-04 
PLIN5 1.15 5.69E-04 
SH3BP5-AS1 -0.97 5.83E-04 
TNFRSF19 -1.22 5.94E-04 
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HIST1H2BE -1.12 6.06E-04 
LPCAT4 0.87 6.17E-04 
FUT11 -0.99 6.59E-04 
AC007388.1 1.09 7.48E-04 
PCSK6 -0.91 7.68E-04 
DDIT4 -1.17 8.00E-04 
PPP1R32 1.14 8.28E-04 
LINC00511 -1.36 8.28E-04 
EDA2R 1.04 1.02E-03 
COL23A1 -1.15 1.10E-03 
PAX7 -1.35 1.11E-03 
NTNG1 1.24 1.13E-03 
SLC25A25-AS1 -0.89 1.13E-03 
SYT5 -1.00 1.20E-03 
C4orf47 -1.21 1.21E-03 
ARRDC4 -0.88 1.25E-03 
ALS2CL 0.96 1.31E-03 
AC022239.3 -1.11 1.34E-03 
AL392083.1 -0.88 1.55E-03 
EGLN1 -0.86 1.63E-03 
LINC01250 -0.92 1.69E-03 
GPR75 -1.14 1.76E-03 
FAM163B -0.96 1.77E-03 
SLC16A14 0.90 1.80E-03 
KCNJ11 1.03 1.90E-03 
PINK1-AS -0.93 1.93E-03 
PSMG3-AS1 -0.84 1.96E-03 
ADAMTS2 -0.91 2.03E-03 
AC021074.1 1.23 2.08E-03 
AL136964.1 0.91 2.13E-03 
RD3 -0.90 2.13E-03 
RIMKLA -0.84 2.14E-03 
AC022239.1 -1.21 2.36E-03 
ZNF547 -1.08 2.37E-03 
MIR34AHG 0.94 2.38E-03 
DGCR5 -0.99 2.43E-03 
SCART1 0.94 2.46E-03 
DCST2 1.15 2.53E-03 
CCBE1 -0.95 2.62E-03 
CHTF18 0.82 2.67E-03 
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KIAA1683 -0.89 2.70E-03 
AC012513.3 -1.09 2.78E-03 
CTH 0.89 2.81E-03 
TCTA -0.90 2.81E-03 
AC011498.7 -1.20 2.81E-03 
AC092198.1 -0.98 2.86E-03 
AFF1 -0.80 2.90E-03 
PGAM1 -1.00 2.92E-03 
THEGL 1.12 2.95E-03 
PCDH9 1.01 2.97E-03 
ZMIZ1 -0.78 3.00E-03 
SCARB1 -0.87 3.00E-03 
ADSSL1 0.84 3.01E-03 
ZNF395 -0.81 3.13E-03 
AL591848.4 -1.14 3.15E-03 
CEP44 0.78 3.20E-03 
RERG -0.87 3.42E-03 
NECTIN1 -0.80 3.56E-03 
PKM -0.86 3.57E-03 
MT-RNR2 0.85 3.81E-03 
RYR2 -1.16 3.86E-03 
TH -1.38 3.89E-03 
ZNF781 -0.92 3.92E-03 
ENO1 -0.84 3.94E-03 
LMO1 -1.03 3.94E-03 
FAM162A -1.05 4.04E-03 
EIPR1-IT1 -1.14 4.09E-03 
EXD3 0.98 4.14E-03 
DUSP4 0.76 4.14E-03 
ZNF596 -0.86 4.16E-03 
HIC2 -0.81 4.19E-03 
AC009533.1 0.90 4.29E-03 
HILPDA -0.78 4.43E-03 
GATA2 -0.84 4.65E-03 
SDCBP2-AS1 -0.97 4.76E-03 
TPRG1L -0.79 4.83E-03 
FAM72B 0.79 4.90E-03 
AL021068.1 1.18 4.98E-03 
PIK3IP1 -0.93 5.17E-03 
TMEM178A 1.14 5.33E-03 
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BBC3 0.86 5.45E-03 
AC105383.1 1.00 5.61E-03 
ATXN7L2 0.81 5.61E-03 
AP4S1 -0.90 5.65E-03 
CNTNAP2 1.17 5.66E-03 
AC144652.1 0.85 5.69E-03 
SLC8A3 -0.77 5.69E-03 
AP000866.1 -1.07 5.72E-03 
AL596202.1 -0.85 5.84E-03 
AC024940.1 1.01 5.84E-03 
SPATA18 0.94 6.22E-03 
ZFHX2 -0.78 6.32E-03 
Z84485.1 1.15 6.37E-03 
AC022748.2 -1.01 6.37E-03 
LINC00926 -1.15 6.53E-03 
OSGIN1 1.12 6.61E-03 
NRIP3 0.84 6.74E-03 
AC021092.1 -0.86 6.82E-03 
ATG16L2 0.79 7.21E-03 
TNIP1 -0.78 7.22E-03 
FASTKD5 -0.77 7.24E-03 
DPY19L1P1 0.96 7.33E-03 
LRRC37A3 -0.79 7.41E-03 
LMO7 0.80 7.47E-03 
ISL2 0.94 7.69E-03 
NR1D2 0.81 7.69E-03 
PWAR6 -0.84 7.70E-03 
GLS2 0.95 7.84E-03 
PGK1 -0.81 7.89E-03 
PLD1 0.83 7.99E-03 
AC017048.3 0.91 8.19E-03 
POLR3H -0.77 8.19E-03 
AP003356.1 -1.08 8.19E-03 
SLC1A2 -1.05 8.68E-03 
CHGA -0.91 8.73E-03 
CYP4V2 -0.76 8.78E-03 
PAQR5 0.82 9.11E-03 
MDH1B -0.99 9.19E-03 
AC010931.2 -0.92 9.31E-03 
PCDH10 0.86 9.46E-03 
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DNAJA1 -0.71 9.51E-03 
SAMD15 -0.96 9.59E-03 
GPR63 0.77 9.70E-03 
DDX50P1 1.01 9.75E-03 
SPTBN5 -0.87 9.75E-03 
AC006058.3 0.97 9.87E-03 
GNAS -0.81 9.87E-03 
MTFP1 -1.16 1.01E-02 
TEX261 -0.74 1.03E-02 
ITGB5 -0.73 1.04E-02 
RAB36 -0.84 1.05E-02 
GAS6-AS2 0.97 1.05E-02 
PDGFC 1.05 1.07E-02 
MYCBPAP 0.80 1.08E-02 
BCOR -0.72 1.09E-02 
ICAM5 1.11 1.09E-02 
UTP14A -0.71 1.10E-02 
AP000911.1 -0.96 1.12E-02 
AMPD3 -0.80 1.12E-02 
SLITRK5 0.81 1.16E-02 
TPI1P2 -1.10 1.16E-02 
RBM44 1.09 1.17E-02 
GRIP2 0.77 1.21E-02 
GAS6 0.71 1.21E-02 
HIST1H2BG -0.98 1.21E-02 
HOXD10 0.86 1.24E-02 
AC021945.1 1.21 1.26E-02 
AC022239.4 -1.14 1.30E-02 
ZDHHC19 0.96 1.34E-02 
AC022239.2 -0.95 1.34E-02 
KIF26B -0.82 1.35E-02 
P2RY6 -1.05 1.36E-02 
ST3GAL6-AS1 -1.02 1.36E-02 
NR1D1 0.93 1.37E-02 
GFOD1 0.86 1.39E-02 
ENDOD1 0.81 1.40E-02 
NGFR 0.79 1.40E-02 
PIH1D2 -1.09 1.43E-02 
HERC2P5 1.02 1.43E-02 
FPGT-TNNI3K 0.96 1.43E-02 
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RRP7BP 0.81 1.43E-02 
CNN2 0.71 1.43E-02 
LZTS1 -0.72 1.44E-02 
UACA 0.70 1.45E-02 
METTL22 0.71 1.46E-02 
SRSF3 -0.69 1.47E-02 
PTOV1-AS1 -1.04 1.47E-02 
POP1 -0.77 1.47E-02 
ZNF571-AS1 -0.94 1.50E-02 
CDHR1 0.83 1.51E-02 
PLOD1 -0.77 1.51E-02 
HS6ST3 1.10 1.51E-02 
SYNPO -0.69 1.51E-02 
FMN1 1.03 1.54E-02 
TRIM24 -0.69 1.54E-02 
SCN5A -0.74 1.56E-02 
SH3D21 -0.72 1.71E-02 
ANKS1B 0.99 1.72E-02 
KIF17 0.79 1.72E-02 
AF131215.5 -0.77 1.77E-02 
SLC25A35 0.76 1.79E-02 
SDAD1P1 -0.80 1.81E-02 
SPNS2 -0.96 1.81E-02 
LINC02268 -0.73 1.85E-02 
CARD9 0.70 1.90E-02 
CD9 -0.88 1.90E-02 
GRB14 0.75 1.93E-02 
RIPOR3 -0.81 1.94E-02 
LINC00632 0.74 1.95E-02 
CLYBL 0.75 1.95E-02 
NTN4 0.89 2.00E-02 
SLC4A11 0.75 2.00E-02 
SLC43A1 0.80 2.01E-02 
SEMA3D 0.99 2.02E-02 
C3orf62 -0.74 2.03E-02 
RAD52 0.70 2.04E-02 
SLC12A4 0.68 2.06E-02 
LINC00342 -0.77 2.06E-02 
ARID3A -0.77 2.10E-02 
FER1L4 -0.75 2.10E-02 
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HIST2H2BE -0.81 2.13E-02 
FUT9 0.93 2.15E-02 
EDIL3 0.92 2.15E-02 
TNNT3 -1.05 2.16E-02 
SNHG14 -0.72 2.17E-02 
FBXO8 -0.70 2.18E-02 
MTRNR2L8 0.90 2.19E-02 
PROX1 -0.68 2.19E-02 
SEMA5B -0.82 2.20E-02 
AP001160.3 -0.93 2.22E-02 
DNAJC30 -0.82 2.25E-02 
HERC3 0.72 2.26E-02 
NELL1 0.69 2.26E-02 
MAN2C1 0.66 2.33E-02 
DHRS3 0.86 2.36E-02 
ERMP1 0.69 2.36E-02 
P2RY11 -0.80 2.37E-02 
AC037459.3 -0.77 2.38E-02 
DHX9 -0.66 2.44E-02 
AC106895.2 -0.74 2.45E-02 
DOK4 -0.69 2.47E-02 
MAGEA12 -0.67 2.47E-02 
DIRC3 -1.10 2.48E-02 
ERO1B 0.71 2.53E-02 
GALNT18 -0.75 2.54E-02 
ARHGEF28 0.70 2.54E-02 
EIF4BP3 0.78 2.58E-02 
CHAC1 0.85 2.60E-02 
CCNA1 0.83 2.65E-02 
ISLR2 -0.68 2.66E-02 
ZNF789 -0.67 2.68E-02 
HSPG2 0.69 2.68E-02 
GTF2IP13 -0.69 2.71E-02 
AC044797.1 -0.98 2.72E-02 
COMMD9 -0.68 2.77E-02 
AC007996.1 -0.96 2.78E-02 
FGF11 -0.93 2.84E-02 
AC097468.1 -1.14 2.88E-02 
VPS33A -0.69 2.89E-02 
ATL1 -0.70 2.90E-02 
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TPI1 -0.76 2.95E-02 
LRP4 0.69 2.97E-02 
GLCCI1 -0.73 3.05E-02 
GPM6A 0.86 3.08E-02 
AL513534.1 -0.83 3.16E-02 
AC120114.1 0.82 3.16E-02 
SCNN1D 0.82 3.17E-02 
AP001922.6 -1.18 3.17E-02 
MSTO2P 0.69 3.19E-02 
SEMA3C 0.68 3.19E-02 
C9orf3 -0.66 3.20E-02 
BLVRB 0.78 3.22E-02 
TMEFF2 0.73 3.32E-02 
AC018521.5 -0.81 3.37E-02 
GRIA2 0.66 3.38E-02 
AC007541.1 0.93 3.38E-02 
PCDH18 0.72 3.38E-02 
LRRC75A -0.73 3.38E-02 
CMTM8 0.90 3.39E-02 
MXD3 0.78 3.39E-02 
LFNG -0.70 3.40E-02 
SOX6 -0.80 3.41E-02 
RHOB -0.79 3.48E-02 
MIRLET7BHG -0.83 3.58E-02 
RNF32 -0.96 3.59E-02 
PCK2 0.63 3.59E-02 
ZNF849P 0.90 3.63E-02 
BNIP3L -0.63 3.65E-02 
TMEM45A -0.72 3.67E-02 
CYB5A -0.74 3.68E-02 
ZNF333 0.66 3.68E-02 
FTX -0.64 3.68E-02 
ITPK1 -0.63 3.68E-02 
TNC -0.79 3.74E-02 
AC048341.2 -0.89 3.74E-02 
AC239868.2 -0.71 3.74E-02 
HIST1H1C -0.75 3.74E-02 
PDP2 0.64 3.76E-02 
ZNF75A -0.66 3.80E-02 
INHA -0.99 3.81E-02 
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ST20-AS1 -0.94 3.82E-02 
TTC39B 0.67 3.88E-02 
AP006623.1 -0.85 3.89E-02 
FBXL2 0.66 3.91E-02 
MYH15 -0.66 3.91E-02 
AC092329.4 -0.80 3.91E-02 
SHMT2 -0.65 3.92E-02 
MANF -0.70 3.95E-02 
ACSL6 0.94 3.98E-02 
HSD17B14 0.73 3.98E-02 
XKR5 0.71 4.00E-02 
AC110285.2 0.80 4.04E-02 
AL358472.2 0.80 4.04E-02 
PPIF -0.64 4.10E-02 
CAMK2A -0.84 4.10E-02 
PGBD2 -0.74 4.14E-02 
ID3 0.79 4.15E-02 
TBX2 0.64 4.17E-02 
KCTD19 0.71 4.18E-02 
PLK2 0.87 4.18E-02 
AC131212.2 0.95 4.22E-02 
EML6 0.73 4.23E-02 
SARDH 0.71 4.23E-02 
ERVMER34-1 0.81 4.25E-02 
PIDD1 0.69 4.33E-02 
HMX2 0.99 4.36E-02 
AC004893.2 -0.73 4.36E-02 
ZEB1-AS1 0.66 4.37E-02 
IRF6 -0.89 4.37E-02 
AC006538.1 -0.90 4.38E-02 
GNRHR2 0.80 4.40E-02 
MALAT1 0.60 4.40E-02 
AL365199.1 -0.88 4.41E-02 
MT-CYB -0.60 4.44E-02 
AC099778.1 -0.91 4.47E-02 
FAM86B3P 0.67 4.47E-02 
HES7 0.86 4.50E-02 
ARID3B -0.63 4.54E-02 
VWA5B2 0.81 4.56E-02 
RIPK1 -0.64 4.56E-02 
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ERBB4 0.68 4.62E-02 
PPP1R26-AS1 -0.97 4.62E-02 
MAGED1 -0.65 4.65E-02 
ADORA2B -0.88 4.68E-02 
MOCS3 -0.66 4.75E-02 
DDX60L 0.67 4.85E-02 
SOX7 -0.75 4.87E-02 
SPECC1L -0.66 4.93E-02 
IPO5P1 -0.72 4.93E-02 





Supplemental File 3: Chapter 4 differentially expressed genes from rotenone treated 
SH-5YSY α-Synuclein knockdown cells. 
 
Genename logFC FDR 
CABP7 -1.64 1.40E-08 
TFAMP1 -1.99 1.97E-08 
NDUFA4L2 -1.65 3.08E-08 
C20orf166-AS1 -1.69 7.84E-08 
AC104129.1 -2.22 9.97E-08 
AC135782.1 -2.36 3.05E-07 
AC138028.2 -1.89 8.47E-07 
CARTPT -1.89 2.14E-06 
TNNI2 -2.02 2.96E-06 
CFAP43 -1.55 3.69E-06 
STC1 -3.71 5.00E-06 
CXCR4 -1.86 6.94E-06 
AL136529.1 -1.72 1.07E-05 
AC138028.1 -1.91 1.10E-05 
CA9 -2.57 1.10E-05 
HIST1H1D -3.32 1.36E-05 
MT-TQ 1.35 4.19E-05 
NEDD9 -1.75 5.25E-05 
DARS-AS1 -2.19 5.25E-05 
GPER1 -1.91 5.85E-05 
AC134312.4 -1.38 6.00E-05 
KCNQ1OT1 -2.23 6.00E-05 
CDKN1C -1.28 6.55E-05 
TBX1 -2.42 1.41E-04 
PDE4C -1.22 1.81E-04 
C20orf24 1.40 1.87E-04 
CA12 -1.84 1.93E-04 
AC134312.1 -1.45 2.63E-04 
GRIK3 -2.28 2.63E-04 
CLCNKA -1.22 3.00E-04 
AC074389.2 -1.86 3.00E-04 
BHLHE40 -1.20 4.30E-04 
TSPEAR-AS1 -1.35 7.41E-04 
MT-TA 1.43 1.08E-03 
CARMN -1.56 1.08E-03 
PIEZO1 -1.13 1.20E-03 
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RSPO1 -1.81 1.28E-03 
NTNG2 -1.21 1.30E-03 
MCHR1 -1.63 1.30E-03 
SNORD69 -2.82 1.31E-03 
NXPH4 -1.33 1.57E-03 
AC022239.3 -1.24 1.65E-03 
CU639417.2 -1.22 1.75E-03 
AP001065.3 -1.59 1.86E-03 
GATA5 -2.85 1.86E-03 
TSPEAR-AS2 -1.32 1.91E-03 
AQP1 -1.12 1.97E-03 
ARHGAP45 -1.37 2.42E-03 
HNF1A -1.79 2.45E-03 
COL23A1 -1.13 2.72E-03 
OLFM1 -1.07 2.99E-03 
AC025279.1 -3.35 2.99E-03 
CDH23 -1.13 3.24E-03 
CEP295NL -2.22 3.65E-03 
PCBP2-OT1 -2.73 3.99E-03 
CABP1 -1.48 5.07E-03 
AL591845.1 -1.08 5.39E-03 
NRP1 -1.27 5.62E-03 
AQP10 -1.35 5.62E-03 
AL109615.3 -1.32 5.66E-03 
TMEM105 -1.37 5.66E-03 
AC008895.1 -2.92 5.66E-03 
ANGPTL4 -1.23 5.75E-03 
IGF2 -0.95 6.29E-03 
AC006042.3 -1.51 6.29E-03 
ACTL8 -1.86 6.29E-03 
CDRT4 -1.67 6.40E-03 
FER1L4 -0.92 6.65E-03 
TLX1 -1.48 6.65E-03 
CAPN8 -1.52 6.86E-03 
NDRG1 -0.96 6.97E-03 
HIST1H2AC -1.05 6.97E-03 
AC004584.3 -2.46 7.39E-03 
FAM43A -1.20 8.07E-03 
ZNF460 -1.39 8.45E-03 
SOX9 -0.96 8.53E-03 
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FOSB -2.13 8.89E-03 
VEGFA -0.99 9.06E-03 
AC138028.5 -1.67 9.43E-03 
N4BP3 -1.02 9.52E-03 
SYT8 -1.32 9.80E-03 
HEY1 -0.94 9.82E-03 
HIST2H2BE -1.14 1.09E-02 
AC007663.1 -1.61 1.11E-02 
AP006284.1 -1.31 1.21E-02 
CROCC2 -2.00 1.22E-02 
SRXN1 2.68 1.31E-02 
PPP1R3C -1.05 1.35E-02 
AC013472.3 -2.53 1.35E-02 
WNT11 -1.98 1.37E-02 
HSPB7 -1.03 1.39E-02 
C2CD4B -1.32 1.68E-02 
SLC18A1 -1.04 1.73E-02 
CU459211.1 -1.96 1.75E-02 
SNURF -2.49 1.78E-02 
HIST1H1E -2.35 1.95E-02 
C6orf99 1.69 1.98E-02 
LOXL2 -0.84 1.99E-02 
MIR616 -1.87 2.12E-02 
TMEM51-AS1 -1.20 2.21E-02 
ADORA2A -0.94 2.23E-02 
AC124283.3 -2.06 2.28E-02 
STARD13 -0.90 2.30E-02 
RSPH9 -1.30 2.44E-02 
SH3D21 -0.83 2.46E-02 
HMCN2 -0.87 2.69E-02 
AP001065.1 -0.97 2.97E-02 
PDZD7 -0.87 3.00E-02 
ZMAT4 -0.96 3.00E-02 
ANGPTL6 -1.69 3.03E-02 
CBLN1 0.92 3.16E-02 
AL138724.1 2.40 3.21E-02 
CARD11 -2.25 3.34E-02 
SOBP -1.07 3.60E-02 
FAM129A 0.84 3.65E-02 
FAM86EP 1.16 3.94E-02 
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HIST1H2BG -1.04 3.99E-02 
TMEFF1 1.09 4.11E-02 
SOSTDC1 1.71 4.39E-02 
AC007336.1 -1.52 4.39E-02 
AC019257.1 -1.93 4.39E-02 
AC013394.1 -2.23 4.39E-02 
AC092447.7 -1.21 4.47E-02 
MT-TS1 1.35 4.53E-02 
DIO3 -0.91 4.57E-02 
TCERG1L -2.26 4.60E-02 
C1QTNF12 -1.56 4.60E-02 





Supplemental File 4: Chapter 5 differentially expressed genes from rotenone treated 
SH-5YSY. 
 
Genename logFC FDR 
RSPO1 3.70 3.0E-20 
TFAMP1 2.07 1.4E-18 
CDKN1C 1.55 9.9E-16 
ELFN1 1.63 2.7E-15 
AC104129.1 3.13 1.1E-14 
TMEM51-AS1 1.54 7.9E-14 
AC134312.1 1.63 9.2E-14 
BHLHE40 1.72 1.6E-13 
AC134312.4 1.62 7.5E-13 
TRIM29 1.88 9.0E-13 
C20orf166-AS1 1.61 1.7E-12 
NEDD9 2.26 1.0E-11 
AL136529.1 2.16 7.1E-11 
AC010931.2 1.61 1.3E-10 
IGF2 1.24 1.3E-10 
CXCR4 1.63 4.8E-10 
HSPB7 1.26 5.0E-10 
VEGFA 1.04 2.0E-08 
ECEL1 1.14 5.7E-08 
DUSP7 1.19 1.2E-07 
GABRP 1.80 1.3E-07 
RTL1 0.95 1.3E-07 
ISLR2 1.08 9.6E-07 
AC138028.2 1.58 1.2E-06 
HTR1E 1.29 1.4E-06 
ASS1 1.92 1.4E-06 
KIAA1614 1.09 2.1E-06 
AP001065.1 1.10 2.4E-06 
IL6 3.95 3.0E-06 
RUNX1 1.37 3.5E-06 
NTNG2 1.07 3.7E-06 
SOBP 0.98 1.2E-05 
TSPEAR-AS1 0.99 2.5E-05 
CA12 2.36 2.9E-05 
PRSS56 2.13 2.9E-05 
AC002480.2 4.63 6.4E-05 
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TSPEAR-AS2 0.95 7.1E-05 
NPY 0.92 7.8E-05 
OLFM1 0.84 8.6E-05 
CFAP43 1.09 9.4E-05 
NDUFA4L2 0.95 9.4E-05 
COL17A1 3.84 1.1E-04 
LINC00304 2.02 1.4E-04 
AQP1 0.80 1.5E-04 
SNCA -0.84 1.5E-04 
ISLR 1.47 2.0E-04 
SSUH2 1.04 2.3E-04 
RET 0.74 3.2E-04 
HEY1 0.82 3.3E-04 
CYB561 0.88 3.7E-04 
IGF2-AS 1.30 7.3E-04 
AL136964.1 -1.02 8.6E-04 
AP001065.3 2.39 1.0E-03 
GDF10 1.06 1.0E-03 
NCAM2 -1.13 1.1E-03 
AL365199.1 1.25 1.1E-03 
CARTPT 1.58 1.1E-03 
CAPN8 2.67 1.2E-03 
AC027228.2 1.22 1.4E-03 
TFPI2 0.79 1.4E-03 
MYO15B -1.31 1.4E-03 
AL138963.3 1.75 1.4E-03 
ALDH8A1 3.59 1.5E-03 
SLC2A1 0.73 1.5E-03 
NXPH4 1.41 1.6E-03 
ID2 1.11 1.6E-03 
CRH 3.00 1.9E-03 
HS3ST2 1.50 1.9E-03 
DIO3 1.08 2.2E-03 
TBX4 -1.28 2.2E-03 
NNAT 0.88 2.3E-03 
PRCD 0.77 2.9E-03 
MALAT1 -0.66 2.9E-03 
DIRAS2 -1.08 2.9E-03 
HS6ST3 -1.35 2.9E-03 
AC053503.5 -1.53 2.9E-03 
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LINC01679 1.26 2.9E-03 
PTGIR 0.87 3.4E-03 
TMEM51 0.81 3.6E-03 
LINC00473 0.81 3.9E-03 
TEX261 0.78 3.9E-03 
GADD45G 0.97 4.0E-03 
MIR186 -1.58 4.1E-03 
AC092198.1 0.96 4.3E-03 
AL390961.2 -1.18 4.5E-03 
AC090897.1 1.04 5.0E-03 
ANO9 -0.74 5.1E-03 
CERK 0.68 5.2E-03 
ERBB4 -0.82 5.3E-03 
KCNQ1OT1 0.76 5.6E-03 
AC107214.2 2.04 6.2E-03 
NDRG1 0.66 6.2E-03 
PGAM1 0.84 6.5E-03 
AQP10 1.57 6.6E-03 
SLC18A1 0.71 6.9E-03 
FAM163B 0.68 6.9E-03 
DOK3 1.10 7.2E-03 
AL513477.1 1.14 7.9E-03 
GATA2-AS1 0.93 8.0E-03 
LDHA 0.78 8.2E-03 
MYOM2 2.37 8.4E-03 
SLC12A3 2.34 8.4E-03 
AC022748.1 1.71 8.4E-03 
GAL 0.85 8.4E-03 
SLC22A18 -0.88 8.4E-03 
PPP1R32 -1.07 8.5E-03 
CCDC81 -1.39 9.5E-03 
NCOA5 0.71 9.7E-03 
AL138724.1 2.77 9.7E-03 
PPM1J -1.44 1.0E-02 
QRICH2 1.00 1.1E-02 
TMEM158 1.40 1.1E-02 
C20orf24 0.90 1.1E-02 
AC138028.5 2.93 1.1E-02 
TLX1 1.28 1.1E-02 
PFKFB3 0.66 1.1E-02 
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AL109615.3 1.55 1.2E-02 
AL161729.1 1.13 1.2E-02 
RGS4 0.62 1.2E-02 
CABP7 0.63 1.2E-02 
AC008443.4 -1.91 1.2E-02 
CYP4V2 0.66 1.2E-02 
SNX30 -0.67 1.2E-02 
LMO7 -0.76 1.2E-02 
AC245060.5 -1.02 1.3E-02 
APLN 0.95 1.3E-02 
ADAM12 0.66 1.4E-02 
AC087276.2 -1.65 1.4E-02 
AC091230.1 2.92 1.4E-02 
LYPD3 -1.59 1.4E-02 
FAM167A 0.62 1.5E-02 
ZNF596 0.75 1.6E-02 
GPER1 1.88 1.6E-02 
PTK6 1.58 1.6E-02 
C17orf97 1.20 1.6E-02 
TMEM200B -1.43 1.6E-02 
SCRG1 -1.65 1.6E-02 
DNM1P47 2.06 1.7E-02 
AC010680.2 1.12 1.7E-02 
CEP44 -0.85 1.7E-02 
NTNG1 -1.12 1.7E-02 
FSTL5 -0.77 1.7E-02 
CARMN 1.31 1.7E-02 
CCND1 0.70 1.7E-02 
THBS1 1.75 1.8E-02 
LINC01547 1.07 1.8E-02 
TBX2-AS1 -0.70 1.8E-02 
CDR1 1.24 1.9E-02 
HSPA5 0.84 1.9E-02 
LINC02348 1.28 2.0E-02 
RPL13AP5 -0.60 2.0E-02 
AC024361.1 -1.47 2.0E-02 
HSPA9P1 1.45 2.1E-02 
LIMA1 0.61 2.1E-02 
DDX60 -1.92 2.1E-02 
AC092139.4 2.85 2.1E-02 
289 
 
FGFR3 -0.91 2.2E-02 
TNFRSF19 0.96 2.2E-02 
ITGB5 0.62 2.5E-02 
AC138028.1 1.60 2.5E-02 
ALS2CL -0.78 2.5E-02 
AL354836.1 1.43 2.7E-02 
DIO3OS 0.86 2.9E-02 
CAVIN1 -2.04 3.0E-02 
AC010809.1 2.16 3.0E-02 
ADM 0.82 3.0E-02 
C14orf144 0.79 3.0E-02 
CFAP44 0.64 3.1E-02 
STEAP2 -0.62 3.1E-02 
AVEN 0.84 3.2E-02 
SCNN1D -0.74 3.2E-02 
GLUD1P2 -0.98 3.2E-02 
AL021368.2 -1.07 3.2E-02 
GRIA2 -0.65 3.2E-02 
BBS5 -0.76 3.3E-02 
FLRT1 0.69 3.6E-02 
AC074389.2 1.83 3.6E-02 
EGLN3 0.80 3.7E-02 
PDZK1 0.80 3.7E-02 
TRIM7 -1.21 3.7E-02 
NOXA1 -1.33 3.7E-02 
VWDE -0.64 3.9E-02 
SNCA-AS1 -1.62 3.9E-02 
FBXO6 -1.23 4.1E-02 
AC008280.3 -1.88 4.3E-02 
HSPA8P5 1.79 4.3E-02 
P2RY1 -1.11 4.7E-02 
ACVR1C -1.40 4.8E-02 






APPENDIX CHAPTER ONE:  
Manganese-induced Parkinsonism in mice is reduced using a novel contaminated 
water sediment exposure model5 
Abstract 
Heavy metals enter the aquatic environment and accumulate within water sediments, but 
these metal-sediment interactions remain to be explored within toxicity studies. We 
developed an exposure model in mice that encapsulates the aquatic microenvironment of 
metals before exposure. Male and female C57/BL6 mice were exposed via their drinking 
water to manganese contaminated sediment (Sed_Mn) or to manganese without sediment 
interaction (Mn) for six weeks. Sediment interaction did not alter weekly manganese 
ingestion from water in males or females. We analyzed motor impairment, a common 
feature in manganese-induced Parkinsonism, using the beam traversal, cylinder, and 
accelerating rotarod tests. Sed_Mn mice performed better overall compared to Mn mice 
and males were more sensitive to manganese than females in both Sed_Mn and Mn 
treatment groups. Our study indicates that metal-sediment interactions may alter metal 
toxicity in mammals and introduces a new exposure model to test the toxicity of metal 




5 This data has been accepted for publication in Environmental Toxicology and Pharmacology on March 





Heavy metal contamination of drinking water poses a significant public health risk 
across the globe (EPA 2015). Exposure to heavy metals such as lead, arsenic, and 
manganese are associated with increased risks of various cancers, declined cognitive 
ability, and altered thyroid function (EPA 2015). The World Health Organization (WHO) 
has sought to mitigate health effects resulting from excess metal exposure via drinking 
water by setting global maximum contaminant levels (MCLs) (WHO 2011). Unfortunately, 
due to the challenges associated with climate change, aging infrastructures, and the lack 
of a comprehensive removal technique, many populations are exposed to levels of metals 
much higher than WHO guidelines (Chowdhury 2016). 
Toxicology studies regularly use mouse models to gain mechanistic insights into 
heavy metal exposure and chronic illnesses. These studies model exposures by using 
invasive techniques such as oral gavage or by repeatedly dosing large concentrations of 
heavy metal salts directly into the water supply. A limitation of this method is the omission 
of complex metal-sediment interactions within water systems that may alter metal toxicity. 
Heavy metals accumulate within sediments and concentrations can exceed those in the 
water by three to five orders of magnitude (Bryan & Langston 1992). Metals can be 
transformed within these sediments into compounds with altered bioavailability and 
behavior (Nicolau 2006). While metal speciation and bioavailability in water is well 
understood; it remains challenging to study these reactions within complex 
microenvironments such as sediments (Bryan & Langston 1992, Islam 2015). The goal of 
this study was to develop an in-vivo exposure model that includes the effects of metal-
sediment interactions to test the toxicity of heavy metals in water. 
To our goal, we used manganese, a common water contaminant with well-studied 
toxic effects in animal studies. Manganese toxicity is associated with neurological 
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dysfunction and manganese-induced Parkinsonism, a neurodegenerative disorder with 
clinical similarities to Parkinson’s disease (Chartlet 2012, Guilarte & Gonzales 2015, 
O’Neal & Zhang 2015, Bouabid 2016, Sarkar 2018). Excess manganese exposures in 
animals have been shown to disrupt mitochondrial function, induce neuroinflammation, 
obstruct neurotransmission, and damage the basal ganglia of the midbrain (Guilarte & 
Gonzales 2015, Bouabid 2016, Sarkar 2018). Extensive neuronal death and tissue 
damage in the midbrain impairs motor function control and can be reliably measured in 
animals using various motor behavioral tests (Brooks & Dunnett 2009). Despite a robust 
animal phenotype, there is a lack of human data on the risks of Parkinson’s disease from 
the ingestion of manganese from drinking water (Chartlet 2012). Therefore, further 
understanding of the mechanisms occurring in the brain following manganese ingestion is 
needed. A recent study in plants observed reduced toxicity of manganese in water with 
the presence of silicates in the soil by reducing uptake into the cytoplasm (Blamey 2018). 
We hypothesized a similar mechanism may occur in mammalian systems. We exposed 
wild-type C57/BL6 mice to manganese contaminated drinking water for six weeks by either 
putting manganese directly into the water (see methods- Mn) or by first incubating water 
with manganese contaminated sediment (see methods- Sed_Mn). The effects of different 
treatments on Parkinsonism in mice were determined by measuring altered motor function 
in three behavioral tests: the beam traversal test, the cylinder test, and the rotarod test. 
The aims of this study were (1) to determine if mice could be exposed to metals via 
contaminated sediment (2) to determine if incubating water with contaminated sediment 
changes the behavioral phenotype over time (3) to determine if there were sex dependent 
effects. Herein we report our mice exposed to manganese contaminated sediment 
produced a Parkinsonian phenotype in males but not females. We observed altered 
manganese toxicity in both males and females exposed to manganese contaminated 
sediment despite having been exposed to the same amount of total manganese (mg) as 
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mice given manganese directly in water (Mn). We observed a trend of increased sensitivity 
of males to manganese treatment in both manganese treated groups (Sed_Mn and Mn) 
in 9at least two behavioral tests.  
2. Methods  
2.1 Chemicals and Manganese Water Preparation: 
Ottawa Sand from Restek (Bellefont, PA) was purchased as the sediment. The 
sediment control contained 1 kg of sand per 2L of Nestle Pure Life water in an autoclaved 
glass bottle. The contaminated sediment was spiked with manganese chloride (Sigma, St. 
Louis, MO) at 1 g MnCl2·4H2O per 1 kg of sediment. The concentration of manganese in 
sediment was selected based on our previous work analyzing heavy metal contamination 
of Baltimore harbor sediments using inductively coupled plasma mass spectrometry (ICP-
MS) (Graham 2009; Wadhawan 2013). Water and spiked sediment were incubated out of 
light at room temperature two weeks before treatment began. The water was filtered from 
the sediment every three days before being given to the mice. The pH of the filtered water 
was monitored during the study and remained between 6-7 which is suitable for 
groundwater. The manganese chloride water solution was prepared fresh every three 
days at a concentration of 0.5 g/L. 
2.2 Animals and Treatment: 
Forty wild-type male and female C57/BL6 mice ages 8-10 weeks were purchased 
from Jackson Laboratory (Bar Harbor, ME). Mice were housed 5 mice per cage on a 14-
10 hour light-dark cycle in a AAALAC accredited facility. Mice were given food and water 
ad libitum. Food with the minimum required manganese content was purchased from 
Research Diets Inc. (New Brunswick, NJ). Mice were held for 10 days to acclimate before 
treatment. All procedures involving animals were performed under the guidance of the 
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National Research Council’s Guide for the Care of Laboratory Animals (NRC 2010) and 
approved by the Johns Hopkins University Animal Care and Use Committee. Mice were 
exposed via their drinking water for six weeks. Treatment groups included water incubated 
with manganese contaminated sediment (Sed_Mn) and water contaminated with 
manganese with no sediment (Mn). They were given freshly prepared water every three 
days. Food and water intake were recorded bi-weekly. Body weights were recorded 
weekly.  
2.3 Manganese Detection Assay and Estimated Daily Exposure: 
Water filtered from the manganese sediment reaction was collected at the 
beginning and the end of the study and stored at -20°C. The detection of manganese in 
water sediment samples was completed using the sodium periodate oxidation method with 
instructions and reagents provided by the manganese test kit model MN-5 purchased from 
HACH (Loveland, CO). A standard curve was generated using three freshly prepared 
manganese standards at 100, 500, and 1000 mg/L. Three technical replicates for each 
standard and sample were measured by UV Vis absorbance at 525 nm in a 96 well clear 
bottom plate. The estimated daily exposure of manganese contaminated sediment water 
was calculated using the average concentration of the two unknown samples and the 
weekly water intake rate of each cage divided by the average body weight (kg) of each 
cage. 
2.4 Behavioral Tests: 
Rotarod Test 
The accelerating rotarod test was used to assess motor coordination on the first 
and last day of treatment. The automated accelerating rotarod from Harvard Apparatus 
(Cambridge, MA) was generously loaned to us by the Jiou Wang laboratory at Johns 
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Hopkins Bloomberg School of Public Health. Each mouse was trained one day prior to 
testing for both timepoints and given as many trials as needed to successfully balance on 
the moving rotarod for three runs with one minute of rest between runs. On test days, the 
mice were given three trials on the rotarod accelerating linearly from 4 rpm to 40 rpm for 
a maximum of five minutes. The latency to fall (seconds) was recorded for each mouse.  
Cylinder Test 
The cylinder test was used to assess balance and exploratory rearing behavior 
every two weeks. Mice were placed in a clear glass cylinder (diameter = 10 cm) under 
minimal light at the end of their dark cycle for a total of two minutes. Rears were defined 
as the lifting of one or both forelimbs above shoulder level and contacting the wall of the 
glass cylinder (Cannon 2009). The mouse must bring all forelimbs back to the ground 
before another rear was counted. Rears were counted by the handler at the time of testing 
and by a blind observer using a video recording of each test.  
Beam Traversal Test 
The beam test was used to assess balance and motor coordination every week. 
Mice were placed on the far end of a wooden rod (diameter = 1.6 cm) approximately 60 
cm from a dark cardboard box containing the home cage bedding. In the first week before 
exposure, mice were trained one day prior to testing for baseline abilities. Training 
consisted of acclimating the mouse to the box and giving the mouse as many trials as 
necessary until it was consistently moving forward across the beam into the box. On 
testing days, if a mouse turned around on the beam or fell off the beam then that trial 
would be discarded. The mouse was video recorded, and the time for the mouse to cross 




One-way analysis of variance (ANOVA) was used to analyze differences in 
behavior between the four mouse treatment groups within each time period for both males 
and females. Two-way ANOVA was conducted to analyze the effect of time and sediment 
incubation on behavioral phenotypes expressed as the fold change compared to the water 
(Ctrl) or sediment water control (Sed). Post hoc analysis was performed with both one-
way and two-way ANOVA using the Tukey Honest Significance Difference test. The 
Student’s t-test was used to compare sex dependent effects on behavioral phenotypes 
expressed as the fold change compared to the water (Ctrl) or sediment water control 
(Sed). Post hoc Bonferroni correction was used for significance of the Student’s t-test. For 
all analyses, p<0.05 was considered significant.  
3. Results 
3.1 Manganese exposure does not alter food/water intake or weight. 
Food and water intake were monitored during the 10-day acclimation period and 
bi-weekly during the six weeks of exposure. The amount of food and water consumed by 
male and female mice remain unchanged during the study regardless of treatment group 
(Figure 1). Intriguingly, the control female cage had a significantly higher water intake rate 
compared to the other female cages that began before treatment and continued 
throughout the study (Figure 1d). We do not believe reduced water intake in the other 
cages was due to manganese exposure. The weight of each mouse was recorded weekly. 
No mouse lost more than 20% of their body weight during the exposure period and the 
change in weight of each mouse was not different among treatment groups (Figure 2). 
Overall male mice gained an average of 0.8 g over the six-week period while female mice 
gained 1.47 g (p≤0.01, Student’s t-test). 
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3.2 Manganese sediment interaction does not alter total manganese in drinking 
water and males consume more total manganese than females. 
The effect of sediment incubation on manganese content was determined from 
filtered water collected at the beginning and end of the six-week exposure period. The 
abundance of manganese in the water was 446 and 473 mg/L, respectively. There was 
no significant difference in the total amount of manganese consumed from water by the 
manganese water (Mn) and the manganese sediment (Sed_Mn) cage for males or 
females (Figure 3a). However, female treatment groups (Mn and Sed_Mn) did consume 
less total manganese than males. We used the average body weight for each group to 
determine if the estimated daily exposure (mg/kg*day) was significantly different for males 
and females. Male Sed_Mn treated mice had a lower estimated daily exposure than 
female Sed_Mn treated mice (54 mg/kg*day and 62 mg/kg*day, respectively). Mice 
treated with manganese directly in the water received the same estimated daily dose of 
approximately 61 mg/kg*day regardless of sex (Figure 3b). 
3.3 Sediment interaction reduces the effect of manganese on beam test 
performance in males. 
We examined the effect of sediment interaction on the development of 
Parkinsonism by using the beam traversal test to examine motor coordination and balance 
weekly during the six weeks of exposure. We recorded the average time over three trials 
for each mouse to cross the beam to the box containing the home cage bedding. No 
significant changes were detected in males or females until week six of exposure (Figure 
4). At week six, only males exposed to manganese directly in water (Mn) took longer to 
cross the beam than the control mice (Figure 4a). The effect of both length of exposure 
and manganese sediment interaction on beam test performance was observed in males. 
Manganese sediment interaction significantly reduced the time to cross the beam in week 
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four and six of exposure (Figure 4b) (two-way ANOVA, p≤0.05). The exposure time 
between week four and week six did not significantly increase the observed effect of 
sediment interaction. Neither female treatment group had reduced performance on the 
beam test during the study and there was no observed effect of sediment incubation on 
the average time to cross the beam (Figure 4c, 4d). Therefore, our results indicate a 
possible gender-dependent behavioral phenotype in response to manganese. 
3.4 Sediment interaction reduces the effect of manganese on cylinder test 
performance in males and females. 
We examined rearing behavior every other week using the cylinder test. Rearing 
describes the lifting of the forelimbs onto the walls of the glass cylinder and allows us to 
analyze motor coordination using natural exploratory behavior without prior training. We 
observed a decrease in rearing behavior in male and female Mn groups at week four and 
six (Figure 5a, 5c). We observed a decrease in rearing behavior in only male Sed_Mn 
mice after six weeks (Figure 5a). The effect of both length of exposure and manganese 
sediment interaction on rearing behavior was observed. Manganese sediment interaction 
significantly reduced the number of rears counted in males and females at week four and 
six (Figure 5b, 5d) (two-way ANOVA, p≤0.05). The length of exposure had a significant 
effect on the rearing behavior in males indicating an increased effect of sediment 
interaction with time (two-way ANOVA, p<0.01). This was not observed in females. 
3.5 Sediment interaction reduces the effect of manganese on rotarod test 
performance in males and females. 
We examined balance and motor coordination at the end of the study using the 
accelerating rotarod test. This test measures the amount of time a mouse can balance on 
a rotating rod and is one of the most common tests used to quantify neurological deficits 
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in rodents (Brooks & Dunnett 2009). We observed a decrease in time on the rotarod in the 
male Mn mice when compared to the control mice (ANOVA, p<0.05) and a slight decrease 
in male Sed_Mn mice (NS, ANOVA, p=0.065) (Figure 6a). Manganese treatment did not 
significantly decrease the time on the rotarod in females (Figure 6c). Manganese sediment 
interaction reduced the fold change in time on the rotarod in both males and females but 
was only significant in females (Student’s t-test, p<0.05) (Figure 6b, 6d).  
3.6 Males performed worse than females in at least one of the three behavioral tests 
in both manganese treated groups. 
We observed differences in behavioral outcomes for males and females exposed 
to manganese during the study. We analyzed motor deficits at week six using the fold 
change in performance compared to the treatment group’s respective controls (Mn/Ctrl; 
Sed_Mn/Sed) (Figure 7). In the beam test, males took a significantly longer time to cross 
the beam than females in the Mn exposure group (Student’s t-test, p<0.05). However, in 
the Sed_Mn exposure group, males and females performed the same and were not 
different than controls. In the cylinder test, males had reduced rearing behavior than 
females exposed to manganese in both groups (Student’s t-test, corrected p<0.05). In the 
rotarod test, males spent slightly less time on the rotarod than females in both exposure 
groups, but these were not found to be significant. Significance was reported with raw 
non-adjusted p-values for each of these hypothesis tests. Discussion 
In this study we used manganese to test our proposed exposure model because 
of its well-studied mechanisms in the brain and its reproducible motor phenotype in mice. 
We chose a commercial sediment for this pilot test to avoid convoluting the end behavioral 
outcome. The commercial sediment was made predominately of silica which is a major 
constituent of watershed and marine sediments. Manganese is known to leach to minerals 
such as silicates in the watershed and mineral content in water sediments has been of 
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interest to study increased risks of neurodegeneration (Choi 2006; Chartlet 2012). The 
sediment used in this model was sterile and had a consistent pH but potential changes in 
these factors on metal toxicity will still need to be studied in the future by using more 
complex sediments in the exposure model. 
We selected an environmentally relevant sediment concentration of manganese of 
1000 mg/kg sediment based on our previous work in the Baltimore City harbor (Graham 
2009; Wadhawan 2013) and expected 0.5g/L as the maximum concentration of total 
manganese in the water after incubation. This concentration was also used for the Mn 
treatment group in which manganese water was prepared fresh every three days. We 
predicted that 0.5 g/L would be sufficient for this model based on another study that used 
the same dose in the drinking water of C57/BL6 males and found significant deposition of 
manganese in the brain and a measurable motor phenotype (Krishna 2014). The 
concentration was not expected to be lethal given numerous studies using concentrations 
≥ 1g/L to study neurotoxic effects in rodents (Chandra 1981; Anderson 2008; Avila 2008; 
Alsulimani 2015). We closely monitored food intake and weight during the study to verify 
that behavioral changes were due to neurotoxic mechanisms and not acute systemic 
failure. We observed no significant reductions in food intake or weight among mice in the 
study (Figure 1 and 2).  
It was unclear whether water incubation with sediment would affect the taste of the 
water and alter the mouse rate of ingestion. We recorded weekly water intake and found 
that mouse drinking behavior was not significantly altered from the pre-exposure 
acclimation period suggesting that mice did not seem to experience any taste aversions 
(Figure 1). We used the sodium periodate oxidation method and UV absorbance to detect 
total manganese content in water after filtration of contaminated sediment. The average 
total manganese was 0.46 g/L indicating that manganese was not simply degraded or 
301 
 
being filtered out of the drinking water. We used the manganese concentration and water 
intake to compare manganese ingestion between treatment groups. We found no 
differences in the amount of manganese consumed weekly within male or female 
manganese treated mice (Figure 3). To determine if males and females received a similar 
dose of manganese we calculated the estimated daily exposure using the weekly 
manganese ingested divided by number of mice per group (n=5) and the average weight 
per group. We did not observe any change in the estimated daily exposure between male 
and female Mn treatment but did observe a reduction in the daily exposure of Sed_Mn 
males compared to Sed_Mn females (Figure 3). 
We successfully exposed mice to manganese via contaminated sediment and 
produced a Parkinsonian phenotype in males as early as four weeks of exposure. Male 
Sed_Mn mice performed significantly worse than male controls in the cylinder test and the 
rotarod test. They performed better than male mice treated with Mn directly in water in all 
three tests after six weeks of exposure despite having the same total amount of Mn in the 
drinking water. The female Sed_Mn group did not develop a phenotype after six weeks of 
exposure. However, female Mn mice only performed worse than controls in one test 
suggesting a possible resistance of females to manganese treatment. This is supported 
by the literature in which multiple studies have reported an increased sensitivity of males 
compared to females possibly due to estrogen inhibition of the NFKB inflammatory 
pathway involved in neurodegeneration (Moreno 2011; Gillies 2014).  
We hypothesized that metal-sediment interactions may alter metal toxicity from 
ingestion of drinking water by changing metal behavior. Manganese bioavailability and 
uptake across physiological membranes depends heavily on its oxidation state. 
Manganese speciation can also alter metal behavior in intracellular fluids. Intracellular 
divalent cations including Mn2+, the most common free cytosolic manganese species, can 
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interact with proteins and effect the function of metabolic enzymes. Divalent manganese 
may also complex with amyloid fibrils, prion proteins, and Lewy body inclusion bodies that 
are highly prevalent in neurodegenerative diseases including Parkinson’s disease (Choi 
2006; Chartlet 2012). These complexes are associated with the observed perturbation of 
intracellular degradation systems such as the ubiquitin-proteasome complex but whether 
divalent metal ion complexes cause or are an effect of misregulated protein 
oligomerization remains uncertain.  
Current animal studies analyzing heavy metal toxicity do not consider the 
microenvironment of the metals in the aquatic environment or the complex interactions 
that occur within sediments. Our study provides an in-vivo model to expose mice to water 
contaminants that simulates sediment interactions. We supported our hypothesis that 
sediment interactions alter metal toxicity in mammals. Future studies should include more 
complex sediments including those with microorganisms that can metabolize metals and 
affect metal behavior in water. Additionally, phenotypic tests may be altered and should 
be selected based on predicted metal contaminants and their target organ systems. Heavy 
metal contamination of drinking water is a global public health issue and mechanistic 
insights into the effects of metal contaminants is needed for the protection of human 
health. Our exposure model can be used to improve toxicity testing on single metal 
contaminants and metal mixtures that are present in water systems.  
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Figure 1. Weekly food and water intake changes in response to manganese 
exposure. 
A-B) Male weekly food and water intake rate by cage from week 0 (pre-exposure) to week 
6.  C-D) Female weekly food and water intake rate by cage from week 0 (pre-exposure) 







Figure 2. Mouse weight change after six weeks of manganese exposure.  
A-B) Male and female total change in weight at week 6 from week 0 (pre-exposure). Red 




Figure 3. Weekly manganese intake and estimated daily dose did not change 
between treatment groups. 
A) Weekly manganese intake (mg) of female and male mice exposed to sediment 
manganese water (Sed_Mn) versus manganese water (Mn). Red bar indicates mean 
(n=6 weeks). There was no difference in the total manganese consumed from water 
between Sed_Mn and Mn treatment groups (ANOVA, p>0.05, not significant NS). Male 
treatment groups consumed higher amounts of manganese than female groups 
(ANOVA, p<0.01, **). 
B) The estimated daily exposure dose for all groups. Males exposed to sediment water 
(Sed_Mn) had a lower daily exposure than females (ANOVA, p<0.01, **). Males and 
females exposed to manganese directly in water (Mn) both had an estimated daily 







Figure 4. Examination of the average time to complete the beam traversal test 
between manganese treatment groups at week 4 and week 6 revealed that sediment 
interaction decreased effect on motor coordination in males. 
A) Average time to cross beam (seconds) ±SEM at week 0 (pre-exposure), week 4, and 
week 6. Male Mn but not Sed_Mn mice took significantly longer to cross the beam than 
control mice at week 6 (ANOVA, p<0.05, *). 
B) Average fold change in time to cross beam ± SEM compared to respective controls 
(Mn/Ctrl; Sed_Mn/Sed). Fold change in time was altered with manganese sediment 
interaction but no significant effect of exposure duration was observed (two-way 
ANOVA, p<0.01, **).  
C) Average time to cross beam (seconds) ±SEM at week 0 (pre-exposure), week 4, and 
week 6. Female mice exposed to manganese did not take longer to cross the beam 
than control mice. 
D) Average fold change in time to cross beam ± SEM compared to respective controls 
(Mn/Ctrl; Sed_Mn/Sed). Fold change in time was not significantly altered in either 






Figure 5. Examination of exploratory rearing behavior between manganese 
treatment groups at week 4 and week 6 revealed that sediment decreased effect on 
rearing activity in males and females.  
A) Average number of rears ±SEM at week 0 (pre-exposure), week 4, and week 6. Male 
Mn mice had significantly reduced rearing behavior compared to control mice at week 
4 (ANOVA, p<0.05, *) and week 6 (ANOVA, p<0.01, **). Male Sed_Mn mice had 
significantly reduced rearing behavior at week 6 only (ANOVA, p<0.01, **) 
B) Average fold change in rearing ± SEM compared to respective controls (Mn/Ctrl; 
Sed_Mn/Sed). Fold change in rearing was altered with manganese sediment 
interaction (two-way ANOVA, p<0.05) and with exposure duration (two-way ANOVA, 
p<0.01, **).  
C) Average number of rears ±SEM at week 0 (pre-exposure), week 4, and week 6. 
Female Mn mice had significantly reduced rearing behavior compared to control mice 
at week 4 (ANOVA, p<0.05, *) and week 6 (ANOVA, p<0.05, *). Female Sed_Mn mice 
did not show reduced rearing behavior compared to control mice. 
D) Average fold change in rearing ± SEM compared to respective controls (Mn/Ctrl; 
Sed_Mn/Sed). Fold change in rearing was altered with manganese sediment 






Figure 6. Examination of the average time on the accelerating rotarod between 
manganese treatment groups after six weeks of exposure reveals decreased effect 
on motor coordination in females. 
A) Average time to fall (s) ±SEM at week 6. Male Mn mice remained on the rotarod for 
significantly less time than control mice at week 6 (ANOVA, p<0.01, **). Male Sed_Mn 
mice also spent less time on the rotarod but it was not significant (ANOVA, p=0.065). 
B) Average fold change in time ± SEM compared to respective controls (Mn/Ctrl; 
Sed_Mn/Sed). Fold change in time was not significantly altered with manganese 
sediment interaction (Student’s t-test, p>0.05). 
C) Average time to fall ±SEM at week 6. There was no significant difference in the 
average time to fall in manganese exposed female groups (ANOVA, p>0.05). 
D) Average fold change in time ± SEM compared to respective controls (Mn/Ctrl; 
Sed_Mn/Sed). Fold change in time was altered with manganese sediment interaction 









Figure 7. Examination of sex differences in behavioral testing reveals increased 
sensitivity of males in at least one behavioral test in both manganese treatment 
groups. 
A) Average fold change of the Sed_Mn treated male and female mice compared to the 
sediment control (Sed) ± SEM at week 6 (Student’s t-test, p<0.05).  
B) Average fold change of the Mn treated male and female mice compared to the control 
± SEM at week 6 (Student’s t-test, p<0.05).  
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